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Abstract 
The WNT pathway plays a key role in development and disease. In addition to 
the better studied ß-catenin dependent pathway, WNT ligands can also activate 
the separate ‘non-canonical’ or Planar Cell Polarity (PCP) pathway. Perturbations 
in the PCP pathway contribute to the pathogenesis of a variety of diseases 
including cardiac and neural tube defects, and to the invasiveness of cancer 
cells. 
 
R-RAS subgroup GTPases share many of the properties of classical RAS GTPases 
including the ability to behave as oncogenes. However, they also have distinct 
functions of their own and how signalling and biological specificity is achieved is 
not fully understood. Using a proteomic approach to identify novel R-RAS 
subgroup effectors led to the identification of VANGL1, a WNT/PCP protein, 
demonstrated to be a novel R-RAS interacting protein.  
 
In this thesis, I have shown that VANGL1 functions as an effector of R-RAS and 
TC21. Using proteomic approaches, multiple VANGL1 interacting proteins have 
been identified and R-RAS, as well as selected Frizzled (FZD) receptors and the 
tyrosine kinase ROR2 can modulate at least some of these VANGL1 interactions. 
Furthermore, VANGL1 leads to the protein degradation of PRICKLE by a 
mechanism that remains to be determined, and R-RAS GTPases are able to 
inhibit this effect.  
 
Using RBD pulldown assays, I was able to show that WNT ligands and ROR2 can 
lead to the activation of R-RAS, and that R-RAS and TC21 are key mediators of 
RHO activation by WNT5a. Finally, I demonstrated that R-RAS/TC21 and VANGL1 
are critically required for directed migration. 
 
The identification of R-RAS activation by WNT ligands and its interaction with 
VANGL1 provides an exciting new link between the R-RAS subgroup of the RAS 
family and the WNT/PCP pathway. 
 
  
5 
 
Acknowledgments  
First and foremost I would like to thank my supervisor Pablo Rodriguez-Viciana 
for giving me the opportunity to work in his laboratory, the supervision and 
guidance throughout my PhD studies and the final push during writing this 
thesis. I also want to thank my thesis examiners for their interest and time, and 
I am looking forward to our discussion. 
I truly enjoyed my PhD time, thanks to an amazing group of work colleagues and 
students. In particular, I would like to thank Kristina for helpful discussions, 
interest and encouragement throughout my project. Work would have not been 
the same without Lucy, my partner in crime, who is a great team mate and 
friend. Thanks to Berna, even long days went by fast and never got dull due to 
creation of a fun work environment and her entertaining personality. 
I also want to thank Marta, Ariadna, Giammy and Konstantinos for helpful 
experimental discussions and conversations about (PhD) life in general and 
guidance through the last 4 years. 
A very warm thank you goes to Michiru Nishita and Prof Yasuhiro Minami and the 
rest of the very hardworking laboratory members at Kobe University for the 
wonderful and unique time in Japan, and especially for the experimental 
assistance during my stay. 
A specific thank you goes to my family, who supported me all along during my 
studies and their interest in my work. Especially my beloved mum, who 
unfortunately is not able to experience this day – I miss you very much. 
And last but not least, without my second family, the Jhalas, a big, fun and 
loving part of my life in London would be missing – I love you all! 
The biggest gratitude I want to express is for Shiv, who supported me through 
the last three years, is always there for me, and is simply a wonderful person. 
Thank you for being at my side.  
 
Thank you all for being part of my long and interesting PhD journey. 
  
6 
 
Table of Contents 
Abstract……………………………………………………………………………………………………………………4 
Acknowledgements………………………………………………………………….…………………..………..5 
Table of Contents…………………………………………………………………………………..………………6 
List of Figures ………………………………………………………………………………………………..……..13 
List of Tables………………………………………………………………………………………………………….17 
Abbreviations…………………………………………………………………………………………………………18 
 
 
CHAPTER 1 ............................................................................................ 24 
1 Introduction ................................................................................... 25 
1.1 RAS superfamily ...........................................................................25 
1.2 RAS subfamily ..............................................................................26 
1.2.1 RAS regulatory proteins: GEFs and GAPs ...................................28 
1.2.2 RAS protein effectors ..............................................................32 
1.2.3 Structural features of RAS proteins ...........................................37 
1.2.4 Post translational modification of RAS proteins ...........................39 
1.3 The R-RAS subgroup .....................................................................43 
1.3.1 R-RAS ...................................................................................43 
1.3.2 TC21 ....................................................................................47 
1.3.3 M-RAS ..................................................................................48 
1.4 RHO GTPases ...............................................................................49 
1.4.1 Rho regulatory proteins: GEFs, GAPs and GDIs ..........................50 
1.4.2 RHO proteins .........................................................................51 
1.4.3 RAC and CDC42 .....................................................................51 
1.5 WNT signalling branches................................................................52 
1.5.1 β-catenin (canonical) WNT-signalling pathway ...........................52 
1.5.2 Planar Cell Polarity (PCP) pathway ............................................55 
7 
 
1.5.3 The WNT/Ca2+ pathway ...........................................................60 
1.6 WNT signalling components ...........................................................62 
1.6.1 WNT ligands ..........................................................................62 
1.6.2 Non-WNT ligand modulators of WNT signalling ...........................63 
1.6.2.1 WNT inhibitors .................................................................63 
1.6.2.2 WNT activators ................................................................64 
1.6.3 Frizzled receptors ...................................................................66 
1.6.4 WNT cell surface receptors ......................................................67 
1.6.4.1 LRP5/6 ............................................................................68 
1.6.4.2 ROR2 ..............................................................................69 
1.6.4.3 PTK7...............................................................................72 
1.6.4.4 RYK ................................................................................73 
1.6.4.5 HSPGs and Syndecans ......................................................73 
1.6.4.6 Tetraspanins ....................................................................74 
1.6.5 Dishevelled proteins ...............................................................74 
1.7 VANGL proteins ............................................................................78 
1.7.1 VANGL1 ................................................................................79 
1.7.2 VANGL2 ................................................................................81 
1.8 Cell migration and invasion processes .............................................83 
1.8.1 Actin structures and actin-binding protein Filamin A ....................84 
1.8.2 Invadopodia structures and matrix metalloproteases ..................85 
1.9 Autophagy ...................................................................................86 
1.10 Aim of my study and outline of subsequent chapters ......................88 
 
CHAPTER 2 ............................................................................................ 89 
2 Materials and Methods .................................................................... 90 
2.1 MATERIALS ..................................................................................90 
2.1.1 Chemical compounds and reagents ...........................................90 
2.1.2 Media and growth plates .........................................................91 
2.1.3 Antibodies .............................................................................92 
8 
 
2.1.4 Plasmids ...............................................................................93 
2.1.5 Primers .................................................................................95 
2.1.6 RNAi sequences .....................................................................95 
2.1.7 Buffers ..................................................................................90 
2.2 DNA TECHNIQUES ........................................................................97 
2.2.1 Basic DNA manipulations .........................................................97 
2.2.1.1 Cloning approach of VANGL1 truncation constructs ...............97 
2.2.1.2 Cloning approach of ARHGEF17 truncation constructs ...........98 
2.2.2 Plasmid mutagenesis ..............................................................99 
2.2.3 DNA gel electrophoresis ........................................................ 101 
2.2.4 Transformation of bacteria ..................................................... 101 
2.2.5 Preparation and purification of plasmid DNA ............................ 102 
2.2.6 DNA sequencing ................................................................... 102 
2.3 RNA TECHNIQUES ...................................................................... 103 
2.3.1 RNA isolation ....................................................................... 103 
2.3.2 Semiquantitative PCR ........................................................... 103 
2.3.3 Visualisation of RT-PCR products ............................................ 104 
2.4 MAMMLIAN CELL CULTURE .......................................................... 105 
2.4.1 Cell lines and culture conditions ............................................. 105 
2.4.2 Thawing and freezing/long term storage of mammalian cells ..... 105 
2.4.3 Manual cell counting and assessment of viability ...................... 105 
2.4.4 IncuCyte based proliferation or phenotype analysis .................. 106 
2.4.5 DNA transfection .................................................................. 106 
2.4.5.1 Lipofectamine2000 transfection of plasmid DNA ................. 106 
2.4.5.2 Polyethylenimine transfection of plasmid DNA .................... 106 
2.4.6 RNAiMAX siRNA transfection .................................................. 106 
2.4.7 Virus generation ................................................................... 107 
2.4.7.1 Retrovirus ..................................................................... 107 
2.4.7.2 Lentivirus ...................................................................... 108 
2.4.8 Generation of stable cell lines ................................................ 109 
9 
 
2.4.8.1 Generation of stably WNT ligand expressing cell lines and 
collection of WNT conditioned media ................................................ 109 
2.4.8.2 Generation of stable cells expressing YFP-fusion proteins for 
localisation studies ........................................................................ 111 
2.5 PROTEIN TECHNIQUES ................................................................ 112 
2.5.1 Preparation of cell extracts and immunoblot analysis ................ 112 
2.5.2 Determination of protein concentractions ................................ 112 
2.5.3 Densitometric analysis .......................................................... 112 
2.5.4 GST-pull down and immunoprecipitation experiments ............... 113 
2.5.5 Expression and purification of recombinant proteins .................. 113 
2.5.6 Generation of GST-RBD beads for RHO/RAS activation assays .... 113 
2.5.7 RAS and RHO binding domain assays ...................................... 114 
2.5.8 In vitro interaction assays ..................................................... 114 
2.5.9 TAP-tagged protein transfection and purification for mass 
spectrometry analysis ....................................................................... 115 
2.5.10 Mass spectrometry analysis ................................................... 116 
2.6 CELL BIOLOGICAL TECHNIQUES ................................................... 117 
2.6.1 Scratch wound migration assays ............................................ 117 
2.6.2 Transwell/Boyden chamber assays ......................................... 117 
2.6.3 Cell polarisation assays: GM130 and MTOC assays ................... 117 
2.6.4 Invadopodia assay ................................................................ 118 
2.6.5 Luciferase reporter assays for β-catenin level detection ............. 119 
2.6.6 Autophagy inducing treatments .............................................. 120 
2.6.7 Statistical analysis ................................................................ 120 
2.7 MICROSCOPY ............................................................................. 121 
2.7.1 Preparation and staining procesdure of cells for fluorescent 
microscopy purposes ......................................................................... 121 
2.7.1.1 PFA fixation and permeabilisation for GM130 stainings ........ 121 
2.7.1.2 Methanol based fixation for γ-tubulin stainings ................... 122 
2.7.2 Localisation studies using confocal flourescence microscopy ....... 122 
 
10 
 
CHAPTER 3 .......................................................................................... 123 
3 Characterisation of VANGL1 as an effector of R-RAS .................... 124 
3.1 Identification of potential novel effector of R-RAS and TC21 ............. 124 
3.2 VANGL1 behaves as an effector of R-RAS subfamily GTPases ........... 128 
3.2.1 R-RAS interacts with VANGL1 in an activation and effector domain 
dependent manner ........................................................................... 128 
3.2.2 VANGL1 and VANGL2 interact specifically with R-RAS subgroup 
members ......................................................................................... 129 
3.2.3 Characterisation of VANGL1-R-RAS interaction using R-RAS effector 
loop mutants and the ∆CAAX truncation .............................................. 132 
3.2.4 R-RAS interacts with the C-terminus of VANGL1 ....................... 134 
3.2.5 R-RAS interaction with VANGL1 is disrupted by the D259E mutant .. 
  .......................................................................................... 136 
3.2.6 R-RAS and VANGL1 interact directly in vitro ............................. 137 
3.3 ARHGEF17/p164RhoGEF behaves as a TC21 and R-RAS effector....... 139 
3.3.1 ARHGEF17/p164RhoGEF interacts with R-RAS and TC21 in an 
activation and effector domain dependent manner ................................ 139 
3.3.2 Mapping of p164RhoGEF domains that interact with TC21 ......... 140 
3.3.3 ARHGEF17/p164RhoGEF and TC21 interact in vitro ................... 143 
3.3.4 ARHGEF17/p164RhoGEF acts as a GEF for RHOA ...................... 144 
3.4 Discussion ................................................................................. 146 
3.4.1 VANGL1 functions as an effector of R-RAS subgroup GTPases .... 146 
3.4.2 ARHGEF17/p164RhoGEF functions as an effector of R-RAS and TC21
  .......................................................................................... 149 
 
CHAPTER 4 .......................................................................................... 151 
4 Identification of VANGL1 interaction partners .............................. 152 
4.1 Initial VANGL1 TAP Screen ........................................................... 152 
4.2 Validation of VANGL1-TAP hits identified by mass spectrometry ....... 154 
4.2.1 Effect of VANGL1 point mutations found in NTC patients on 
interaction with SCRIB and DVL3 ........................................................ 160 
11 
 
4.3 Modulation of VANGL1 interactions by R-RAS ................................. 162 
4.3.1 VANGL proteins or R-RAS GTPases do not modulate canonical WNT 
signalling ......................................................................................... 162 
4.3.2 Active R-RAS modulates a subset of VANGL1 binding partners ... 163 
4.4 WNT ligand and Frizzled effects on VANGL1 interactions .................. 165 
4.4.1 WNT ligand generation and assessment .................................. 166 
4.4.2 Assessment of WNT ligand responsiveness in a panel of cell lines .... 
  .......................................................................................... 167 
4.4.3 Frizzled expression alters sensitivity towards WNT ligands ......... 170 
4.4.4 FZDs and ROR2 specifically stimulate VANGL1 interaction with DVL2 
  .......................................................................................... 172 
4.4.5 TC21 can co-immunoprecipitate with ROR2 or VANGL1 in the 
prsence of specific FZD receptors ....................................................... 174 
4.4.6 WNT5a modulates VANGL1 interaction with DVL but not SCRIB, 
CASK or DLG1 .................................................................................. 176 
4.5 Proteomic analysis of VANGL1 interaction and their modulation by R-
RAS, mFZD5 and ROR2 ........................................................................ 179 
4.6 Discussion ................................................................................. 181 
4.6.1 Identification and characterisation of VANGL1 interacting proteins ... 
  .......................................................................................... 181 
4.6.2 Frizzled expression leads to enhanced VANGL1-DVL2 interaction 185 
 
CHAPTER 5 .......................................................................................... 191 
5 R-RAS GTPases inhibit VANGL1 induced PRICKLE degradation ..... 192 
5.1 VANGL1 interacts with PRICKLE1 and stimulates its destabilisation ... 192 
5.2 R-RAS GTPases inhibit VANGL1 induced PRICKLE1/2 protein 
destabilisation ..................................................................................... 195 
5.3 VANGL1 localises to vesicle like structures upon autophagy induction 197 
5.4 VANGL1 subcellular localisation studies ......................................... 202 
5.5 Discussion ................................................................................. 207 
 
12 
 
CHAPTER 6 .......................................................................................... 210 
6 Effect of WNT ligands and Frizzled receptors on R-RAS and RHO 
activation ............................................................................................ 211 
6.1 Establishment of RAS binding domain assays ................................. 211 
6.2 WNT ligands activate R-RAS ........................................................ 216 
6.3 R-RAS and TC21 is required for WNT5a dependent activation of RHOA 
and RHOB ........................................................................................... 220 
6.4 Discussion ................................................................................. 225 
 
CHAPTER 7 .......................................................................................... 228 
7 Role of VANGL1 and R-RAS in polarised migration ........................ 229 
7.1 VANGL1 and R-RAS are required for migration ............................... 230 
7.2 VANGL1 and R-RAS are required for scratch induced polarisation ..... 237 
7.3 VANGL1 depletion leads to increased invadosome formation ............ 241 
7.4 Discussion ................................................................................. 244 
 
CHAPTER 8 .......................................................................................... 248 
8 Final Discussion and Summary ..................................................... 249 
8.1 Conclusions and and proposed model ............................................ 249 
 
CHAPTER 9 .......................................................................................... 256 
9 References .................................................................................... 257 
  
13 
 
List of Figures 
Figure 1.1: RAS proteins cycle between a GTP-bound active and a GDP-bound 
inactive state. ..........................................................................................26 
Figure 1.2: Overview of RAS subfamily proteins. .........................................27 
Figure 1.3: RAS regulatory proteins and effectors. ......................................28 
Figure 1.4: Domain overview of RAS regulatory proteins…….. .......................30 
Figure 1.5: Overview of RASGEF and RASGAP GTPase substrate specificity .....31 
Figure 1.6: RAS effector pathways. Upon stimulation, RAS proteins interact with 
a multitude of effector proteins involved in various cellular processes. .............32 
Figure 1.7: The RAS-RAF-ERK signalling pathway ........................................33 
Figure 1.8: Phosphoinositide 3-kinases are RAS effectors. ............................34 
Figure 1.9: Overview of RAL effectors and associated signalling pathways ......36 
Figure 1.10: Structure of RAS proteins ......................................................38 
Figure 1.11: C-terminal RAS membrane targeting signals ............................40 
Figure 1.12: Post translational modifications of RAS proteins ........................41 
Figure 1.13: RAS post translational modifications lead to various subcellular 
localisations .............................................................................................42 
Figure 1.14: Oncogenic classical Ras proteins are structurally highly similar to 
R-RAS proteins .........................................................................................43 
Figure 1.15: Overview of RHO GTPase family..............................................49 
Figure 1.16: β-catenin (canonical) WNT signalling .......................................54 
Figure 1.17: Asymmetrical distribution of planar cell polarity proteins in 
Drosophila ...............................................................................................56 
Figure 1.18: PCP phenotype examples in Drosophila and mammals ...............57 
Figure 1.19: WNT/Planar Cell Polarity signalling ..........................................58 
Figure 1.20: Convergent extension and planar polarity ................................59 
Figure 1.21: WNT/Ca2+ signalling ..............................................................61 
Figure 1.22: WNT ligand structure and post-translational modifications of 
WNT3a and WNT5a proteins .......................................................................62 
Figure 1.23: Non-WNT ligands modulators .................................................65 
Figure 1.24: Schematic of Frizzled receptor key features and binding proteins 
and modulators ........................................................................................67 
Figure 1.25: Overview of WNT modulating receptors and their effect on 
downstream WNT signalling .......................................................................68 
Figure 1.26: Schematic representation of the LRP5/6 domain structure .........69 
Figure 1.27: Structure of ROR-family receptor tyrosine kinase ROR2 .............70 
Figure 1.28: ROR2/WNT5a signalling in regulation of cell polarity, migration and 
invasion...................................................................................................71 
14 
 
Figure 1.29: DVL proteins form the branching point of WNT pathways ...........75 
Figure 1.30: VANGL1 and VANGL2 proteins display a high degree of sequence 
similarity .................................................................................................78 
Figure 1.31: Topological model and structural features of VANGL1 ................80 
Figure 1.32: Polarity of migrating cells .......................................................83 
Figure 1.33: Schematic model of the autophagy process ..............................87 
Figure 2.1: Examples of Gateway cloning vectors ........................................94 
Figure 2.2: Expression analysis of Flag-VANGL1 point mutants and truncation 
constructs in HEK293T cells ..................................................................... 101 
Figure 2.3: Analysis of WNT3a conditioned media biological activity and optimal 
culture and storage conditions .................................................................. 110 
Figure 3.1: Tandem affinity purified R-RAS V38 interactors, identified by mass 
sprectrometry ........................................................................................ 125 
Figure 3.2: Tandem affinity purified TC21 V12 interactors, identified by mass 
spectroscopy .......................................................................................... 126 
Figure 3.3: Proposed model of how R-RAS GTPases could act downstream of 
WNT ligands in the non-canonical WNT signalling pathway ........................... 127 
Figure 3.4: VANGL1 interacts with R-RAS activation and effector domain 
dependent ............................................................................................. 129 
Figure 3.5: R-RAS GTPases interact in an activation-dependent manner with 
VANGL1 and VANGL2 .............................................................................. 130 
Figure 3.6: Interaction of endogenous VANGL1 and other effectors with RAS 
family GTPases. ...................................................................................... 131 
Figure 3.7: R-RAS effector domain mutations do not affect VANGL1 interaction, 
whereas deletion of the CAAX box completely inhibits VANGL1 binding .......... 133 
Figure 3.8: VANGL1 interacts with R-RAS through its C-terminus in a PDZ-motif 
independent fashion ................................................................................ 135 
Figure 3.9: VANGL1 point mutations D259E identified in neural tube defect 
(NTD) patients disrupts binding to R-RAS .................................................. 137 
Figure 3.10: R-RAS interacts directly with the cytoplasmic C-terminus of 
VANGL1 ................................................................................................. 138 
Figure 3.11: ARHGEF17/p164RhoGEF binds specifically to TC21 and R-RAS .. 140 
Figure 3.12: Mapping of the p164RhoGEF binding region to TC21................ 142 
Figure 3.13: In vitro interaction between p164RhoGEF and TC21 ................ 143 
Figure 3.14: p164RhoGEF is an activator of RHOA in HEK293T cells ............ 144 
Figure 3.15: Alignment of RAS, RAP2 and R-RAS subgroup members .......... 147 
Figure 3.16: R-Ras interaction chapter summary ...................................... 148 
Figure 3.17: TC21 interaction summary ................................................... 150 
15 
 
Figure 4.1: VANGL1-TAP approach lead to identification of novel interaction 
partners ................................................................................................ 153 
Figure 4.2: Validation of VANGL1 interactions identified by TAP ................... 156 
Figure 4.3: Validation of TAP-identifed VANGL1 interacting proteins............. 158 
Figure 4.4: VANGL1 D259E mutant disrupts binding to DVL3 but not SCRIB . 160 
Figure 4.5: Expression of VANGL proteins or activated R-RAS/TC21 do not alter 
β-catenin reporter activity ....................................................................... 163 
Figure 4.6: R-RAS modulates a subset of endogenous VANGL1 binding partners 
involved in cell polarity and WNT signalling ................................................ 164 
Figure 4.7: Recombinant WNT3a, but not WNT5a or WNT7a is able to stimulate 
canonical β-catenin signalling ................................................................... 167 
Figure 4.8: WNT ligands differentially stimulate DVL2 phosphorylation in tumour 
derived cell lines but have no effect on non-transformed breast cell lines ....... 169 
Figure 4.9: HMECs expressing mFzd5 gain responsiveness to WNT3a and 
WNT5a ligands ....................................................................................... 171 
Figure 4.10: FZDs and ROR2 cooperate to stimulate VANGL1-DVL2 binding .. 173 
Figure 4.11: ROR2 co-expressed with FZD2 is able to immunoprecipitate 
endogenous TC21 in HEK293T cells ........................................................... 175 
Figure 4.12: VANGL1 is able to immunoprecipitate endogenous TC21 but not R-
RAS in two breast cell lines stably expressing mFzd5 .................................. 176 
Figure 4.13: WNT5a stimulation of HMEC mFzd5 cells leads to modulation of 
VANGL1 and VANGL2 interaction with DVL proteins, but not CASK or DLG1 ... 177 
Figure 4.14: WNT5a treatment enhances binding of DVL2 and DVL3 to VANGL1 
after 60 min, but SCRIB or CASK interactors are not modulated ................... 178 
Figure 4.15: Summary of proteins identified by mass spectrometry in VANGL1 
affinity purifications ................................................................................ 180 
Figure 4.16: Overview of R-RAS VANGL1 interaction and binding partners ... 190 
Figure 5.1: VANGL1 and VANGL2 interact with and destabilise PRICKLE1 ..... 193 
Figure 5.2: R-RAS subgroup GTPases are able to rescue VANGL1 induced 
destabilisation of PRICKLE1 and PRICKLE2 ................................................. 196 
Figure 5.3: VANGL1 and PRICKLE1 localise to ring-like structures suggestive of 
autophagosomes .................................................................................... 198 
Figure 5.4: YFP-PRICKLE1 and YFP-VANGL1 exhibit similar subcellular 
localisation............................................................................................. 199 
Figure 5.5: Treatment with Chloroquine (CQ) causes acumulation of VANGL1 
and VANGL2 but not PRICKLE1 or DVL2 in autophagosome-like structures ..... 201 
Figure 5.6: VANGL1 localises to various subcellular compartments, whereas R-
RAS or TC21 are mostly found membrane associated .................................. 203 
16 
 
Figure 5.7: Localisation of YFP-VANGL1 and YFP-VANGL2 ........................... 205 
Figure 5.8: Chapter summary ................................................................. 209 
Figure 6.1: RAF1 or RALGDS RAS binding domain (RBD) constructs are able to 
precipitate activated RAS and R-RAS ......................................................... 213 
Figure 6.2: EGF activates H-RAS not R-RAS or TC21 in HEK293T or HeLa cells.
 ............................................................................................................ 214 
Figure 6.3: Characterisation of RAS family GEF activity towards RAS and R-RAS 
GTPases ................................................................................................ 216 
Figure 6.4: WNT5a stimulation leads to sharp and short lived R-RAS activation 
peak around 3 min after treatment ........................................................... 217 
Figure 6.5: WNT5a stimulation leads to transient activation of flag-R-RAS in 
U2OS cells ............................................................................................. 218 
Figure 6.6: ROR2 expression leads to sustained R-RAS activation in U2OS ... 219 
Figure 6.7: WNT5a and WNT7a are able to activate R-RAS in different cellular 
contexts ................................................................................................ 220 
Figure 6.8: ROR2 and Frizzled receptors stimulate RHOA activation ............. 222 
Figure 6.9: Expression of ROR2 in combination with FZD2 stimulates RHOA 
activity .................................................................................................. 223 
Figure 6.10: R-RAS and TC21 depletion inhibits RHOA and RHOB activation by 
WNT5a but not FBS ................................................................................. 224 
Figure 6.11: Chapter summary ............................................................... 227 
Figure 7.1: Establishment of wound scratch assays ................................... 230 
Figure 7.2: VANGL1 and  R-RAS/TC21 are required for wound closure ......... 232 
Figure 7.3: VANGL1 knock down leads to a more severe migration defect than 
VANGL2 ................................................................................................. 233 
Figure 7.4: Loss of VANGL1 or R-RAS/TC21 inhibits membrane protrusion and 
migration ............................................................................................... 234 
Figure 7.5: VANGL1 or R-RAS/TC21 are required for transwell migration ...... 236 
Figure 7.6: VANGL1, SCRIB or R-RAS delays Golgi wound orientation .......... 238 
Figure 7.7: Loss of VANGL1 or R-RAS/TC21 disrupts MTOC polarisation towards 
a wound ................................................................................................ 239 
Figure 7.8: Downregulation of SCRIB levels leads to VANGL1 gel migration shift.
 ............................................................................................................ 240 
Figure 7.9: VANGL1 or  R-RAS/TC21 knock down reduces invadosome 
formation. ............................................................................................. 242 
Figure 7.10: MMP-13 expression is regulated through VANGL1 but not R-RAS or 
TC21 ..................................................................................................... 243 
Figure 8.1: R-RAS-VANGL1 signalling model ............................................. 251 
17 
 
List of Tables 
Table 1: Applied primary antibodies, working dilutions and corresponding 
suppliers..................................................................................................92 
Table 2: Applied siRNA oligo sequences ......................................................96 
Table 3: Primer sequences for generation of VANGL1 truncation constructs.....97 
Table 4: PCR cycling parameters for VANGL1 truncation constructs ................98 
Table 5: Primer sequences for generation of ARHGEF17 truncation constructs. 98 
Table 6: Primer sequences for generation of VANGL1 point mutant construct 100 
Table 7: PCR cycling parameters for site-directed mutagenesis.................... 100 
Table 8: Primer sequences for RT-PCR. ..................................................... 103 
Table 9: RT-PCR cycling conditions .......................................................... 104 
 
  
18 
 
Abbreviations 
aa   amino acid 
AF6   Acute lymphoblastic leukaemia-1 Fused gene on chr. 6 
AMBRA  Activating Molecule Beclin-Regulated Autophagy 
AP-1   Activator Protein-1 
APC   Adenomatous Polyposis Coli 
aPKC   atypical Protein Kinase C 
ATGs   autophagy regulators 
BBS   Bardet-Biedl Syndrome 
BCR   B-Cell antigen Receptor 
BGH   Bovine Growth Hormone 
BSA   Bovine Serum Albumin 
C17ORF62  Chromosome 17 Open Reading Frame 62 
CamKII  Calcium/calmodulin-dependent Kinase II 
CASK   CAlcium/calmodulin-dependent Serine protein Kinase 
CBP   Calmodulin Binding Peptide  
CE   Convergent Extension 
CELSR   Cadherin, EGF LAG Seven-pass G-type receptor 1 
CK    Casein Kinase  
CM   Conditioned Media 
CMV   Cytomegalovirus 
CQ   Chloroquine 
CRD   Cysteine Rich Domain 
C-terminal  Carboxy-terminal 
CTGF   Connective Tissue Growth Factors 
CTHRC1  Collagen Triple Helix Repeat-Containing 1 
CXCR2   CXC-motif chemokine Receptor 2 
DAAM   DVL Associated Activator of Morphogenesis 1 
DAB2IP  Doc-2/DAB2 Interactive Protein 
DAG   Diacylglycerol 
DAPI   4',6-diamidino-2-phenylindole 
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DEPC   Diethylpyrocarbonate 
Dgo   Diego 
DH   Dbl Homology 
Dkk   Dickkopf 
DLG1   Disks Large homolog 1 
DMSO   Dimethyl Dulfoxide 
DPI   Dots Per Inch 
DTT   Dithiothreitol 
DVL/Dsh  Dishevelled 
ECM   Extracellular Matrix 
E.coli   Escherichia coli 
EGF   Epidermal Growth Factor 
ERK   Extracellular signal Regulated Kinase 
ETS   E26-Transcription factor proteins  
FAK   Focal Adhesion Kinase 
FBS   Foetal Bovine Serum 
FL   Full Length 
FLNa   Filamin A 
FTase   Farnesyl Transferase 
FZD   Frizzled 
GAP   GTPase Activating Protein 
GEF   Guanine nucleotide Exchange Factor 
GMP-PNP  5'-Guanylyl imidodiphosphate 
GPC3   Glypican 3 
GPCR   G Protein Coupled Receptor 
GSK3   Glycogen Synthase Kinase 3 
GST   Glutathione S-Transferase 
GTP   Guanosintriphosphat 
GTPases  Guanosine Triphosphatases 
HEK293T  Human Embryonic Kidney 293 T cells 
HSPGs   Heparansulfate Proteoglycans 
HVR   Hypervariable Region 
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ICMT1   Isoprenylcystein Carboxymethyltransferase 1 
JNK   c-Jun NH2-terminal Kinase 
KAI1/CD82  Kangai1/Cluster of Differentiation 82 
LB   Luria Bertani 
LiCl   Lithium Chloride 
LIM   LIN-11, Isl1 and MEC-3 
LC3   microtubule-associated protein 1 Light Chain 3 
LDLR   Low-Density Lipoprotein Receptor 
Lp   loop tail 
LPHN2   Latrophilin 2 
LRP   Low density lipoprotein-Related Protein 
Ltap   Loop-Tail-Associated Protein 
MAP   Mitogen-Activated Protein 
MINK1   Misshapen-like Kinase 1 
MMP   Matrix Metalloprotease 
MOPS   3-(N-morpholino)propanesulfonic acid 
MS   Mass Spectrometry 
MST   Mammalian Sterile-20-like protein kinase-1 
MTOC   Microtubule-Organizing Center 
Myr   myristolated 
NDFIP1  Nedd4 Family Interacting Protein 1 
NF-AT   Nuclear Factor of Activated T cells 
NMDAR  N-methyl-D-aspartate glutamate ligand-gated ion channel 
          receptors 
NMT   N-Myristoyltransferase 
NTD   Neural Tube Defect 
O/N   Overnight 
PAK   p21-activated kinases 
PBS   Phosphate Buffered Saline 
PCP   Planar Cell Polarity 
PCR   Polymerase Chain Reaction  
PDZ    PSD-95-Discs-large-ZO-1;  
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PE   Phosphatidylethanolamine 
PET   Polyethylene terephthalate 
PI3K   Phosphatidylinositide 3-Kinases  
PFA   Paraformaldehyde 
PH   Pleckstrin Homology 
PIP2   Phosphatidylinositol 4,5-bisphosphate 
PIP3   Phosphatidylinositol (3,4,5)-triphosphate 
PK   PRICKLE 
PKA   cAMP-dependent Protein Kinase A  
PKC   Protein Kinase C 
PLC   Phospholipase C 
PTM   Post Translational Modification 
PP1   Protein Phosphatase 1 
PP2A   Protein Phosphatase 2A  
PRD   Proline Rich Domain 
PTK7   tyrosine-Protein Kinase-like 7 
PTKR   Protein Tyrosine Kinase Receptor 
PTase   Palmitoyltransferase 
PVDF   Polyvinylidene Fluoride 
R1A   Protein Kinase A type 1 regulatory subunit alpha 
RA   RAS Associating 
RAB3GAP1  Rab3 GTPase-activating protein catalytic subunit 
RAL   RAS-like 
RALBP1  RAL-Binding Protein-1 
RALGDS  RAL Guanine nucleotide Dissociation Stimulator 
RASAL   RASGAP-Activating-Like 
RASGRF  RAS-specific Guanine-nucleotide-Releasing Factor 
RASGRP  RAS-specific Guanine-nucleotide-Releasing Protein 
RASIP1  RAS Interacting Protein 1 
RASSF   RAS Association domain-containing Family 
RBD   RAS/RHO Binding Domain 
RCE1   RAS Converting Enzyme-1 
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REM   RAS Exchange Motif 
RHO   RAS Homologous 
RHOGDI  RHO GDP Dissociation Inhibitor 
RIN   RAS interaction/interference protein 
RLIP76  76 kDa RAL-Interacting Protein 
RFG   RAS Family GTPases 
ROCK   Rho Associated Kinase 
ROR2   Receptor tyrosine kinase-like Orphan Receptor 
R-RAS   Related RAS 
RSPO   R-Spondins 
RT   Room Temperature 
RT-PCR  Reverse Transcript PCR 
RTK   Receptor Tyrosine Kinase 
RYK   Receptor related to tyrosine Kinase 
SBP   Streptavidine Binding Peptide 
Scr   Scramble 
SCRIB   SCRIBBLE 
SDC   Syndecan 
SEM   Standard Errors of the Means 
SF9   Spodoptera frugiperda  
sFRP   secreted Frizzled-Related Proteins 
SH   SRC homology 
SHOC2  soc-2 suppressor of clear homolog  
SOS   Son of Sevenless 
SOST   Sclerostin 
Stbm   Strabismus 
SYNJ2BP  Synaptojanin 2 Binding Protein 
TAP   Tandem Affinity Purification 
TAE   Tris-Acetate-EDTA buffer 
TE   Tris-EDTA buffer 
TCA   Trichloroacetic Acid 
TCF   T-Cell Factor 
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TCR   T-Cell Receptor 
TF8   Transcription Factor 8 
TFF   Trefoil Family Factors 
TIAM   T-cell lymphoma Invasion And Metastasis 1 
TK   Tyrosine Kinase 
TM4SF   Tetra Membrane Spanning Family 
TM   Transmembrane domain  
tri   trilobite 
Ub   Ubiquitin 
UFD1L   Ubiquitin Fusion Degradation 1-Like 
UTR   Untranslated Region 
VANGL1  Vang-like 
WD40   WD40 repeat protein 
Wg   Wingless  
WGEF   Weak similarity GEF 
WIF   WNT Inhibitory Factor 
WNT   Wingless/Int-1 
wt   Wild Type 
YIF   Yip1 Interacting Factor  
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1 Introduction 
Cancer is a diverse disease affecting one out of four people and is characterised 
among others by uncontrolled cell growth, evasion of apoptosis and invasion 
(Hanahan and Weinberg 2000; Hanahan and Weinberg 2011). 
RAS proteins play critical roles in multiple biological processes including 
proliferation, differentiation and survival, and are one of the most frequently 
mutated oncogenes detected in human cancer with an incidence of about 30% 
(Barbacid 1987; Bos 1989; Campbell and Der 2004; Karnoub and Weinberg 
2008).  
Consequently, considerable efforts have been made to understand how RAS 
proteins work and how their transforming activity can be blocked therapeutically 
(Kloog and Cox 2000; Rodriguez-Viciana et al. 2005; Baines et al. 2011). In 
addition, a better understanding of the full spectrum of effector pathways 
regulated by RAS proteins is critical for comprehension of their many biological 
functions and their contribution to human disease in order to develop more 
specific treatment options (Rodriguez-Viciana et al. 2004).  
 
 
1.1 RAS superfamily 
The RAS superfamily of small guanosine triphosphatases (GTPases) consists of 
over 150 human members and is subdivided into at least five major branches 
based on structural homology, sequence and function (RAS, RHO, RAB, ARF, and 
RAN subfamilies) (Figure 1.2A) (Wennerberg et al. 2005; Karnoub and Weinberg 
2008). 
 
GTPases act as nucleotide driven switches, cycling between an inactive GDP-
bound and an active GTP-bound state (Figure 1.1). The transition from an 
inactive to active conformation is achieved by guanine nucleotide exchange 
factors (GEFs), which stimulate the dissociation of GDP and subsequent 
exchange to GTP (Schmidt and Hall 2002). This in turn induces a conformational 
change, enabling the respective GTPase to recognise downstream targets, 
termed effector proteins. The active state is terminated by the antagonising 
effect of GTPase activating proteins (GAPs), which accelerate the intrinsic 
GTPase activity of RAS proteins by several orders of magnitude, rendering the 
GTPase GDP-bound, and consequently inactive (Takai et al. 2001; Bernards and 
Settleman 2004). 
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Figure 1.1: RAS proteins cycle between a GTP-bound active and a GDP-bound 
inactive state. Receptor tyrosine kinases (RTK), G-protein coupled receptors (GPCR)  
and other types of membrane receptors (not shown) are able to activate guanine 
exchange factors (GEFs), which in turn stimulate GDP release and GTP exchange. Binding 
of GTP induces a conformational change within the switch 1 and switch 2 region of RAS 
proteins, enabling effector interaction. This state is terminated by GTPase activating 
proteins, enhancing RAS poor intrinsic GTPase activity, rendering the protein GDP-bound 
and thus inactive. 
 
1.2 RAS subfamily 
RAS proteins are highly conserved and are found in all organisms from yeast to 
human (DeFeo et al. 1981; Chang et al. 1982; Takai et al. 2001; Wennerberg et 
al. 2005). Within the RAS superfamily, RAS lends its name to a subgroup 
consisting of at least 39 members encoded by 36 genes in the human genome 
(Figure 1.2). The best-studied genes of this family are the classical RAS proteins 
encoded by H-RAS, K-RAS, and N-RAS genes (Figure 1.2B, blue square).  
 
RAS proteins serve as signalling hubs, activated in response to a wide range of 
extracellular stimuli, regulate cytoplasmic signalling networks that control gene 
expression and regulation of cell proliferation, differentation and survival 
(Wennerberg et al. 2005; Karnoub and Weinberg 2008).  Because of their critical 
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roles in human oncogenesis they are the focus of intense research (Downward 
2003; Repasky et al. 2004; Roberts and Der 2007). 
 
 
Figure 1.2: Overview of RAS subfamily proteins. (A) The RAS superfamily is divided 
in five major families based on structure homology and function. (B) To date, 39 RAS 
proteins are known, encoded by 36 genes in the human genome. Blue square highlights 
the classical H-, K-, and N-RAS proteins. Red circle indicates the RAS related subgroup 
(R-RAS branch), which share many biological functions with classical RAS proteins such as 
the ability to act as oncogenes. Parts of the figure were taken from Karnoub and 
Weinberg, 2008. 
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1.2.1 RAS regulatory proteins: GEFs and GAPs 
RAS signalling activity is regulated by RASGEFs and RASGAPs, mediating RAS 
GDP/GTP bound state. Eight RASGEFs are encoded by mammalian genomes and 
include two isoforms of Son of Sevenless (SOS), two RAS specific guanine-
nucleotide releasing factor (RASGRF) proteins and four RAS specific guanine 
nucleotide releasing protein (RASGRP) members (Figure 1.3 and Figure 1.4A) 
(Vigil et al. 2010). 
 
 
Figure 1.3: RAS regulatory proteins and effectors. RAS proteins are activated 
through guanine exchange factors (GEFs) of the Son of Sevenless (SOS), RAS-specific 
guanine-nucleotide-releasing protein (RASGRP) and RAS-specific guanine-nucleotide-
releasing factor (RASGRF) families. GEFs facilitate the exchange from GDP to GTP and 
thus render RAS GTP bound, which then interacts with various downstream effectors 
modulating cellular processes such as gene expression, proliferation,  survival, cell cycle 
entry, cytoskeletal dynamics and differentiation. Termination of the signal is achieved by 
RAS GTPase activating proteins (GAP), strongly enhancing RAS protein intrinsic GTPase 
activity and thus rendering RAS GDP-bound and thus inactive. For more details see text. 
CAPRI-calcium-promoted RAS inactivator, GAP1IP4BP-GAP1 InsP4-binding protein, MEK-
MAPK/ERK kinase; NF1-neurofibromin 1, PLCε-phospholipase Cε, PI3K-phosphoinositide 
3-kinase, RALGDS-RAL guanine nucleotide dissociation stimulator, RASAL-RASGAP-
activating-like, RASSF-RAS association domain-containing family, RIN1-RAS and RAB 
interactor 1, SYNGAP-synaptic RASGAP, TIAM1-lymphoma invasion and metastasis-
inducing 1. Figure taken from Ahearn et al., 2012. 
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The best characterised GEF is SOS due to its role downstream of receptor 
tyrosine kinases (RTKs) (Figure 1.7) (Yang et al. 2013). Each GEF contains a 
CDC25 homology catalytic domain, which stimulates the release of GDP, and is 
flanked by at least one adjacent RAS exchange motif (REM) (Figure 1.4A). The 
Dbl homology domain (DH) mediates GDP/GTP exchange on RHO GTPases 
(Rossman et al. 2005), and is located adjacent to the pleckstrin homology (PH) 
domain, which facilitates membrane association. SOS specific histone homology 
domains interact with negatively charged phospholipids (Figure 1.4A) (Yadav and 
Bar-Sagi 2010).  
Similar to SOS, RASGRFs also contain tandem REM-CDC25 and DH-PH domains, 
in addition to calmodulin-binding motif containing conserved I and Q residues 
(Figure 1.4A). RASGRF promotes RAS activation downstream of N-methyl-D-
aspartate glutamate ligand-gated ion channel receptors (NMDARs) through 
receptor stimulated Ca2+ influx (Krapivinsky et al. 2003; Tian et al. 2004). 
Both SOS and RASGRF exhibit a dual specificity for RAS and RAC GTPases, 
providing a link between RAS activation and the function of RAS and RHO 
proteins (Fan et al. 1998; Kiyono et al. 1999; Kiyono et al. 2000; Wennerberg 
and Der 2004). 
RASGRPs, also termed CalDAG-GEFs, form a group which is activated by 
diacylglycerol (DAG) and phorbol ester. They share a common domain 
architecture of a REM-CDC25 tandem domain, followed by a pair of Ca2+ binding 
atypical EF hands and C1-protein kinase C conserved region 1, able to bind DAG 
and phorbol esters (Figure 1.4A) (Mitin et al. 2006). Among the four members, 
variations in GTPase specificity, expression, subcellular localisation and signal 
regulation have been observed. RASGRP3 is reported to exhibit the broadest 
GTPase substrate specificity, including RAP1 and RAP2 (Figure 1.5) (Mitin et al. 
2006).  
RAS activity is negatively regulated through GAPs, stimulating RAS poor intrinsic 
GTPase activity by several orders of magnitude through stabilising the transition 
state of the nucleophilic attack of water, mediated by insertion of an ‘Arg finger’, 
thus terminating signalling (Bernards 2003; Bernards and Settleman 2004). 
RASGAPs share a common ~250 amino acid RASGAP catalytic domain, but 
otherwise do not shows sequence similarity or consistent domain structures in 
the adjacent RASGAP flanking regions (Figure 1.4B) (Bernards and Settleman 
2004). 
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Figure 1.4: Domain overview of RAS regulatory proteins. (A) RAS specific GEFs.  In 
addition to the CDC25 domain, SOS and RASGRF contain Dbl homology (DH) and 
pleckstrin (PH) domains. Other domains found in RASGEFs include: H2A-histone 2A 
homology, IQ-short calmodulin-binding motif containing conserved I and Q residues, EF-
Ca2+-binding EF hand, and C1-protein kinase C conserved region 1, which binds DAG and 
phorbol esters. (B) RAS specific GAPs. RASGAPs have a common ~250 amino acid α-
helical catalytic domain (RasGAP). Other RASGAPs domains include: SH2-Src homology 2, 
SH3-Src homology 3, PH, C2-protein kinase C conserved region 2, serving as a Ca2+-
dependent lipid-binding motif, Sec14-Sec14p-like lipid-binding domain and BTK-Bruton’s 
tyrosine kinase cysteine-rich zinc-binding motif. Figure from Mitin et al, 2005. 
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There are eight RAS specific GAPs known, of which p120 RASGAP/RASA1 and the 
tumour suppressor neurofibromin are the best studied (Dasgupta and Gutmann 
2003; Bernards and Settleman 2004). Others are the synaptic RASGAP/SYNGAP, 
GAP1m/RASA2, GAP1IB4BP/RASA3, and the two calcium activated GAPs 
CAPRI/RASA4 and RASGAP-activating-like (RASAL) (Figure 1.4B) (Mitin et al. 
2006; Rojas and Santos 2006). 
Despite the similar domain structure of GAP1m, GAP1IB4BP, CAPRI and RASAL, 
these RASGAP members exhibit different modes of regulation and plasma 
membrane association. GAP1m exhibits a distinct perinuclear and cytosolic 
localisation, which translocates to the plasma membrane upon EGF stimulation. 
In contrast, GAP1IB4BP displays a constitutive plasma membrane association 
(Lockyer et al. 1997; Cozier et al. 2000), and its RASGAP activity might be 
regulated through inositol 1,3,4,5 tetrakisphosphate (Cullen et al. 1995).   
Both CAPRI and RASAL undergo Ca2+ stimulated C2-dependent plasma 
membrane association (Lockyer et al. 2001; Walker et al. 2004). In summary, 
Ca2+ regulation is able to control activities of RASGAPs and RASGEFs. 
 
 
 
Figure 1.5: Overview of RASGEF and RASGAP GTPase substrate specificity. 
1Conflicting reports for substrate specificity have been made. Figure from Mitin et al, 
2006. 
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SYNGAP is expressed primarily in the brain and localises to glutamatergic 
synapses and is positively regulated through phosphorylation of 
calcium/calmodulin-dependent kinase II (Oh et al. 2004). 
Doc-2/DAB2 interactive protein (DAB2IP) has been demonstrated to exhibit 
RASGAP activity in vitro, and its gene expression has been reported to be 
reduced in certain cancers (Wang et al. 2002). 
 
 
1.2.2 RAS protein effectors 
 
 
Figure 1.6: RAS effector pathways. Upon stimulation, RAS proteins interact with a 
multitude of effector proteins involved in various cellular processes. See section 1.2.1 and 
1.2.2 for details. Abbreviations are: AF6-acute lymphoblastic leukaemia-1 fused gene on 
chromosome 6, CD1-cadherin domain-1, CDC42-cell division cycle-42, ELK-ETS-like 
protein, ERK-extracellular signal regulated kinase, ETS-E26-transcription factor proteins, 
Ins(1,4,5)P3-inositol-1,4,5-trisphosphate, JNK-Jun N-terminal kinase, MEK-mitogen-
activated protein kinase/ERK kinase, NF-κB-nuclear factor-κB, PI3K-phosphoinositide 3-
kinase, PKB/C-protein kinase B/C, PLA/Cε/D- phospholipase A/Cε/D, RalBP1-Ral-binding 
protein-1, RASSF-RAS association domain-containing family, Rin1-RAS 
interaction/interference protein-1, SAPK-stress-activated protein kinase, SHP2-Src-
homology 2 domain-containing protein Tyr phosphatase-2, TIAM1-T-cell lymphoma 
invasion and metastasis-1. Figure from Karnoub and Weinberg 2008. 
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The first identified and also best characterised RAS effectors were RAF 
serine/theonine kinases (Moodie et al. 1993; Vojtek et al. 1993; Warne et al. 
1993; Zhang et al. 1993; Wellbrock et al. 2004), through which RAS activates 
the growth-regulatory mitogen-activated protein (MAP) kinase cascade and the 
E26-transcription factor proteins (ETS) (Figure 1.7) (Ahearn et al. 2012). This 
pathway has been demonstrated to be necessary and sufficient for RAS induced 
transformation of murine cells (Leevers et al. 1994; Stokoe et al. 1994; 
Khosravi-Far et al. 1995; White et al. 1995). The identification of  BRAF 
mutations in cancers, generally in a mutually exclusive manner with RAS 
mutations, underscores the importance of a this pathway downstream of RAS 
function and in oncogenesis (Rajagopalan et al. 2002). 
 
 
Figure 1.7: The RAS-RAF-ERK signalling pathway. Upon stimulation of a protein 
tyrosine kinase receptor (PTKR) with growth factors, the cytoplasmic GRB2-SOS complex 
is recruited to the plasma membrane through association of the GRB2-SH2 domain to 
phosphorylated  residues of the activated receptor. Interaction of the PH domain of SOS 
with phospholipids induces a conformational change which allows binding of membrane 
localised RAS and leads to its activation through GTP loading. RAS then initiates 
downstream signalling through recruitment of RAF1 to the membrane and stimulation of 
its kinase activity.  RAF kinases then phosphorylate and activate MEK, which then 
activates ERK, followed by phosphorylation and activation of multiple transcription factors 
including ELK. Figure from Ahearn et al, 2012. 
 
The second best characterised RAS effectors are the p110 (α, β, γ and δ) 
catalytic subunit of class I Phosphoinositide 3-kinases (PI3K) (Rodriguez-Viciana 
et al. 1994; Castellano and Downward 2010). PI3K signalling mediates cell 
34 
 
growth, proliferation, differentiation, motility, survival and intracellular 
trafficking, which if deregulated, results in cancer (Cain and Ridley 2009; 
Vanhaesebroeck et al. 2012).  
 
 
 
Figure 1.8: Phosphoinositide 3-kinases are RAS effectors. (A) PI3K are activated 
through binding of the regulatory p85 subunit the SRC homology (SH2) domain to the 
phosphorylated receptor YxxM motif or through RAS binding of the catalytic subunits in a 
GTP dependent manner. Class IA PI3Ks are activated through receptor tyrosine kinases 
(RTKs), whereas Class IB PI3K are either G-protein couple receptor (GPRC) or RAS 
activated.  (B) The catalytic subunit of PI3K comprises a lipid kinase activity and 
catalyses phosphorylation of Phosphatidylinositol 4,5-bisphosphate (PIP2) to 
Phosphatidylinositol (3,4,5)-triphosphate (PIP3). PTEN- Phosphatase and tensin 
homologue. 
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PI3Ks generate lipid second messengers by phosphorylation of phosphoinositides 
at the 3’ position (Class I: phosphatidylinositol (3,4,5)-triphosphate) (Figure 
1.8), which then recruit and bind downstream effectors such as AKT or lead to 
stimulation of RAC and RHO through respective GEF activation (Welch et al. 
2003; Costa et al. 2007; Cain and Ridley 2009).   
 
Both described pathways, MAPK and PI3K, display a critical role in RAS mediated 
oncogenesis, supported by the frequent mutational activation of BRAF (13%, 
COSMIC database, www.sanger.ac.uk/genetics/CGP/cosmic) and PIK3CA (19%). 
 
RAL guanine nucleotide dissociation stimulator (RALGDS) was the first of RAL 
(RAS-like) exchange factors (RALGEFs) identified to be RAS effector proteins 
(Kikuchi et al. 1994; Spaargaren and Bischoff 1994). RALGDS possesses 
sequence homology with the REM and CDC25 domains found in RASGEFs. 
However, studies revealed that RALGDS does not display an exchange activity 
for RAS and rather is selective for RALA and RALB (Neel et al. 2011). 
 
RAL interacts with multiple, functionally divergent downstream effector proteins 
involved in endocytosis, exocytosis, actin organisation, phosholipid metabolism 
and second messenger generation (Figure 1.9) (Neel et al. 2011). Effectors are 
RALBP1 (Ral binding protein 1)/RLIP76 (76 kDa Ral-interacting protein) (Cantor 
et al. 1995; Jullien-Flores et al. 1995), the octameric exocyst complex including 
Sec5 and Exo84 (Moskalenko et al. 2002; Moskalenko et al. 2003), 
Phospholipase C delta 1 (PLCδ1) (Sidhu et al. 2005), or the actin filament 
crosslinking  protein FilaminA required for RALA induced filopodium formation 
(Ohta et al. 1999; Ohta et al. 2006).  
 
In addition, RAS GTPases interact with a wide array of other effectors that are 
less well characterised. RAS interaction/interference protein 1 (RIN1) has been 
described as a GEF for RAB5-like proteins, implicated in endocytosis downstream 
of RAS stimulating growth factors such as EGF (Han and Colicelli 1995; Tall et al. 
2001).  
 
T-cell lymphoma invasion and metastasis 1 (TIAM1) has been described as a 
RAS effector and acts as a RAC specific GEF, that links RAS signalling to RAC, 
which regulates the actin cytoskeleton and stimulates p21-activated kinases 
(PAK) and c-JUN activated kinase (JNK) (Lambert et al. 2002). TIAM deficient 
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mice displayed a resistance to RAS induced skin carcinogenesis, suggesting that 
TIAM activity is required for RAS transformation (Malliri et al. 2002). 
 
 
 
Figure 1.9: Overview of RAL effectors and associated signalling pathways. RAL 
downstream effectors mediate endocytosis, exocytosis, actin re-organisation, 
phospholipid metabolism and generation of second messengers. Also, RAL has been 
shown to activate various transcription factors and to regulate gene expression.   PC-
phosphadidylcholine, PA-phosphatidic acid. Figure from Neel et al., 2011. 
 
ALL (acute lymphoblastic leukaemia) 1 fused gene on chromosome 6 (AF6) or 
AFADIN was identified by RAS-GTP affinity chromatography (Kuriyama et al. 
1996), and has been characterised to contain both microtubule and actin binding 
motifs, suggesting that AF6 might participate in cytoskeletal processes 
downstream of RAS (Ponting and Benjamin 1996). Indeed, studies suggest that 
AF6 associates with proteins that are involved in regulation of polarity, and to 
localise to adherens junctions (Mandai et al. 1997). 
 
Activation of the RAS effector Phospholipase C-ε (PLCε) leads to generation of 
diacylglycerol through the cleavage of Phosphatidylinositol 1,4,5-bisphosphate 
into Phosphatidylinositol (4,5)-triphosphate. This in turn promotes the release of 
Ca2+ and the activation of PKC (Kelley et al. 2001; Song et al. 2001).  
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RAS association domain-containing family 5 (RASSF5) also known as NORE1 has 
been identified as a RAS effector protein (Vavvas et al. 1998), which possesses 
pro-apoptotic functions (Khokhlatchev et al. 2002; Vos et al. 2003) and a 
potential involvement in cell migration (Dallol et al. 2005). Although the 
functional mechanism is not fully elucidated yet, preliminary evidence links 
RASSF proteins to the mammalian sterile-20-like protein kinase-1 (MST1) and 
MST2, and to the Hippo signalling pathway (Tommasi et al. 2005; Cho et al. 
2006; Varelas et al. 2010; Heallen et al. 2011).  
 
In mitogenically stimulated cells, a complex formation of a RASGAP and the 
cellular protein p190 has been observed (Moran et al. 1991). p190 contains a 
carboxy-terminal domain that functions as a GAP for the RHO family GTPases, 
and thus the RASGAP-p190 complex may serve to couple RAS- and RHO-
mediated signalling pathways. 
 
More recent and less well characterised RAS effectors are the RAS interacting 
protein 1 (RASIP1), also known as RAIN, which is required for endothelial cell 
motility, angiogenesis and vessel formation (Xu et al. 2009; Xu et al. 2011). The 
regulator of G-protein signalling 14 (RGS14) has been demonstrated to 
facilitates the formation of a selective RAS-GTP/RAF/MEK/ERK multi-protein 
complex to promote sustained ERK activation, which regulates H-RAS dependent 
neuritogenesis  (Willard et al. 2007; Willard et al. 2009). The protein impedes 
mitogenic signal propagation (IMP1A) E3 ligase member acts as a steady-state 
resistor within the RAF/MEK/ERK kinase module, and is directly regulated by RAS 
(Matheny et al. 2004; Matheny and White 2009).  
 
 
1.2.3 Structural features of RAS proteins 
RAS proteins share a highly conserved G domain, involved in Mg2+ and 
nucleotide binding and nucleotide hydrolysis (residues 1-164). The exchange of 
GDP to GTP leads to conformational changes in two stretches of the protein, the 
switch I (Asp30 - Asp38) and switch II (Gly59 – Glu67) regions, located close to 
the γ-phosphate group of the activating GTP. The third structurally important 
element of RAS GTPases is the P-loop (Gly10 – Ser17), which winds around the 
β- and γ-phosphates and contributes to most of the required energy for GTP 
binding (Figure 1.10) (Milburn et al. 1990).  
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Overlapping with switch I is the core RAS effector domain (Tyr32 - Tyr40), also 
known as effector loop, which is important for downstream interactions with 
effectors or inactivating proteins like GAPs (Figure 1.10) (Wennerberg et al. 
2005). 
Single amino acid activating mutations in RAS genes are frequently detected in 
human cancers (Cox and Der 2010). For example, replacement of P-loop located 
Gly12 residue in H-RAS with any other amino acid except proline results in an 
increased tumour transforming potential due to its importance for GTP binding 
(Clark et al. 1985).  
 
 
Figure 1.10: Structure of RAS proteins. (A) RAS proteins consist of a GTP binding 
domain (residues 1-164) and a C-terminal hypervariable region (amino acids 166-189) 
that contains isoform-specific membrane binding and trafficking determinants. Further 
strutural motifs include the phosphate binding motif P-loop, switch I and II regions as well 
as a C-terminal targeting sequence (CAAX motif). (B) Nucleotide-dependent structural 
rearrangements. The differences between the inactive GDP bound and the active GTP-
bound RAS are confined to mainly in two regions, termed switch I and switch II, both of 
which are required for the interactions of RAS with its regulators and effectors. The γ-
phosphate induces significant changes in the orientation of the switch II region through 
the interactions that it establishes with Thr35 and Gly60. Notably, these two residues are 
among the most conserved residues in the GTPase family, suggesting that the 
mechanisms of GTP binding (and hydrolysis) are essentially the same among various 
members. Figure adapted from Karnoub and Weinberg, 2008. 
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The oncogenic mutation Gln61Leu positioned in switch II, impairs GTP hydrolysis 
as a result of its catalytically essential residue involved in GAP interaction (Resat 
et al. 2001; Karnoub and Weinberg 2008; Cox and Der 2010). 
 
1.2.4 Post translational modification of RAS proteins 
RAS proteins are post-translational modified (PTM) through hydrophobic groups, 
dictating specific subcellular localisations, that are essential for biological activity 
(Hancock 2003; Hancock and Parton 2005; Wright and Philips 2006; Ahearn et 
al. 2012). 
 
RAS proteins terminate with a CAAX tetrapeptide, were C represents a cysteine 
residue, A - any aliphatic amino acid and X symbolises any residue, which in 
conjunction with immediate upstream cysteine residues form the membrane 
targeting sequence, dictate interaction with distinct membrane compartments 
and subcellular localisations (Figure 1.11A) (Wright and Philips 2006; Eisenberg 
et al. 2013).  
 
Notably, all CAAX proteins still require a second signal for trafficking to the 
plasma membrane (Hancock et al. 1990). In case of H-RAS, N-RAS and K-
RAS4A, the second signal is comprised of Cys residues that are palmitoylated, a 
process also known as acylation (Resh 1999).  For K-RAS4B, the second signal 
consists of a polybasic Lys-rich region with a net positive charge that is believed 
to form an eloctrostatic interaction with the negatively charged phospholipids at 
the plasma membrane (Figure 1.11A). 
 
The CAAX motif recognition sequence is modified by the enzyme farnesyl 
transferase (FTase), which attaches a farnesyl group to the cysteine residue via 
a thioester bond. Next, the last three amino acids (AAX) are proteolytic cleaved, 
catalysed by the RAS converting enzyme-1 (RCE1) and the now C-terminal 
cysteine residue undergoes a methylesterification mediated by isoprenylcystein 
carboxymethyltransferase 1 (ICMT1). In addition, RAS proteins are further 
modified with palmitoyl groups at different cysteine residues in the vicinity of the 
C-terminus performed through palmitoyltransferase (PTase), which is required 
for membrane association (Figure 1.11B) (Wright and Philips 2006).  
 
Besides attachment of polyisoprenoid lipids, RAS GTPases are found to be further 
post translationally modified through phosphorylation, nitrosylation, 
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ubiquitinylation and peptidyl-prolyl isomerisation, which are conditional upon cell 
activation, redox state or microbial pathogenesis (Figure 1.12) (Ahearn et al. 
2012). 
 
 
Figure 1.11: C-terminal RAS membrane targeting signals. (A) This figure illustrates 
the hypervariable region (HVR) of H-, K- and N-RAS proteins. Highlighted in yellow is the 
first post translational modification (PMT) motif, the cysteine residue forming the 
membrane targeting CAAX motif, which is farnesylated. An additional upstream ‘second’ 
signal is required for plama membrane targeting, shaded in green. For H-RAS, N-RAS and 
K-RAS4A, the second signal consists of Cys residues that are palmitoylated. For K-RAS4B, 
the second signal consists of a polybasic region with a net positive charge of eight (pink) 
and Ser181 residue, which is the principal site of phosphorylation is highlighted in blue. 
Figure adapted from Ahearn et al, 2012. (B) C-terminal processing of RAS proteins. 
Membrane association is absolutely required for RAS GTPase function and takes place 
through C-terminal modification of the CAAX motif. Farnesyltransferase (FTase) covalently 
attaches a farnesyl group (F, orange) to the final cysteine residue, followed by protealytic 
cleavage of the last three amino acids (AAX) by RAS converting enzyme-1 (RCEI). The 
now terminal farnesylated cysteine is carboxymethylated by isoprenylcystein 
carboxymethyltransferase 1 (ICMT1). RAS proteins are further modified (with the 
exception of K-RAS-4B) through attachment of palmitoyl groups (red lines) catalysed 
through palmitoyltransferase (PTase). Figure taken from Karnoub and Weinberg, 2008. 
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A recent study showed that the cis–trans prolyl isomerase 12 kDa FK506-binding 
protein (FKBP12) functions in the regulation of RAS depalmitoylation (Ahearn et 
al. 2011) through isomerization of the Gly–Pro peptidyl-prolyl bond at position 
178–179. This constitutes a molecular timer for acylation and therefore this 
modification gained more appreciation for signalling purposes (Lu et al. 2007). 
 
 
Figure 1.12: Post translational modifications of RAS proteins. Overview of reported 
post-translational modifications (PTMs) for H-RAS (top) and K-RAS4B (bottom). Sites of 
mono-ubiquitylation and di-ubiquitylation are indicated with blue spheres (Ub-ubiquitin). 
Note that glucosylation and ADP-ribosylation modifications have been only observed in 
cells intoxicated with bacterial virulence factors. All other PTMs are intrinsic to all 
eukaryotic cells, which have been implicated in RAS trafficking and signalling. Figure from 
Ahearn 2012. 
 
H-RAS, N-RAS and K-RAS4B were recently shown to be substrates for mono- 
ubiquitination and di- ubiquitination modifications (Jura et al. 2006; Sasaki et al. 
2011). The responsible E3 ligase was identified as rabaptin 5-associated 
exchange factor for RAB5 (RABEX5), which requires RIN for RABEX5-dependent 
RAS ubiquitination (Xu et al. 2010). RIN1, through its function as a GEF for 
RAB5, is believed to promote the RAB5-dependent recruitment of RABEX5 to 
endosomal sites, where H-RAS ubiquitination takes place. Thus, ubiquitination 
regulates trafficking of H-RAS to and from endosomes, indicating that this 
modification poses an additional way to regulate RAS compartmentalisation, and 
the spatial control of its signalling output.  
Similarly, phosphorylation of K-RAS at Ser181 by PKC reduces the net charge of 
the polybasic region, thus leading K-RAS4B to lose affinity for plasma membrane 
association and to accumulate on endomembranes (Ballester et al. 1987; Bivona 
et al. 2006). 
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The RAS Cys118 residue is highly conserved among RAS isoforms, and it is the 
most surface-exposed Cys on these GTPases. Studies revealed that Cys118 could 
be nitrosylated when exposed to nitric oxide (NO) (Lander et al. 1995b; Lander 
et al. 1996). Even though S-nitrosylation does not alter the structure of RAS, 
this modification leads to enhanced guanine nucleotide exchange (Lander et al. 
1995a; Williams et al. 2003), which promotes more efficient RAS activation. 
Once the ER localised CAAX processing is complete, RAS isoforms diverge into 
their subsequent trafficking routes (Wright and Philips 2006). Palmitoylated RAS 
proteins (H-RAS, N-RAS and K-RAS4A) travel to the Golgi, where they get 
acylated. This step traps them into the Golgi, and leads to incorporation into 
transport vesicles and to enter the secretory pathway.  
In contrast, K-RAS4B does not shuttle to the Golgi but instead associates directly 
with the plasma membrane. Whether this is achieved through diffusion or by an 
as yet unknown mechanism remains elusive (Figure 1.13) (Choy et al. 1999; 
Apolloni et al. 2000).   
On the membrane, RAS proteins are able to become enriched with the 
cholesterol-binding protein caveolin and localise to specific plasma membrane 
micro-domains (lipid raft or non-raft domains) (Simons and Ikonen 1997; Prior 
et al. 2001) (Figure 1.12). It seems that functional activation of RAS depends on 
its release from lipid-raft micro-domains in the plasma membrane and its 
redistribution to nearby sites thus enabling interaction with various downstream 
effectors (Prior et al. 2001). 
  
 
Figure 1.13: RAS post translational modifications lead to various subcellular 
localisations. See text for details. Figure from Karnoub 2008. 
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1.3 The R-RAS subgroup 
Within the Ras subfamiliy, the related Ras (R-RAS) subgroup shares the highest 
similarity with classical Ras proteins (H-, K- and N-RAS ) and exhibits significant 
oncogenic potential (Figure 1.2B, red circle) (Saez et al. 1994; Graham et al. 
1999; Movilla et al. 1999; Erdogan et al. 2007; Erdogan et al. 2008). Three R-
RAS family members have been characterised, R-RAS (Lowe et al. 1987), TC21 
(R-RAS2)(Drivas et al. 1990) and M-RAS (R-RAS3) (Matsumoto et al. 1997). 
Although, this subgroup shares many biochemical and biological properties with 
classical Ras proteins such as an identical effector domain, overlapping GEFs and 
GAPs and the ability to act as oncogenes, evidence suggest that R-RAS GTPases 
have distinct properties and functions to classical RAS proteins (Zhang et al. 
1996; Huff et al. 1997; Self et al. 2001) (Figure 1.14).  
 
 
1.3.1 R-RAS  
The founding member R-RAS shares a 55% aa identity with H-RAS and was 
discovered using a low stringency hybridisation probe of H-RAS, underscoring 
the high similarity to the classical H-, K- and N-RAS proteins (Lowe et al. 1987) 
(Figure 1.14). Accordingly, R-RAS and RAS share at least two GAPs, 
p120RASGAP and neurofibromin, the exchange factor RASGRF and effectors RAF, 
PI3K, RalGDS, RIN and AF6 (Rey et al. 1994; Spaargaren and Bischoff 1994; 
Spaargaren et al. 1994; Gotoh et al. 1997; Marte et al. 1997; Ebinu et al. 1998).  
 
 
 
Figure 1.14: Oncogenic classical Ras proteins are structurally highly similar to R-
RAS proteins. R-RAS displays a 55% amino acid homology to H-RAS, and structural 
conserved features such as the effector loop mediating downstream effector binding, are 
entirely identical between classical RAS proteins and the members of the R-RAS branch. 
Figure adapted from Karnoub and Weinberg, 2008. 
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Further, oncogenic activating mutants in human cancers analogous to those of 
found in the H-RAS oncogenes, have been identified for R-RAS GTPases 
(COSMIC database).  
 
Despite the fact that R-RAS proteins share many regulatory and effector proteins 
with RAS proteins (Ehrhardt et al. 2002), R-RAS causes a transformed 
phenotype which is distinct from that induced by RAS (Self et al. 2001). 
Therefore, it is likely that R-RAS controls signalling and cellular processes which 
are distinct from classical RAS proteins. Indeed, R-RAS does not activate MAP 
kinase pathways and is only weakly oncogenic (Self et al. 2001). Furthermore, 
R-RAS activates α5β1 integrin independently of PI3K, through a different 
mechanism to H-RAS (Zhang et al. 1996; Sethi et al. 1999; Kinashi et al. 2000). 
RALBP1 also termed RLIP76, is the only effector known to date exclusive to R-
RAS that is not shared with other classial RAS family members, and mediates 
adhesion-dependent RAC activation and cell migration (Goldfinger et al. 2006). 
 
R-RAS differs from classical RAS proteins structurally through e.g. an N-terminal 
26 amino acid extension, and differs at nine amino acids within the extended 
effector region across amino acids 23-46 (Lowe et al. 1987; Self et al. 1993; 
Holly et al. 2005). N-terminal truncated R-RAS failed to activate RAC and 
resulted in reduced cell spreading compared to full length R-RAS protein in 32D 
mouse myeloid cells, whereas adhesion or subcellular localisation was not 
affected (Holly et al. 2005).  
 
Active R-RAS was demonstrated to increase ligand binding activity of integrins 
and to stimulate the adhesive properties of suspension cells (Zhang et al. 1996). 
In this context it has been further shown that R-RAS is able to antagonise H-RAS 
mediated integrin activation suppression (Sethi et al. 1999). R-RAS integrin 
regulation seems to be mediated through the effector loop and prenylation site 
of R-RAS (Oertli et al. 2000) possibly through a distinct plasma membrane 
micro-domain distribution (Hansen et al. 2003). Further, it has been 
demonstrated that R-RAS effects on integrin activation are negatively regulated 
through phosphorylation of the effector domain tyrosine residue Tyr66 by Eph 
receptor kinase EphB2 (Zou et al. 1999) or c-SRC, measured by cell adhesion 
reducing effects (Zou et al. 2002). Notably, it has been reported that R-RAS  
activation of integrin signalling could be a bi-directional system, since R-RAS has 
been observed to be activated downstream of integrin-mediated adhesion 
(Wozniak et al. 2005). 
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Studies focussing on R-RAS C-terminal sequences employing R-RAS/RAS 
chimeras, showed that the last 53 amino acids are necessary and sufficient to 
specify the contrasting biological activities beween R-RAS and RAS. Identified 
properties included H-RAS induced integrin suppression, reactive oxygen species 
production and morphological effects of transformed cells (Hansen et al. 2002).  
 
R-RAS acts as a regulator of cell adhesion through effects on integrin affinity 
(Keely et al. 1999; Hansen et al. 2003), and focal adhesion formation (Berrier et 
al. 2000; Kwong et al. 2003). For example, in T47D breast cells active R-RAS 
strongly stimulates focal adhesion kinase (FAK) and p130Cas phosphorylation by 
an unknown mechanism (Kwong et al. 2003). Using a H-RAS/R-RAS chimera 
approach mapped the focal adhesion targeting signal to the C-terminal end of R-
RAS (Furuhjelm and Peranen 2003). It is further known that R-RAS promotes 
adhesion-induced activation of RAC through its effector PI3K (Marte et al. 1997; 
Berrier et al. 2000; Holly et al. 2005).   
 
R-RAS has been found to interact with Oxysterol-binding protein (OSBP)-related 
protein 3 (ORP3) (Goldfinger et al. 2007; Lehto et al. 2008). ORP3 is highly 
expressed in epithelial, neuronal and hematopoietic cells and has been described 
to be involved in integrin signalling and organisation of the actin cytoskeleton 
(Lehto et al. 2001). Therefore it has been proposed that R-RAS – ORP3 
interaction is able to regulate cell-cell and cell-matrix adhesion (Lehto et al. 
2008). 
 
As noted above, the exclusively R-RAS binding protein RLIP76 (does not bind H-
RAS or RAP1) mediates the R-RAS induced effect on cell spreading and migration 
through ARF6 (Goldfinger et al. 2006). Activated ARF6 stimulates adhesion-
induced RAC1 activation, leading to lamellipodium formation and cell migration 
(Radhakrishna et al. 1999; Santy and Casanova 2001; Goldfinger et al. 2006). 
Additional studies confirm a role of R-RAS in cell migration through the spatial 
regulation of RAC and RHO (Wozniak et al. 2005; Shang et al. 2011). Consistent 
with this, activated R-RAS has been shown to promote cell migration of breast 
(Keely et al. 1999; Jeong et al. 2005) and cervical epithelial cells (Rincon-Arano 
et al. 2003; Mora et al. 2007) and has been identified as a cancer linked gene 
(Nishigaki et al. 2005). In the latter study using gastric cancer samples, it was 
discovered that gene demethylation of specific CpG sites within the first intron of 
R-RAS causes activation in more than half of the tested samples (Nishigaki et al. 
2005). 
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Further evidence for a role of R-RAS in actin cytoskeleton re-modelling and cell 
migration stems from interaction with the actin-binding scaffolding protein 
FilaminA (FLNa), which also binds to integrin β1, β2, β7 tails. FLNa is necessary 
for tumour cell metastasis and vascular remodelling (Ott et al. 1998; de Curtis 
2001; Yamazaki et al. 2005; Feng et al. 2006). Studies in human melanoma 
cells M2 showed that R-RAS functionally associates with FLNa and thereby 
regulates integrin dependent migration (Gawecka et al. 2010) or maintenance of 
endothelial barrier function in human coronary artery endothelial cells (Griffiths 
et al. 2011).  
 
R-RAS was found enriched on both early and recycling endosomes, and displayed 
a higher activity if endosome located compared to the plasma membrane, 
resulting in RGL2 effector recruitment (a GEF for RALA) (Takaya et al. 2007).   
 
Active R-RAS lengthened the duration of initial membrane protrusion and 
promoted the formation of ruffling lamellipodia and the lack of filopodia 
structures, which might be mediated through activity of PLCε, (Ada-Nguema et 
al. 2006). Consistently, studies in COS-7 cells showed that R-RAS localises to the 
leading edge of migrating cells, where it regulates membrane protrusion and 
ruffle formation (Conklin et al. 2010). Furthermore, it has been demonstrated 
that endogenous R-RAS co-localises with β-integrin in ruffles and endocytic 
vesicles and R-RAS is required for integrin accumulation into ruffles (Conklin et 
al. 2010). In addition, it has been described that active R-RAS is able to convert 
RIN2 from a GEF to an adaptor protein which preferentially binds RAB5. Active 
RAB5 then triggers the endocytosis of ECM bound/active integrins and active R-
RAS to early endosomes, which then mediates the TIAM-mediated activation of 
RAC1 (Sandri et al. 2012). 
 
Semaphorins are large secreted and transmembrane molecules involved in axon 
guidance, which are modulated by plexins and signal to the cytoskeleton in a 
RHO and RAC dependent manner (Kolodkin et al. 1993; Tamagnone et al. 1999). 
Plexins have been proposed to behave as GAPs specific for R-RAS and M-RAS, 
suggesting a selective role for R-RAS proteins in plexin-regulated signalling 
pathways, involved in cell migration and axon guidance (Oinuma et al. 2004; 
Kruger et al. 2005; Pasterkamp 2005; Saito et al. 2009; Oinuma et al. 2010). 
However, a more recent paper suggested that Plexins are GAPs for RAP1 rather 
than R-RAS (Bos and Pannekoek 2012). 
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R-RAS null mice are viable and fertile with no obvious abnormalities and normal 
tissues upon histologic examination (Komatsu and Ruoslahti 2005). However, R-
RAS deficient mice exhibited exaggerated neointimal thickening in response to 
arterial injury and increased angiogenesis in implanted tumours (Komatsu and 
Ruoslahti 2005). Expression of R-RAS is mainly restricted to endothelial cells and 
vascular smooth muscle cells, where is has been found to regulate blood vessel 
remodelling, through to integrin-mediated cell adhesion to ECM components 
(Zhang et al. 1996; Kinbara et al. 2003; Komatsu and Ruoslahti 2005). 
Moreover, a recent study confirmed this observation and established R-RAS as a 
critical regulator of vessel integrity and function during tumour vascularisation 
(Sawada et al. 2012).  
 
 
1.3.2 TC21 
TC21 was initially cloned from a human teratocarcinoma cDNA library using 
oligonucleotides corresponding to the conserved region of RAS genes (Drivas et 
al. 1990). TC21 shows similar transformation ability than H-RAS (Graham et al. 
1999) and mutated TC21 has been found in human tumours (Chan et al. 1994; 
Huang et al. 1995; Barker and Crompton 1998) and COSMIC database. 
Moreover, overexpression of  TC21 has been associated with oral, breast, 
hepatocellular and esophagous carcinoma (Clark et al. 1996; Arora et al. 2005; 
Sharma et al. 2005; Luo et al. 2010; Macha et al. 2010).  
 
TC21 has been found to be essential for survival and maintenance of B- and T 
lymphocytes, through linking respective antigen receptors to PI3K-mediated 
survival pathways (Delgado et al. 2009). Moreover, TC21 and RHOG mediate 
T cell receptor internalisation from the immunological synapse through 
phagocytosis (Alarcon and Martinez-Martin 2011; Martinez-Martin et al. 2011). 
 
TC21 deficient mice do not display major alterations in viability, growth rates, 
cardiovascular parameters, or fertility but exhibit a delay in mammary gland 
development (Larive et al. 2012). TC21 is expressed in the same cell types as R-
RAS (Kozian and Augustin 1997; Komatsu and Ruoslahti 2005; Larive et al. 
2012) and they share overlapping regulatory proteins, and thus might mediate 
similar cellular functions (Ohba et al. 2000; Self et al. 2001; Ehrhardt et al. 
2002).  
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1.3.3 M-RAS 
The last identified R-RAS member is M-RAS (208aa) or R-RAS3, which was first 
cloned from mouse skeletal muscle myoblasts and rat brain (Matsumoto et al. 
1997). M-RAS is predominantly expressed in the central nervous system, and is 
implicated in re-organisation of the actin cytoskeleton and promotes neurite 
outgrowth in PC12 cells (Matsumoto et al. 1997; Kimmelman et al. 2002; Nunez 
Rodriguez et al. 2006; Sun et al. 2006). Plexins also function as GAPs for M-RAS 
and thereby suppress dentritic outgrowth and branching (Saito et al. 2009). 
Further, the MRAS gene has been identified by genome wide associated studies 
to be a new susceptibilty locus for coronary heart disease (Erdmann et al. 2009). 
 
Despite the high homology of M-RAS and R-RAS, these GTPases perform 
different functions due to differential effector coupling (Marte et al. 1997; Nunez 
Rodriguez et al. 2006). M-RAS activates MAPK signalling through BRaf, 
stimulating neurite outgrowth, even though activation by EGF seems to be more 
sustained compared to prototypic RAS.  Furthermore, phosphatase holoenzyme 
comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as a highly 
specific M-RAS effector to modulate RAF activity (Rodriguez-Viciana et al. 2006). 
 
M-Ras null mice appeared phenotypically normal, including lack of detectable 
morphological and neurological defects, or alteration of MAPK/PI3K signalling 
(Nunez Rodriguez et al. 2006). 
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1.4 RHO GTPases 
Ras HOmologous (RHO) GTPases form another subgroup of the RAS superfamily 
and regulate cytoskeletal architectures associated with cell migration and 
polarity, adhesion, proliferation and differentiation (Figure 1.2A and Figure 1.15) 
(Etienne-Manneville and Hall 2002; Raftopoulou and Hall 2004; Ridley 2006; 
Heasman and Ridley 2008; Vega and Ridley 2008).  
RHO family small GTPases act as molecular switches and are activated by GEFs 
and inhibited by GAPs as described earlier for RAS proteins (Figure 1.1). A third 
level of regulation is provided by the stoichiometric binding of RHO GDP 
dissociation inhibitor (RHOGDI), masking prenyl modification and promoting 
cytosolic sequestration (DerMardirossian and Bokoch 2005; Cherfils and Zeghouf 
2013).  
 
Figure 1.15: Overview of RHO GTPase family. The RHO GTPase group consists of 20 
members subdivided into eight branches. High sequence similarity is found between 
proteins within the RAC and RHO subfamilies. Figure taken from Heasman and Ridley, 
2008. 
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The RHO GTPase familiy is comprised of more than 20 distinct proteins with the 
best characterised members RHOA, RAC1 and CDC42, acting as regulators of 
actin cytoskeleton re-arrangements (Heasman 2008 #482). In addition to the 
wide range of cellular processes from cell polarity and movement, cell shape, 
cell-cell and cell-matrix interactions (Etienne-Manneville and Hall 2002; 
Raftopoulou and Hall 2004; Ridley 2006), RHO familiy proteins play additional 
roles in a variety of cellular processes, including secretion, smooth muscle 
contraction, migration, neurite retraction and gene transcription (Etienne-
Manneville and Hall 2002; Jaffe and Hall 2002; Jaffe and Hall 2005).  
 
1.4.1 RHO regulatory proteins: GEFs, GAPs and GDIs 
About 71 different GEFs for RHO family members (RhoGEFs) belonging to the Dbl 
protein family, which share the typical tandem motif consisting of a Dbl 
homology (DH) domain, responsible for exchange activity, and a pleckstrin 
homology (PH) domain, involved in subcellular localisation of the GEFs 
(Blomberg et al. 1999; Zheng 2001; Schmidt and Hall 2002; Hall 2012). In 
addition to this tandem motif, RhoGEFs often contain one or more additional 
signal transduction domains, like SH2, SH3, PDZ and additional PH domains. 
Therefore, they often function as molecular bridges between different signal 
transducion pathways (Zheng 2001; Schmidt and Hall 2002). 
 
In addition, characterisation of a protein DOCK and its orthologues led to the 
identification of a second sequence-unrelated family of GEFs, which consist of 11 
members in the mammalian genome (Meller et al. 2005).  The substrates of 
DOCK family proteins appear to be RAC and CDC42 GTPases only (Hall 2012). 
 
So far, 67 RHO family GAPs within the mammalin genome have been reported. 
RHOGAPs  harbour a bcr homology (BH) domain (Diekmann et al. 1991; Hall 
2012). In addition, three RHO family GDIs have been identified, which inhibit the 
dissociation of GDP from RHO (Matsui et al. 1990).   
Identification of RHO family GTPase effectors is hard due to the lack of CRIB 
domains. Nonetheless, more than 100 targets have been reported to interact 
with the RHO family (Bishop and Hall 2000). About one third are kinases and a 
large number are scaffold or adaptor proteins. Analysis of RHO GTPases 
signalling pathways is a challenging task due to the fact that RHO, RAC and 
CDC42 are able to interact with 20 or 30 different proteins in a GTP dependent 
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manner. This led to the hypothesis that each of the mentioned small GTPases is 
able to regulate numerous distinct signalling transduction pathways.   
 
1.4.2 RHO proteins 
RAS homologue gene family member A (RHOA), RHOB and RHOC are highly 
homologous, but appear to have divergent biological functions (Wheeler and 
Ridley 2004). Carboxy-terminal modifications and differences in subcellular 
localisation allow these three proteins to respond to and act on distinct signalling 
molecules (Wennerberg and Der 2004; Wheeler and Ridley 2004). 
RHOA, the best studied member of the three has been demonstrated to function 
in regulation of actomyosin contractility, cytokinesis, focal adhesion assembly 
and cell polarity (Barry and Critchley 1994; Kimura et al. 2000; Bi et al. 2005; 
Van Keymeulen et al. 2006).  
 
RHOB is involved in regulation of cell shape, migration and adhesion, but also 
has been discovered to play a role in protein trafficking and in CXC-motif 
chemokine receptor 2 (CXCR2)-mediated chemotaxis (Neel et al. 2007; 
Sandilands et al. 2007; Wheeler and Ridley 2007). Recent studies showed that 
RHOB is able to differentially control Akt function in endothelial cells during 
breast tumourigenesis, and that RHOB regulates cell migration through altered 
focal adhesion dynamics (Witze et al. 2008; Vega et al. 2012; Kazerounian et al. 
2013). 
 
1.4.3 RAC and CDC42 
RAC and CDC42 play key signalling roles in cytoskeletal re-organisation, 
membrane trafficking, transcriptional regulation, cell growth and development 
(Ridley 2001c; Wennerberg and Der 2004; Heasman and Ridley 2008).  
RAC1 promotes lamellipodium formation and membrane ruffling, whereas CDC42 
stimulates filopodia and actin microspike formation (Ridley 1999; Ridley 2001a). 
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1.5 WNT signalling branches 
The WNT pathway regulates vital developmental processes during 
embryogenesis, including cell-fate specification, tissue patterning, cell polarity, 
and cell movements during morphogenesis. In addition, this pathway plays key 
roles in adult tissue homeostasis, stem cell renewal and has been implicated in  
tumourigenesis (Veeman et al. 2003a; Logan and Nusse 2004; Reya and Clevers 
2005; Zallen 2007). 
Notably, the WNT signalling pathway comprises a complex network of ligands, 
cognate receptors and co-receptors and agonistic/antagonistic modulators acting 
to activate a vast intracellular downstream signalling network (Niehrs 2012), 
which will be discussed in more detail in the following section 1.6. 
 
The best studied branch of the signaling network is commonly known as 
canonical signalling pathway and results in ß-catenin dependent gene 
transcription and regulation of cell fate decisions (Logan and Nusse 2004; 
Kikuchi et al. 2009; MacDonald et al. 2009). Less well-defined cascades, known 
as ß-catenin independent or non-canonical pathways, include the WNT/Ca2+ 
pathway and the planar cell polarity branch, involved in cytoskeletal 
rearrangements and cell movements (Veeman et al. 2003a; Zallen 2007). 
Overall, these pathways collectively regulate cell survival, cell proliferation, cell 
fate determination, cell polarity, tissue patterning, and tissue homeostasis 
(Veeman et al. 2003a; Reya and Clevers 2005; Zallen 2007; MacDonald et al. 
2009). These three major signalling pathways associated with WNT-receptor 
interaction, are outlined in more detail below. 
 
1.5.1 β-catenin (canonical) WNT-signalling pathway 
Canonical β-catenin WNT signalling is highly conserved across species, and 
carries out essential roles in cell proliferation, survival and cell fate specification. 
In addition, this signalling cascade is associated with tumourigenesis, in 
particular with colorectal cancer (Giles et al. 2003; Logan and Nusse 2004; Reya 
and Clevers 2005; MacDonald et al. 2009; Clevers and Nusse 2012; Niehrs 
2012).  
 
In the unstimulated state (in the absence of WNT ligands), β-catenin - the 
fundamental player of the pathway (Willert and Nusse 1998), is phosphorylated 
and targeted for proteasomal degradation. Cytosolic β-catenin is bound to a 
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destruction complex formed by several proteins including the scaffolding protein 
AXIN, adenomatous polyposis coli (APC), casein kinase 1 alpha (CK1α) and 
glycogen synthase kinase 3 beta (GSK3β) (Aberle et al. 1997; Ikeda et al. 1998; 
Kishida et al. 1998; Kitagawa et al. 1999; Liu et al. 2002; Hino et al. 2003). 
CK1α phosphorylates β-catenin at Ser45 (Amit et al. 2002). This phosphorylation 
event primes β-catenin for subsequent phosphorylation by GSK3β at residues 
Ser33, Ser37, and Thr42 (Yost et al. 1996; Liu et al. 2002; Yanagawa et al. 
2002). This N-terminal phosphorylation pattern is recognised by the E3 Ubiquitin 
ligase β-TRCP, which performs ubiquitination of β-catenin, leading to subsequent 
proteasomal degradation (Marikawa and Elinson 1998; Stamos and Weis 2013). 
 
Activation of canonical signalling is triggered by WNT proteins (section 1.6.1) 
and is further modulated through agonists/antagonists of WNT ligands or 
cognate receptors (section 1.6.2). Binding of WNT ligands (such as WNT1, 
WNT3a or WNT8) to Frizzled (FZD) receptors lead to plasma membrane 
recruitment and association of the cytoplasmic destruction complex with 
phosphorylatyed LRP5/6, which loses its ability to target β-catenin for 
proteasomal degradation (Figure 1.16). This in turns results in an increase of 
cytoplasmic β-catenin levels and subsequent translocation to the nucleus, where 
it associates with transcriptional co-activators like CREB-binding protein 
(CBP/p300), BRG1 and CDC73. Binding of β-catenin to T-cell factor (TCF) 
transcription factor displaces Groucho, and the β-catenin complex can then 
stimulate WNT target gene transcription (Figure 1.16B). WNT responsive genes 
include among others c-Myc, cyclinD1 and Axin2 (Hurlstone and Clevers 2002; 
Clevers and Nusse 2012). 
 
Notably, mutations at phosphorylation sites targeted by the destruction complex 
lead to the stabilisation of β-catenin protein levels and have been found in many 
tumour cell lines (Morin et al. 1997). 
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Figure 1.16: β-catenin (canonical) WNT signalling. (A) In the unstimulated (WNT 
off) state, a destuction complex is formed of DVL, AXIN, CK1, GSK3β, APC and β-catenin, 
which leads to phosphorylation and subsequent ubiquitination of β-catenin through the E3 
Ubiquitin ligase β-TRCP. β-catenin is then degraded by the proteasome. WNT signalling is 
initiated (WNT on) through WNT ligand binding to Frizzled receptors and co-receptors 
LRP5/6. This pathway stimulation leads to association of the intact degradation complex 
with phosphorylated LRP, which still is able to capture and phosphorylate β-catenin, but 
the ubiquitination by β-TRCP is blocked. This leads to β-catenin accumulation in the 
cytoplasm, and eventually nuclear translocation. (B) In the absence of WNT ligands, TCF 
occupies and represses its target genes, assisted by transcriptional co-repressors such as 
Groucho. Upon WNT activation, nuclear translocated β-catenin replaces Groucho from TCF 
and recruits transcriptional co-activators and histone modifiers such as BRG1, CBP, 
CDC73, BCL9, and Pygopus to drive target gene expression. APC - adenomatous polyposis 
coli, CK1-Caseine kinase 1, DVL – Dishevelled, GSK3β – glycogen synthase kinase 3β, 
LRP5/6 - LDL receptor-related proteins 5&6, TCF - T-cell factor. Figure taken from Clevers 
and Nusse, 2012.  
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1.5.2 Planar Cell Polarity (PCP) pathway 
Planar Cell Polarity (PCP) was originally identified in insects and then extensively 
studied in Drosophila (Lawrence and Shelton 1975; Gubb and Garcia-Bellido 
1982). This pathway regulates the polarity of epithelial cells within a plane 
orthogonal to their apical – basal axis, thus resulting in uniform coordinated 
polarised cells and cellular behaviour across a field (Tree et al. 2002; Jenny 
2010). In multicellular organisms, PCP is required for establishment and co-
ordination of cell polarities and regulation of directional morphogenesis during 
embryonic development and tissue morphogenesis. Studies in mammalian model 
systems elucidated that PCP is involved in neural tube closure through 
convergent extension movements, asymmetric cell division, orientation of cilia 
and sensory hair cells, axon guidance and cell motility (Tissir and Goffinet 2005; 
Seifert and Mlodzik 2007; Zallen 2007; Rida and Chen 2009; Jenny 2010; 
Goodrich and Strutt 2011; Gray et al. 2011). 
 
Genetic studies in Drosophila identified a group of core PCP genes, in which 
mutations caused misorientation of bristles of the Drosphila wing and 
disarrangement of the ommatidia in the Drosophila eye (Figure 1.18B and F) 
(Adler 2002; Tree et al. 2002; Seifert and Mlodzik 2007; McNeill 2010). These 
include the membrane-spanning Frizzled proteins (Vinson and Adler 1987; Adler 
et al. 1997), Strabismus (VANGL) (Taylor et al. 1998; Wolff and Rubin 1998), 
Flamingo (CELSR) (Chae et al. 1999; Usui et al. 1999) and the cytoplasmic 
proteins Dishevelled (Theisen et al. 1994), Prickle (Gubb et al. 1999) and Diego 
(Inversin) (Feiguin et al. 2001). 
  
The hallmark of the PCP activation in Drosophila is the asymmetric distribution of 
the aforementioned PCP proteins (Figure 1.17). Frizzled, Dishevelled and Diego 
preferentially localise to the distal side and Strabismus and Prickle to the 
proximal side of the cell. Thus, Frizzled and Strabismus complexes are 
asymmetrically localized in a mutually exclusive manner, whereas the atypical 
cadherin Flamingo localises both distally and proximally (Usui et al. 1999; 
Axelrod 2001; Strutt 2001; Tree et al. 2002; Lawrence et al. 2004; Chen et al. 
2008). This asymmetric membrane localisation is presumed to lead to polarised 
localisation and/or activation of associated components and downstream 
effectors and thereby elicit tissue-specific responses (Adler 2002; Tree et al. 
2002; Seifert and Mlodzik 2007; Vladar et al. 2009; McNeill 2010). 
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Figure 1.17: Asymmetrical distribution of planar cell polarity proteins in 
Drosophila. The hallmark of PCP activity is asymmetric distribution of PCP core proteins 
along the proximal-distal axis. Vangl proteins binds to Prickle (Pk) and form a complex at 
the proximal end of the cell. Whereas the Wnt receptor Frizzled (Fzd) binds to Diego 
(Dgo) and Dishevelled (Dsh) to form a complex at the distal site of the cell. CELSR1 
localises both distally and proximally and recruits Vangl or Fzd to the membrane. 
Abbreviations: aPKC - atypical protein kinase C,  CELSR1 - Cadherin, EGF LAG seven-pass 
G-type receptor 1, PATJ - Pals1-associated tight junction protein, Scrib – Scribble. Figure 
taken from Muthuswamy and Xue, 2012. 
 
 
The PCP pathway is well conserved across species (Figure 1.18), but differences 
have been observed between Drosophila and vertebrate model systems. For 
example, additional proteins have been identified in vertebrates, which are 
proposed to function in PCP signalling (Wang and Nathans 2007). SCRIB and 
PTK7 mutants exhibit classic PCP phenotypes and they show genetic interaction 
with VANGL2 (Murdoch et al. 2003; Lu et al. 2004b). Furthermore, to date no 
WNT ligand has been identified to initate PCP signalling in Drosophila (Wu and 
Mlodzik 2009), whereas in vertebrates WNT ligands WNT11 (Zhou et al. 2007), 
WNT5a (Qian et al. 2007), and possibly WNT9b (Karner et al. 2009) have been 
shown to be required for PCP activation (Mlodzik 2002; Fanto and McNeill 2004; 
Simons and Mlodzik 2008; Wallingford 2012). 
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Figure 1.18: PCP phenotype examples in Drosophila and mammals. The left hand 
side column displays wild type appearance, compared to the right hand column side, 
demonstrating a PCP defect in the respective tissue. (a,b) Drosophila wing hair patterns, 
(c,d) mouse skin hairs (in dorsal view of neck), (e,f) Drosophila eye neuroepithelium, 
(g,h) mouse inner ear neuroepithelium. Orientation of inner ear sensory cells is 
representated as arrows in the schematic below. Figure from Klein and Mlodzik, 2005. 
 
In contrast to β-catenin signalling (section 1.5.1), β-catenin independent/PCP 
signalling is much less understood. This is further hampered by the fact that 
Frizzled receptors and Dishevelled proteins participate in all known WNT 
signalling cascades, complicating PCP signalling analysis (Figure 1.19). In 
addition, PCP studies mostly rely on in vivo phenotypic analysis, due to the lack 
of convenient biochemical reporter assays such as the TCF/LEF based luciferase 
assay (TOPFLASH).  
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Even though Frizzled receptors and DVLs are shared upstream components of 
various WNT pathways, different ligands and co-receptors might be involved in 
activation of specific WNT branches (see section 1.6) (van Amerongen et al. 
2008; Niehrs 2012).  
 
 
Figure 1.19: WNT/Planar Cell Polarity signalling. The Planar Cell Polarity (PCP) 
pathway is stimulated by WNT ligands such as WNT5a or WNT11, which bind to Frizzled 
receptors or (co)-receptors such as ROR2 or RYK (not displayed). The WNT-Frizzled 
complex recruits DVL, which then associates with DAAM. This in turn stimulates RHO 
GTPases such as RHOA, which subsequently activates RHO associated kinase (ROCK). 
DVL is also able to activate RAC, resulting in c-Jun N-terminal kinase (JNK) signalling. 
Both RHO GTPases RHO and RAC modulate actin cytoskeletal rearrangements thus 
regulating cellular polarity and migration. DAAM - DVL associated activator of 
morphogenesis 1, ROR2 – RTK-like orphan receptor. Figure taken from Staal et al, 2008.  
 
Genetic and biochemical studies in flies and vertebrates have shown that the 
WNT/PCP branch regulates cytoskeletal rearrangements and thereby controls 
processes like epithelial cell polarisation, directed cell migration and oriented  
cell divisions (Figure 1.19) (Bellaiche et al. 2001; Jessen et al. 2002; Wallingford 
et al. 2002; Ciruna et al. 2006).  
This is achieved, at least partly, through DVL mediated activation of RHO 
subfamiliy GTPases RHO and RAC, which in turn stimulates RHO associated 
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kinase (ROCK) activity and activation of JNK (Figure 1.19) (Winter et al. 2001; 
Marlow et al. 2002; Habas et al. 2003; Jaffe and Hall 2005). Furthermore, 
PRICKLE or VANGL proteins have been reported to be instrumental in this 
context  (Park and Moon 2002; Takeuchi et al. 2003; Veeman et al. 2003b; 
Phillips et al. 2005; Gao et al. 2011). 
 
Perturbations in the PCP pathway contribute to the pathogenesis of a variety of 
diseases including cardiac and neural tube defects, the two most common types 
of birth defects (Ciruna et al. 2006; Wen et al. 2010; Bartsch et al. 2012; Tada 
and Kai 2012).  
 
 
 
Figure 1.20: Convergent extension and planar polarity. (A) Vertebrate embryos 
convert from spherical eggs into elongated animals by a process called convergent 
extension (CE). (B) In the frog, convergent extension is achieved through cell 
intercalation. This process requires co-ordinated migration towards each other 
(convergence), intercalating along a single axis and a mediolateral extension, yielding a 
cell population which shaped a short and wide arrangement into along and narrow one. 
(C) This process involves stabilisation of lamellipodia specifically on the mediolateral 
faces, and it is thought that crosstalk between neighbouring cells is critical to the 
positioning of lamellipodia. The control of this process is complicated by the fact that cells 
are constantly changing neighbours. Figure from Wallingford 2004. (Wallingford 2004) 
 
Another observed PCP-linked disorder is the genetic disorder Bardet-Biedl 
syndrome (BBS) (Fliegauf et al. 2007), which is a ciliopathic disorder, 
characterised principally by obesity, retinitis, polydactyly, hypogonadism and 
pigmentosa (Beales et al. 1999). Affected gene products are the BBS proteins, 
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which are found in the basal body and cilia of the cell (Ansley et al. 2003). BBS 
proteins are involved in intraflagellar transport, a bi-directional transportation 
activity along the long axis of the ciliary shaft that is essential 
for ciliogenesis and the maintenance of cilia (Blacque et al. 2004). PCP has been 
linked to BBS since it was demonstrated that PCP signalling is essential for 
directional beating of motile cilia, which play a crucial role in the movement of 
materials and cells (Vladar et al. 2009; Wallingford 2010; Wallingford and 
Mitchell 2011). Further, PCP controls tissue level of multi-ciliated cells through 
VANGL2, CELSR2, and CELSR3, which are required for establishment of rotation 
(Mitchell et al. 2009; Guirao et al. 2010; Tissir et al. 2010; Wallingford and 
Mitchell 2011) 
 
Aberrant regulation of planar cell polarity has further been linked to polycystic 
kidney disease (Simons and Mlodzik 2008; Luyten et al. 2010) and 
Nephronophthisis type 2, a renal cystic disease cause by a mutation in the PCP 
component Inversin (Otto et al. 2003; Simons et al. 2005). 
 
Overall, the β-catenin (canonical) pathway has been linked to carcinogenesis, 
while the planar cell polarity (PCP) pathway is implicated in cell motility and 
metastasis (Clevers and Nusse 2012; Muthuswamy and Xue 2012). 
 
 
1.5.3 The WNT/Ca2+ pathway 
The non-canonical WNT/Ca2+ pathway is stimulated by a distinct group of WNT 
ligands like WNT5a or WNT11 (Slusarski et al. 1997a; Slusarski et al. 1997b; 
Westfall et al. 2003; Wang et al. 2010) and Frizzled receptors such as FZD2 
(Slusarski et al. 1997a; Niu et al. 2012), leading to an intracellular increase of 
the second messenger Ca2+ (Figure 1.21). This in turn leads to activation of 
calcium/calmodulin-dependent kinase II (CamKII) (Kuhl et al. 2000a) and 
protein kinase C (PKC) (Sheldahl et al. 1999). PKC then translocates to the 
plasma membrane where it interacts with target proteins (Sheldahl et al. 1999).  
 
The calcium responsive factor nuclear factor of activated T-cells (NF-AT) acts 
downstream of CamKII and is involved in the development of cardiac, skeletal 
muscle, and nervous systems (Kuhl et al. 2000b; Kohn and Moon 2005). 
Furthermore, the WNT/Ca2+ pathway mediates cell migration and has been 
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implicated in the promotion of malignant progression and cell invasiveness of 
cancer cells (Weeraratna et al. 2002; Kuhl 2004).  
WNT5a induced PKC signalling has been shown to increase melanoma cell 
motility through elevated Snail and Vimentin and decreased E-cadherin 
expression (Dissanayake et al. 2007). 
 
Thus, WNT/Ca2+ signalling modulates cell movement and behaviour and induces 
structural changes similar to PCP (Torres et al. 1996; Kuhl et al. 2001; Okamoto 
et al. 2007; Witze et al. 2008); but the extent, to which this pathway overlaps 
with PCP still remains uncertain (Bryja et al. 2009; Andersson et al. 2010; Gao 
et al. 2011).  
 
Notably, besides Frizzled proteins, WNT5a ligand binding to ROR2 has been 
demonstrated to activate Ca2+/CamKII pathway and is required for axonal 
pathfinding in mammalian brain development (Logan and Nusse 2004; Li et al. 
2009a; Nishita et al. 2010a).  
 
 
Figure 1.21: WNT/Ca2+ signalling. A subset of WNT ligands and Frizzled (FZ) receptors 
is able to increase intracellular Ca2+ levels, leading to subsequent activation of 
calcium/calmodulin-dependent kinase II (CamKII) and protein kinase C (PKC) 
downstream of Dishevelled (DVL). The calcium responsive factor NF-AT acts as 
transcription factor involved in cell fate specifications and cellular movement. NF-AT - 
nuclear factor of activated T-cells. Figure taken from Ciani and Salinas, 2005. (Ciani and 
Salinas 2005) 005 #638}  
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1.6 WNT signalling components 
1.6.1 WNT ligands 
The human genome harbours 19 WNT genes, which encode functionally distinct 
WNT proteins whose expression is spatially and temporally regulated during 
development (Moon et al. 1997; Logan and Nusse 2004; Mikels and Nusse 
2006b). WNT ligands are secreted hydrophobic glycoproteins, which are similar 
in size (350 - 400 amino acids) and possesses 22 to 24 cysteine residues (Figure 
1.22) (Miller 2002; Mikels and Nusse 2006b). WNT proteins bind to the Frizzled 
family of seven-pass transmembrane proteins and activate intracellular WNT 
signalling pathways depending on receptor context (Kohn and Moon 2005; 
Cadigan and Liu 2006).  
 
 
Figure 1.22: WNT ligand structure and post-translational modifications of 
WNT3a and WNT5a proteins. WNTs are produced from precursor proteins and post 
translational modified (glycosylation and lipid modification), before being secreted form 
the cell surface in a matured and active form. WNT proteins are similar in size, rangeing 
from 320 to 400 amino acids in length, and containing between 22-24 cysteine residues. 
Figure taken from Kikuchi et al, 2011. 
 
Historically, WNT ligands were subdivided into two functional groups: canonical 
WNT ligands and non-canonical WNT ligands. Canonical WNTs such as WNT1, 
WNT3, WNT3a or WNT7a are classified by the ability to induce duplication of the 
embryonic axis in Xenopus laevis embryos or to induce transformation of 
mammary epithelial cells (Wong et al. 1994; Shimizu et al. 1997), whereas non-
canonical WNT ligands have been reported to alter morphogenetic movements or 
be involved in tumourigenesis through pro-migratory effects as reported for 
WNT2, WNT4, WNT5a, WNT5b, WNT6, WNT7b or WNT11 (Wong et al. 1994; Du 
et al. 1995; Shimizu et al. 1997). 
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WNT3 has been demonstrated to activate canonical and non-canonical WNT 
signalling and to regulate cell motility through activation of RHO GTPases 
(Shibamoto et al. 1998; Endo et al. 2005). WNT5 (Slusarski et al. 1997b; 
Weeraratna et al. 2002; Qian et al. 2007) and WNT11 (Zhou et al. 2007) 
activate β-catenin independent pathways, modulating embryonic cell movement 
and polarity (Veeman et al. 2003a).  
However, WNT5a has also been observed to signal through the canonical WNT 
pathway depending on the receptor context (Mikels and Nusse 2006a). In 
addition, WNT5a is found upregulated in many human tumours and stimulates 
cell motility and invasiveness of tumour cells (Iozzo et al. 1995; Weeraratna et 
al. 2002; Kurayoshi et al. 2006; Pukrop et al. 2006; Dissanayake et al. 2007).  
 
1.6.2 Non-WNT ligand modulators of WNT signalling 
WNT/β-catenin signaling is modulated at many levels by a number of 
evolutionarily conserved secreted or transmembrane inhibitors or activators of 
WNT signalling. With few exceptions, these antagonists and agonists are not 
pure WNT modulators, but also affect additional signaling pathways, such as 
TGF-β and FGF signalling (Cruciat and Niehrs 2012). 
 
1.6.2.1 WNT inhibitors 
Secreted Frizzled-related proteins (sFRP) were the first WNT antagonists to be 
identified. These proteins are approximately 300 amino acids in size and contain 
a signal sequence, a Frizzled-like cysteine-rich domain (CRD), and a small 
conserved hydrophilic C-terminus harbouring a netrin-related motif (Rattner et 
al. 1997). sFRPs are able to bind WNT proteins and FZD receptors in the 
extracellular compartment, which prevents WNT/FZD binding (Wawrzak et al. 
2007), similarily to the WNT inhibitory protein (WIF), which can bind WNTs, 
thereby inhibiting interactions between WNT and WNT receptors (Figure 1.23) 
(Bovolenta et al. 2008).  
 
Other WNT inhibitors include proteins of the Dickkopf (DKK) (Bafico et al. 2001; 
Semenov et al. 2001) and the WISE/Sclerostin (SOST) (Li et al. 2005; Semenov 
et al. 2005) families, which antagonise signalling by binding to LRP5/6 and thus 
preventing  FZD/LRP complex formation. 
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Mouse Cerberus protein (Cerl-1), in contrast to Xenopus, does not bind WNT 
ligands and thus does not inhibit WNT signalling (Piccolo et al. 1999; Belo et al. 
2000). Rather, Cerberus proteins form key regulators of Nodal signalling and 
play an important role in the establishment of left-right asymmetry in the 
vertebrate embryo (Zhu et al. 1999; Tavares et al. 2007; Vonica and Brivanlou 
2007). 
   
Insulin-like growth factor binding protein 4 (IGFBP-4) has been shown to bind 
directly to LRP6 and FZD8 through the the C-terminal thyroglobulin domain and 
thus blocks WNT3a binding (Zhu et al. 2008). 
  
The transmembrane WNT inhibitors Shisa (Yamamoto et al. 2005; Furushima et 
al. 2007; Pei and Grishin 2012), Waif1 (Kagermeier-Schenk et al. 2011), 
Adenomatosis polyposis coli down regulated 1 (APCDD1) (Takahashi et al. 2002; 
O'Shaughnessy et al. 2004), and Tiki1 (Zhang et al. 2012) antagonise WNT 
signalling by preventing ligand–receptor interactions or WNT receptor 
maturation.  
 
1.6.2.2 WNT activators 
Two WNT ligand unrelated tyes of proteins – Norrin and R-spondins (RSPO), 
promote WNT signalling by binding to WNT receptors or releasing a WNT-
inhibitory step (Kazanskaya et al. 2004; Xu et al. 2004; Kim et al. 2005; de Lau 
et al. 2012). Norrin binds to FZD4 (but only to that member of the Frizzled 
family), while RSPO2 interacts with FZD8 and LRP6 (Nam et al. 2006; Wei et al. 
2007). 
 
Connective tissue growth factors (CTGF) associate with the extracellular matrix 
(ECM) and mediate cell adhesion, cell migration and chemotaxis (Hall-Glenn and 
Lyons 2011; Jun and Lau 2011; Kubota and Takigawa 2011). They have been 
further implicated to regulate WNT signalling through its ability to bind the LRP6 
co-receptor (Mercurio et al. 2004).   
 
The secreted glycoprotein collagen triple helix repeat-containing 1 (CTHRC1) has 
been demonstrated to promote cell migration (Pyagay et al. 2005) and 
melanoma cell adhesion and survival (Ip et al. 2011). Recent studies, however, 
found that CTHRC1 selectively activates the WNT/PCP pathway by stabilising 
WNT/FZD/ROR2 complex formation (Yamamoto et al. 2008). 
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Figure 1.23: Non-WNT ligands modulators. Domain structure of WNT antagonists and 
agonists. Signal peptides are indicated in red. For more information refer to text. 
Abbreviations: NTR-Netrin related motif, WIF-WNT-inhibitory factor 1 domain, EGF-
epidermal growth factor-like domain, CT-cystine knot-like domain, IB-insulin growth 
factor binding protein domain, TY-thyroglobulin type-1 domain, TM-transmembrane 
domain, L-leucine-rich repeats, TSP-thrombospondin type-1 domain.  Figure from Cruciat 
and Niehrs, 2012. (Cruciat and Niehrs 2012) 
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1.6.3 Frizzled receptors 
Frizzled (FZD) receptors belong to the seven transmembrane-spanning G-
protein-coupled receptor (GPCR) superfamily, and are characterised by a large 
extracellular N-terminal region containing a cysteine-rich domain, involved in 
WNT ligand binding (Bhanot et al. 1996; Hsieh et al. 1999; Schulte and Bryja 
2007). The intracellular C-terminus interacts with the PDZ domain of DVL 
proteins through the highly conserved internal KTxxxW motif (Wong et al. 2003). 
Therefore, Frizzled proteins act as WNT receptors and provide the link between 
the extracellular WNT ligand and the intracellular components of WNT signalling 
cascades (Figure 1.24) (Bhanot et al. 1996). 
The mammalian FZD subfamily is comprised of 10 members (FZD1 to FZD10), 
which mediate and modulate different pathway activation and signalling outcome 
upon binding to various co-receptors and/or other secreted proteins like Norrin, 
RSPO or CTHRC1 (see section 1.6.2) (Xu et al. 2004; Cadigan and Liu 2006; 
Nam et al. 2006; Hendrickx and Leyns 2008; Yamamoto et al. 2008; Cruciat and 
Niehrs 2012). 
Like WNT proteins, Frizzled receptors have been grouped historically into two 
classes: one class is thought to stimulate the β-catenin pathway, whereas the 
other group is able to stimulate the Ca2+ pathway (Kuhl et al. 2000b). However, 
this understanding has been challenged by observations that Frizzled receptors, 
for example FZD4 can signal both β-catenin dependently (Ye et al. 2009) and 
independently (Robitaille et al. 2002; Descamps et al. 2012), based on cell, 
receptor and ligand context. FZD3 and FZD6 on the other hand have been 
strongly implicated in PCP signalling, due to observed neural tube closure defects 
in Fzd3/Fzd6 double deficient mice and defects in hair orientation of inner ear 
sensory cells (Wang et al. 2006; Stuebner et al. 2010; Wen et al. 2010).  
FZD2 has been indicated in β-catenin signalling outcomes and non-canonical 
context (Ishitani et al. 2003; Li et al. 2008; Verkaar et al. 2009) and has been 
linked to heart disease (Blankesteijn et al. 1996; Blankesteijn et al. 1997).  
 
 
67 
 
 
Figure 1.24: Schematic of Frizzled receptor key features and binding proteins 
and modulators.  Frizzled proteins belong to the serpentine receptors composed of a 
conserved extracellular cysteine rich domain (CRD) involved in WNT ligand binding, a 
highly divergent linker region, and seven transmembrane spaning regions. The variable 
intracellular C-terminal domain contains a highly conserved KTxxxW motif important for 
DVL binding and initiation of WNT signalling, followed by a VTTE PDZ interacting motif. 
FRPs - Frizzled-Related Proteins,  CTGF - Connective Tissue Growth Factor.  Figure taken 
from Schulte et al, 2007. 
 
 
1.6.4 WNT cell surface receptors  
Initiation of WNT signalling depends first and formost on the WNT ligand and 
bound Frizzled receptor. In the mammalian system, WNTs and FZDs belong to 
large, multigene families and another layer of complexity is added through 
various (co)-receptors and cytoplasmic proteins, which determine the signalling 
outcome (Figure 1.25) (Niehrs 2012; van Amerongen 2012).  
One proposed co-receptor for PCP signalling is the receptor tyrosine kinase ROR2 
(section 1.6.4.2), which contains an extracellular cysteine rich domain, acting as 
receptor for WNT ligands (Minami et al. 2010). Other receptor tyrosine kinases, 
which have been implicated in PCP signalling are RYK (section 1.6.4.4) 
(Yoshikawa et al. 2003; Li et al. 2009a; Lin et al. 2010; Macheda et al. 2012) 
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and PTK7 (section 1.6.4.3) (Lu et al. 2004b; Shnitsar and Borchers 2008; 
Peradziryi et al. 2011). 
 
 
 
Figure 1.25: Overview of WNT modulating receptors and their effect on 
downstream WNT signalling. The main WNT ligand receptors are Frizzled (Fz) proteins. 
However, an expanding number of co-receptors can modulate WNT signalling outcome. 
For example, PTK7 and ROR transmembrane receptors in conjunction with Frizzled are 
able to bind to WNT ligands and to modulate β-catenin dependent and β-catenin 
independent (PCP) pathways. LGR can bind R-spondin, which enhances response to low 
dose WNT ligands, and has been demonstrated to interact and co-internalise with LDL-
receptor related proteins (LRP)/Fz complexes, which are established β-catenin pathway 
activators. LGR - leucine-rich repeat containing G protein-coupled receptor PTK – Protein 
Tyrosine Kinase 7, ROR – Receptor tyrosine kinase-like Orphan Receptor, PCP – Planar 
Cell Polarity. Figure from Vincent and Beckett, 2011. (Vincent and Beckett 2011). 
 
 
1.6.4.1 LRP5/6  
LDL receptor-related proteins 5&6 (LRP5/6) function as co-receptors for WNT 
ligand interaction and are required for β-catenin signalling pathway activation 
(Pinson et al. 2000; Tamai et al. 2000). 
They are single-pass transmembrane proteins belonging to the low-density 
lipoprotein receptor (LDLR)-related protein family. LRP5 and LRP6 are highly 
homologous and display redundant roles during development (He et al. 2004; 
Kelly et al. 2004). Structurally, they contain four EGF and three LDLR repeats 
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within the extracellular domain, and proline-rich motifs in the cytoplasmic part 
(Figure 1.26) (Brown et al. 1998).  
 
 
Figure 1.26: Schematic representation of the LRP5/6 receptor domain structure. 
The extracellular domain of LRP5/6 is about 1400 amino acids (aa) long and contains 
YWTD domains, EGF-like repeats (E1-E4), and LDL receptor repeats (LDLR), important for 
WNT ligand binding or interaction with modulating proteins like Sclerostin or Dickkopf. 
The short 215 aa cytoplasmic C-terminus is comprised of five PPSPXS motifs and 
juxtaposed casein kinase 1 (CK1) sites. Both serine residues within the PPSPXS motif are 
phosphorylated after WNT ligand stimulation and are required for β-catenin stabilisation. 
TM-transmembrane domain. Figure from Kikuchi et al, 2011.  
 
Upon WNT ligand stimulation, LRP6 is phosphorylated at multiple sites including 
Thr1479, Ser1490, and Thr1493 by kinases such as GSK-3β and CK1, which is 
required for AXIN recruitment to the plasma membrane facilitating β-catenin 
accumulation and downstream nuclear signalling (Figure 1.16) (Tamai et al. 
2004; Davidson et al. 2005; Zeng et al. 2005). 
 
1.6.4.2 ROR2 
The ROR-family of receptor tyrosine kinases (RTKs) (originally identified as RTK-
like orphan receptors) are evolutionarily conserved from nematode to human 
and carry out important roles in regulation of cellular migration, polarity of 
asymmetric cell divisions, and axonal outgrowth of neurons (Forrester et al. 
1999; Oishi et al. 1999; Al-Shawi et al. 2001; Curtin et al. 2003). In 
vertebrates, ROR-family RTKs contains two structurally related members, ROR1 
and ROR2, which are widely expressed during embryogenesis and may play 
differential roles during development of the nervous system (Oishi et al. 1999; 
Green et al. 2008).  
Ror2 null mice display (similar to Wnt5a knockout mice), PCP and CE defects, 
manifested as defects in ciliary bundles of cochlear hair cells and shortened 
anterior-posterior body axis, respectively (Yamaguchi et al. 1999; Seifert and 
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Mlodzik 2007; Minami et al. 2010). In addition, mouse models revealed that 
Ror2 mutations display widespread skeletal abnormalities, and are responsible 
for two classes of genetic skeletal disorders in human, dominant brachydactyly 
type B and recessive form of Robinow syndrome (Afzal et al. 2000; Oldridge et 
al. 2000; Schwabe et al. 2000; van Bokhoven et al. 2000). 
Both, ROR1 and ROR2, act as receptor or co-receptor for WNT5a that can bind 
extracellular cysteine-rich domain, initiating intracellular signalling cascades 
(Oishi et al. 2003; Mikels and Nusse 2006a; Fukuda et al. 2008; Nishita et al. 
2010b). However, ROR2 is also able to signal independently of its cytoplasmic 
domain through its association with Frizzled (at least FZD7) via their respective 
CRDs (Figure 1.27) (Oishi et al. 2003; Nishita et al. 2010b). 
 
 
Figure 1.27: Structure of ROR-family receptor tyrosine kinase ROR2. ROR2 is a 
single spanning transmembrane protein with an extracellular immunoglobuline (Ig) –like 
domain, WNT ligand binding frizzled like cysteine rich domain (CRD) and a membrane 
proximal Kringle domain. The latter two are assumed to mediate protein-protein 
interactions. The intracellular cytoplasmic tyrosine kinase (TK) domain is followed by a 
serine threonine flanked proline rich domain (PRD). 
 
WNT5a signalling through ROR2 regulates cell polarity, motility and invasiveness 
via non-canonical WNT signalling pathways (Figure 1.28) (Veeman et al. 2003a; 
Kohn and Moon 2005; Kikuchi and Yamamoto 2008). In fact, ROR2 has been 
established to mediate the WNT5a signal both in vivo and in vitro (Qian et al. 
2007; Green et al. 2008; Minami et al. 2010; Gao et al. 2011). In addition, 
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WNT5a/ROR1 and WNT5a/ROR2 activated WNT signalling cascades are involved 
in neuronal progenitor cell maintenance as well as neurite extension and synapse 
formation in the developing nervous system (Endo et al. 2012a). ROR2 also 
plays a crucial role in canonical WNT signalling inhibition (Torres et al. 1996; 
Topol et al. 2003; Westfall et al. 2003; Mikels and Nusse 2006a; Li et al. 2008). 
 
 
Figure 1.28: ROR2/WNT5a signalling in regulation of cell polarity, migration and 
invasion. ROR2 acts as a co-receptor in non-canonical WNT signalling and has been 
implicated in various functions. (A) Upon binding of WNT5a to the extracellular frizzled-
like cysteine rich domain (CRD), the formed ROR2/Frizzled/WNT5a complex is able to 
modulate cell polarity and migration through activation of c-Jun N-terminal kinase (JNK) 
downstream of DVL, and binding of actin binding protein filamin A (FLNa), which 
associates with the C-terminal proline rich domain of ROR2. (B) WNT5 binding to ROR2 
leads to recruitment and activation of protein tyrosine kinase c-SRC and results in 
phosphorylation of the cytoplasmic serine/threonine rich domain of ROR2. This leads in 
osteosarcoma cells to induced expression of matrix metalloprotease 13 (MMP-13) through 
activation of c-SRC, DVL, JNK and AP-1 signalling.  AP1 - activator protein 1. 
 
ROR2 is required for WNT5a induced polarised cell migration and mediates 
formation of filopodia through interaction with the actin binding protein filamin A 
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(FLNa) (Figure 1.28A) (Nishita et al. 2006). Furthermore, polarised cell migration 
experiments showed that WNT5a stimulated lamellipodium formation and 
microtubule organizing centre (MTOC) reorientation is mediated through 
ROR2/FLNa/JNK signalling (Nomachi et al. 2008).   
It has been shown that atypical Protein Kinase C (aPKC) associates with DVL, 
functioning upstream of JNK, suggesting a possible functional link between 
WNT5a/ROR2/FLNa/JNK and CDC42/PAR/aPKC pathways in polarised cell 
migration (Schlessinger et al. 2007). 
Although the roles of WNT5a in cancers remain controversial, ROR1 and ROR2 
have been demonstrated to promote tumour progression (Enomoto et al. 2009; 
Wright et al. 2009; Ford et al. 2012; Daneshmanesh et al. 2013) (Figure 1.28). 
 
 
1.6.4.3 PTK7 
The transmembrane protein kinase 7 (PTK7) displays extracellular 
immunoglobulin domains and an intracellular tyrosine kinase homology domain, 
which is evolutionary conserved but lacks catalytic activity (Mossie et al. 1995; 
Kroiher et al. 2001). PTK7 functions in cell adhesions, cell migration, cell 
polarity, proliferation, actin cytoskeleton reorganisation and embryogenesis 
related apoptosis in order to regulate processes such as epithelial tissue 
organisation, neural tube closure and neural crest formation as well as axon 
guidance (Lu et al. 2004b; Toyofuku et al. 2004; Shnitsar and Borchers 2008; 
Meng et al. 2010). 
 
It has been demonstrated that PTK7 participates in WNT signalling through 
acting as a co-receptor in both β-catenin dependent and independent WNT 
signalling cascades, and is involved in the choice of signalling outcome (Shnitsar 
and Borchers 2008; Wehner et al. 2011; Peradziryi et al. 2012). Despite the lack 
of any known WNT protein binding domain, PTK7 has been reported to co-
immunoprecipitate with WNT3a and WNT8 but not with WNT5a or WNT11 
(Peradziryi et al. 2011). 
 
In addition to WNT signalling, PTK7 has been shown to regulate other signalling 
pathways by functioning as co-receptor with membrane receptors like Plexin A1 
and VEGFR1 (Shin et al. 2008; Wagner et al. 2010; Lee et al. 2011). 
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Furthermore, recent studies showed that PTK7 is a target of matrix 
metalloproteases (MMP) 14 and ADAM17, leading to proteolytic degradation and 
extracellular domain shedding, thus resulting in enhanced cell proliferation, 
migration, and facilitated cancer cell invasion (Golubkov et al. 2010; Na et al. 
2012). Originally identified in colon carcinoma cells (Mossie et al. 1995), PTK7 
has been further demonstrated to be frequently deregulated in other types of 
cancer (Easty et al. 1997; Muller-Tidow et al. 2004; Prebet et al. 2010; Gobble 
et al. 2011). 
 
 
1.6.4.4 RYK 
The transmembrane atypical receptor related tyrosine kinase RYK is required for 
normal axon guidance and neuronal differentiation during development and 
involved in WNT signalling (Hovens et al. 1992; Stacker et al. 1993; Fradkin et 
al. 2010).  
RYK functions as a WNT receptor through its WNT protein binding WIF domain 
and has been demonstrated to regulate convergent extension movements in 
Xenopus embryos through FZD7 and DVL endocytosis (Patthy 2000; Kim et al. 
2008). In addition, RYK plays a role in mammalian planar cell polarity signalling, 
forming a complex with VANGL2 and modulating its stability (Andre et al. 2012; 
Macheda et al. 2012). 
Overall, mammalian RYK is able to mediate both β-catenin dependent and 
independent signalling pathways downstream of WNT3a, WNT5a and WNT11 (Lu 
et al. 2004a; Li et al. 2009a; Lin et al. 2010). RYK deficient mice exhibit 
craniofacial defects associated with perturbed Eph receptor crosstalk (Halford et 
al. 2000). 
 
 
1.6.4.5  HSPGs and Syndecans 
Heparansulphate proteoglycans (HSPGs) are important for concentrating and 
stabilising of WNT proteins on the cell surface (Fuerer et al. 2010). Moreover, 
HSPGs modulate β-catenin independent signalling. For example Glypican 3 
(GPC3) binds to WNT5a and enhances WNT5a dependent JNK activity and is 
required for gastrulation movements in zebrafish (De Cat et al. 2003; Song et al. 
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2005). GPC4 interacts with WNT11 and enhances WNT stimulated cell migration 
(Ohkawara et al. 2003). However, recent evidence suggests that GPCs might be 
also involved in β-catenin dependent signalling (Capurro et al. 2005). It has 
been suggested that the localisation of GPCs (lipid raft or non-lipid raft micro 
domains) might be important for selective WNT cascade activation (Sakane et al. 
2012).  
The syndecan (SDC) protein family also regulates WNT signalling and they have 
been implicated in β-catenin dependent (Alexander et al. 2000) and independent 
pathway modulation (Munoz et al. 2006; Ohkawara et al. 2011).  
 
1.6.4.6 Tetraspanins 
Tetraspanins are cell surface glycoproteins with four transmembrane domains 
and are able to form multimeric complexes with other cell surface proteins 
(Yanez-Mo et al. 2009). Tetraspanin proteins function in many cellular processes 
including differentiation, adhesion, signal transduction, and play critical roles in 
the suppression of cancer cell motility and metastasis (Richardson et al. 2011; 
Rubinstein 2011; Sala-Valdes et al. 2012). The tetraspanin family member 
TSPAN12 binds to FZD4 and promotes complex formation of FZD4 co-operatively 
with Norrin, thereby activating the β-catenin signalling cascade (Junge et al. 
2009).  
 
 
1.6.5 Dishevelled proteins 
DVL proteins are key components of WNT signalling and interact with more than 
50 proteins (Wallingford and Habas 2005; Gao and Chen 2010). They form 
multi-component signalling complexes and constitute the branching point of WNT 
signalling cascades (Figure 1.29A) (Gao and Chen 2010). Mammals encode three 
members of the Dishevelled family, DVL1, DVL2 and DVL3, which all contain the 
conserved structural features required for downstream WNT signalling (Figure 
1.29B).  
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Figure 1.29: DVL proteins form the branching point of WNT signalling pathways. 
(A) WNT ligands bind to Frizzled receptors (FZD), which then recruits DVL to the plasma 
membrane and depending on receptor context, activates β-catenin (canonical) signalling 
or β-catenin independent pathways such as WNT/PCP or WNT/Ca2+ branches. Refer to 
section 1.5. (B) Conserved structural domains of DVL proteins. The N-terminal DIX 
(Dishevelled/Axin) domain is followed by a basic and serine/threonine rich region (basic) 
and a PDZ (PSD-95, DLG1, ZO1) domain, which facilitates interaction with other proteins. 
The C-terminus habours a proline-rich (pro-rich) region, which is followed by a DEP 
(Dishevelled, EGL-10, Pleckstrin) domain. Canonical WNT signalling involves the DIX and 
PDZ domain, whereas for non-canonical WNT signalling the DIX domain is dispensable 
and the PDZ and DEP domains are required. 
 
During canonical WNT signalling, DVL is required for clustering of Frizzled and 
LRP6 receptors in order to form polymers for subsequent phosphorylation events 
of LRP6 (Cong et al. 2004b; Zeng et al. 2005; Bilic et al. 2007). DVL is recruited 
to Frizzled receptors via its PDZ domain (Wong et al. 2003) and forms polymers 
at the plasma membrane through its DIX domain, providing a platform for Axin-
GSK3β relocation (Cliffe et al. 2003; Schwarz-Romond et al. 2007; Yokoyama et 
al. 2012).  
DVL proteins also associate with actin fibres and cytoplasmic vesicular 
membranes and mediate endocytosis of the FZD receptor after WNT stimulation 
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(Capelluto et al. 2002; Chen et al. 2003). Further, DVL has been observed to 
shuttle from the cytoplasm to the nucleus and to interact with c-JUN and β-
catenin (Itoh et al. 2005; Gan et al. 2008).  
Upon initiation of non canonical WNT/PCP signalling, DVL associates with DVL 
associated activator of morphogenesis 1 (DAAM1) through its PDZ domain 
(Habas et al. 2001; Liu et al. 2008a). In conjunction with WGEF (weak similarity 
GEF) this complex then stimulates RHO activity and subsequently leads to RHO 
associated kinase (ROCK) activation, resulting in cytoskeleton remodelling 
(Figure 1.19) (Habas et al. 2001). In addition, DVL is able to stimulate RAC, 
which in turn can activate the downstream effector JNK, which regulates polarity, 
embryonic cell movements (Habas et al. 2003), and dendrite growth (Rosso et 
al. 2005).  
The DIX domain is dispensable for PCP and RHO/RAC activation but is critically 
required for the β-catenin pathway (Veeman et al. 2003a; Wharton 2003). In 
contrast, the DEP domain is obligatory for RHO activation and stimulation of JNK 
activity (Boutros et al. 1998; Li et al. 1999; Habas et al. 2003). 
In addition, DVL has been implicated in the modulation of WNT/Ca2+ signalling 
(Sheldahl et al. 2003), aPKC activity in hippocampal neurons (Dollar et al. 2005; 
Zhang et al. 2007) and is required for mTorc activation by WNT (Mak et al. 
2005; Inoki et al. 2006). 
WNT stimulation leads to hyper-phosphorylation of DVL, but the mechanism and 
function remains incompletely understood. Kinases which have been 
demonstrated to phosphorylate DVLs are Casein kinase 1є (CK1є) (Klimowski et 
al. 2006), CK2 (Wharton 2003) and PAR1 (Elbert et al. 2006). 
DVL protein stability is controlled through proteasomal or lysosomal degradation. 
DVL proteins are targeted for proteasomal degradation through HECT-type 
ubiquitin ligase NEDL1 (Miyazaki et al. 2004) or KLHL12 (Angers et al. 2006) or 
mediated through a degradation complex involving PRICKLE1 (Carreira-Barbosa 
et al. 2003). Lysosomal destabilisation of DVL is mediated by Dapper (Cheyette 
et al. 2002; Zhang et al. 2006) or through a negative WNT signalling feedback 
loop (Jung et al. 2009). DVL2 has been reported to be degraded by the 
autophagy pathway as part of a negative feedback loop of WNT regulation (Gao 
et al. 2010). 
DVL1 null mice are viable and fertile but display social interaction abnormalities 
(Lijam et al. 1997; Long et al. 2004). In contrast, DVL2 null mice displayed 
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somite segmentation defects and cardiac outflow tract abnormalities, which is 
also responsible for perinatal lethality of half of the offspring (Hamblet et al. 
2002). DVL3 knockout mice show similar cardiac outflow tract abnormalities as 
observed for DVL2, but display a mild PCP defect of misoriented stereocilia in the 
organ of Corti (Etheridge et al. 2008; Wynshaw-Boris 2012).  
Individual DVL proteins can rescue knock outs of other DVL genes, suggesting 
functional redundancy, which is also consistent with overlapping expression 
patterns (Sussman et al. 1994; Klingensmith et al. 1996; Tsang et al. 1996; 
Wang et al. 2005; Etheridge et al. 2008). Notably, overexpression of DVL has 
been reported in certain cancers (Okino et al. 2003; Uematsu et al. 2003). 
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1.7 VANGL proteins  
VANGL proteins are tetra-membrane-spanning proteins, which are highly 
conserved from fly to human. In flies and worms only one Vangl gene can be 
found, whereas zebrafish, mouse and human contain two VANGL homologues 
with the exception of frogs, where only a VANGL2 homologue was identified 
(Torban et al. 2004).  
 
The mammalian VANGL1 and VANGL2 proteins share a 73% total-amino-acid 
identity if compared to each other, and a 44% (VANGL1) or 50% (VANGL2), 
similarity to the Drosophila homologue strabismus (stbm), suggesting that the 
vertebrate genes evolved by gene duplication from a common ancestor present 
in flies (Figure 1.30) (Torban et al. 2004).  
 
 
Figure 1.30: VANGL1 and VANGL2 proteins display a high degree of sequence 
similarity. Alignment of mouse VANGL1 and VANGL2 protein sequences. Identical amino 
acid (aa) residues of both sequences are highlighted in grey and transmembrane  portions 
are indicated through a black line runnig above the respective amino acids. The C-
terminal PDZ-binding motif (ETSV) is indicated by a box and the D255E and S464N 
mutations causing neural tube defects in looptail (Lp) mice are indicated by arrowheads. 
Figure taken from Torban et al, 2004. 
 
Further, both proteins present two solvent accessible extracellular loops and an 
intracellular amino and carboxy terminus, and share the same C-terminal ESTV 
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motif, promoting protein interactions with PDZ domain containing proteins 
(Figure 1.31) (Nourry et al. 2003; Torban et al. 2004). 
 
The presence of a N-terminal cytoplasmic serine/threonine cluster motif is 
evolutionarily conserved among vertebrate VANGL1 and VANGL2 orthologs and 
phosphorylation events in this cluster are required for at least VANGL2 activity   
(Daub et al. 2008; Gao et al. 2011).  
 
Vangl homologues were initially discovered in a study of polarity establishment 
in the Drosophila eye and termed strabismus (Wolff and Rubin 1998). X-
irradiation-induced mutations of the stbm locus showed disruption of polarity of 
multiple structures like the orientation of bristles (leg) and hairs (wing) (Figure 
1.18b) or affect correct ommatidial rotation (eye) (Figure 1.18f). Studies of 
Vangl function in vertebrates using Zebrafish and Xenopus as model organisms 
demonstrated a role in mediation of cell movements during gastrulation (Park 
and Moon 2002).  
 
Van gogh-like (VANGL) proteins play a role in planar cell polarity and convergent 
extension movements (see section 1.5.2) (Torban et al. 2004; Torban et al. 
2008; Torban et al. 2012). Studies in vertebrate systems further identified 
VANGL proteins to function in unexpected developmental processes such as 
asymmetric cell division, left-right asymmetry and morphogenesis of different 
tissues (Torban et al. 2012).  
 
 
1.7.1 VANGL1  
Human VANGL1, also termed Strabismus Drosophila homologue 2 (STB2), 
encodes a 524-amino-acid protein, distributed over eight exons. Northern blot 
analysis detected 4.8- and 6.8-kb transcripts in nearly all human tissues 
examined  (Katoh 2002; Yagyu et al. 2002; Kalabis et al. 2006). VANGL1 
proteins localise to various subcellular departments such as cytoplasmic vesicular 
structures, co-localisation with E-cadherin or at the plasma membrane (see 
section 5.4) (Kalabis et al. 2006). 
 
Mouse model studies using an inactivating mutation in the Vangl1 gene showed 
that heterozygous mutants mice were viable and fertile, whereas homozygous 
mutants displayed subtle alterations in polarity, displayed by inner hair cells 
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orientation of the cochlea (Torban et al. 2008). Crosses between Vangl1 and 
Vangl2 heterozygous mice showed profound developmental defects, including 
severe craniorachischisis, inner ear defects, and cardiac abnormality, suggesting 
a genetic interaction between Vangl1 and Vangl2  (Torban et al. 2008).  
 
In addition, mutational analysis of neural tube defects (NTDs) patients revealed 
a set of VANGL1 point mutations across highly conserved amino acids, including 
the corresponding amino acids affected in the VANGL2 looptail mouse D255E and 
S464N (Figure 1.30 and Figure 1.31) (Kibar et al. 2007; Kibar et al. 2009). 
These findings suggests that VANGL proteins play an important role in 
developmental processes such as co-ordinated cellular migration in convergent 
extension movements during neurulation. 
 
 
Figure 1.31: Topological model and structural features of VANGL1. This figure 
illustrates the four transmembrane domains, intracellular and extracellular segments and 
their respective position in the primary amino acid sequence of VANGL1. Amino acid 
residues in VANGL1 and VANGL2 associated with neural tube defects in mice and humans 
are depicted in yellow, whereas loss of function mutations have been demonstrated, are  
shaded in pink.  The PDZ interacting tetrapeptide ETSV is coloured in green. Amino acids 
highlighted in blue represent consensus tyrosine based and di-leucine motifs associated 
with protein sorting and membrane targeting. Figure from Iliescu et al, 2011. 
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Whereas the link of VANGL1 to developmental tube defects is relatively weak 
(homozygous mice for VANGL1 are normal and fertile), an increasing body of 
evidence suggests a strong connection between high levels of VANGL1 
expression and cancer progression/promotion. Several studies using colorectal 
cancer cells observed VANGL1 involvement in promotion of migration and 
invasion processes, while knock down of VANGL1 in various carcinoma cells 
showed inhibited growth and reduced migration (Yagyu et al. 2002; Lee et al. 
2004; Kalabis et al. 2006; Kho et al. 2009; Lee et al. 2009; Ryu et al. 2010).  
 
Expression analysis of gastric tumour samples showed higher VANGL1 levels 
compared to adjacent normal tissue (Lee et al. 2005). This ties in with the 
observation that VANGL1 expression in breast cancer cancer patients leads to a 
poor outcome prognosis, based on the demonstarted relationship between high 
VANGL1 expression and breast cancer relapse (Anastas et al. 2011).  
 
Taken together, mammalian VANGL1 is involved in neural tube closure during 
gastrulation and neurolation processes, and modulates cell migration and 
invasion processes in adult tissues, which can contribute to malignant 
phenotypes such as abnormal tissue polarity, invasion and metastasis as found 
in human cancers.  
 
 
1.7.2 VANGL2 
VANGL2 (521 aa) is a well established PCP core protein and interacts with a 
multitude of WNT and PCP signalling components. Ranging from WNT (co)-
receptors, ROR2 (Gao et al. 2011), RYK (Andre et al. 2012; Macheda et al. 
2012) and PTK7 (Lu et al. 2004a) (see section 1.6.4), Frizzled receptors 
(Montcouquiol et al. 2006), DVL2 (Torban et al. 2004; Shafer et al. 2011), 
SCRIB (Montcouquiol et al. 2003; Montcouquiol et al. 2006), to RHO GTPase 
RAC1 (Lindqvist et al. 2010). Further, VANGL2 regulates the endocytosis and cell 
surface level of membrane type-1 matrix metalloproteinase (MMP14 or MT1-
MMP) modulation of MMP endocytosis (Williams et al. 2012a; Williams et al. 
2012b). 
A mouse model termed looptail (Lp) exhibited independent mutations in the 
VANGL2 locus, thus giving VANGL2 the alternative name Loop-tail associated 
protein (Ltap), displayed typical PCP defects (Kibar et al. 2001a; Kibar et al. 
2001b; Torban et al. 2007). Loop-tail (Lp) mouse model homozygotes die in 
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utero of severe craniorachischisis, display defects in the inner ear cochlea hair 
orientation, heart outflow tract defects and defects of the musculoskeletal 
system characterised by fused ribs (Montcouquiol et al. 2003; Phillips et al. 
2005; Torban et al. 2008). 
VANGL2 point mutations have been identified to contribute to NTDs (Kibar et al. 
2011) and several identified mutations are homologous to those found in 
VANGL1, such as Lp specific VANGL2 loss of function mutation S464N and 
mutant D255E (Kibar et al. 2001a; Kibar et al. 2001b; Guyot et al. 2011). These 
mutations have been demonstrated to affect plasma membrane targeting and 
result in ER retention, where protein half-life is reduced and stability affected by 
increased proteasome dependent degradation (Gravel et al. 2010). 
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1.8 Cell migration and invasion processes 
Cell migration is essential for various cellular activities during the development 
and maintenance of multicellular organisms. Tissue formation during embryonic 
development, wound healing and immune responses require the orchestrated 
movement of cells in particular directions to specific locations. Cell migration 
involves coordination between protrusion at the anterior end of the cell, 
construction of new adhesive foci on the substratum, breakdown of old adhesive 
foci, and retraction of the posterior end of the cell (Ridley 2011). RHO GTPases 
control all the processes required for spatio-temporal coordination of protrusion, 
contraction, assembly and disassembly of cell-matrix adhesion, which are 
required for a moving cell (Ridley 2001b; Ridley 2011). 
 
 
Figure 1.32: Polarity of migrating cells. (A) Application of a chemotactic gradient to a 
randomly migrating cell initiates direction sensing. Notably, front-rear polarisation is 
required for migration per se, but is not sufﬁcient for chemotaxis. (B) Cell orientation 
following direction sensing is crucial to promote directed (or oriented) migration, but is 
not sufﬁcient to drive cell migration. Orientation of the nucleus-centrosome axis is a good 
indicator of cell orientation during directed migration of most cell types. Actin-driven 
protrusions (lamellipodia) are shaded in red, microtubules are coloured in dark green and 
centrosome in light green. Straight red lines represent stress ﬁbers and red patches 
correspond to focal complexes and focal adhesions. N illustrates the nucleus. Figure from 
Etienne-Manneville, 2008. (Etienne-Manneville 2008). 
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1.8.1 Actin structures and actin-binding protein Filamin A 
Actin and myosin II play major roles in cell migration. Actin, a ubiquitous 
eukaryotic protein, is the major component of the cytoskeleton, controlling cell 
structure and motility (Herman 1993; Ridley 2001b). Actin exists mainly as a 
fibrous polymer (F-actin), but in response to cytoskeletal re-organising signals 
during processes such as cytokinesis, endocytosis, or stress. Cofilin promotes 
fragmentation and depolymerisation of F-actin, resulting in an increase in the 
monomeric globular form (G-actin) (Condeelis 2001). The Arp2/3 complex 
stabilises F-actin fragments and promotes formation of new actin filaments 
(Condeelis 2001).  
Lamellipodia are actin projections on the mobile edge at the front of the cell and 
form a two-dimensional actin mesh, which pulls the cell forward across a 
substrate during the process of cell migration (Ridley 2011). Actin microspikes 
spreading beyond the lamellipodium frontier are termed filopodia (Small et al. 
2002). RAC stimulates lamellipodium formation, while Cdc42 promotes 
filopodium construction (Hall 1998). 
Filamin A (FLNa) is a 280-kD actin-crosslinking protein, which regulates re-
organisation of the actin cytoskeleton by interacting with integrins, 
transmembrane receptor complexes, and second messengers (Ohta et al. 2006; 
Kim and McCulloch 2011; Nakamura et al. 2011). Filamins crosslink actin 
filaments into orthogonal networks in the cytoplasm and participate in the 
anchoring of membrane proteins to the actin cytoskeleton (Maestrini et al. 1993; 
Fox et al. 1998). In addition, cell motility-independent functions of FLNa at cell-
cell contacts and adherens junctions affect the development of organs (Feng et 
al. 2006). 
Interestingly, R-RAS (Gawecka et al. 2010; Griffiths et al. 2011) and ROR2 
(Nishita et al. 2006; Nomachi et al. 2008) have been demonstrated 
independently to be interactors of FLNa, and are required for migration 
processes or endothelial barrier maintenance. 
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1.8.2 Invadopodial structures and matrix metalloproteases 
Invadopodia are cell membrane localised, actin rich protrusions, extending into 
the extracellular matrix (ECM) where they are able to degrade ECM components 
(Linder et al. 2011; Murphy and Courtneidge 2011; Ridley 2011; Sibony-
Benyamini and Gil-Henn 2012). Invadopodia are therefore thought to be key 
structures of cell invasion (Linder et al. 2011; Sibony-Benyamini and Gil-Henn 
2012).   
β1A integrin is a master regulator of invadosome organisation and function, 
mediated by matrix metalloproteinase MMPs (Destaing et al. 2010). MMPs belong 
to a family of proteases that target extracellular proteins including other 
proteases, growth factors, cell surface receptors and adhesion molecules 
(McCawley and Matrisian 2001). Among MMPs, MMP-2, MMP-3, MMP-7, MMP-9 
and MMP-13 have been characterised as important factors for normal tissue 
remodelling during embryonic development, wound healing, tumour invasion, 
angiogenesis, carcinogenesis and apoptosis (Nagase et al. 1990; Vu et al. 1998; 
Sternlicht et al. 1999; Coussens et al. 2002; Kudo et al. 2012). MMPs are 
synthesised as pro-enzyme and are activated by releasing the inhibitory 
propeptide domain in order to yield an active, full length protease (Nagase et al. 
1990). 
Notably, WNT5a-ROR2 signalling confers MMP-13 linked invasive properties 
assessed by invadopodium formation (Figure 1.28B) (Enomoto et al. 2009). In 
addition, VANGL2 has been reported to regulate endocytosis and cell-surface 
availability of MMP14, resulting in proteolytic degradation or remodelling of the 
extracellular matrix (Cantrell and Jessen 2010; Williams et al. 2012a; Williams et 
al. 2012b).  
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1.9 Autophagy 
Protein turnover takes place through the ubiquitin mediated proteasome 
pathway or is lysosome mediated (Ciechanover 2005). Autophagy or 
autophagocytosis is a key mechanism that clears unnecessary or dysfunctional 
cellular components through the lysosomal machinery or recycles nutrients 
during starvation or stress periods, thus maintaining cellular energy levels 
(Mizushima and Klionsky 2007).  
 
Macroautophagy, the main pathway, generally eradicates damaged cell 
organelles or unused proteins. This process is tightly regulated through highly 
conserved genes termed autophagy regulators (ATGs), which are required at 
several steps along the process and orchestrate for instance the induction, cargo 
recognition and packaging or vesicle formation (Mizushima et al. 2011). 
Autophagy is stimulated  in response to unfavourable conditions such as nutrient 
deprivation and is initiated through phagophore formation by class III PI3K, Atg6 
(also known as Beclin-1) and ubiquitin-like conjugation reactions (Figure 1.33). 
 
During phagophore nucleation, cytosolic proteins, protein aggregates and 
organelles are enclosed, and recruitment of ATG proteins such as ATG12, ATG5, 
ATG16 and covalent lipidated ATG8 together with transmembrane ATG9 facilitate 
phagophore extension. Upon completion of the double membrane organelle 
known as an autophagosome vesicle, ATG proteins start to dissociate, and fusion 
of the autophagosome with a lysosome results in a autolysosome and 
subsequent degradation of the organells content through acidic lysosomal 
hydrolases (Figure 1.33) (Yorimitsu and Klionsky 2005; He and Klionsky 2009).  
 
To date, the processed form of microtubule-associated protein 1 light chain 3 
(LC3) is the only reliable protein marker associated with completed 
autophagosomes and phagophores (Mizushima and Yoshimori 2007; Klionsky et 
al. 2008). LC3 also known as ATG8, is a ubiquitin like protein involved in 
autophagosome formation (Figure 1.33) (Kabeya et al. 2000). LC3 is initially 
synthesised as proLC3 (unprocessed form), which is converted into a 
proteolytical processed form lacking C-terminal amino-acids (LC3-I). Mature LC3 
(LC3-II) is achived through modification of LC3-I by phosphatidylethanolamine 
(PE) conjugation (Kabeya et al. 2000; Klionsky et al. 2007).  
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Interestingly, a recent study by Gao and colleagues demonstrated negative 
regulation of WNT signalling through promotion of DVL2 degradation (Gao et al. 
2010).   
 
 
 
Figure 1.33: Schematic model of the autophagy process. Class III PI3K complex 
mediates the formation of the phagophore membrane, enwrapping organelles, cytosolic 
proteins and aggregates. This step could be inhibited through Bcl-2, which binds and 
inhibits Beclin-1, a component of the PI3K complex. Atg proteins like Atg12, Atg5, Atg16 
and phosphatidylethanolamine (PE) conjugated Atg8 are recruited to the forming 
phagophore, in conjunction with the transmembrane protein Atg9, assisting the 
phagophore expansion step. Upon completion of vesicle formation, Atg proteins start to 
dissociate from the now formed autophagosome, enabling autophagosome-lysosome 
fusion and subsequent cargo degradation through acidic lysosomal hydrolases. Bcl-2 - B-
cell lymphoma 2, PI3K - Phosphatidylinositide 3-kinase. Figure from He and Klionsky, 
2009.  
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1.10 Aim of my study and outline of subsequent chapters 
 
RAS proteins mediate important cellular functions such as gene expression, 
proliferation, differentiation and survival through a wide variety of effector 
proteins. Despite overlapping regulatory and effector proteins, and similar 
biochemical and biological features between oncogenic RAS and the closely 
related R-RAS members, they can also exhibit divergent regulation of signalling 
and cellular processes. Therefore, a better understanding of the full spectrum of 
effector pathways regulated by RAS family GTPases is critical to comprehend 
their many biological functions and their contribution to human disease. 
 
In order to identify novel effector proteins specific to R-RAS members, Dr. 
Rodriguez-Viciana carried out a non-biased proteomic Tandem Affinity 
Purification (TAP) approach employing active R-RAS subgroup members as baits. 
This led to discovery of VANGL1 protein, a component of the WNT/Planar Cell 
Polarity pathway, as a potential novel effector of R-RAS proteins. 
 
The aim of this thesis project was to validate and characterise the novel R-RAS- 
interactions, identified by TAP to study how R-RAS members regulate VANGL1 
function and how VANGL1 may contribute to the signalling properties of R-RAS. 
In addition, the possibility was tested that R-RAS GTPases function downstream 
of WNT ligands in the PCP pathway, co-ordinating the regulation of VANGL 
proteins in order to control polarity and cell motility.  
 
Cell motility and migration play a paramount role in both normal embryogenesis 
and the development of diseases such as cancer. Therefore, experiments were 
carried out to analysis and assess a role of R-RAS and VANGL1 in regulation of 
cell movement and invasion.    
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2 Materials and Methods 
2.1 MATERIALS 
2.1.1 Chemical compounds and reagents 
Human WNT3a (5036-WN), WNT5a (645-WN) and WNT7a (3008-WN) ligands 
were purchased from R&D. Murine Wnt3a (315-20) ligand was obtained from 
Peprotech. The proteasomal inhibitor MG132 (Santa Cruz Biotechnology) was 
prepared as 10 mM stock solution in Dimethyl sulfoxide (DMSO). 
Polyethyleneimine (Polysciences Inc) transfection stocks were prepared as 1 
mg/mL solution in water and sterile filtered. Polybrene (hexadimethrine 
bromide), a cationic polymer used to increase the efficiency of retrovirus or 
lentivirus cell culture infections, was prepared as 5 mg/mL sterile filtered 
aqueous solution and applied as 5 µg/ml final concentration. Crystal violet dye 
(Sigma) was prepared as a 0.5% solution in 10% methanol/water mix. 
Paraformaldehyde (PFA) 4% w/v was dissolved in PBS at 60°C while stirring and 
subsequently aliquoted and frozen for long term storage. Aliquots were thawed 
when required and used immediately for fixation purposes. Autophagy reagents 
3-methyladenine, Bafilomycin A, and Chloroquine were obtained from Sigma. 
Hanks balanced salt solution (HBSS) for amino acid starvation was obtained from 
Invitrogen. For immunoprecipitation experiments, Streptavidin sepharose or 
Protein A / Protein G sepharose were obtained from GE Healthcare. Non-
targeting control siRNA conjugated with Alexa Fluor Red (46-5318, Invitrogen) 
was used to assess siRNA transfection efficiency. 
If not stated otherwise, chemical reagents were obtained from Sigma. 
 
2.1.2 Buffers 
Coomassie stain: 0.2% (w/v) Brilliant Blue R (Sigma), 10% acetic acid (BDH), 
50% methanol (BDH). 
Coomassie destain: 10% acetic acid, 50% methanol. 
DNA loading buffer (10x): 0.00125 g/mL Bromophenol Blue, 40% TE, 60 % 
Glycerol. 
Lysis buffer (LB-E): pH 7.4; PBS supplemented with 1% w/v Triton X-100, 1 mM 
EDTA, 1mM Dithiothreitol (DTT), Protease inhibitor cocktail (Roche) and 
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Phosphatase inhibitor solution (10mM NaF, 2mM  Na3VO4, 2 mM Na4P2O7 , 2 mM 
β-glycerophosphate). 
Lysis buffer (LB-M): pH 7.4; PBS supplemented with 1% w/v Triton X-100, 5 mM 
MgCl2, 1mM DTT, Protease inhibitor cocktail (Roche) and Phosphatase inhibitor 
solution (10mM NaF, 2mM  Na3VO4, 2 mM Na4P2O7 , 2 mM β-glycerophosphate). 
3-(N-morpholino)propanesulfonic acid (MOPS) running buffer: pH 7.7,  50 mM 
MOPS, 50 mM Tris Base, 0.1% SDS, 1 mM EDTA. 
Phosphate buffered saline (PBS) buffer: pH 7.4; 137 mM NaCl, 2.7 mM KCl, 10.1 
mM Na2HPO4, 1.76 mM KH2PO4).  
Protein loading buffer (4xLDS): 40% glycerol, 4% lithium dodecyl sulfate (LDS), 
4% Ficoll-400, 0.8 M triethanolamine-Cl, pH 7.6, 0.025% phenol red, 0.025% 
coomassie G250, 2mM EDTA disodium. This buffer was purchased from 
Invitrogen and supplemented with 0.25 M DTT to achieve reducing capability. 
Tween supplemented PBS (PBST): 0.1% Tween in PBS. 
Transfer buffer: 10 % (w/v) Methanol, 25 mM Bicine, 25 mM Bis-Tris, 1 mM 
EDTA. 
Tris-Acetate-EDTA buffer (TAE): 40 mM Tris, 20 mM acetic acid, 2.5 mM EDTA. 
Tris-EDTA buffer (TE): pH 8, 10 mM Tris, 1 mM EDTA. 
 
2.1.3 Media and growth plates 
Luria Bertani (LB) was prepared using 10 g/L Bacto™-Tryptone (BD), 5 g/L 
Bacto™-yeast extract (BD), 10 g/L NaCl (Sigma), 1 g/L Glucose as a ready to 
dissolve mix (Sigma). LB selection media contained either 100 µg/mL Ampicillin 
(Sigma) or 50 µg/mL Kanamycin (Gibco). LB growth plates were prepared as LB 
media above and supplemented with 15 g/L agar (Sigma) and selection plates 
were supplemented with appropriate antibiotic post autoclaving. 
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2.1.4 Antibodies 
Table 1: Applied primary antibodies, working dilutions and 
corresponding suppliers. 
antibody clonal host dilution catalogue number  and 
supplier 
AF6 p rabbit 1:500-
1:2000 
#A50520, 35/AF6, Trans-
duction 
pAKT (S473) p rabbit 1:1000 9271, Cell Signaling 
BRAF m mouse 1:2000 sc-5284, F7, Santa Cruz 
γ-Tubulin m mouse 1:500 Clone GTU-88, T6557, Sigma 
CASK m mouse 1:1000 sc-13158, C-6, Santa Cruz 
DLG1 (SAP97) m mouse 1:1000 sc-9961, 2D11, Santa Cruz 
DVL-1 m mouse 1:500 sc-8025, 3F12, Santa Cruz 
DVL-2 p rabbit 1:1000 sc-13974, H-75, Santa Cruz 
DVL-2 m mouse 1:1000 sc-8025, 10B5, Santa Cruz 
DVL-3 m mouse 1:1000 sc-8025, 4D3, Santa Cruz 
ERK p rabbit 1:2000 9102, Cell Signaling 
pERK, 
(T202/Y204) 
p rabbit 1:2000 9101S Cell Signaling 
Flag  m mouse 1:1000-
1:15000 
F3165, M2, Sigma 
Flag p rabbit 1:1000-
1:15000 
F7425, 0.4mg/mL, Sigma 
GM130 m mouse 1:200 610822, clone 35, BD 
Transduction laboratories 
GST-tag m rabbit 1:5000 2625, Cell Signaling 
His-tag m mouse 1:2000 2366, Cell Signaling 
H-RAS p rabbit 1:1000 sc-520, C-20, Santa Cruz 
JNK1 p rabbit 1:1000 sc-571, FL, LOT D121, Santa 
Cruz 
pJNK 
(T183/Y185) 
p rabbit 1:1000 9251, Cell Signaling 
LC3B p rabbit 1:1250 2775, Cell Signaling 
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LRP6 m rabbit 1:1000 2560, Cell Signaling 
pLRP6 
(Ser1490) 
p rabbit 1:1000 2568, Cell Signaling 
Myc p rabbit 1:2000 sc-789, A-14, Santa Cruz 
PP1 m mouse 1:1000 sc-7482, E-9, Santa Cruz 
RHOA m mouse 1:1000 sc-418, 26C4, Santa Cruz 
RHOB p rabbit 1:1000 sc-180, C-119, Santa Cruz 
R-RAS m mouse 1:500 sc-81930, YC-16, Santa Cruz 
R-RAS p rabbit 1:500 sc-523, C-19, Santa Cruz 
SCRIB m mouse 1:1000 sc-55543, C-6, Santa Cruz 
Syntenin-1 m mouse 1:1000 sc-100336, S-31, Santa Cruz 
Tubulin-HRP p rabbit 1:5000 PM054-7, MPL 
TC21 m mouse 1:500 Sc-8193, 37-Y, Santa Cruz 
TC21 p rabbit 1:1000 In house generation 
VANGL1 m mouse 1:1000 MAB5476, Clone 497707, R&D 
systems 
VANGL1 p rabbit  1:15000 In house generation, serum1 
and pre-sera 
Note: Antibodies are indicated as monoclonal (m) or polyclonal (p) and were 
prepared in 3% BSA/PBST supplemented with 0.02% NaN3. 
 
2.1.5 Plasmids 
For all cloning and subcloning vector construction, the Invitrogen Gateway® 
Cloning Technology was employed (www.invitrogen.com/gateway).  
This system relies on cloning the gene of interest into an Entry vector (pENTR, 
see Figure 2.1A), which then can be amplified in bacteria and forms the donation 
vector for any subsequent subcloning step into various destination vectors by a 
simple and fast recombination reaction.  Destination vectors (for an example 
refer to mammalian GST-tagged destination vector pDEST27, Figure 2.1B) are 
available for a wide range of applications and systems (E. coli, yeast, insect, or 
mammalian cell) and thus provide a fast, reliable and convenient method of 
construct generation.  
For interaction studies in mammalian cells, pcDNA™ destination vectors were 
used, which are designed for constitutive expression in mammalian cell lines 
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under the Cytomegalovirus (CMV) enhancer-promoter for high-level expression 
and a Bovine Growth Hormone (BGH) polyadenylation signal and transcription 
termination sequence for enhanced mRNA stability. Further, a SV40 origin 
enables episomal replication and simple vector rescue in cell lines expressing the 
large T antigen such as employed HEK293T cells (Figure 2.1B).  
 
 
Figure 2.1: Examples of Gateway cloning vectors. (A) Genes of interest are cloned 
in pENTR vectors flanked by attL1 and attL2 sites for site-specific recombination. (B) 
Genes of interest cloned into pENTR vectors can be shuttled to secondary vectors, termed 
destination vectors, through a fast and efficient recombination reaction using Clonase II 
enzyme mix. A wide range of vectors is available for expression in various systems. 
Vector maps were taken from the Gateway manual available at: 
www.invitrogen.com/gateway. 
 
 
 
95 
 
All pENTR clones were generated by Lucy C. Young, Marta Mũnoz-Alegre or Pablo 
Rodriguez-Viciana using Image clones or human placental pLIB cDNA library 
(PT3230.1) (Clontech) as templates for PCR. After cloning, pENTR vectors were 
sequenced and used for destination vector generation by means of 
recombination reactions. 
Recombination reactions were performed by combining 0.5 µL Entry clone 
miniprep DNA, 0.2 µL desired Destination vector (100 ng), 1.3 µL 0.2x TE buffer 
and 0.5 µL 5x Gateway® LR Clonase II Plus enzyme mix (Invitrogen). The 
reaction volume was well mixed and microcentrifuged to collect at the bottom of 
the tube. The reaction was incubated at room temperature for at least 60 
minutes up to O/N before transforming into bacteria and subsequent DNA 
isolation as outlined in 2.2.4 and 2.2.5.  
 
2.1.6 Primers 
Cloning primers for mutagenesis reactions were generated and obtained from 
Invitrogen and were delivered lyophilised. Oligos were resuspended with 0.2x TE 
to yield a stock solution of 100 pmol/µL (100 µM), incubated for 5 min and then 
vortex thoroughly. Working stocks for Polymerase chain reactions (PCR) were 
prepared at 10 pmol/µL (10 µM) with 0.2x TE.  
 
2.1.7 RNAi sequences 
RNAi duplex oligonucleotides (Stealth RNAi™) were designed and ordered from 
Invitrogen. Supplied lyophilised primers were reconstituted with 
Diethylpyrocarbonate (DEPC) treated water to yield a master stock concentration 
of 100 µM. Working stock concentrations were generated from the master stock 
at concentrations of 20 µM and 4 µM stock using DEPC-treated water. All 
employed RNAi duplexes were initially tested for respective protein knock down 
efficiency. In order to prevent off target effects, dose dependent experiments 
were carried out to determine minimal siRNA concentrations for efficient knock 
down, which were observed to be in the range between 2nM to 10nM (data not 
shown). Furthermore, time course experiments were carried out in order to 
estimate the longevity of the knock down effect, which lasted up to 7 days in a 
fast proliferating cell line such as HEK293T (data not shown). 
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Table 2: Applied siRNA oligo sequences 
siRNA Target sequence 
R-RAS-1 5'-GAG AGC AGU ACA UGC GUG CUG GCC A-3' 
R-RAS-2 5'-UCG CCA UUA ACG ACC GGC AGA GUU U-3' 
TC21-1 5'-CAG UAU AUG AGG ACU GGC GAA GGC U-3' 
TC21-2 5'-GGA UCG UGA UGA GUU CCC AAU GAU U-3' 
VANGL1-1 5'-AGG CCG AAC AUG AAC GGC GAG UAA A-3' 
VANGL1-2 5'-CAA UAU GAC AAG GAC CGC UGG CUC U-3' 
VANGL2-1 5'-CGU CUD UGU GCU GCG UGC CCU GCU U-3' 
VANGL2-2 5'-UCG UGG UCU CCU ACU GGC UCU UCU A-3' 
Scribble-1 5'-GCG UCA GCG UCA UCC AGU UCC UGG A-3' 
Scribble-2 5'-GGC CUA CGG GAA CUG UGC AUC CAG A-3' 
Shoc2-2 5'-UAC CUU CGC UUU AAU CGU AUA-3' 
scramble 5'-UUC UCC GAA CGU GUC ACG UUU-3' 
The number post the dash indicates individual siRNA oligos, targeting different 
regions of the same gene of interest. 
 
In order to assess transfection efficiency of siRNA molecules, an Alexa Fluor® 
555-labeled, double-stranded RNA (Invitrogen, BLOCK-iT™ Alexa Fluor® Red 
Fluorescent Oligo Cat. No. 14750-100) was transfected alongside as control and 
assessed by fluorescence microscopy for successful delivery 24-48 h post 
tranfection. Alexa 555 is a duplex with the same length, charge, and 
configuration as standard siRNA and its sequence is not homologous to any 
known gene.  
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2.2 DNA TECHNIQUES 
2.2.1 Basic DNA manipulations 
2.2.1.1 Cloning approach of VANGL1 truncation constructs 
Subcloning tasks were carried out utilising the Invitrogen Gateway® technology 
with ClonaseTM II (Invitrogen) approach (see section 2.1.5.). DNA digestions 
were performed using New England Biolabs restriction enzymes and the supplied 
buffers according to the instructions of the manufacturer. Routinely, 0.5 µg of 
DNA was utilised for diagnostic restrictions, and 1-5 µg of DNA for preparative 
digests for subsequent use in ligation reactions. DNA restriction digests were 
usually carried out at 37°C for 2 h according to instructions of the manufacturer. 
For primer sequences and template plasmids used in this study, refer to Table 3. 
Chosen bands of DNA were cut out of the gel and purified using QIAquick Gel-
extraction kit (Qiagen) according to the instructions of the manufacturer. For 
ligation reactions 1 µL of T4 ligase (Invitrogen), T4 ligase reaction buffer 
(Invitrogen), vector and insert DNA were added together to a final reaction 
volume of 10 µL. The ratio of vector to insert was maintained at 1:3 and ligation 
was carried out for 1 h to overnight at room temperature. Subsequently, 5 µL of 
ligation reaction was transformed into chemically competent bacteria 
(Invitrogen) as described in section 2.2.4. 
Table 3: Primer sequences for generation of VANGL1 truncation 
constructs. 
Con- 
struct 
Size  
[bp] 
Forward primer (5’ -> 3’) 
Reverse primer (3’ -> 5’) 
Tm 
[°C] 
VANGL1-N 343 caccggatccatggataccgaatccacttattc 
cacgaattcttaggtgaggcccaggtagcgtttgc 
59 
63 
VANGL1-C1 852 caccggatccgagctcaggcagctgcagccca 
cgcgaattcttaaacggatgtctcagactgta 
67 
57 
VANGL1-C2 426 caccggatccgagctcaggcagctgcagccca 
cacgaattcttaggctttctgctgctcctcagcc 
67 
62 
VANGL1-C3 426 caccggatccccaggggaggtgatggaccctag 
cgcgaattcttaaacggatgtctcagactgta 
67 
57 
VANGL1-
∆PDZ-BM 
1560 caccggatccatggataccgaatccacttattc 
cacgaattcttaagactgtaagcgaaggacaaatttg 
59 
57 
Note: For a detailed features and overview about truncated regions refer to 
Figure 3.8. Annealing temperatures were calculated using Promega online 
calculation tool, referring to salt adjusted Tm.  
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Table 4: PCR cycling parameters for VANGL1 truncation constructs 
Segment Cycles Temperature Time 
1 1 94°C 3 minutes 
2 25 94°C 
(denaturation) 
30 seconds 
55°C (annealing) 30 seconds 
72°C (extension) 2 minutes 
3 1 72°C 2 minutes 
4 1 16°C ∞ 
Note: The extension time is determined by the length of the expected longest 
fragment of 1.6 kb (1 kb per minute for extension). 
 
 
2.2.1.2 Cloning approach of ARHGEF17 truncation constructs 
Subcloning and DNA handling techniques were carried out as described above for 
generation of VANGL1 truncations and respective PCR reactions were carried out 
using the cycle parameters as outlined in Table 4.  
Table 5: Primer sequences for generation of ARHGEF17 truncation 
constructs. 
Con- 
struct 
Size  
[bp] 
Forward primer (5’ -> 3’) 
Reverse primer (3’ -> 5’) 
Tm 
[°C] 
ARHGEF17-N 1530 caccgaattcatggcccgccgcctgccccgca 
cacgcggccgctcagtgcttccgcatgtccacctgtg 
68     
69 
ARHGEF17-
∆N 
3040 caccgaattcatggccagcaagtgctgcagcaagc 
cacgcggccgctcacaccctccacaggaggagg 
64     
69 
ARHGEF17-
C1 
2440 caccgaattcatgggtgtgcggagtgccgaggaggc 
cacgcggccgctcacaccctccacaggaggagg 
67     
69  
ARHGEF17-
∆C 
2120 caccgaattcatggcccgccgcctgccccgca 
cacgcggccgctcacacacgggcatggcgctccgc 
68     
72 
ARHGEF17-
C2 
1454 caccgaattcagccacacgcctcacggctcctccg 
cacgcggccgctcactggtaggcctcagggtcgacact 
69 
70 
ARHGEF17-
C3 
487 caccgaattcagctccgtgtggctgggcactgag 
cacgcggccgctcagacgtctacttctgccagctgct 
65 
68 
ARHGEF17- 722 caccgaattcagctccgtgtggctgggcactgag 65 
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C4 cacgcggccgctcagactgcagccaagaagcggac 69 
ARHGEF17-
C5 
977 caccgaattcagctccgtgtggctgggcactgag 
agtgtgggaggtgtcctcctccaccaaaac 
65     
67 
Note: annealing temperatures were calculated using Promega online calculation 
tool, referring to at salt adjusted Tm. (http://www.promega.com/techserv/tools 
/biomath/calc11.htm) 
 
 
2.2.2 Plasmid mutagenesis 
Generation of VANGL1 point mutations by site directed mutagenesis 
A PCR approach was used to introduce VANGL1 point mutations at reported 
residues associated with neural tube defects and impairment of Dishevelled 
binding (Kibar et al. 2007) by means of site directed mutagenesis using the Quik 
change strategy (Stratagene). Extensions of the oligonucleotide primers, 
containing desired point mutations (Table 6), were generated with the PfuUltraTM 
high-fidelity polymerase, producing a mutated plasmid (Hemsley et al. 1989). 
The amplified product was subsequently DpnI treated, which specifically cleaves 
fully methylated GMe6ATC sequences. As a result, the bacterially generated DNA 
used as template for amplification was digested and while the unmethylated 
product of the PCR reaction is left intact. The product of this digestion reaction 
was used to transform chemically competent Escherichia coli (E.coli) bacteria 
and colonies formed on selection plates were sequenced to confirm successful 
mutations. 
PCR reactions were carried out in 50 µL volumes using provided reagents of the 
Quik Change® II Site-Directed Mutagenesis Kit (Stratagene), according to the 
instructions of the manufacturer. Conditions for amplification are shown in Table 
7, utilised primers are summarised in Table 6 below. 
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Table 6: Primer sequences for generation of VANGL1 point mutant 
constructs 
Con- 
struct 
Size 
[bp]  
Forward primer (5’ -> 3’) 
Reverse primer (3’ -> 5’) 
VANGL
1-
V239I 
1572 ctcttcatccattacctggccatcatcctgctggagctcaggcagctgc 
gcagctgcctgagctccagcaggatgatggccaggtaatggatgaagag 
VANGL
1-
D259E 
1572 gctgcaggtggtccgctccaccgagggcgagtcccgcttctacagcctg 
caggctgtagaagcgggactcgccctcggtggagcggaccacctgcagc 
VANGL
1-
R274Q 
1572 gcctgggacacctgagtatccagcaagcagcattggtggtcctagaaaat 
attttctaggaccaccaatgctgcttgctggatactcaggtgtcccaggc 
VANGL
1-
M328T 
1572 gccactggccagtcccgggccacgattgctgcagctgctcggcgcag 
ctgcgccgagcagctgcagcaatcgtggcccgggactggccagtggc 
VANGL
1-
S467N 
1572 tctctacacagtggaggcttgtcaatgatgaggctgtgactaatggatt 
aatccattagtcacagcctcatcattgacaagcctccactgtgtagaga 
 
 
Table 7: PCR cycling parameters for site-directed mutagenesis 
Segment Cycles Temperature Time 
1 1 95°C 30 seconds 
2 18 95°C 
(denaturation) 
30 seconds 
55°C (annealing) 1 minute 
68°C (extension) 11 minutes and 
35 sec 
3 1 4°C ∞ 
Note: The extension time was determined by the length of the amplified plasmid 
(1 kb per minute for extension). 
 
In order to test expression of the generated point and truncation mutants of 
VANGL1, plasmids were transfected into HEK293T cells and subjected to 
immunoprecipitation (as described in section 2.5.4). Coomassie staining of a size 
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separated protein gel displayed similar expression levels of VANGL1 point 
mutants, except mutant D259E, which was expressed at a significantly lower 
level. VANGL1-N or C-terminal truncation proteins appeared to be equally 
expressed whereas VANGL1-C2 or C3 fragments showed severely reduced 
protein levels (Figure 2.2).  
 
 
Figure 2.2: Expression analysis of Flag-VANGL1 point mutants and truncation 
constructs in HEK293T cells. 2ug of Flag-VANGL1 constructs were transfected into 
HEK293T cells, lysed after 48 hours and subjected to immunoprecipitation using Flag 
affinity beads. Immunocomplexes were size spearated on SDS-PAGE and Coomassie 
stained. Asteriks depict respective VANGL1 proteins. 
 
2.2.3 DNA gel electrophoresis 
In order to visualise DNA fragments from diagnostic digests or for cloning 
purposes, 1% or 1.2% agarose gels (Invitrogen) were prepared using 1x TAE 
buffer and TrackIt™ 1 Kb Plus DNA Ladder (1 µl) (Invitrogen, 0.1 µg/µL,) was 
run alongside for size estimation. 
 
2.2.4 Transformation of bacteria  
Chemically competent E.coli DH5α cells (Invitrogen) were gently thawed on ice, 
5 µL of prechilled ligation reaction or gateway reaction mix was added to 50 µl 
aliquots of bacterial cell suspension and then kept on ice for 10 min. 
Subsequently, bacteria were heat-shocked at 42°C for 45 sec, recovered on ice 
for another 2 min, combined with 250 µL LB or S.O.C. solution (0.5 % Bacto 
tryptone, 2 % Bacto yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 
mM MgSO4, 20 mM glucose) and incubated for one hour at 37°C at 200 rpm. 
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Bacteria suspensions were spread on LB culture plates supplemented with either 
100 µg/mL Ampicillin or 50 µg/mL Kanamycin and incubated overnight at 37°C. 
Single colonies formed on the plates were picked and grown for extraction of 
plasmid DNA. 
 
2.2.5 Preparation and purification of plasmid DNA 
Bacterial DNA for analytical purposes was isolated from 1.5 mL minipreparation 
cultures utilizing a QIAprep® mini kit (Qiagen), and for generation of plasmid 
stocks, 50 mL E.coli cultures were extracted using QIAprep® midi kit (Qiagen) 
according to the instructions of the manufacturer.  
 
2.2.6 DNA sequencing 
DNA sequencing was performed by an inhouse service using AB sequencing 
technology. Supplied ab1 format files were visualised using Finch TV software. 
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2.3 RNA TECHNIQUES 
2.3.1 RNA isolation 
Total RNA from SaOS2 cells of equivalents of six well plates were prepared using 
ISOGEN reagent (Life Sciences). 500 µL ISOGEN was added to a PBS washed 
well of cells and incubated for 1 min at RT. Next, the ISOGEN solution was 
collected in an eppendorf tube and after 5 min incubation at RT, 100 µL 
chloroform added, vigorously shaken for 15 sec and incubated at RT for 2 min. 
Aqueous phase was separated from organic phase by spinning at 20 000 x g for 
15 min at 4°C, following transfer of the aqueous phase to a fresh tube. 
Subsequently, 250 µL isopropanol was added, briefly vortexted and incubated for 
10 min at RT. Precipitated RNA was collected as pellet by spinning at 20 000 x g 
for 10 min at 4°C, and the pellet washed with 70% ethanol/water solution, 
before spinning again at 20 000 x g for 5 min at 4°C and subsequent aspiration 
of ethanol solution. Yielded pellets were air dried at 37°C and dissolved in RNAse 
free water. Concentration of yielded RNA was determined using a 
spectrophotometer (Hitachi U-1900). 
 
2.3.2 Semiquantitative PCR 
For semi-quantitative reverse-transcription polymerase chain reaction, 0.5 µg of 
total RNA was used and the polymerase chain reaction was performed using the 
SuperScript One-Step RT-PCR kit (Invitrogen) according to the instructions of 
the manufacturer using the primer sequences listed in Table 8. MMP-13 specfic 
PCR reactions were carried out using following conditions for 40 cycles (Table 9) 
The amount of 18S rRNA was amplified using the same conditions as outlined for 
MMP-13 reactions (Table 9) for 25 cycles. The relative amount of MMP-13 was 
normalised using 18S RNA. 
 
Table 8: Primer sequences for RT-PCR. 
Gene Primer sequences  
(forward/reverse) 
Prod. 
size 
MMP-13 
5'-AAC ATC CAA AAA CGC CAG AC-3' 
5'-GGA AGT TCT GGC CAA AAT GA -3' 
166 bp 
18S rRNA 
5'-ATG GCC GTT CTT AGT TGG TG -3' 
5'-CGC TGA GCC AGT CAG TGT AG -3' 
217 bp 
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Table 9: RT-PCR cycling conditions 
Segment Cycles Temperature Time 
1 1 50°C (DNA synthesis) 30 minutes 
2 1 94°C (denaturation) 2 minutes 
3 
25 (18S) 
40 (MMP-13) 
94°C (denaturation) 15 seconds 
55°C (annealing) 30 seconds 
68°C (extension) 30 seconds 
4 1 68°C (final extension) 1 minute 
5 1 4°C ∞ 
 
 
2.3.3 Visualisation of RT-PCR products 
5 µL of RT-PCR product were combined with 1 µL 10x DNA loading buffer and 
separated on a 1.8 % agarose/TAE gel (Nacalai). For product size estimation, a 
broad range DNA ladder (Nacalai) was run alongside. 
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2.4 MAMMLIAN CELL CULTURE 
2.4.1 Cell lines and culture conditions 
Immortalised human mammary epithelial cells HMEC, HMLE, 184A1 and MCF10A 
were cultured in DMEM F12 media (Invitrogen) maintained as described in 
(Debnath et al. 2003) supplemented with 2mM L-Glutamine (Gibco) in the 
absence of Penicillin/Streptomycin. Human breast adenocarcinoma MDA-MB-231 
and MCF-7, alveolar basal epithelia adenocarcinoma A549, colorectal carcinoma 
HCT116, embryonic kidney cells 293 (HEK293T), osteosarcoma SaOS2 and 
U2OS, cervical carcinoma HeLa and mouse parental L cell lines were maintained 
in DMEM supplemented with 10% fetal bovine serum (FBS) (HyClone). Cells 
were grown in 150 mm dishes (Falcon) and passaged by washing with PBS and 
trypsinised by applying 0.05% Trypsin/EDTA (Gibco) solution for 5 up to 20 min. 
Cell lines were long term stored in FBS supplemented with 10% DMSO and 
placed in the vapour phase of liquid nitrogen. 
 
2.4.2 Thawing and freezing/long term storage of mammalian cells 
Cells were retrieved from liquid nitrogen and thawed in 37°C in a water bath, 
warm medium added and spun at 400 x g for 5 min to pellet cells. The pellet was 
resuspended in fresh medium and transferred to the appropriate cell culture 
dish. Medium was replaced the following day.  
For long term storage of cell lines, cells were trypsinised and pelleted at 400 x g 
for 4min. Supernatant were aspirated and the pellet resuspended in freezing 
medium, containing  10% DMSO and 90% FBS. Aliquots of 1ml cell suspension 
were transferred into cryogenic vials (Corning) and placed in a  styrofoam box 
and kept at -80°C for 24h, before transferred to liquid nitrogen. 
 
2.4.3 Manual cell counting and assessment of viability 
For seeding purposes and cell number determination, 10 µL of single cell 
suspension was applied to a Neubauer haemocytometer (VWR). Cells were 
counted in four independent areas of the haemocytometer and mean values 
were determined as cell number per mL. Cell viability was analysed by the 
Trypan blue dye (Sigma) exclusion method. Equal amounts of cell suspension 
are mixed with 0.4% trypan blue solution (Sigma), both populations either 
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positive or negative for dye staining were counted and viability was expressed as 
percentage of viable (dye negative) cells.  
2.4.4 IncuCyte based proliferation or phenotype analysis 
Cells were counted manually and seeded in 24 well or 6 well plates at various 
densities, depending on the cell line and rate of proliferation. They were then 
placed in the IncuCyte (Essen Instruments) and well density was measured 
every 2h until cells reached complete confluence. Medium was changed regularly 
(every 48h) between readings. Readings were analysed using MS Office Excel. 
 
2.4.5 DNA transfection 
2.4.5.1 Lipofectamine2000 transfection of plasmid DNA  
For overexpression experiments, 1.5x106 HEK293T cells were seeded in six-well 
dishes 2-4 h prior transfection. For each transfection reaction, 4 µL 
Lipofectamine2000 (Invitrogen) pre-incubated with 96 µL Opti-MEM for 5 min 
were mixed with 2.0 µg of plasmid DNA pre-diluted into 100 µL Opti-MEM 
(Gibco). After 20 min incubation at RT, the transfection solution was then added 
drop-wise to cells. After 16-24 h, additional 2 mL of full media was added to 
each well in order to boost growth and cells were harvested the following day.  
2.4.5.2 Polyethylenimine transfection of plasmid DNA  
For overexpression experiments, 2x106 HEK293T cells were seeded in six-well 
dishes 2-4 h prior transfection. For each transfection reaction, 2.0 µg of plasmid 
DNA prediluted into 200 µL Opti-MEM (Gibco) were mixed with 8 µg 
polyethylenimine (PEI) (as aqueous solution of 1mg/mL). After 30 min 
incubation at RT the transfection solution was then added drop-wise to cells. 
After 16-24 h, additional 2 mL of full media was added to each well in order to 
boost growth and cells were harvested the following day. When performing 
transfections in 24 wells plates, 0.5 µg DNA constructs and 2ug polyethylenimine 
were combined in 100 µL Opti-MEM per reaction. 
 
2.4.6 RNAiMAX siRNA transfection 
Forward transfection protocols 
U2OS cells were plated the day before, at a density of 0.75x106 cells per 24 well 
in a total volume of 500 µL regular growth media. The next day, 6 pmol RNAi 
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duplex was diluted in 50 µL serum free OptiMEM®I medium (Gibco), while 1µL of 
RNAiMAX reagent was diluted with 50 µL serum free OptiMEM®I medium and 
mixed gently. RNAi duplex and RNAiMAX mixtures were combined and incubated 
at room temperature for 15 min, before adding the incubated mixture dropwise 
to wells and mix gently by rocking the plate. The final volume per 24 well came 
up to 600 µL, which yielded in a final of 10nM RNAi duplex concentration. 16h 
post transfection, the complete medium was changed and cells were either 
wound scratched or lysed for knock down efficiency verification 72h post 
transfection.  
Oligonucleotide delivery efficiency into mammalian cells was assessed by 
transfection of a red-labelled dsRNA oligomer (BLOCK-iT-Alexa), which does not 
display any homology to any known gene sequences.   
 
Reverse transfection protocols 
Reverse transfection protocols were applied for Saos2 invadopodia experiments. 
Transfection mixes were prepared as above by combining 100uL OPTIMEM/RNAi 
oligonucleotide solution with a 98 µL OPTIMEM / 2µL RNAiMAX mix, followed by a  
15 min of incubation at RT. Transfection mix, media and 2x105 Saos2 cells were 
combined to yield a 1mL volume prior adding to 6 wells. Media was changed 16h 
later and cells were manipulated 72h post transfection.   
 
2.4.7 Virus generation 
2.4.7.1 Retrovirus 
For generation of retrovirus containing supernatants in 60 mm dishes, 5 x 106 
cells of the retrovirus producer cell line Phoenix Eco 293 were seeded 4 h before 
transfection. Cells were lipid-complex transfected using 5µg FBneo plasmids 
diluted in 250 µL OPTIMEM, which was combined with 10 µL Lipofectamine2000 
per 250 µL OPTIMEM, followed by a 20 min incubation period at room 
temperature. The transfection mix was added drop wise onto cells while rocking 
gently, leading to final volume of 2.5mL. The next morning, culture media was 
exchanged with 3 mL regular growth medium and ecotrophic retrovirus 
supernatants were harvested at 24, 48, 72 hours after this by replacing collected 
supernatant with 3mL regular growth media. Harvested virus was either frozen 
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in 1 mL aliquots and stored at -80°C or utilised for immediate subsequent 
infection of EcoR target cells. 
2.4.7.2 Lentivirus 
Lentiviral constructs were employed due to its convenient ability to infect most 
cell types including primary or non-dividing cells, and as an alternative to 
retroviral transduction approaches in case of lack of required stable EcoR cell 
lines. 
In order to generate lentivirus supernatants for transduction purposes and 
generation of stable cell lines, 2 x 106 HEK293T cells were seeded in 35 mm 6 
well plates in a final volume of 1.5 mL.  After allowing cells to settle for 4 h, a 
PEI transfection approach (refer to 2.4.5.2) was carried out in order to deliver all 
required packaging vectors for virus particle production. Cells were triple 
transfected with 0.73 µg of the gag-pol expressor plasmid p8.91, 0.43 µg of the 
VSV-G expressor vector pMDG, and 0.84 µg of either pLEOC (Blasticidin 
resistance) or pLEX (Puromycin resistance) lentiviral destination vector.  Medium 
was replaced 16 hours later with 1 mL growth medium, and virus harvest was 
commenced 48h after transfection. Aliquots of 1 mL viral supernatants were 
supplemented with a final concentration of 5 µg/mL Polybrene in order to 
increase transduction efficiency and aliquots were either frozen or used fresh for 
transduction of target cell lines. Virus collection was performed on three 
consecutive days 48h, 72h and 96h post initial transfection.  
In order to transduce mammalian cells with lentiviral particles, cells were seeded 
into 6-well dishes and allowed to grow overnight to 50% to 70% confluency. 
Next day, frozen virus stocks in 1 ml aliquots including 5µg/ml Polybrene were 
thawed at 37°C and then spun for 1 min at 15000 x g rpm at 4°C in order to 
pellet residual cells in the supernatant. Then, cell medium was replaced by 1ml 
of the virus/Polybrene solution and plates were gently rocked every 30 min to 
increase viral transduction efficiency. After 4 hour of incubation, remaining 
supernatant was removed and replaced with 2ml of growth medium for 24h 
before adding the appropriate selective agent. The appropriate selection is vector 
dependent and media was either supplemented with 2.5 µg/mL Puromycin 
(Sigma) or 5-10 µg/mL Blasticidin (Sigma), until sensitive control populations 
died under selection pressure. Remaining transduced cell populations were either 
expanded and used for experiments or frozen for long term storage. 
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2.4.8 Generation of stable cell lines 
2.4.8.1 Generation of stably WNT ligand expressing cell lines and collection of 
WNT conditioned media 
Respective WNT ligand genes were cloned into retroviral FB destination vectors 
and used for Retrovirus generation. Mouse L cells were subsequently transduced, 
Geneticin (G418, 500 µg/mL) selected and grown to confluency. WNT ligand 
conditioned media was collected from 15 cm dishes of control (eGFP) or stable 
WNT ligand expressing L cells after reaching confluency. Conditioned media was 
collected every 24 h over the course of three days, centrifuged to remove cell 
debris and stored at 4°C for up to two months or snap frozen and stored at -
80°C for long term storage. 
Generated WNT ligand conditioned media was tested for biological activity using 
ß-catenin dependent transcription Luciferase reporter assay or Dvl2 
phosphorylation shift assessed by western blotting.  
Dilution of WNT3a CM with regular growth media at 1:2 (50%) or 1:4 (25%) 
ratios revealed that the biological activity is not compromised compared to 
undiluted CM (100%) (Figure 2.3A). In fact, the 1:2 (50%) dilution seemed to 
enhance the biological activity by about 35%, suggesting that at least WNT3a 
CM might contain other antagonistic factors besides WNT3a, which are able to 
modulate activation of canonical signalling. Further, a single freeze/thaw (F/T) 
cycle of WNT3a CM does not significantly affect its biological activity, allowing 
long term storage of CM at -80°C (Figure 2.3A).    
Since I planned to use WNT CM media for various stimulation experiments, 
which might be sensitive to high FBS concentrations (above 0.25%), I assessed 
WNT3a ligand activity with conditioned medium containing various FBS 
concentrations using the β-catenin luciferase readout. Conditions ranged from 
using serum free, BSA supplemented serum free, 0.25% FBS or regular growth 
media levels, which demonstrated that WNT3a activity is 3-4 fold less in WNT 
conditioned media containing low or no FBS. Therefore, we generally produced 
WNT ligand CM in the presence of 10% FBS (Figure 2.3B). 
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Figure 2.3: Analysis of WNT3a conditioned media biological activity and optimal 
culture and storage conditions. HEK293T cells were co-transfected with TOPFLASH 
(firefly luciferase) and renilla luciferase reporter constructs. 24h post transfection, cells 
were stimulated for 16h with WNT3a conditioned media prior cell harvest. Cell extracts 
were assayed for firefly and renilla luciferase activities and data obtained were normalised 
for renilla activity. β-catenin levels were expressed as fold increase across analysed 
samples using control CM stimulated cells as reference. (A) WNT3a conditioned media 
(CM) either undiluted (100%) or diluted 1:2 (50%) or 1:4 (25%) as indicated were 
compared to a frozen and thawed (F/T) sample and assessed for biological activity. 
Treatment with Lithium Chloride (LiCl, 30 mM, 16h) served as positive control. (B) In 
order to examine if FBS concentrations during WNT3a CM generation affect its signalling 
effectiveness, conditioned media with varied FBS amounts were compared for canonical 
pathway activation. Expression of β-catenin or DVL3 served as positive canonical 
stimulation control. eGFP transfection was used as transfection and background control. 
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2.4.8.2 Generation of stable cells expressing YFP-fusion proteins for localisation 
studies 
In order to analyse subcellular localisation of VANGL or other proteins of interest, 
YFP-VANGL1, YFP-VANGL2, YFP-Dvl2 and others as outlined on respective figures 
were subcloned into lentivirus pLEX-YFP (Puromycin selection) destination 
vectors and viral supernatants generated as described above (refer to 2.4.7.2). 
Cells were infected and selected as outlined in 2.4.7.2 and seeded on coverslips 
for immuno-fluorescent analysis (2.7.1.1) or biochemical analysis. 
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2.5 PROTEIN TECHNIQUES 
2.5.1 Preparation of cell extracts and immunoblot analysis  
Cells extracts were prepared by washing cells once with ice-cold PBS and adding 
lysis buffer LB-E or LB-M, while rocking dishes for 5 – 10 min at 4°C. Extracts 
were collected and centrifuged at 15,000 x g for 15 min at 4 °C and normalised 
according to the Bradford protocol including BSA-standard curve see below 
(Bradford 1976). 10 µg of protein lysates were generally loaded on 4-20% 
gradient NuPage SDS–polyacrylamide gels (Invitrogen) and blotted on a 
polyvinylidene fluoride (PVDF) membrane (Amersham). Membranes were 
coomassie stained for visualisation of protein content, blocked for 1 h in blocking 
buffer (5% non-fat dried milk (Sigma)/PBST) and incubated with primary 
antibody according to Table 1 in 3% BSA/PBST supplemented with 0.02% NaN3 
at 4 °C overnight. Membranes were washed three times with PBST and 
incubated for 1 h either with donkey anti-rabbit-HRP 1:5000 (Amersham) or 
sheep anti-mouse-HRP 1:5000 (Amersham), followed by washing three times 
with PBST and immunodetection was performed by application of a 
chemiluminescence detection system (Insight Biotechnology) and exposed to 
medical x-ray film (Fujifilm). 
 
2.5.2 Determination of protein concentractions 
Protein contents were determined based on the Bradford protocol (Bradford 
1976) employing a BSA standard curve from 10 to 120 µg/mL protein content 
using a protein assay dye reagent concentrate (Bio-Rad, 500-0006) according to 
instructions of the manufacturer and measuring absorbance at 595 nm. 
Unknown protein samples were calculated from BSA readings using a linear 
regression approach. 
 
2.5.3 Densitometric analysis 
Western blot films were scanned at a resolution of 600 dots per inch (dpi) and 
saved in jpg format at maximum quality. Bands of interest were selected and 
intensity measured of each individual band as outlined in 
http://lukemiller.org/index.php/2010/11/analyzing-gels-and-western-blots-with-
image-j. Background values were subtracted and densities displayed as fold 
increase. 
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2.5.4 GST-pull down and immunoprecipitation experiments 
Cell lysates for interaction studies (either IP or pull down experiments) were 
harvested and centrifuged as described above. GST-proteins were purified using 
glutathione beads (Amersham), Flag-tagged proteins were immunoprecipitated 
with Flag-beads (Sigma) using an equivalent of 10 µL packed beads. Lysates 
were incubated with respective agarose beads for 2 h while rotating at 4°C and 
subsequently washed 3 times with lysis buffer without protease and phosphatase 
inhibitors. After completion of washes, beads were drained with a needle (25G, 
Terumo) and proteins eluded with LDS sample buffer. Interaction were analysed 
by Westen botting as described above. 
 
2.5.5 Expression and purification of recombinant proteins 
Competent E.coli strain BL21(DE3) (Invitrogen) were transformed with desired 
expression constructs. A two ml overnight culture from an individual bacterial 
colony was used to inoculate 900 mL LB/ampicillin (100 µg/mL) media per 
construct and incubated at 37°C at 200 rpm until reaching an optical density 
(OD) value of OD600=0.6. Cultures were induced with 1 mM IPTG (Isopropyl-β-D-
Thiogalactopyranoside) and kept shaking for four additional hours. Bacteria were 
then pelleted at 4500 rpm (JLA-10.500 rotor, 3847 x g) at 4 °C for 20 min, and 
the supernatant was discarded. Pellets were resuspended in 20 mL PBS-E lysis 
buffer containing 0.5 mg/mL Lysozyme (Sigma), protease inhibitors (tablet, 
Roche), 5 µg/mL DNase (Sigma) and 5 mM β-Mercaptoethanol on ice. Next, 
resuspended bacteria were lysed using a sonication approach of 4 rounds at 45 
sec each on ice and debris was pelleted by centrifugation at 20000 rpm (JA-
25.50 rotor, 32816 x g). Fusion proteins were then purified from the yielded 
lysate with either His, Glutathione, Streptavidin or Flag beads during incubating 
for 2-4h at 4°C and gentle rotation. After three to four wash steps, proteins were 
either eluted using the respective elution buffer or sample buffer (LDS).  
 
2.5.6 Generation of GST-RBD beads for RHO/RAS activation assays 
Respective GST- Raf, RalGDS or Rhodekin binding domain (RBD) fusion proteins 
were expressed in E.coli and lysed as described above. Lysates were purified 
using glutathione beads for 2h while gently rotating at 4°C, before collecting 
beads by centrifugation at 2000 x g for 4 min. Supernatant was either discarded 
or used for a second round of GST-purification. GST-beads were washed for four 
114 
 
times with PBS-0.1% Trition X-100 and once with LB-M/50% Glycerol before 
storing beads as 1:4 in PBS-M/glycerol (50% Glycerol). An equivalent of 10 uL 
packed beads were run on a SDS-PAGE gel in order to assess amount of bound 
protein and purity, and appropriate stimulated lysates were used to test if GST-
RBD beads are able to enrich respective GTPases. 
 
2.5.7 RAS and RHO binding domain assays 
RAS binding domain (RBD) assays can estimate various endogenous RAS-family 
protein activities and have been employed to analyse R-RAS and RHO levels in 
mammalian cells upon various stimulations. In order to monitor levels of 
activated R-RAS GTPases in cell lysates, I used GST-fusions of the Ras-binding 
domain (RBD) of the RAS effector RAF1 (residues 2–140) or RALGDS (C-terminal 
97 residues), exploiting the fact that RAS family proteins only bind effectors in 
the GTP-bound state (Brtva et al. 1995; de Rooij and Bos 1997; Franke et al. 
1997). Cells were lysed in LB-M lysis buffer, and cleared lysates incubated for 45 
min at 4°C with 10 µL packed GST-RBD glutathione sepharose beads (see 
2.5.6). Beads were washed three times, and bound proteins were eluted with 
LDS sample buffer and resolved by SDS-PAGE. Activated H-RAS, R-RAS or TC21 
was detected by immunoblotting using respective antibodies (Table 1). 
 
The cellular level of GTP-loaded RHOA and RHOB was determined using a GST 
fusion protein containing the RHO binding domain of Rhotekin (GST-RBD), 
corresponding to residues 7-89 of Rhotekin, which specifically precipitates GTP-
RHO from cell lysates (Ren and Schwartz 2000; Mezzacappa et al. 2012). Cells 
were lysed in LB-M lysis buffer, and cleared lysates incubated for 45 min at 4°C 
with 10 µL packed GST-RBD glutathione sepharose beads (see 2.5.6). Beads 
were washed three times, and bound proteins were eluted with LDS sample 
buffer and resolved by SDS-PAGE. Activated RHOA or RHOB was then detected 
by immunoblotting using respective antibodies (Table 1). 
 
2.5.8 In vitro interaction assays  
Spodoptera frugiperda (Sf9) cells were infected with baculoviruses expressing 
GST-VANGL1 truncations (N and C-terminal) or various ARHGEF17/p164RhoGEF 
C-terminal truncations (C1-C5). His-R-RAS, His-TC21 and effector proteins were 
expressed and purified from bacteria as described above (section 2.5.5). In vitro 
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interactions were carried out by loading purified His-R-RAS or His-TC21 with 
either GDP or the non-hydrolysable analogue of GTP (GMP-PNP) by incubation 
for 5 min at 37°C in loading buffer (20 mM Hepes (pH 7.5), 50 mM NaCl, 5 mM 
EDTA, 5 mg/mL BSA) in a 20-fold molar excess of GDP or GMP-PNP. Reactions 
were stopped by placing the tubes on ice and adding MgCl2 to a final 
concentration of 20 mM. 0.5 µg GDP/GMP-PNP loaded R-RAS or TC21 was 
combined with 15 µL of packed glutathione beads  bound to GST-VANGL1 or 
GST- ARHGEF17/p164RhoGEF (or other effector proteins) in a tube containing 
200 µL of PBS, 5 mM MgCl2, 0.1% Triton X-100. After 1-3 h of incubation at 4°C 
while rotating, GST-beads were washed three times with PBS, 5 mM MgCl2, 0.1% 
Triton X-100, needle drained and LDS sample buffer added. After separation on 
4-12% SDS-PAGE gels, western blots were performed using His antibodies. 
 
2.5.9  TAP-tagged protein transfection and purification for mass 
spectrometry analysis 
For the transient expression approach, eight confluent 15cm dishes (Greiner) of 
HEK293T cells per condition were seeded at 50% confluence in a volume of 
15mL, and transfected 3h post seeding using the PEI approach (2.4.5.2). Per 15 
cm dish 10 µg TAP6-VANGL1 plasmid were combined with GST-R-RAS expression 
plasmids (10 µg), mFzd5 (5ug), ROR2 (5 µg) or empty vector (5-10 µg) to yield 
a total of 20 µg plasmid DNA, which was combined with 80 µg PEI reagent. The 
media was exchanged 5 h post transfection with 20 mL growth media and cells 
were additional boosted with 10 mL media 16 h later. HEK293T cells were 
harvested 48h after transfection and cells extracts were prepared by washing 
cells twice with ice-cold PBS and collected in PBS-M lysis buffer (1.6 mL per 
plate) on ice (2.1.2). Extracts were centrifuged at 20,000 x g for 20 min at 4 °C 
to pellet cellular debris. The soluble fraction was incubated with 250µl packed 
Streptavidin high performance beads (GE Healthcare, 17-5113-01) per condition 
for 2 hours at 4°C while rotating gently. Beads were pelleted through 
centrifugation at 2000 x g for 5 min and column washed four times (VWR, 
gravity flow columns) to remove unbound proteins. Bound proteins were eluted 
by supplementing 2.5mM biotin in PBS-M wash buffer and shaking beads gently 
for 10 min prior draining the beads and collecting the eluate. In order to increase 
eluate protein concentration, proteins were precipitated using a Trichloroacetic 
acid (TCA) approach. Eluates were supplemented with 2% deoxycholate/PBS 
(1/100 of total volume) and TCA (1/20 of total volume), vortexed and incubated 
on ice for 30 min. Precipitated proteins were pelleted by centrifugation at 15000 
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x g at 4°C for 30 min, and supernatants were carefully aspirated before pellets 
were washed with 500 µl acetone. Pellets were collected again through spinning 
at 15000 x g at 4°C for 5 min and the acetone removed in order to air dry the 
remaining pellet. Dried pellets were dissolved in 30µl of 2x LDS sample buffer, 
and left O/N at RT. 
 
2.5.10 Mass spectrometry analysis  
LDS samples were resolved on a 4-12% NuPAGE gels (Invitrogen) and stained 
with SimplyBlueTM SafeStain (Invitrogen) according to the instructions of the 
manufacturer. Visualised bands were compared to control/background TAP-
samples and differential bands were excised with a clean scalpel and proteins 
were digested in-gel with trypsin as described previously (Rosenfeld et al. 1992) 
and under http://msf.ucsf.edu/ingel.html.  
Mass spectrometry analysis was carried out by Juan A. Oses-Prieto at the 
Department of Pharmaceutical Chemistry (University of California, San Francisco, 
California 94143, USA), as described previously (Rodriguez-Viciana et al. 2006).  
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2.6 CELL BIOLOGICAL TECHNIQUES 
2.6.1 Scratch wound migration assays  
Cells were seeded in 24 well plates (Imagelock plates distributed by Essen 
Instruments), grown to confluency and scratch wounded using a woundmaker 
(Essen Instruments) using 10 µL sterile tips. Wells were washed up to three 
times with PBS in order to remove debris, and 500 µL media added. Plates were 
placed in the Essen Instruments IncuCyte device and the wound area including a 
small area of the bordering monolayer of cells monitored over time. Images were 
automatically taken over a course of two days with intervals of one to two hours. 
Scratch induced migration was analysed by tracking the cell repopulation of the 
wound in percent over a period of time and plotting a graph over time using 
Essen Instruments provided software IncuCyte version 2010A. 
 
2.6.2 Transwell/Boyden chamber assays 
Transwell migration of U2OS was examined by means of 8 µm pore PET 
membranes of 24-well transwell inserts (BD Biosciences). 72h post 
siRNA/RNAiMax transfection, U2OS cells were trypsinised and resuspended in 
serum-containing DMEM at a density of 250,000 cells/mL.  200 µl cell suspension 
was plated into each insert (upper chamber), which were placed into lower 
chambers containing 800 µl DMEM/10% FBS. Cells were left to settle on the PET 
membrane, which required serum presence and after 90 min, media in the top 
chamber was exchanged with 200 µL serum free media, thus generating a 
chemoattractant gradient towards the lower chamber.  The assay was 
terminated after 14 h, and non-migrated cells were removed from the upper 
chamber with a cotton bud and migrated cells were fixed and stained with 0.5% 
crystal violet/10% Methanol for 15 min. Residual staining solution was rinsed off 
with water and images taken using a 10x magnification. The number of migrated 
cells was determined using pictures of five representative fields and normalised 
as percent of migrated cells using initial seeding densities for calculation. 
 
2.6.3 Cell polarisation assays: GM130 and MTOC assays 
To assess polarisation in response to wounding, cells were plated on coverslips 
and transfected with siRNAs using RNAiMAX lipid complexes as described in 
section 2.4.6. 72 h post transfection, confluent cell monolayers were wounded 
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with a sterile pipette tip, wells washed with PBS to remove debris and cells were 
allowed to migrate for 4h (GM130 experiments) or 60-90 min (γ-tubulin 
experiments).  Cells were fixed, permeabilised and stained as described in 
section 2.7.1.  
 
2.6.4 Invadopodia assay 
Preparation of Alexa Fluor568-gelatin coated coverslips  
Prewarmed Alexa Fluor568-gelatin (type A, 300 bloom, Sigma G-1890, prepared 
by M. Nishita) was mixed with regular gelatin (25 mg/mL) at equal volumes at 
37°C until completely melted. For 12 coverslips (18 mm, Matsunami), 75 µL of 
Alexa Fluor568 was mixed with 75 µL of regular gelatin on a parafilm piece on a 
heating block until completely dissolved. Coverslips were placed onto the gelatin 
drop for one sec, excess gelatin removed with an aspirator and the coverslip 
submerged into ice cold 0.5% Glutaraldehyde/PBS (Nacalai tesque, freshly 
prepared) solution for 15 min. Next, Glutaraldehyde/PBS was removed and 
coverslips were washed three times with PBS and subsequently 1mL of 5 mg/mL 
NaBH4 /PBS (Sigma, S9125-100, freshly prepared) added, following three min 
incubation at RT. Subsequently, NaBH4 /PBS solution was removed and 
coverslips washed three times with PBS, before adding 70% ethanol/ddH2O in 
order to sterilise coverslips at RT for 15min. After aspiration of the 
ethanol/ddH2O mixture, coverslips were washed three times with sterile PBS, 
and either kept for storage purposes wrapped in aluminium foil at 4°C to avoid 
bleaching or were used immediately, which required at least 1h quenching with 2 
mL culture medium at 37°C. Before cells were seeded onto Alexa Fluor568 
treated coverslips, cell culture medium was removed and coverslips were washed 
two more times with culture medium before seeding of cells.    
 
Experimental process 
Saos2 cells were reverse transfected as outlined in section 2.4.6 and 72h later 
trypsinised and counted in order to plate 3.2 x 105 cells per coverslip. Cells were 
seeded in regular growth media and allowed to attach for 9h. Experiments were 
terminated at this time point through a single wash with PBS and immediate 
fixation using 4% PFA (Nacalai) for 10 min. Formation of invadosomes was 
assesses after actin counterstaining with phalloidin. Thus, fixed coverslips were 
washed twice with PBS and cells permeabilised for 5 min with 0.2% Triton 
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X100/PBS. Next, coverslips were washed twice with PBS and blocked for 60min 
with 2% FBS/PBS at RT before staining with 2% FBS/PBS supplemented with 
1:500 Phalloidin-488 (Cambrex, PA-3010) and 1:1000 DAPI  (4',6-diamidino-2-
phenylindole) (Sigma, 1mg/mL) for 1h. Coverslips were washed three times for 
10 min each, before mounting on glass slides (Matsunami) using ProLong Gold 
antifade mounting media (Invitrogen, P36930). Invadosome formation was 
quantified by microscope imaging of 30 representative fields per condition at 
similar cell densities per coverslip at 40x magnification and counting of Alexa 
Fluor 568 depleted “black spots” indicating ECM degradation.  
 
2.6.5 Luciferase reporter assays for β-catenin level detection 
The TCF/LEF reporter assay was employed to monitor the biological activity of 
WNT ligands through activation of the β-catenin dependent pathway in in 
cultured cells. WNT ligand binding leads to stabilisation and nuclear translocation 
of β-catenin, which complexes with TCF/LEF transcription factors, leading to the 
activation of WNT-responsive genes. The TCF/LEF-responsive luciferase construct 
encodes the firefly luciferase reporter gene under the control of a minimal CMV 
promoter and tandem repeats of the TCF/LEF transcriptional response element 
(TRE) (Korinek et al. 1998; Ishitani et al. 1999). Lithium is a selective inhibitor 
of the serine/threonine protein kinase GSK-3β at a relatively high concentration 
(IC50 = 2 mM) and has been employed as a positive assay control in all 
experiments (Klein and Melton 1996; Stambolic et al. 1996). 
HEK293T cells were seeded at a density of 3.2 x 105 per 24 well, and 4 h later 
Lipofectamine2000 co-transfected using 75ng of the TOPFLASH reporter 
construct LEF-Luc (TOPT, firefly luciferase), 2.5 ng control reporter construct 
Renilla-Luciferase, alongside with 100 ng pcDNA3 expression constructs such as 
the positive controls β-catenin, DVL2 or empty vector in case of ligand 
treatment. The next morning, cells were boosted with 500 µl of growth medium 
and 24h post transfection, media was exchanged for WNT ligand conditioned 
media, recombinant WNT ligands or treated with LiCl acting as an activation 
control for 16h prior harvest. For luciferase detection, a Dual Dual-Luciferase® 
Reporter Assay System (Promega) was employed, which is based on a two-step 
detection method. Cells were passively lysed according to instructions of the 
manufacturer followed by sequential measurements of firefly (Photinus pyralis) 
and Renilla (Renilla reniformis) luciferase activities from a single sample. The 
firefly luciferase reporter is measured first by adding Luciferase Assay Reagent II 
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(LAR II) and after quantifying the firefly luminescence, this reaction is quenched, 
and the Renilla luciferase reaction is initiated by simultaneously adding Stop & 
Glo® Reagent to the same reaction tube. Light emissions were detected using a 
luminometer (Varioscan platereader) and the obtained luciferase values were 
normalised for variations in transfection efficiency by using the renilla internal 
control (Renilla detection), and are expressed as fold stimulation of firefly 
luciferase activity.  
 
2.6.6 Autophagy inducing treatments 
For starvation purposes and autophagy induction, cells were washed three times 
with PBS and incubated with HBSS for 6h. Autophagy stimulation and activity 
was assessed by LC3B-II cleavage. In order to inhibit starvation induced 
autophagy, cells were treated with HBSS containing 10 mM 3-methyladenine, 
25µM Chloroquine or 30nM Bafilomycin A for indicated time points.  
 
2.6.7 Statistical analysis 
Data is reported as ±standard errors of the means (SEM) and were examined by 
one way analysis of variance (ANOVA). Statistical significance was determined at 
p<0.05 for all experiments.  
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2.7 MICROSCOPY 
2.7.1 Preparation and staining procesdure of cells for fluorescent 
microscopy purposes 
2.7.1.1 PFA fixation and permeabilisation for GM130 stainings 
Cells were grown and manipulated on coverslips (VWR, 13 mm for 24 wells if not 
stated otherwise) and washed with PBS once prior to 4% PFA/PBS fixation for 15 
min at RT. Subsequently, the PFA/PBS solution was aspirated and washed three 
times with PBS for 5 min each in order to remove all PFA traces. Cells were 
permeabilised with 0.1% Triton X-100/PBS for 10 min at RT, washed once with 
PBS and blocked by incubation with 4% BSA/PBS for 45 – 60 min. Primary 
antibodies were applied as a dilution in 2% BSA/PBS solution O/N (16h) at 4°C, 
and coverslips were placed in a hydrated chamber. For polarisation experiments 
assessing Golgi reorientation, GM130 antibodies were used at 1:200 dilution 
(Transduction, 610822, clone 35). After completion of the primary antibody 
incubation period, coverslips were washed three times for 5 min each with 2% 
BSA/PBS solution, followed by application of the appropriate secondary antibody. 
For GM130 experiments Goat anti-mouse, Alexa-488 conjugated antibodies 
(Pierce) diluted 1:200 in 2% BSA/PBS were used and coverslips incubated for 45 
min at RT protected from light. In order to counter stain the cellular nucleus, 
coverslips were immediately treated with Hoechst stain (Sigma H6024) at a 
concentration of 0.5 µg/mL in 2% BSA/PBS for 10 min and subsequently washed 
twice for 5 min each with 2% BSA/PBS, followed by one PBS wash for 5 min. 
Coverslips were desalted by dipping each slide into distilled water, briefly air 
dried and placed on a glass microscopy slide with a drop of mounting media 
(Dako S3023). Slides were imaged using a Zeiss AxioImager A1 and images 
taken of confluent areas or the wound edge.  
PFA fixation was usually employed for visualisation of exogenously expressed 
YFP- or GFP-fusion proteins and associated localisation studies. In several 
experiments, actin was counterstained using Phalloidin/methanol solution 
(Sigma, P1951) at a concentration of 0.25 µg/mL carried out simultaneously with 
the Hoechst nucleus staining step. 
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2.7.1.2 Methanol based fixation for γ-tubulin staining 
Cells were grown and manipulated on coverslips (VWR, 13 mm for 24 wells if not 
stated otherwise) and washed with PBS once prior to 100% ice cold methanol 
fixation for 10 min at -20°C, and PBS washed three times, followed by 1 h BSA 
blocking in 4% BSA/PBS at RT. Immediately after, coverslips were incubated in a 
hydrated chamber with anti-γ-tubulin primary antibody (Sigma, GTU-88) at a 
1:500 dilution in 2%BSA/PBS O/N (16h) at 4°C. After completion of the primary 
antibody incubation period, coverslips were washed three times for 5 min each 
with 2% BSA/PBS solution, followed by application of the appropriate secondary 
antibody. For γ-tubulin MTOC experiments Goat anti-mouse, Alexa-488 
conjugated antibodies (Pierce) diluted 1:200 in 2% BSA/PBS were used and 
coverslips incubated for 45 min at RT protected from light. In order to counter 
stain the cellular nucleus, coverslips were immediately treated with Hoechst stain 
(Sigma H6024) at a concentration of 0.5 µg/mL in 2% BSA/PBS for 10 min and 
subsequently washed twice for 5 min each with 2% BSA/PBS, followed by one 
PBS wash for 5 min. Coverslips were desalted by dipping each slide into distilled 
water, briefly air dried and placed on a glass microscopy slide with a drop of 
mounting media (Dako S3023). Slides were imaged using a Zeiss AxioImager A1 
and images taken of confluent areas or the wound edge.  
 
2.7.2 Localisation studies using confocal flourescence microscopy   
Fixation protocols were carried out at described above (section), samples were 
desalted as outlined before and images acquired at 40x, 63x or 100x using 
either air or oil objectives on a Perkin Elmer spinning disc confocal microscope. 
Images were processed using Velocity software version 5.4.   
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CHAPTER 3 
 
Characterisation of 
VANGL1 as a R-RAS 
effector 
 
and 
ARHGEF17/p164RhoGEF 
as a TC21 effector 
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3 Characterisation of VANGL1 as an effector of R-RAS 
As outlined in the introduction chapter, R-RAS and H-RAS share many 
biochemical and biological properties, as well many downstream effectors and 
regulatory proteins (GEFs and GAPs), including the ability to behave as 
oncogenes (Buday and Downward 1993; Self et al. 1993; Rey et al. 1994; 
Spaargaren and Bischoff 1994; Spaargaren et al. 1994; Gotoh et al. 1997; Marte 
et al. 1997; Ebinu et al. 1998). However, R-RAS appears to have specific 
functions of its own, including effects on integrin mediated adhesion, being 
clearly distinct from classical RAS proteins (Zhang et al. 1996; Suzuki et al. 
2000; Self et al. 2001; Hansen et al. 2003; Kinbara et al. 2003; Pozzi et al. 
2006). How R-RAS regulates integrin activation is not known. A study using 
partial loss of function effector mutants in combination with pharmacologic 
inhibitors revealed that no known R-RAS effector could account for the observed 
effect, suggesting the existence of yet unidentified effector(s) which mediate(s) 
the effects of R-RAS on integrin activation (Oertli et al. 2000).  
Dr Rodriguez-Viciana optimised the Tandem Affinity Purification (TAP) method in 
order to identify novel RAS family interactors. This methodology has been shown 
to work efficiently and successfully in identification of the SHOC2-PP1 
phosphatase holoenzyme as a specific M-RAS effector (Rodriguez-Viciana et al. 
2006). This approach was then employed to identify other novel binding partners 
of R-RAS GTPases using activated R-RAS and TC21 as baits. 
 
 
3.1 Identification of potential novel effector of R-RAS and 
TC21 
Dr Rodriguez-Viciana performed three independent TAPs using the constitutively 
active R-RAS mutant G38V (V38) as bait in three different cell lines: human 
embryonic kidney (HEK) HEK293, HEK293T, and adeno-
carcinomic human alveolar basal epithelial A549 cells. R-RAS co-purified proteins 
identified by mass spectrometry (MS), which were not detected in control baits 
are listed in Figure 3.1. 
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Figure 3.1: Tandem affinity purified R-RAS V38 interactors, identified by mass 
sprectrometry. Cells expressing TAP-tagged R-RAS V38 constructs were lysed, tag-
precipitated and co-purified proteins identified by mass spectromery. TAP approaches 
were perfomed in HEK293 (A), EGF stimulated HEK293T (B) or A549 cells (C). 
 
Identification of the well-described R-RAS effectors such as RAF1/CRAF and RINs 
serve as validation control for this unbiased proteomic approach, indicating that 
the addition of the TAP tag does not compromise R-RAS function in vivo (Figure 
3.1). 
In addition to RAP1GDS, a protein that interacts with multiple RAS and RHO 
family GTPases in a GTP-independent manner (Yamamoto et al. 1990; Mizuno et 
al. 1991; Hamel et al. 2011), VANGL1 was identified in all three performed 
purifications (Figure 3.1). 
VANGL proteins are highly conserved from fly to humans and the Drosophila 
melanogaster homologue strabismus (stbm) has been described as one of the 
core components of the WNT/PCP pathway. Therefore, VANGL1 presents an 
intriguing target due to the potential novel link between RAS signalling and the 
β-catenin/non canonical WNT pathway. 
Employing TC21 G12V as bait in a parallel TAP approach resulted in co-
purification of several known RAS family effectors such as CRAF, ARAF, RIN1, 
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MLLT4/AFADIN/AF6 and the RALGEF RGL2 (Rodriguez-Viciana et al. 2004), again 
validating the sensitivity of the approach (Figure 3.2). In addition, 
ARHGEF17/p164RhoGEF, a RHOA activating nucleotide exchange factor 
(Rumenapp et al. 2002) was identified in A549 cells (Figure 3.2C). 
This discovery led to the intriguing hypothesis that R-RAS could act downstream 
of WNT ligands and modulate VANGL1 function in the WNT/PCP pathway, while 
TC21 is also able to modulate RHO GTPase activation through 
ARHGEF17/p164RhoGEF. Recruitment of other factors such as PI3Ks or RALGEFs 
could then enable the regulation of cell polarity and motility (Figure 3.3). 
 
 
Figure 3.2: Tandem affinity purified TC21 V12 interactors, identified by mass 
spectroscopy. Cells expressing TAP-tagged R-RAS V38 constructs were lysed, tag-
precipitated and co-purified proteins identified by mass spectromery. TAP approaches 
were perfomed in HEK293 (A), EGF stimulated HEK293T (B) or A549 cells (C). 
 
To validate VANGL1 and ARHGEF17/p164RhoGEF as novel R-RAS GTPase 
effectors, characterisation experiments are described in two separate sequential 
sections. The initial part of this chapter focuses on the VANGL1 and R-RAS 
interaction (section 3.2), and this is followed by the interaction validation of 
ARHGEF17/p164RhoGEF as a novel effector of TC21 (section 3.3). 
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Figure 3.3: Proposed model of how R-RAS GTPases could act downstream of 
WNT ligands in the non-canonical WNT signalling pathway. R-RAS subgroup 
members are activated upon binding of WNT ligands (WNT) to Frizzled receptors (FZD) by 
an unknown mechanism. R-RAS GTPases are able to recruit VANGL1, 
ARHGEF17/p164RhoGEF as well as other factors such as Phosphatidylinositide 3-kinases 
(PI3K)  or RAL guanine exchange factors (GEFs) in order to modulate cell adhesion, 
polarity and motility through the activation of  RAL and RHO GTPases. R-RAS GTPases 
could be also activated by Receptor Tyrosine Kinases (RTK), Notch ligands or Trefoil 
family factors (TFFs). DVL - Dishevelled. 
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3.2 VANGL1 behaves as an effector of R-RAS subfamily 
GTPases 
3.2.1 R-RAS interacts with VANGL1 in an activation and effector domain 
dependent manner 
TAP experiments identified VANGL1 as a potential R-RAS interacting protein. In 
order to validate and to characterise this interaction, co-transfection approaches 
utilising HEK293T were performed, due to the lack of a commercially available 
endogenous antibody for VANGL1. This system is based on co-transfection of a 
glutathione S-transferase (GST) tagged bait construct and respective flag-tagged 
potential interactors. After pull down of GST-proteins with gluthathione beads, 
binding to the GST-bait is verified by immunoblotting using flag-antibodies. 
Notably, avoiding antibody based beads for immunoprecipitation has been 
demonstrated to decrease background and increase signal to noise ratio in co-
transfection experiments (Rodriguez-Viciana and McCormick 2006). 
To validate VANGL1 as a true R-RAS effector, VANGL1 is required to bind to R-
RAS in a GTP-dependent manner, therefore constitutively active mutants of R-
RAS (G38V and Q87L, analogous to H-RAS oncogenic mutants G12V and Q61L) 
were used for binding studies.  
Further, RAS effector proteins interact with RAS through a defined small stretch 
termed the effector domain, only when the RAS is GTP bound and thus active. A 
point mutation in the effector domain of R-RAS (D64A, equivalent to D38A in H-
RAS) leads to disruption of effector protein binding in the activated background 
(Oertli et al. 2000; Repasky et al. 2004). Therefore, this point mutation was 
employed to assess RAS effector domain dependent binding of VANGL1. In 
addition to the initial biochemical interaction studies, further biological assays 
were carried out in order to address the R-RAS – VANGL1 functional relevance 
(see section 4.3 and chapter 7).  
Co-expression experiments in HEK293T cells showed a strong preferential 
binding of VANGL1 to R-RAS activating mutants V38 or L87 over R-RAS wild type 
(wt), whereas no interaction with the effector domain mutants V38 A64 or L87 
A64 could be detected, confirming an activation dependent interaction with R-
RAS as well effector domain mediated binding (Figure 3.4). This fulfils the 
requirements of a RAS family effector protein (Repasky et al. 2004). The closely 
related GTPase RAP2 fails to precipitate VANGL1 and therefore was used as 
background control (Figure 3.4).  
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R-RAS L87 showed considerably higher binding than R-RAS V38 and was 
therefore preferentially employed in all subsequent experiments (Figure 3.4). 
Preferential interaction with the L87 versus the V38 homologous active mutants 
have been previously reported for several effectors of RAS Family GTPases 
(RFGs) and may be related to the fact that the L87 substitution falls within the 
switch II effector domain (and may thereby have structural effects on effector 
interactions (Figure 1.10) (McCormick 1992). 
 
 
Figure 3.4: VANGL1 interacts with R-RAS activation and effector domain 
dependent. HEK293T cells were co-transfected with flag-VANGL1 and either GST-RAP2 
(negative control) or GST-R-RAS expression plasmids, and GST-pulldowns were probed 
with flag antibody by western blot. Both constitutively active R-RAS mutants (V38 or L87) 
and effector domain mutants (V38 A64 or L87 A64) were used to verify activation 
dependent interaction and effector domain binding. wt- wildtype protein, PD-pull down. 
Levels of GST baits were determined by staining the western blot membrane with 
coomassie blue prior to antibody incubation (n=5). 
 
 
3.2.2 VANGL1 and VANGL2 interact specifically with R-RAS subgroup 
members  
In order to investigate the specificity of the interaction among closely related 
GTPases, binding of VANGL proteins to a panel of RAS Family GTPases was 
tested. VANGL1 and VANGL2 interact in an activation-dependent manner with 
members of the R-RAS subgroup but not with other RAS family members such as 
oncogenic RAS protein (N-RAS) or RAP proteins (RAP1, RAP2) (Figure 3.5). 
Notably, under conditions of overexpression of RAS family GTPases (RFGs), the 
interaction between VANGL1 is restricted to R-RAS subgroup members, 
highlighting the specificity of interaction.  
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The levels of expression of TC21 (and RAP1) achieved with our expression 
plasmids are always consistently lower compared to other RFGs, and therefore 
the relative amounts of co-immunoprecipitated proteins have to be considered 
with respect to the levels of baits. With this consideration in mind, VANGL1 can 
be seen to interact preferentially with R-RAS and TC21 compared to M-RAS 
(Figure 3.5).  
 
 
Figure 3.5: R-RAS GTPases interact in an activation-dependent manner with 
VANGL1 and VANGL2. GST-tagged constructs of wild-type (wt) and activated mutants 
(V12, L87, L71, L81) of RAS family GTPases (RFG) were expressed in HEK293T cells 
together with flag-tagged VANGL1 or VANGL2. GST-RFGs were purified with glutathione 
beads and interacting VANGL proteins detected by western blotting using anti-flag 
antibodies. PD – pull down. GST-bait levels was visualised by Coomassie blue staining of 
the western blot membrane prior to antibody incubation (n=3). 
 
Flag-VANGL2 can also be detected to associate with R-RAS subgroup GTPases 
but with significant lower affinity; much longer exposures had to be carried out 
during chemoluminescent detection and signal above background was not as 
high as observed for VANGL1. VANGL2 is known to hetero-dimerise with VANGL1 
(Belotti et al. 2012) and therefore at least a certain fraction of the VANGL2 
detected level could be indirectly associated through endogenous VANGL1. 
Furthermore, VANGL1 but not VANGL2 was repeatedly found by mass 
spectrometry to co-purify with R-RAS (Figure 3.1). Therefore, we decided to 
focus our studies on VANGL1. 
After testing and verification of multiple commercially available VANGL1 
immunoglobulins, one antibody was identified to detect immunoprecipitated 
VANGL1 protein (data not shown), enabling to study the interaction of R-RAS 
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GTPases with endogenous VANGL1. Due to unavailability of good 
immunoprecipitating antibodies against R-RAS GTPases coupled to the fact that 
R-RAS GTPase interaction is strictly GTP dependent, and no potent R-RAS 
stimulators were known, exogenously expressed activated R-RAS proteins were 
required to be expressed for effector interaction experiments (Figure 3.6). 
 
 
Figure 3.6: Interaction of endogenous VANGL1 and other effectors with RAS 
family GTPases. Flag-tagged constructs of wild-type (wt), activated mutants (V or L) or 
respective effector domain mutants (VA or LA) of Ras family GTPases (RFG) were 
expressed in HEK293T cells. Flag-GTPases were purified 48h after transfection with flag 
affinity beads and endogenous proteins detected by western blotting using indicated 
antibodies. IP – Immunoprecipitation, PP1C – protein phosphatase 1C. Applied mutants 
were the following: RAP2 V12 or V12 A38, R-RAS L87 or  L87 A64, TC21 L71 or L71 A48, 
M-RAS L81 or L81 A48, and N-RAS V12 or V12 A38. 
 
Endogenous VANGL1 immunoprecipitates with activated R-RAS and TC21, and 
only very faint interaction could be detected with M-RAS (Figure 3.6), consistent 
with a preferential interaction with these two R-RAS subgroup members 
observed in previous co-expression experiments (Figure 3.5). It could be 
confirmed that interaction of endogenous VANGL1 with R-RAS takes place in a 
strict activation and effector domain dependent manner and no interaction with 
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closely related GTPases (N-RAS, RAP2) was detected, illustrating VANGL1’s 
binding specificity to R-RAS subgroup members (Figure 3.6).  
Probing for other known RFG effector proteins within the same 
immunoprecipitates, served as internal controls for functionality of each 
transfected RFG and confirmed differential binding specificities among RFGs 
(Rodriguez-Viciana et al. 2006). Protein phosphatase 1 (PP1) interacts 
exclusively with M-RAS, whereas BRAF can bind the R-RAS subgroup but with 
lower affinity than N-RAS. The junctional multidomain protein AFADIN/AF6 is the 
more promiscuous effector of this panel, being able to bind to all GTPases tested 
in this study (Figure 3.6). 
It is not uncommon to be able to detect some effector binding to ectopically 
expressed wild type RAS proteins due to the fact that a small proportion of the 
total protein (that may vary between RFGs) is expected to be bound to GTP at 
least in overexpression conditions (Figure 3.6).   
 
 
3.2.3 Characterisation of VANGL1-R-RAS interaction using R-RAS 
effector loop mutants and the ∆CAAX truncation 
Selective partial loss of function effector domain mutants of H-RAS have been 
described previously and demonstrated to be a useful tool to dissect signalling 
by the different Ras effector pathways (Rodriguez-Viciana et al. 1997; Kinashi et 
al. 2000; Oertli et al. 2000). In order to identify R-RAS mutants that are able to 
selectively disrupt or retain the ability to interact with VANGL1, and thus could 
be used as tools to help elucidate the differential contribution of VANGL1 to R-
RAS signalling properties, a set of homologous effector mutations to that 
described for H-RAS were generated (Figure 3.7A). This is based on the fact that 
the core effector binding domain of R-RAS is identical to those in H-RAS. Further, 
this study included a CAAX domain deletion (∆CAAX) construct to test if 
membrane localisation affects interaction. These constructs were then expressed 
in HEK293T cells and tested for interaction with VANGL1 or other known 
effectors (Figure 3.7B and C). 
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Figure 3.7: R-RAS effector domain mutations do not affect VANGL1 interaction, 
whereas deletion of the CAAX box completely inhibits VANGL1 binding. (A) Partial 
protein alignment of R-RAS and H-RAS including the effector domain (orange box, R-RAS 
residues V58-Y66, H-RAS residues V32-Y40). Identical amino acids are marked as 
asteriks (*) and partial loss-of-function effector mutants are highlighted in red, and 
repective activated effectors are indicated below. This figure was adapted from Oertli et 
al. 2000. (B) GST-tagged constructs of wild-type (wt) and activated mutants (V12, L87) 
of RFGs were expressed in HEK293T cells together with flag-tagged VANGL1. GST-
GTPases were purified with glutathione beads and interacting proteins detected by 
western blotting using anti-flag, AF6 or BRAF antibodies. As a negative control for binding 
served active RAP2 (V12 mutant). (C) Deletion of the R-RAS CAAX motif completely 
disrupts interaction with VANGL1. HEK293T cells were transfected with R-RAS effector 
domain mutant (A64) or C-terminal CAAX motif (∆) deletion constructs in both activating 
backgrounds (V38 and L87). RAP2 V12 served as background binding control. Lysate 
harvest, purification and detection was carried out as decribed in B. 
 
VANGL1 binds strongly to constitutively active R-RAS L87, but introduction of 
any of the effector domain point mutation tested led to a significant reduction of 
interaction. The less well described effector domain T61S, exhibits a slightly 
milder disruption effect on the VANGL1 binding to R-RAS, whereas the most 
severe inhibiting effect is observed with the effector domain mutant D64A, which 
completely abolishes effector interaction and thus is commonly termed defective 
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mutant (Figure 3.7B). Probing for binding of endogenous R-RAS effectors BRAF 
and AFADIN/AF6 showed that all employed effector domain mutants completely 
disrupted binding to R-RAS (Figure 3.7B). Experiments carried out using 
respective mutants in R-RAS V38 background showed similar results (data not 
shown).  
In summary, all employed effector loop mutants decreased binding to VANGL1 
as well as other effectors and therefore, unfortunately, I was not able to identify 
partial loss of function R-RAS mutants.  
Interestingly, deletion of the R-RAS CAAX motif in both activating backgrounds 
completely disrupts VANGL1 interaction comparable to the level of the defective 
mutant R-RAS D64A (Figure 3.7C). The CAAX motif is essential for appropriate 
post translational processing and targeting of RFGs to the plasma membrane 
(Ahearn et al. 2012), suggesting that membrane localisation of R-RAS is critically 
required for interaction with VANGL1, which itself is a transmembrane protein.  
R-RAS ∆CAAX was still able to interact efficiently with the membrane associated 
AF6/AFADIN, or with BRAF (Figure 3.7C). In clear contrast to VANGL1, deletion 
of the CAAX box increased the affinity of the interaction with AF6/AFADIN, while 
having little effect on BRAF binding (Figure 3.7C).  
 
3.2.4 R-RAS interacts with the C-terminus of VANGL1   
RAS effectors interact through a distinct small region termed RAS Binding 
Domain (RBD). Studies on known RAS effectors such as RAF, PI3K and RALGEFs 
showed that their respective RBDs share little sequence homology but certain 
structural similarity. Hence, there is the assumption that a wider array of 
unidentified RBDs exists, based on the fact that there are also RFG effectors, 
which do not show any RBD similarity to any of the aforementioned three 
effector proteins (Matheny et al. 2004; Rodriguez-Viciana et al. 2006). 
VANGL1 protein structure prediction revealed four transmembrane domains and 
a C-terminal tetra-peptide PDZ binding motif. No other domain or motif similarity 
has been identified. In order to map which part of VANGL1 is binding to R-RAS, 
one N-terminal (excluding TM region) and various C-terminal VANGL1 truncation 
mutants were generated (Figure 2.2) and tested in co-expression experiments 
(Figure 3.8).  
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The larger C-terminus part was subdivided into two equal pieces based on no 
apparent notable domain structure (C2 and C3). Also a C-terminal fragment 
lacking the C-terminal tetra-peptide motif (ETSV), required for PDZ-domain 
interaction was generated (∆PDZ-BM) (Figure 3.8A) (Saras and Heldin 1996; 
Songyang et al. 1997). 
Expression of VANGL1 truncation constructs resulted in similar protein levels, 
except for the shorter C-terminal constructs C2 (Figure 2.2) and C3 (Figure 
3.8B), which expressed at considerably lower protein levels. 
 
Figure 3.8: VANGL1 interacts with R-RAS through its C-terminus in a PDZ-motif 
independent fashion. (A) Schematic of VANGL1 protein and generated truncation 
mutants. TM-transmembrane spanning regions, ∆PDZ-BM, truncation of the PDZ domain 
interacting tetrapeptide. (B) Mapping of the R-RAS interaction region on VANGL1. Flag- 
VANGL1 or truncations shown in A were co-expressed with GST-R-RAS wild type (wt), 
activated L87 (L) or effector domain mutant L87 A64 (LA) in HEK293T cells. After 48 h, 
cells were lysed and immunoprecipitated using glutathione beads. Interactions and levels 
of expression were visualised by western blot using flag antibody of GST pull downs and 
lysates, respectively. 
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Under comparable expression levels of VANGL1 constructs (except C3 
truncation), GTP-dependent R-RAS interaction is observed with the full length 
protein, complete C-terminus (C1) and the ∆PDZ-BM truncation with similar 
affinity. No interaction of R-RAS L87 could be observed with the VANGL1 N-
terminal fragment (Figure 3.8B). This leads to the conclusion that R-RAS 
interaction with VANGL1 maps to the C-terminus in a PDZ motif independent 
manner. 
Even employing very long exposures, no interaction could be detected with 
VANGL1-C2 (data not shown) or VANGL1-C3. Therefore, VANGL1-C2 or VANGL1-
C3 regions appear insufficient for binding, and the interaction with R-RAS can 
only be mapped to the C-terminus without further refinement (Figure 3.8B). 
Similar results were achieved using the activated R-RAS V38 mutant in VANGL1 
mapping experiments (data not shown).  
 
3.2.5 R-RAS interaction with VANGL1 is disrupted by the D259E mutant 
Point mutants of VANGL1 have been identified in a cohort of neural tube defect 
patients (Figure 1.31A) (Kibar et al. 2007; Kibar et al. 2009). In order to test 
whether reported VANGL1 mutations disrupt the interaction with R-RAS, five C-
terminal point mutations were generated and included in VANGL1 co-expression 
interaction studies (Figure 2.2 and Figure 3.9A). 
VANGL1 interaction with R-RAS takes place in an activation and effector domain 
dependent manner with VANGL1 V2391I, R274Q and M328T point mutants at a 
similar level compared to wild type (wt) or the ∆PDZ-BM truncation. Expression 
of the D259E mutation construct leads to similar protein levels as the wild type 
or point mutant M328T, but no interaction with R-RAS could be detected under 
these conditions. Although longer exposures showed residual interaction, this 
binding is no longer effector domain dependent and is therefore unspecific. 
Interestingly, this mutant is homologous to the looptail mouse VANGL2 D255E 
mutant, known to be involved in neural tube defects (Figure 3.9B).  
Another analogous point mutation initially identified in the looptail mouse, 
S467N, appears to be defective on short exposures, but expression levels of this 
protein are considerably lower than other point mutants or wild type VANGL1. 
On longer exposures, specific binding of VANGL1 S467N to R-RAS L87 could be 
detected at similar levels than wild type (Figure 3.9B).  
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Detection of endogenous AFADIN/AF6 served as binding control for transfected 
RAP2 and R-RAS constructs (Figure 3.9B). 
 
 
Figure 3.9: VANGL1 point mutations D259E identified in neural tube defect 
(NTD) patients disrupts binding to R-RAS. (A) Overview of VANGL1 structure and 
location of employed NTD point mutations. TM-transmembrane domain. (B) HEK293T 
cells were co-transfected with flag-tagged VANGL1 wt or respective point mutants as 
indicated above with either GST-tagged activated R-RAS (L87) or effector domain mutant 
(L87 A64). After 48 h, cells were lysed and immunoprecipitated using glutathione beads. 
Interactions were detected by western blot using flag-antibodies. 
 
 
3.2.6 R-RAS and VANGL1 interact directly in vitro 
Identification of VANGL1 as a novel R-RAS interacting protein by TAP or co-
immunoprecipitation does not elucidate if this interaction is direct or mediated 
through other proteins. In order to establish if VANGL1 binds to R-RAS in a direct 
fashion, an in-vitro assay was employed which tests interaction of purified, GDP 
or GTP loaded R-RAS with purified GST-VANGL1 fusion proteins (Figure 3.10). 
Recombinant VANGL1-N and VANGL1-C1 truncations (Figure 3.8A) were 
expressed as GST-fusion proteins and purified from an insect cell line 
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(Spodoptera frugiperda, SF9) or from bacteria (E.coli). As positive control for R-
RAS interaction, other known effector proteins, either RBD (CRAF) or fragments 
containing the RBD (AF6, RASSF5) were expressed in bacteria as GST-fusion 
proteins and included in the assay. VANGL1 truncations, CRAF, AF6 or RASSF5 
purified proteins were then incubated with either a GDP or GMP-PMP (a non-
hydrolysable GTP analogue) loaded bacterial purified His-tagged R-RAS. 
Detection of associated R-RAS was performed by western blotting for the His-tag 
after extensive washing of glutathione pull-downs. 
Included assay controls of established effectors, such as CRAF, AF6 or RASSF5, 
exhibited the expected pattern of preferred interaction to the GMP-PMP (GTP) 
bound over GDP-bound R-RAS, indicating direct binding in an activation 
dependent fashion (Figure 3.10) (Spaargaren et al. 1994).  
The C-terminal domain of VANGL1 (VANGL1-C1) also shows a similar level of 
preferential binding to GMP-PMP bound R-RAS, indicating that VANGL1 interacts 
directly with R-RAS in the activated conformation. Identical results were 
obtained when VANGL1 protein was purified from either bacterial or insect cell 
sources (Figure 3.10).  
 
 
Figure 3.10: R-RAS interacts directly with the cytoplasmic C-terminus of 
VANGL1. In vitro interaction complex formation between VANGL1 and R-RAS. Bacterial 
purified His-tagged R-RAS was loaded with either GDP or GMP-PMP (non-
hydrolyzable analogue of GTP) and added to immobilized GST-VANGL1 truncations (either 
N- or C-terminal) purified from bacterial or insect cell origin or well-known indicated 
effector proteins (indicated by asteriks). After immunoprecipitation and washes, bound R-
RAS was detected by western blotting using an His-tag antibody. Indicated amounts of 
proteins used in this assay (2.5% and 10%) were run alongside to serve as reference. 
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Very low residual binding of VANGL1 N-terminus (VANGL1-N) at similar levels to 
the GDP and GTP form of R-RAS was observed, suggesting that this interaction is 
non-specific, and further confirming previous results that the VANGL1 N-
terminus is not involved in R-RAS binding (Figure 3.10).  
 
 
3.3 ARHGEF17/p164RhoGEF behaves as a TC21 and R-RAS 
effector   
This section will focus on characterisation of ARHGEF17/p164RhoGEF interaction 
with the R-RAS subgroup members and its ability to act as a RHOA GEF. 
 
3.3.1 ARHGEF17/p164RhoGEF interacts with R-RAS and TC21 in an 
activation and effector domain dependent manner 
Initial binding studies were designed to verify that ARHGEF17/p164RhoGEF 
interaction with TC21 takes place in an activation dependent and effector domain 
mediated manner. Binding affinity between two available constitutive activating 
mutants of TC21 (V13 and L71) and their respective effector domain mutants 
were carried out. Due to the lack of any commercially available antibodies for 
ARHGEF17/p164RhoGEF, and failure to successfully generate an antibody 
against a N-terminal ARHGEF17/p164RhoGEF fragment purified from bacteria, 
the following binding studies were carried out in a co-expression study as 
described earlier for VANGL1 (refer to 3.2.1).  
ARHGEF17/p164RhoGEF interaction with TC21 was observed with both activating 
mutants (V13, L71), but no binding could be detected with the effector domain 
mutation or the wild type protein. Also, despite a lower expression of TC21 L71 
and its respective effector domain mutant, it appears that 
ARHGEF17/p164RhoGEF demonstrates a higher affinity to TC21 L71 over TC21 
V13 (Figure 3.11A). 
Testing the binding specificity of other R-RAS subgroup members (R-RAS, M-
RAS) or closely related RAS family GTPases (N-RAS, RAP1/2) showed that 
ARHGEF17/p164RhoGEF binds to R-RAS L87 and both TC21 activating mutants 
but not to any other GTPase tested in this panel. Comparing R-RAS V38 and R-
RAS L87 activating GTPases at similar expression levels, p164RhoGEF seems to 
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only bind to R-RAS L87. No interaction with the third R-RAS member M-RAS 
could be observed, rendering ARHGEF17/p164RhoGEF interaction specific to 
TC21 and R-RAS (Figure 3.11B). 
 
 
Figure 3.11: ARHGEF17/p164RhoGEF binds specifically to TC21 and R-RAS. (A) 
HEK293T cells were co-transfected with GST-TC21 and flag-p164RhoGEF expression 
vectors. GST-TC21 was purified with glutathione beads and interacting proteins detected 
by western blotting using anti-flag antibodies. (B) GST-tagged constructs of wild-type 
(wt) and activated RFG mutants were expressed in HEK293T cells together with flag-
p164RhoGEF. GST-RFGs were purified as described in A. PD - pull down, RFG - Ras Family 
GTPases. Levels of GST-RFGs were measured  by coomassie staining of membrane. 
 
 
3.3.2 Mapping of p164RhoGEF domains that interact with TC21 
RHO GEFs interact with and activate members of the RHO family of small 
GTPases through Dbl homology (DH) domains. These exchange factors are 
characterised by the presence of a Dbl domain in tandem with a pleckstrin 
homology (PH) domain, which interacts with lipids and proteins. Together, these 
two domains constitute the minimum structural unit necessary for the activity of 
Dbl family proteins (Zheng 2001; Schmidt and Hall 2002). Interestingly, 
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p164RhoGEF does not contain any detectable PH motif by conventional domain 
prediction, but has a WD40 domain, which has been reported for two additional 
GEFs: GrinchGEF and GEF10 (Rumenapp et al. 2002; Winkler et al. 2005; Mohl 
et al. 2006).  
Therefore, truncation constructs of p164RhoGEF were generated in order to map 
the TC21 binding region and to test if the WD40 domain is required for 
interaction. Truncation constructs were designed to cover the N-terminus or C-
terminus including or excluding the DH domain. Further, the C-terminal part was 
shortened to be either WD40 domain excluding, or to contain the WD40 domain 
only or a truncation thereof (Figure 3.12A).  
Binding studies employing all generated truncations showed varied levels of 
expression, p164RhoGEF-C1 and -C2 being the highest expressed, whereas the 
shorter C-terminal truncations (p164RhoGEF-C3, -C4 and ∆N) expressed at very 
low levels (Figure 3.12B).   
Full length p164RhoGEF (FL) binds to active TC21, whereas no interaction with 
the N-terminal fragments p164RhoGEF-N or DH domain containing construct 
p164RhoGEF-∆C could be detected. In contrast, a C-terminal fragment lacking 
the N-terminus (p164RhoGEF-∆N) exhibited an even higher binding affinity to 
TC21 than the full length protein, even though it was expressed at greatly 
reduced levels (Figure 3.12B).   
Examining C-terminal truncations excluding the WC40 domain (p164RhoGEF-C2) 
compared to the DH lacking complete C-terminus (p164RhoGEF-C1) at similar 
expression levels, the WD40 excluding truncation displayed a significantly 
reduced interaction with TC21 L71. This indicates that the WD40 domain might 
not be critically required for binding but has a supporting role (Figure 3.12B).  
Taken together these results suggest that TC21 likely interacts predominantly 
with the region between the DH and WD40 domains although the integrity of the 
WD domain is likely contributing for a higher affinity interaction. 
Notably, flag-p164RhoGEF protein levels in lysates were consistently 
considerably higher when TC21 L71 was co-expressed suggesting that active 
TC21 may have an effect on the protein stability of p164RhoGEF (Figure 3.12B). 
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Figure 3.12: Mapping of the p164RhoGEF binding region to TC21. (A) Schematic of 
p164RhoGEF truncation mutants and summary regarding binding affinity towards 
activated TC21 (amounts of + indicates binding strength). DH-Dbl-homologous domain. 
(B). Flag-full length (FL)  p164RhoGEF or truncations as illustrated in A were co-
transfected with either wild type (wt) or activated GST-TC21 (L71) in HEK293T cells. 48 h 
post transfection, cells were lysed and purified using glutathione beads. Interactions and 
protein levels on lysates were detected by western blot using a flag-antibody. Due to its 
low expression, C4 fragment has been indicted with asteriks. 
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3.3.3 ARHGEF17/p164RhoGEF and TC21 interact in vitro  
To establish if ARHGEF17/p164RhoGEF, interacts with TC21 in a direct manner, 
in vitro binding assays were carried out as described above for R-RAS (see 
section 3.2.6).  
Full length and C-terminal p164RhoGEF fragments were expressed and purified 
from baculovirus infected Sf9 cells. The N-terminal domain of AF6 containing the 
two RAS associating (RA) domains was used as a positive control. Full length 
(FL) and p164RhoGEF-C1 exhibit GTP dependent binding to TC21, comparable to 
that observed for AF6 (Figure 3.13). In contrast to the results detected in the 
interaction studies in HEK293T cells, p164RhoGEF-C2 purified from baculovirus 
was unable to interact with TC21 in vitro. We do not know the reasons for this 
discrepancy but this may be related to differences in protein folding or post-
translational modification occurring in mammalian and insect cells. Regardless, 
the preferential GTP-dependent interaction seen between purified proteins in 
vitro strongly suggests that ARHGEF17/p164RhoGEF interacts directly with TC21 
and thus behaves as a true direct effector (Figure 3.13). 
   
 
Figure 3.13: In vitro interaction between p164RhoGEF and TC21. Bacterial purified 
His-tagged TC21 was loaded with either GDP or GMP-PMP (GTP) and added to immobilised 
GST-p164RhoGEF truncations as indicated (Figure 3.12A) purified from Sf9 cells. After 
extensive washes of glutathione beads, bound TC21 was detected by western blotting 
using a His-tag antibody. Indicated amounts of proteins used in this assay (2.5% and 
10%) were run alongside to serve as reference. AF6 served as a TC21 effector proteins. 
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3.3.4 ARHGEF17/p164RhoGEF acts as a GEF for RHOA  
ARHGEF17/p164RhoGEF has been demonstrated to be a RHOA specific GEF 
(Rumenapp et al. 2002). In order to confirm that ARHGEF17/p164RhoGEF is able 
to activate the RHOA, and to establish RHO activation assays to be used in 
future experiments (see later section 6.3), various GEFs were co-transfected 
with myc-RHOA and RHOA activation measured using Rhotekin-RBD pull-down 
assays  (Habas and He 2006). ARHGEF19/WGEF, which has been reported to be 
involved in WNT regulated convergent extension and to act as GEF for RHOA 
(Tanegashima et al. 2008) was also cloned and used in parallel, as well as the 
ARHGEF17/p164RhoGEF related proteins ARHGEF10L/GrinchGEF and 
ARHGEF10/GEF10). 
Cells were also stimulated as positive control with serum which is known to 
trigger activation of RHO GTPases, as well as with EGF, which has been shown to 
be a much weaker activator (Ridley and Hall 1992). mSOS was included as 
negative control, since it acts as nucleotide exchange factor for RAS 
GTPases and RAC (Figure 3.14) (Chardin et al. 1993; Nimnual and Bar-Sagi 
2002). 
 
 
Figure 3.14: p164RhoGEF is an activator of RHOA in HEK293T cells. Empty vector 
or GEFs (mSOS, ARHGEF19, ARHGEF17/p164RhoGEF, ARHGEF10 and ARHGEF10L) were 
co-transfected with myc-RHOA. 32h post transfection, cells were serum deprived for 16h 
and either stimulated with 100 ng/mL EGF or 10% final serum for indicated times, or left 
untreated (-). The GTP form of RHOA was pulled down (PD) from HEK293T cell lysates 
using GST-RBD (RHO Binding Domain from Rhotekin). Activated RHOA fraction was 
detected using myc antibodies.   
 
145 
 
HEK293T cells stimulated with serum or EGF show a small increase in 
precipitated activated RHOA over basal level (-). Expression of the RASGEF 
mSOS elevated activated RHOA levels only slightly over basal levels, whereas 
the ARHGEF19 exhibited a significant increase. Expression of 
ARHGEF17/p164RhoGEF on the other hand strongly increased the amount of 
activated myc-RHOA and therefore represents a very potent RHOA guanine 
nucleotide exchange factor (Figure 3.14). 
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3.4 Discussion 
3.4.1 VANGL1 functions as an effector of R-RAS subgroup GTPases 
Using activating or disrupting mutants of RAS family GTPases, I have shown that 
VANGL1 demonstrates all the hallmarks required to be a true effector of R-RAS 
and TC21. VANGL1 binds preferentially to the activated mutants compared to the 
wild type protein and the interaction is disrupted by mutations in the effector 
domain. Furthermore, a GTP-dependent interaction can also be observed in vitro 
binding assays using purified proteins, suggesting that the interaction is direct. 
This interaction is also very specific for R-RAS subgroup members, as even 
under conditions of overexpression no binding to any other tested RAS family 
GTPase could be detected. Taken together, these results indicate that VANGL1 is 
a direct and specific effector of R-RAS and TC21. 
VANGL2 can also be detected in co-transfection studies associating with R-RAS 
GTPases. However, this interaction is significantly weaker compared to VANGL1. 
Because VANGL1 and VANGL2 can hetero-dimerise ((Belotti et al. 2012) and our 
own TAP data), it is possible that the weak association detected with VANGL2 is 
being mediated through VANGL1, and additional experiments are required to 
address this possibility. Regardless, it is clear that there are important 
differences between VANGL1 and VANGL2 function, which need to be further 
understood (see section 4.2) (Torban et al. 2004; Tissir and Goffinet 2006), and 
our results suggest VANGL1 is preferentially regulated by R-RAS GTPases. 
Notably, R-RAS L87 has higher affinity for VANGL1 (and AF6), but not other 
effectors such as BRAF, compared to the V38 activating mutant. Both mutants 
are located within areas important for nucleotide binding, V38 in the so called P-
loop, whereas the L87 oncogenic mutant localises within the switch II region, 
which is also responsible for binding of effector proteins. Hence an amino acid 
change within the switch II region can modulate both nucleotide and effector 
binding, which has been previously shown for p120GAP (McCormick 1992). 
Both VANGL isoforms bind specifically to R-RAS subgroup GTPases only, and not 
to other closely related RAS family proteins like RAP2 or N-RAS, despite the fact 
that R-RAS subgroup members and N-RAS share identical effector domains. It 
has been suggested that specificity of interaction might be mediated through the 
sequences flanking the core effector domain, the so called specificity regions 
(Khosravi-Far et al. 1998). Furthermore, our own data as described above 
suggests that the switch II region is important for VANGL1 interaction. 
Therefore, both amino acid differences flanking the effector domain and in the 
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switch II region may account for this differential interaction with R-RAS GTPases. 
Consistent with this idea, the switch II loop of R-RAS and TC21 exhibits an 
identical amino acid pattern, which differs in two amino acids to classical RAS 
proteins, and shows one residue alteration compared to M-RAS (Figure 3.15). 
 
 
Figure 3.15: Alignment of RAS, RAP2 and R-RAS subgroup members. Indicated 
GTPases were aligned  across switch I and switch II, including flanking regions. Identical 
amino acids are depicted as asteriks and subscript number specify residue number of 
respective amino acid position.  
 
VANGL1 has four transmembrane domains and is therefore predicted to be a 
membrane protein (Iliescu et al. 2011). Localisation studies reported various 
subcellular distributions including plasma membrane in MDCK cells (Gravel et al. 
2010; Iliescu et al. 2011) and ER in COS7 cells (Merte et al. 2011) (see also 
section 5.4). Notably, VANGL1 interaction with R-RAS requires the membrane 
targeting CAAX motif, in contrast to other effectors such as the membrane 
associated AF6 or BRAF, the latter one being only partially affected (Stokoe et al. 
1994). Therefore, unlike for other effectors, R-RAS needs to be membrane 
bound in order to interact with VANGL1. 
The domain structure of VANGL1 does not suggest any enzymatic activity; 
therefore it is likely that R-RAS/TC21 regulates VANGL1 function at least partly 
by regulating its localisation in some contexts: upon activation, RRAS/TC21 
would recruit VANGL1 to specialised signalling platforms at the membrane micro-
domains where they reside. Furthermore, R-RAS/TC21 binding could also 
regulate (stimulate or inhibit) the association of VANGL1 with its interacting 
partners and thus modulate its signalling properties. 
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VANGL1 point mutations have been found in sporadic and familial cases of neural 
tube defects (Kibar et al. 2007; Kibar et al. 2009). These mutants also 
demonstrated defects in convergent extension in a zebrafish model, 
strengthening the point of VANGL protein involvement in neural tube closure and 
migration, and a high degree of functional conservation across vertebrates 
(Reynolds et al. 2010).  
Interaction studies analysing binding of VANGL1 point mutant D259E, identified 
in human NTDs, demonstrated it to be defective for DVL protein interaction 
(Kibar et al. 2007). VANGL1 D259E also disrupts binding to R-RAS. This suggests 
that R-RAS and DVL proteins bind to the same site of VANGL1 and therefore may 
compete for interaction. In addition, this mutant is located within the first half 
the C-terminus, which also has been shown to be required for R-RAS-VANGL1 
interaction. The VANGL2 homologous point mutant is the conserved Looptail 
mouse D255E substitution, which has been reported to have a reduced protein 
half-life, and fails to be shuttled to the plasma membrane (Gravel et al. 2010). 
Instead, VANGL2 D255E proteins are retained in the ER lumen due to 
impairment of binding to the transport protein SEC24b (Merte et al. 2011; 
Wansleeben et al. 2011).  
 
 
Figure 3.16: R-RAS interaction summary. (A) VANGL1 is a direct and specific 
effector of the R-RAS subgroup and does not bind to closely related GTPases. 
(B) This interaction is mediated through VANGL1’s C-terminus, and R-RAS 
requires the membrane-targeting CAAX motif for VANGL1 binding. Furthermore, 
R-RAS-VANGL1 binding is also disrupted through the VANGL1 point mutant 
D259E, implicated in neural tube defects. 
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3.4.2 ARHGEF17/p164RhoGEF functions as an effector of R-RAS and 
TC21 
Using constitutively active TC21 in a TAP, we identified various interactors, 
several of which have been previously published. One hit, identified in A549 
cells, was ARHGEF17. This gene encodes for a 164kDa large RhoGEF, thus also 
known as p164RhoGEF.  
Initial validation experiments demonstrated that ARHGEF17/p164RhoGEF binds 
to both TC21 activated mutants and R-RAS L87 in an activation and effector 
domain dependent. No interaction with M-RAS, RAP1, RAP2 or N-RAS could be 
observed.  
Interestingly, ARHGEF17/p164RhoGEF does not contain any detectable PH motif, 
but encompasses a WD40 domain, which in addition has been reported for 
further two GEFs: GrinchGEF and GEF10 (Rumenapp et al. 2002; Winkler et al. 
2005; Mohl et al. 2006). However, a recent publication challenged this finding 
and descibed that ARHGEF17/p164RhoGEF contains a functional PH domain, 
which was not detected previously using convential domain prediction software 
due to an ~70  residue α-helical domain insertion (Mitin et al. 2012). 
Furthermore, the original paper describing ARHGEF17/p164RhoGEF (Rumenapp 
et al. 2002) predicted a size of 164 kDa, but annotations by Croix and colleagues 
descibed ARHGEF17 with an extensive N-terminal domain, resulting in a 
predicted 222 kDa protein in size (St Croix et al. 2000). 
 
As observed from our experiments, and consistent with literature reports (De 
Toledo et al. 2000; Rumenapp et al. 2002), ARHGEF17/p164RhoGEF acts as a 
RHOAGEF. A more detailed study further illuminated that 
ARHGEF17/p164RhoGEF is able to activate RHOB and RHOC isoforms, but fails to 
activate RAC or CDC42 (Mitin et al. 2012). 
 
The ARHGEF17/p164RhoGEF N-terminus has been reported to contain a novel 
actin binding domain, and has been found to be actin stress fibre associated, 
independently of DH/PH domains (Mitin et al. 2012). Notably, TC21 has been 
mapped to interact with ARHGEF17/p164RhoGEF C-terminus downstream of the 
DH domain.    
 
The original paper describing ARHGEF17/p164RhoGEF (Rumenapp et al. 2002) 
showed a restricted tissue expression in the mouse with predominate expression 
in the heart. Furthermore, our own TAP data identified ARHGEF17/p164RhoGEF 
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interacting with TC21 in A549 cells but not HEK293T, consistent with its 
differential expression in different cell types.  
 
Due to unavailability of commercial antibodies, considerable time and effort was 
devoted to express and purify from bacteria recombinant fragments of 
ARHGEF17/p164RhoGEF (and VANGL1) to be used for the generation of 
polyclonal antibodies. Disappointingly, when the outsourced rabbit serum was 
received, it could not efficiently recognise or immunoprecipitate even the 
overexpressed tagged protein for reasons that are not clear.  Because of the 
likely cell type specific expression of ARHGEF17/p164RhoGEF and the 
unavailability of antibodies to detect its expression, further studies would have 
been significantly complicated and thus it was decided with my supervisor to 
focus my PhD studies on VANGL1 and its role as an effector of R-RAS GTPases. 
 
 
 
Figure 3.17: TC21 interaction summary. The RhoGEF protein p164RhoGEF binds to R-
RAS and TC21 through its C-terminus in an activation and effector domain dependent 
manner. This leads to the speculation that R-RAS subgroup GTPases could modulate the 
WNT-PCP member VANGL1 and RHO GTPase activating factors in order to modulate 
cellular motility, adhesion and polarity. 
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4 Identification of VANGL1 interaction partners 
4.1 Initial VANGL1 TAP Screen 
Initial studies in fruit flies identified the VANGL1 homologue strabismus as a core 
PCP protein (Wolff and Rubin 1998; Jenny et al. 2003). Despite great advances 
in the WNT signalling field, very little is known about VANGL1 and its role in PCP 
in higher vertebrates.  
In order to identify in a non-biased approach VANGL1 interacting proteins that 
may shed light on its function in mammalian cells, we used a proteomic 
approach by transient expression of TAP-tagged VANGL1 in HEK293T cells.  
Three independent TAP purifications were performed by Dr Rodriguez-Viciana 
and in one case active R-RAS G38V was co-expressed. Proteins identified by 
mass spectrometry are listed in Figure 4.1. Increased sensitivity was achieved 
with each purification and the last VANGL1-TAP was performed only with co-
expressed R-RAS V38. Therefore no comparison between purifications or the 
effects of R-RAS on purified interaction could be made. Consequently, further 
biochemical experiments were employed to investigate if R-RAS has a 
modulating effect on VANGL1 interacting proteins (see section 4.3).  
Several TAP-identified VANGL1 binding proteins confirmed previously reported 
interactions, known to be involved in polarity such as DVL2, DVL3, SCRIB and 
DLG1 (Lee et al. 2003; Torban et al. 2004; Torban et al. 2008; Courbard et al. 
2009), validating our approach.  
In addition to these known interactors, multiple novel interactors were identified, 
including additional proteins involved in polarity (LIN7C, CASK, CELSR2, LPHN2), 
several that suggest an role for VANGL1 in vesicle trafficking (YIF1B, Sec24B, 
RAB3GAP2) (Figure 4.1). 
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Figure 4.1: VANGL1-TAP approach lead to identification of novel interaction 
partners. TAP-VANGL1 construct was expressed in HEK293T cells, and co-purified 
proteins identified by mass spectrometry. List of novel VANGL1 interactors categorised by 
performed TAP experiment are ranked by detected unique peptides, from highest to 
lowest. (A) Initial VANG1 TAP approach. (B) Second VANGL1-TAP, which has been EGF 
stimulated prior to cell lysis. (C) Final VANGL1-TAP in which active R-RAS V38 has been 
co-expressed. 
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4.2 Validation of VANGL1-TAP hits identified by mass 
spectrometry 
Initial validation of VANGL1 binding proteins focused on polarity proteins for 
which commercially antibodies were available and hence would allow detection of 
endogenous proteins. This approach included Disks large homolog 1 (DLG1), 
Calcium/calmodulin-dependent serine protein kinase 3 (CASK), SCRIB, as well as 
the WNT signalling components DVL2 and DVL3 (Figure 4.2). 
For all interaction studies, flag-VANGL constructs were transfected in HEK293T 
cells and immunoprecipitations were probed with antibodies against endogenous 
proteins (Figure 4.2B). It is worth noting that all chosen polarity proteins contain 
at least one PDZ domain. In order to assess whether VANGL1 PDZ binding motif 
was mediating the interaction, a VANGL1 mutant lacking the four last amino 
acids (∆PDZ-BM) was also employed. In addition, to test for the specificity of 
PDZ domain interactions, the PDZ domain containing protein AFADIN/AF6, which 
was not identified by mass spectrometry, was included in my interaction studies.  
DLG1, CASK and SCRIB interact with both VANGL1 and VANGL2 and the 
interaction is dependent on the PDZ-binding motif of VANGL1. Of note, DLG1 and 
CASK have been reported to interact (Sabio et al. 2005) and therefore could be 
part of a complex with one mediating the interaction with the other. SCRIB and 
DLG1 have also been reported to interact in Drosophila and mammalian context 
(Humbert et al. 2008; Li et al. 2009b; Massimi et al. 2012). However, SCRIB 
was detected in all three TAP purifications, whereas other proteins including 
DLG1 were only detected in the more sensitive last TAP (Figure 4.1C). 
Furthermore, a performed TAP with SCRIB as bait detected VANGL but not DLG1 
(data not shown). These results suggest that SCRIB and DLG1 are binding 
independently to VANGL1.  
In contrast to DLG1, CASK and SCRIB, DVL proteins interact preferentially with 
VANGL1 compared to VANGL2. Furthermore, the interaction with DVL proteins 
appears not to be mediated by their PDZ domains as VANGL1 lacking the PDZ-
binding domain can still efficiently interact with DVL3 whereas it is only partially 
disrupted in the case of DVL2.  
The control AF-6 did not show binding to VANGL1 or VANGL2 above background 
levels, illustrating specificity of VANGL protein interaction with PDZ domain 
containing proteins (Figure 4.2B). 
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Figure 4.2: Validation of VANGL1 interactions identified by TAP. (A) Overview of 
protein structure and respective protein domains. VANGL1 (∆PDZ-BM) lacks the PDZ 
domain interacting tetra-peptide motif ETSV. Protein sizes are indicated as amino acid 
(aa) counts. This figure was constructed using the SMART database (http://smart.embl-
heidelberg.de). Note that all indicated endogenous proteins possess at least one PDZ 
domain. Depicted protein domains are abbreviated as follows: TM - Transmembrane, LRR 
– Leucine Rich Repeat, PDZ - PSD-95-Discs-large-ZO-1, PK - Protein kinase, L27 - Lin-2 
and Lin-7, SH3 - SRC Homology 3, GuKc- Guanylate kinase , DIX – Dishevelled and Axin, 
DEP - Dishevelled, Egl-10 and Pleckstrin, RA - Ras-association, FHA - forkhead-
associated. (B) VANGL1 interaction with CASK, DLG1 and SCRIB takes place in an strict 
PDZ-dependent manner, whereas DVL proteins are only partially (DVL2) or mildly affected 
(DVL3) by the VANGL1 PDZ motif truncation. Flag-VANGL1 (V1), VANGL2 (V2) or control 
constructs were transfected into HEK293T cells, and flag-proteins were purified using flag 
affinity beads and interaction with endogenous proteins were detected by western blotting 
probing for indicated antibodies. The type I regulatory subunit of protein kinase A (R1A) 
was used as background control. 
 
In summary, relative to the amount of bait expression, which is always lower for 
VANGL2, the polarity proteins DLG1 and CASK showed higher affinity for 
VANGL2, whereas SCRIB in turn seems to bind with similar affinity to both 
VANGL proteins (Figure 4.2B). Overall, it appears that proteins implicated in 
epithelial cell polarity display a strong dependency on the VANGL1 PDZ-binding 
motif for interaction. 
Several novel VANGL1 binding proteins identified by TAP could not be assessed 
on endogenous level due to the lack of reliable commercially available 
antibodies. Therefore, a subset of potential interactors were cloned by PCR and 
expressed as flag-tagged constructs, in co-transfection studies with GST-VANGL 
baits as performed before (section 3.3.1).  
It is worth noting that many of the proteins identified by TAP contain at least one 
transmembrane domain, such as CELSR proteins (Figure 4.3A). However, due to 
their long extracellular domain and resulting cloning issues it was decided to only 
use the cytoplasmic part for interaction studies. In addition, KAI/CD82 was not 
identified by TAP but was reported as a VANGL1 interacting protein (Lee et al. 
2004). Because of its role in cancer it was considered to be of interest and was 
also cloned and included in the study (Figure 4.3A) (Lee et al. 2005; Rowe and 
Jackson 2006; Kho et al. 2009; Lee et al. 2009; Ryu et al. 2010).  
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Both VANGL proteins demonstrate binding to YIF1B (Figure 4.3B and Figure 
4.6B), but it seems that YIF1B has a higher affinity for VANGL2, whereas no 
interaction could be detected with DVL2, which was used as background control 
(Figure 4.3B).  
Another link for a potential role of VANGL1 in protein trafficking is provided by 
Synaptojanin 2 binding protein (SYNJ2BP) a widely expressed small 145 aa 
protein containing a single PDZ domain and a C-terminal transmembrane helix. 
Initial interaction studies with VANGL1 confirmed a strong specific binding 
(Figure 4.3B), which is critically PDZ motif dependent and could not be observed 
for wild type VANGL2, DVL2 or DVL3 (Figure 4.6B). 
The uncharacterised chromosome 17 open reading frame 62 (C17ORF62) gene 
encodes for a 187 amino acid protein, consisting of a single pass N-terminal 
transmembrane helix. Interaction studies revealed that C17ORF62 exhibits a 
strong interaction with VANGL1 but not DVL2 or other control proteins (Figure 
4.3B). 
Nedd4 family proteins are involved in protein trafficking and protein degradation, 
binding to their targets directly or through the adaptor protein Nedd4 family 
interacting protein 1 (NDFIP1) (Putz et al. 2008). Interaction studies between 
VANGL1 and NDFIP1 demonstrated a strong interaction, which is not observed 
for DVL2 or a control protein (Figure 4.3B).  
RAB3GAP1 encodes the catalytic subunit of a RAB GTPase activating protein 
forming a heterodimer with a non-catalytic subunit (RAB3GAP2), which 
specifically regulates the activity of the RAB3 subfamily of small G proteins 
(Diekmann et al. 2011). RAB3 proteins are involved in regulated exocytosis of 
neurotransmitters and hormones and are required for normal eye and brain 
development (Lledo et al. 1994; Corbeel and Freson 2008; Fukuda 2008; 
Stenmark 2009). 
Binding studies using both RAB3GAP subunits individually revealed that only the 
catalytic protein (RAB3GAP1), but not RAB3GAP2 binds to VANGL1 (Figure 4.3B 
and data not shown). Interestingly, RAB3GAP2 and not RAB3GAP1 has been 
observed to bind to DVL2 (data not shown). 
Due to its large extracellular protein structure, only the complete cytoplasmic 
regions starting immediately after the 7TM region of CELSR1 and CELSR2 
proteins were cloned and used for interaction studies. Interestingly, binding of 
VANGL1 to CELSR cytoplasmic truncations was only observed with the 
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cytoplasmic fraction of CELSR2, whereas CELSR1 failed to interact with VANGL1 
(Figure 4.3B), despite the fact that expression of the CELSR1 construct yielded 
much higher protein levels than CELSR2 (data not shown). 
 
 
Figure 4.3: Validation of TAP-identifed VANGL1 interacting proteins. (A) 
Schematic of validated proteins depicting structural features such as transmembrane 
regions (TM) or PDZ domains. Protein sizes are indicated in amino acids (aa). (B) GST-
tagged constructs of wild-type VANGL1, DVL2, or R1A serving as control, were co-
expressed with potential flag-tagged VANGL1 interactors in HEK293T cells. Cells were 
harvested 48h post transfection and subjected to purification using glutathione beads. 
Interactions were detected using flag-antibodies. Protein appreviations and functions are 
detailed in the text. Note that CELSR1 and CELSR2 are membane proteins with a long 
extracellular domain, but for technical reasons, this study only employed the respective 
cytoplasmic C-termini. KAI1/CD82, a heavily glycosylated protein, has been reported to 
migrate at different molecular sizes at around 27kDa and 45 kDa depicted by asterisks 
(Wang et al. 2012). 
 
The membrane glycoprotein Kangai1 (KAI1) also termed Cluster of 
Differentiation 82 (CD82) is a member of the tetraspanin transmembrane 
superfamily (TM4SF) (Yanez-Mo et al. 2009; Wang et al. 2011). VANGL1 was 
identified to interact with the C-terminus of KAI1/CD82, and thus enables to 
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modulate VANGL1 function through this binding and therefore might act as a 
negative regulator of cell motility (Zhang et al. 2003; Lee et al. 2004; Rowe and 
Jackson 2006).  
Carried out interaction studies in HEK293T cells exogenously expressing VANGL1 
and KAI1/CD82 confirmed reported binding, whereas no interaction to the 
control protein or DVL2 was detected (Figure 4.3B). KAI1/CD82 is a heavily 
glycosylated protein and post translational modification studies confirmed 
various KAI1 moieties, which could be distinguished on SDS-PAGE (Wang et al. 
2012).  Notably, VANGL1 binds to both KAI1/CD82 forms, but it seems that 
there is a preference for the faster migrating form of KAI1/CD82 (lower band 
Figure 4.3B), taking overall expression levels in consideration. 
Interaction studies showed that VANGL2 and VANGL1 bind each other due to the 
ability of these proteins to form heterodimers and therefore were not included in 
this interaction study (Belotti et al. 2012).  
Validation of LIN7C as VANGL1 binding partner was tested in overexpression 
approaches or by endogenous binding assays. However, I was unable to observe 
convincing binding of LIN7C to either VANGL1 or VANGL2, therefore detection of 
LIN7C in VANGL1-TAP screens could be a case of indirect co-purification due to 
binding as a complex member. For example, CASK and Lin7C form a complex to 
target the epidermal growth factor receptor basolaterally in C. elegans (Kaech et 
al. 1998; Doerks et al. 2000). Also, DLG1 forms a complex with LIN7 members 
(A or C) and MPP-7, modulating stability and localisation of DLG1 to cell-cell 
junctions (Bohl et al. 2007).  
The VANGL1-TAP hit ubiquitin fusion degradation 1-like (UFD1L) protein is an 
essential component of the ubiquitin-dependent proteolytic pathway and is able 
to delay cell cycle progression in response to ER stress (Chen et al. 2011). 
Mutations in this gene have been associated with cardiac and craniofacial defects 
(Yamagishi et al. 1999). However, interaction studies were not able to confirm 
binding of UFD1L to VANGL1 (data not shown). 
In conclusion, VANGL1-TAP approaches led to the identification of multiple novel 
VANGL1 interacting proteins, displaying a wide range of structural and functional 
properties, but with a enrichment in PDZ domain or transmembrane domain 
containing proteins. Therefore, VANGL1 seems to be involved in various cellular 
functions ranging form cellular polarity establishment to vesicular trafficking. 
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4.2.1 Effect of VANGL1 point mutations found in NTC patients on 
interaction with SCRIB and DVL3  
Screening of neural tube defect patients revealed a set of VANGL1 point 
mutations across highly conserved amino acids, of which mutant D259E lost the 
ability to interact with R-RAS (Figure 3.9). Therefore it was intriguing to test if 
this particular mutation influences VANGL1 binding to other interaction partners 
(Kibar et al. 2007; Kibar et al. 2009; Bartsch et al. 2012). Thus, a panel of flag-
tagged VANGL1 point mutants including the ∆PDZ binding motif truncation were 
expressed in HEK293T cells and tested for endogenous SCRIB or DVL3 binding 
(Figure 4.4).  
 
Figure 4.4: VANGL1 D259E mutant disrupts binding to DVL3 but not SCRIB. 
VANGL1 interacts with SCRIB via its C-terminus in an PDZ-dependent manner, but none 
of the employed NTD mutants show disruption of binding. On the other hand, DVL3 binds 
to VANGL1 C-terminus in a PDZ independent manner and is disrupted by the D259E 
mutant. Flag-tagged constructs of wild-type VANGL1 (V1) or VANGL2 (V2), VANGL1- N or 
C-terminal fragments or point mutants as indicated were expressed in HEK293T cells. 
Flag-constructs were purified with flag affinity beads 48 hours later. Detection of 
endogenous SCRIB or DVL3 was performed by western blotting using respective 
endogenous antibodies. Employed extracellular soluable binding protein (EB4.1a) served 
as control protein. NTD - neural tube defects.  
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None of the tested point mutants of VANGL1 (Figure 3.9) interferes with SCRIB 
binding, consistent with the possibility that the interaction is exclusively 
mediated by the PDZ-binding motif of VANGL1 to a PDZ of SCRIB (Figure 4.4).  
Among the reported mutations identified in neural tube defect patients, only 
VANGL1-D259E severely impairs binding to DVL3 but not SCRIB, suggesting that 
this mutation disrupts selective protein interactions (Figure 4.4). Notably, this 
point mutation is identical to the one observed to disrupt R-RAS binding 
specificity (Figure 3.9). 
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4.3 Modulation of VANGL1 interactions by R-RAS 
4.3.1 VANGL proteins or R-RAS GTPases do not modulate canonical 
WNT signalling 
Initial experiments in zebrafish demonstrated that the VANGL homologue 
trilobite (tri) is able to antagonise canonical WNT signalling, while promoting c-
JUN phosphorylation (Park and Moon 2002). In conjunction with the observation 
that VANGL2/tri interacts with DVL/dsh, these findings suggest that VANGL1 
might be able to modulate the PCP pathway downstream of WNT ligands and 
Frizzled activation through its interaction with DVL (Park and Moon 2002). 
Particularly, since it has been observed that activation of either the canonical or 
PCP pathway seems to be exclusive within a given cell (Vincent and Beckett 
2011). Therefore, it was intriguing to test whether R-RAS or VANGL proteins 
have a modulating effect on WNT canonical signalling, analysing β-catenin 
activity using a β-catenin/TCF-mediated transactivation luciferase assay. 
To assess a potential effect of VANGL1 or R-RAS on WNT signal modulation in a 
mammalian context, exogenous expression of VANGL or R-RAS GTPases in 
combination with β-catenin firefly luciferase and renilla control reporter 
constructs were transfected into HEK293T cells.  
Overexpression of VANGL1 or VANGL2 did not alter β-catenin reporter activity 
compared to the GFP transfection control or unstimulated cells. Similarly, no 
effect of activated R-RAS or TC21 was observed (Figure 4.5). Thus, under these 
conditions tested, VANGL or R-RAS GTPases do not affect basal β-catenin levels. 
However, stimulation of the canonical pathway could be detected by transfection 
of DVL2 or DVL3 constructs, which were able to increase reporter activity by 
more than 15-fold (Figure 4.5). As positive control in this assay served 
expression of a non-degradable N-terminal β-catenin truncation (∆N-β-cat), 
which prevents its phosphorylation and thus impairs proteasome targeting, 
leading to stimulation of reporter activity by approximately 350-fold (Yost et al. 
1996; Amit et al. 2002). 
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Figure 4.5: Expression of VANGL proteins or activated R-RAS/TC21 do not alter 
β-catenin reporter activity. HEK293T cells were co-transfected with the TCF-4 
luciferase (firefly) (TOPFLASH) reporter construct and a Renilla vector, together with 
indicated plasmids. Cell extracts were harvested and analysed 40h post transfection for 
firefly and renilla luciferase activities. Data obtained were normalised for Renilla activity. 
RLU – relative luciferase units. GFP transfection sample served as transfection control. 
Expression of transfected plasmids were confirmed by western blotting. 
 
 
4.3.2 Active R-RAS modulates a subset of VANGL1 binding partners 
As noted before, VANGL1 does not display catalytic activity and therefore it is 
likely that R-RAS governs VANGL1 function by regulating either localisation to 
specialised signalling platforms and/or modulation of its interactions within these 
signalling platforms. 
In order to test the possibility of an R-RAS modulation effect on VANGL1 
interacting proteins, co-transfection studies were performed in which the ability 
of flag-VANGL1 to interact with endogenous proteins in the presence of activated 
R-RAS L87 or the defective mutant L87-A64 was assessed. 
Interestingly co-expression of active R-RAS decreased the interaction with 
SCRIB, CASK, DLG1 and DVL2, whereas it has no effect on the interaction of 
VANGL1 with SYNTENIN-1 (Figure 4.6A), a VANGL1 interacting protein identified 
in a subsequent TAP experiment (section 4.5).  
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Figure 4.6: R-RAS modulates a subset of endogenous VANGL1 binding partners 
involved in cell polarity and WNT signalling. (A) In order to test R-RAS specific 
modulation of VANGL1 binding partners, flag-VANGL1 was co-tranfected with either GST- 
R-RAS L87 or GST-R-RAS L87 A64, and lysates were purified 48h post transfection using 
flag beads. Binding of endogenous VANGL1 interactors were detected using the respective 
antibodies as indicated above. As background binding control served flag-GFP. (B) 
Activated R-RAS modulates VANGL1 interaction with the cytoplasmic portion of CELSR2-
C2, SYNJ2BP and YIF1B. Due to the lack of endogenous antibodies for both proteins, flag-
R-RAS L87 or L87 A64 was co-expressed with flag-YIF1B, flag-SYNJ2BP or flag-CELSR-C2 
in addition with GST-tagged DVL3, VANGL2 (V2), VANGL1 (V1) or respective PDZ binding 
motif mutant (∆PDZ). As background binding control served R1A. Cells were harvested 48 
h later and subjected to gluthathion purification and were probed for binding proteins 
using a flag antibody. 
 
165 
 
Due to the unavailability of antibodies to detect the endogenous proteins, the 
effect of R-RAS on the interaction with ER and Golgi localised YIF1B and 
SYNJ2BP, as well the cytoplasmic domain of CELSR2 (CELSR2-C2) was tested in 
co-transfections assays with tagged constructs. In contrast to the inhibitory 
effect of R-RAS on the interaction of VANGL1 with polarity proteins shown in 
Figure 4.6A, expression of active R-RAS had a modest stimulatory effect on the 
interaction of VANGL1 with CELSR2-C2, YIF1B and SYNJ2BP (Figure 4.6B). 
 
4.4 WNT ligand and Frizzled effects on VANGL1 interactions 
The ability of activated R-RAS to differentially modulate distinct subsets of 
VANGL1 binding partners suggested a model that R-RAS upon activation by WNT 
ligands could regulate VANGL1 function in polarity/PCP.  
The next sections will describe the characterisation of ligands and cellular 
systems that was performed in order to be able to assess the role of R-RAS and 
VANGL1 in polarity downstream of WNT ligands in mammalian cells. 
To investigate VANGL1’s physiological role(s) and a potential modulation of these 
by R-RAS, a cellular based system was required in order to investigate VANGL1 
biological function downstream of WNT signalling, focussing on PCP activation. 
Initial studies of the PCP pathway were carried out in fruit flies and pathway 
activation read-outs assessed included alignment of wing hairs, hexagonal 
packing of wing epithelial cells, or the orientation of photoreceptors in the eye 
(Mlodzik 2002; Zallen 2007). In zebrafish or Xenopus models, DVL membrane 
recruitment or developmental defects such as convergent extension is used to 
assess PCP activation or disruption (Tada and Kai 2009). In higher vertebrates, 
cochlea stereocilia orientation of the neurosensory hair cells is a commonly used 
in-vivo assessment (Lewis and Davies 2002; Wallingford 2012). 
Because our lab does not have direct access to any of these developmental 
systems, my studies focused on identifying biochemical and cell based assays of 
WNT ligand stimulation in a panel of mammalian cell lines.  
A commonly applied read out of WNT ligand stimulation in mammalian cells is to 
observe an upward mobility shift of phosphorylated DVL when analysed by SDS-
PAGE (Gonzalez-Sancho et al. 2004; Bryja et al. 2007b). However, since this 
technique is not able to distinguish between canonical versus PCP activation, this 
is a straight forward but limited approach (Gonzalez-Sancho et al. 2004; Angers 
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and Moon 2009). Other biochemical assays are assessment of JNK 
phosphorylation at residues T183/Y185 or activation of the heterodimeric 
transcription factor activator protein-1 (AP-1), which might be cell type specific 
(Boutros et al. 1998; Cheyette et al. 2002; Yamanaka et al. 2002; Pukrop et al. 
2006; Nomachi et al. 2008; Nishita et al. 2010b).  
In order to test above mentioned methods, the next step was to obtain or 
generate WNT ligands and to find a readout that demonstrated biological activity 
in the particular cell type.  
 
4.4.1 WNT ligand generation and assessment 
For a long time, research studies using WNT ligands were mostly hampered by 
the fact that these lipid-modified, hydrophobic secreted proteins are hard to 
isolate and purify. At the time of these studies, WNT3a, WNT5a, WNT7a ligands 
had just become commercially available. In order to address the possibility that 
other WNT ligands might be preferentially involved in the regulation of R-RAS 
and/or VANGL1, it was decided to generate our own panel of WNT ligands 
independently. This approach required stable transduction of WNT ligand 
constructs into mouse L cells and collection of resulting conditioned media, which 
then can be used for subsequent cell based assays (2.4.8.1) (Shibamoto et al. 
1998). 
Initial experiments were performed with commercial WNT ligands that were 
subsequently compared with our own generated ligands. Commercially available 
WNT3a, WNT5a and WNT7a ligands were tested using a β-catenin based 
luciferase reporter assay, and employing lithium chloride (LiCl) as positive 
control due to inhibition of GSK3β function and thus leading β-catenin 
accumulation (Klein and Melton 1996). 
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Figure 4.7: Recombinant WNT3a, but not WNT5a or WNT7a is able to stimulate 
canonical β-catenin signalling. HEK293T cells were co-transfected with TOPFLASH and 
Renilla luciferase reporter constructs. 24h post transfection, cells were stimulated for 13h 
with recombinant WNT ligands WNT3a (R&D, 300 ng/mL), WNT3a (Peprotech (PT), 300 
ng/mL), WNT5a (500 ng/mL) or WNT7a (1 µg/mL) prior cell harvest. Treatment with 
lithium chloride (LiCl, 30 mM, 13h) served as positive control. Cell extracts were assayed 
for firefly and renilla luciferase activities and data obtained were normalised for renilla 
activity. Reporter construct levels (Firefly luciferase) were expressed as fold increase 
across analysed samples using unstimulated cells (unstim) as reference. 
 
WNT3a (R&D source) ligand treatment resulted in elevated β-catenin levels by 
about 4.5 fold, whereas WNT3 ligand obtained from Peprotech (PT) at the same 
concentration proved more potent by increasing intracellular β-catenin levels by 
over 14-fold compared to untreated cells (Figure 4.7).  
Samples stimulated with recombinant WNT5a or WNT7a ligand failed to show a 
significant elevation of β-catenin levels, indicating that these ligands do not 
activate β-catenin dependent signalling in this context and thus biological activity 
cannot be tested with this method (Figure 4.7). 
 
4.4.2 Assessment of WNT ligand responsiveness in a panel of cell lines 
Upon WNT ligand interaction with Frizzled receptors, DVL proteins are recruited 
to the membrane and are regulated through phosphorylation events (Schulte et 
al. 2005; Bryja et al. 2007b; Bernatik et al. 2011). Hence, activation of WNT 
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signalling could be assessed by analysis of DVL hyper-phosphorylation in gel 
shift assays (Figure 4.8 and Figure 4.9) (Bryja et al. 2007b).  
The ability of cells to activate WNT signalling cascades depends on the available 
WNT ligands, expression of cognate receptors and co-receptors (Gordon and 
Nusse 2006; Green et al. 2008; Kikuchi et al. 2009; Sato et al. 2010; Niehrs 
2012). In order to identify a suitable cellular system for subsequent experiments 
in this study, a panel of tumour cell lines were chosen from breast (MCF-7, MDA-
MB-231), lung (A549), colon (HCT-116), bone (SaOS2) or neuroblast origin 
(IMR32, SY5YSH), as well non-transformed immortalised cell lines of mammary 
epithelial origin and investigated for response to WNT ligands 3a, 5a and 7a 
(Figure 4.8).  
Notably, all investigated cancerous cell lines employed in the panel showed a  
response to WNT5a conditioned media after two hours of treatment, 
demonstrated by a slower migrating form of DVL2 (Figure 4.8A upper part). 
Stimulation of the same cell line panel with WNT3a conditioned media showed 
responsiveness, with the exception of MDA-MB-231 cells, displayed by a 
phosphorylation induced shift of DVL2. However, WNT7a conditioned media did 
not seem to stimulate any of the tumour derived cell lines (Figure 4.8A upper 
section).  
However, even though all tested tumour cell lines respond to WNT3a and WNT5a 
CM, there are cell line dependent preferences. For example HCT-116 and SaOS2 
cells show a similar DVL2 phosphorylation shift in response to WNT3a and 
WNT5a CM, A549 cells react more strongly to WNT3a, whereas MDA-MB-231 
cells respond very strongly to WNT5a as judged by DVL2 phosphorylation shift 
(Figure 4.8). 
In contrast, treatment of four different immortalised non-tumorigenic mammary 
epithelia cell lines with WNT3a, WNT5a or WNT7a conditioned media failed in all 
four tested cell lines to induce a DVL2 phosphorylation shift (Figure 4.8A lower 
part). 
In order to assess if generated WNT conditioned media performs similar to 
recombinant commercially available purified WNT ligands, SaOS2, HCT116 and 
MDA-MB-231 were treated either with WNT3a, WNT5a, WNT7a CM or 
corresponding recombinant ligands under similar conditions and lysates were 
analysed for DVL2 phosphorylation shift (Figure 4.8A upper part and B). Overall, 
CM and recombinant ligands yielded the same DVL2 migration pattern, except 
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for MDA-MB-231 cells, which showed a strong response to recombinant WNT3a 
ligand, which was not observed for WNT3a CM. This could be due to lower ligand 
concentration in WNT3a CM.  
 
Figure 4.8: WNT ligands differentially stimulate DVL2 phosphorylation in tumour 
derived cell lines but have no effect on non-transformed breast cell lines. 
Assessment of WNT responsiveness in a panel of cell lines. Cancerous and non-
tumourigenic cell lines were chosen in order to test responsiveness to selected WNT 
ligands and analysed by DVL2 migration on SDS-polyacrylamide gels. (A) A549 (lung 
adenocarcinoma), SaOS2 (osteosarcoma), HCT-116 (colorectal carcinoma), MCF7 and 
MDA-MB-231 (breast adenocarcinoma), or non-tumorigenic mammary epithelia cell lines 
MCF10A, 184A1, HMEC and HMLE cell lines (normal) were grown to confluency, regular 
growth media aspirated and replaced with either control (cCM), indicated WNT ligand 
conditioned media or left untreated (-). Cells were lysed after 2 hours and analysed by 
Western blot for endogenous DVL2 protein shift. (B) U2OS (osteosarcoma), HEK293T 
(embryonic kidney), SY5YSH and IMR32 (human neuroblastoma) cell lines were grown to 
confluency and treated with recombinant WNT3a (225 ng/mL), WNT5a (225 ng/mL) or 
WNT7a (550 ng/mL) for 2h or left untreated (-). Cells were harvested and probed for 
endogenous DVL2. Recombinant and conditioned media induced a similar DVL2 
phosphorylation shift when compared to SaOS2, HCT-116 or MDA-MB-231 cells under 
both stimulation conditions (A versus B).  
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Assessment of WNT ligand responsiveness of neuroblastoma derived SY5YSH or 
IMR32 cells displayed a strong DVL2 phosphorylation shift if stimulated with 
recombinant WNT3a or WNT5a, but not if treated with WNT7a ligand. Notably, 
HEK293T cells have a high basal level of phosphorylated DVL2 (Figure 4.8B).  
 
4.4.3 Frizzled expression alters sensitivity towards WNT ligands 
WNT ligands bind to Frizzled receptors in order to activate downstream signalling 
cascades. Since there are 19 different WNT ligands and 10 Frizzled receptors 
known in mice and humans, it is difficult to find appropriate ligand-receptor 
combinations for in vitro studies. Therefore, we first tested if overexpression of 
Frizzled receptors could stimulate WNT signalling or enable cells to selectively 
respond to specific WNT ligands. Based on reports in the literature of their 
involvement in non-canonical WNT signalling (Wang et al. 2006; De Marco et al. 
2012), FZD5 and FZD6 were cloned and stably expressed by lentiviral 
transduction in HMEC and MDA-MB-231 cells. For technical reasons, a human 
FZD5 construct could not be cloned. Alignment of human FZD5 and mouse 
Frizzled5 (mFzd5) indicted a 97% amino acid identity and was therefore used as 
alternative in all corresponding experiments. 
The effect of mFzd5/FZD6 expression in HMEC cells, which were unresponsive to 
various WNT ligand conditioned media (Figure 4.8A lower part and Figure 4.9A) 
was assessed by DVL2 phosphorylation induced shift by immunoblotting.  
Expression of either mFzd5 or FZD6 in HMEC cells resulted in a slight increase of 
endogenous DVL2 phosphorylation, compared to vector control cells (Figure 
4.9A, lanes 5, 9 and 1, respectively). Interestingly, stimulation of mFzd5 cells 
with WNT3A or WNT5A CM resulted in a clear phospho-shift of DVL2. In contrast, 
expression of FZD6 did not lead to increased responsiveness towards WNT3a or 
WNT5a CM, indicating that FZD6 might not bind to WNT3a or WNT5a ligands in 
this cellular context (Figure 4.9A). 
In contrast, expression of mFzd5 or FZD6 in MDA-MB-231 cells led to a higher 
constitutive level of hyper-phosphorylated DVL2, which could not be further 
stimulated by WNT3A or WNT5A  ligands (Figure 4.9B). 
Therefore, overexpression of the mFzd5 receptor provides a great tool to 
stimulate formerly unresponsive HMEC cells with WNT ligands and this system is 
utilised in a later section. 
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Because R-RAS GTPases could possibly function downstream of only selected 
Frizzled receptors that could be expressed or function together with co-receptors 
in a cell-type specific manner, we decided to employ and expand the 
aforementioned overexpression approach of Frizzled receptors. Out of the eight 
remaining Frizzled members available in a mammalian system, we achieved to 
clone further FZD2, FZD3, FZD4, and FZD7 by PCR from cDNA clones ordered 
from Open Biosystems.  
 
 
Figure 4.9: HMECs expressing mFzd5 gain responsiveness to WNT3a and WNT5a 
ligands. Human mammary epithelial cells (HMECs) or breast adenocarcinoma cells (MDA-
MB-231) were transduced using lentiviral vectors encoding mFrizzled5 (mFzd5-mouse 
homologue), Frizzled6 (FZD6) or empty vector, serving as control. (A) Responsiveness of 
HMECs towards WNT ligand 3a and 5a was assessed by DVL2 gel shift post treatment with 
either control conditioned media (cCM), indicated WNT ligand conditioned media or cells 
that were left untreated in regular growth conditions (-). Treatment of indicated CMs were 
performed for 2h. Activation by WNT ligands was assessed by immunoblotting for 
phosphorylation shift of endogenous DVL2 protein. (B) Assessment of MDA-MB-231 cells 
response to WNT5a or WNT3a conditioned media in stably expressing mFzd5 or FZD6 
cells. Treatments were carried out as described for A. 
 
Expression of mFzd5 but not FZD6 in HMEC resulted in a slight increase of basal 
DVL2 phosphorylation, which was further stimulated by WNT3a and WNT5a, 
indicating that mFzd5 exogenous expression renders these cells responsive to 
these ligands. On the other hand, expression of both mFzd5 and FZD6 in MDA-
MB-231 cells, resulted in a maximal DVL2 shift that cannot be further stimulated 
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(Figure 4.9). This suggests that expression of at least a subset of Frizzled 
receptors is able to induce a DVL2 phosphorylation-shift, suggesting that 
expression of Frizzled receptors alone can stimulate downstream signalling 
without WNT ligand interaction. Therefore, taking advantage of this tool, we 
used the cloned panel of Frizzled receptors including FZD2 and mFzd5, which 
have been suggested to carry a role in non-canonical signalling (Sato et al. 
2010; Yu et al. 2012). Further, this also enabled us to test which Frizzled and/or 
ROR2 combination could be useful for further experiments.  
 
4.4.4 FZDs and ROR2 specifically stimulate VANGL1 interaction with 
DVL2 
Expression of ROR2 in HEK293T cells strongly increases the amount of DVL2 co-
immunoprecipitating with VANGL1 compared to the empty vector sample (Figure 
4.10A). Similarly, expression of mFZD5, FZD2, FZD4 and FZD7, but not FZD3 or 
FZD6, stimulated VANGL1 binding to DVL2, suggesting that the ability to 
modulate the VANGL1-DVL interaction is specific to a subset of FZD receptors 
(Figure 4.10A). Furthermore, under conditions where exogenous expression of 
ROR2 or Frizzled proteins stimulates the interaction of VANGL1 with DVL2, no 
effect was seen on the interaction of VANGL1 with SCRIB, CASK or DLG1 
suggesting that a subset of Frizzled receptors or ROR2 specifically modulate 
VANGL1 interaction with DVL proteins (Figure 4.10A). 
It has been reported that ROR2 can act as co-receptor for Frizzled proteins 
prompting the question if ROR2 and Frizzled could further stimulate the VANGL1-
DVL2 interaction in a cooperative manner (Nishita et al. 2010b) (Figure 4.10B). 
Hence, the same panel of Frizzled proteins were co-expressed in the presence or 
absence of ROR2 and flag-VANGL1 constructs, and lysates were flag-VANGL1 
immunoprecipitated and probed for endogenous DVL2 interaction (Figure 4.10C). 
Co-expression of ROR2 and FZD2 is able to further increase bound DVL2 to 
VANGL1 compared to ROR2 expression alone. This cooperative effect was also 
observed with a FZD4, mFzd5 or FZD7 - ROR2 combination, but not in case of 
Frizzled receptor FZD3 or FZD6 (Figure 4.10C). 
Furthermore, two mutations of mFzd5 were included in this study, the point 
mutation W530G and a deletion of the C-terminal PDZ binding motif (Figure 
4.10C).   
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Figure 4.10: FZDs and ROR2 cooperate to stimulate VANGL1-DVL2 interaction. 
(A) HEK293T cells were transfected with indicated Frizzled (FZD) and ROR2 constructs 
together with flag-VANGL1. Two days after transfection, cells were harvested, 
immunoprecipitated using flag-sepharose beads and probed for endogenous DVL2, CASK, 
DLG1 and SCRIB. (B) Schematic of WNT signalling pathway (incomplete illustration), 
focused on the PCP branch and our observations of ROR2 and FZD overexpression. (C) 
Co-expression of Frizzled and ROR2 cooperate to increase VANGL1-interacton with DVL2 
but not other proteins. Flag-VANGL1 was co-transfected with a panel of FZD receptors in 
the absence or presence (+) of ROR2. Cell harvest, immunoprecipitation and detection 
was carried out as in A. Flag-tagged Protein Kinase A regulatory subunit type 1 (R1A) and 
GFP constructs were expressed for assessment of background binding. Note that part C of 
this figure represents one gel, where the vertical line indicates omitted lanes. 
 
The highly conserved cytosolic KTxxxW motif of Frizzled receptors interacts with 
the PDZ domain of DVL proteins and is required for Frizzled-induced 
translocation of DVL to the plasma membrane and DVL phosphorylation 
(Umbhauer et al. 2000). The mFzd5 W530G point mutation localises to this motif 
and has been demonstrated to disrupt the receptors’ association with DVL 
(Umbhauer et al. 2000; Cong et al. 2004b). Deletion of the PDZ binding motif in 
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mFzd5 (mFzd5-∆PDZ-BM) interferes with binding of a multitude of PDZ domain 
containing proteins, but not with DVL, as binding takes place through the 
conserved KTxxxW motif (Figure 1.24) (Cong et al. 2004b; Wawrzak et al. 
2009). 
mFZD5-W530G expression fails to enhance VANGL1-DVL2 interaction, whereas 
deletion of the ∆PDZ-BM has no effect on the ability of mFzd5 to stimulate the 
VANGL1-DVL2 interaction. This suggests that DVL2 needs to be recruited to the 
membrane through its interaction with mFzd5 in order to interact with VANGL1 
with increased affinity (Figure 4.10C).  
It has been reported that DVL2 is phosphorylated at the plasma membrane 
through CK1 (Cong et al. 2004a; Bryja et al. 2007a; Bryja et al. 2007b). 
Consistently, endogenous DVL2 immunoprecipitations with VANGL1 displayed a 
slower migration pattern compared to the detected respective lysate band, 
suggesting that VANGL1 might bind to a specific modified moiety of DVL2 (Figure 
4.10C, compare immunoprecipitated lanes to lysate lane on the right hand side).  
 
4.4.5 TC21 can co-immunoprecipitate with ROR2 or VANGL1 in the 
presence of specific FZD receptors 
As demonstrated earlier, a subset of Frizzled proteins are able to stimulate DVL2 
binding to VANGL1, which is further enhanced if ROR2 is co-expressed (Figure 
4.10C). This suggests that this particular subset of Frizzled proteins and/or ROR2 
is able to activate intracellular non-canonical WNT signalling pathways.  
Based on our results we hypothesised that certain WNT ligands, acting through 
their specific receptors, may activate R-RAS GTPases in the context of non-
canonical WNT signalling. The ROR2 tyrosine kinase in particular is an attractive 
candidate to mediate this effect, as other RTKs are well known to activate RAS 
family GTPases. 
In order to study a possible association of R-RAS GTPases with ROR2, a C-
terminal flag-tagged ROR2 construct was transiently expressed in HEK293T cells 
in combination with FZD proteins and the associations of endogenous TC21 was 
analysed by western blot after flag immunoprecipitations. Remarkably, co-
expression of FZD2 stimulates the interaction of ROR2 with endogenous TC21, 
whereas FZD4 and mFZD5 only have a marginal effect. Therefore, in some 
contexts, ROR2 can associate with TC21 (Figure 4.11). 
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For technical reasons it was difficult to perform similar experiments in other cell 
types such as HMEC and MDA-MB-231 cells as transient transfection efficiency is 
much lower than HEK293T cells. Unfortunately, the cell lines stably expressing 
ROR2 were generated using an untagged ROR2 construct therefore precluding 
analogous HEK293T cell experiments.  
 
 
Figure 4.11: ROR2 co-expressed with FZD2 is able to immunoprecipitate 
endogenous TC21 in HEK293T cells. C-terminal flag-tagged ROR2 was co-transfected 
with FZD2, FZD4, mFzd5 and FZD7, and cell lysates were harvested 48 h post 
transfection and purified using flag-sepharose beads. Immunoprecipitates were probed for 
endogenous TC21 protein using a specific antibody.  
 
However, in MDA-MB-231 and HMEC cells stably expressing flag-tagged VANGL1 
in the context of mFZD5 stable exogenous expression, VANGL1 is able to co-
purify endogenous TC21 but not R-RAS (Figure 4.12). Since VANGL1 is a strict 
GTP dependent interactor of R-RAS GTPases, this suggests that mFzd5 
expression in this cellular context may be able to selectively activate TC21.  
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Figure 4.12: VANGL1 is able to immunoprecipitate endogenous TC21 but not R-
RAS in two breast cell lines stably expressing mFzd5. MDA-MB-231 or HMEC cells 
were transduced using a lentiviral mFzd5 construct and selected, before a second round 
of lentiviral infection with either flag-VANGL1 (V1) or Flag-NF2 was performed. Cells were 
lysed and flag immunoprecipitates probed for endogenous R-RAS or TC21. 
 
 
4.4.6 WNT5a modulates VANGL1 interaction with DVL but not SCRIB, 
CASK or DLG1 
HMEC cells stably expressing mFzd5 become responsive to WNT5a as shown in 
Figure 4.9A, and provided an attractive cellular system to study the effects of 
WNT5a stimulation. Therefore, tagged VANGL1 or VANGL2 were stably 
introduced into HMEC mFzd5 cells and the resulting cell lines were subsequently 
used to study the effect of WNT5a on VANGL interactions with endogenous 
proteins (Figure 4.13). 
Treatment of HMEC mFzd5 cells with WNT5a conditioned media for two hours 
stimulated binding of VANGL1 to DVL1 and DVL3 compared to control media. 
Similar results could be observed for VANGL2, albeit levels are much lower 
(Figure 4.13). Probing for additional endogenous VANGL1/2 interactors, using 
the same immunoprecipitated samples, did not display WNT5a mediated 
modulation effects for CASK or DLG1 proteins (Figure 4.13). 
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Figure 4.13: WNT5a stimulation of HMEC mFzd5 cells leads to modulation of 
VANGL1 and VANGL2 interaction with DVL proteins, but not CASK or DLG1. HMEC 
cells stably expressing mFzd5 were transduced by lentivirus encoding TAP2-VANGL1 (V1), 
TAP2-VANGL2 (V2) or TAP2-NF2 as a control. Cells were grown to confluence and 
stimulated for 2h with WNT5a conditioned media (+) or control conditioned media (-), 
lysed and subjected to streptavidin pull downs. Binding of endogenous VANGL interaction 
partners was analysed by western blot using indicated antibodies. The TAP2 tag harbours 
a calmodulin binding peptide (CBP) and a streptavidine binding peptide (SBP) tag. 
VANGL2 baits after pull down are indicated by asteriks. 
 
As observed before, CASK and DLG1 bind to both VANGL proteins with a 
preference for VANGL2, considering lower bait levels for VANGL2. In contrast, 
DVL proteins appear to selectively interact with VANGL1 as compared to VANGL2 
(Figure 4.2B and Figure 4.13). 
It is known that ligand induced RTK stimulation results in rapid intracellular 
downstream signalling within seconds to minutes after ligand binding. Therefore, 
it was interesting to determine in what time frame this occurs. Thus, I 
transiently expressed TAP6-tagged VANGL1 into HEK293T cells and treated cells 
with WNT5a conditioned media in a time course dependent manner over four 
hours (Figure 4.14).  
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Figure 4.14: WNT5a treatment enhances binding of DVL2 and DVL3 to VANGL1 
after 60 min, but SCRIB or CASK interactors are not modulated. HEK293T cells 
were transfected with TAP6-VANGL1 or TAP6-control constructs. 44h after transfection, 
cells were stimulated either with conditioned WNT5a media (WNT5a CM) at time points 
indicated above or control media (Control CM) for either 10 or 120 min. Cells were 
harvested and immunoprecipitated using flag-sepharose beads and probed with the 
indicated endogenous antibodies. TAP6 contains a large tag cassette, harbouring an EE-
tag, streptavidine binding peptide, histidine-tag and flag-tags.  
 
Stimulation of HEK293T cells with WNT5a conditioned media resulted in 
enhanced DVL2 and DVL1 binding to VANGL1, which could be observed from 60 
min after WNT5a application and was sustained for four hours (Figure 4.14). In 
contrast, no effect on the interaction with SCRIB or CASK is seen at any time 
point. Therefore, WNT5a selectively stimulates the association of VANGL1 with 
DVL2, which takes place in a delayed manner. 
Taken together, these experiments showed that either WNT5a or Frizzled 
proteins in cooperation with ROR2 are able to stimulate VANGL1-DVL2 
interaction. This binding is specific for DVL proteins, preferentially interacting 
with VANGL1 over VANGL2.  
WNT5a mediated enhanced VANGL1-DVL2 stimulation displays a response delay 
of approximately 60 min that may correlate with potential phosphorylation of 
DVL2, possibly by CK1. Furthermore, TC21 could be immunoprecipitated with 
ROR2 if FZD2 was co-expressed. Likewise, TC21 could be detected to precipitate 
with VANGL1 if mFzd5 was stably expressed, indicating that TC21 could be 
activated but in a Frizzled and ROR2 context dependent manner.   
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4.5 Proteomic analysis of VANGL1 interaction and their 
modulation by R-RAS, mFZD5 and ROR2 
ROR2 and mFzd5 both selectively stimulate VANGL1 interactions with DVL 
proteins and when expressed together cooperate to enhance this interaction 
(Figure 4.10).  On the other hand, active R-RAS appears to negatively regulate 
several VANGL1 interactions (Figure 4.6). 
In order to shed more light on the VANGL1 interactome and study in an unbiased 
approach how these interactions may be modulated in vivo, an additional 
proteomic study was performed. TAP-tagged VANGL1 was affinity purified from 
cells co-expressing either mFzd5, ROR2, a combination thereof, activated (L87) 
or dominant negative R-RAS (N43) (Figure 4.15).  
This purification achieved high sensitivity and in addition to proteins already 
detected in previous TAPs, multiple potential novel VANGL1 interactors were 
identified. Furthermore, many of the proteins appear to be modulated in one or 
more of the conditions tested, as suggested by this semi-quantitative approach. 
A summary of the mass spectrometry results is shown in Figure 4.15. 
Co-expression of R-RAS L87 led to the identification by mass spectrometry of 
fewer peptides for DVL proteins, SCRIB and DLG1, suggesting that active R-RAS 
decreases these interactions with VANGL1. This is consistent with the results 
obtained previously (Figure 4.6) and independently suggests that R-RAS, upon 
activation, is likely to modulate the VANGL1 interactome. 
The mass spectrometry results for this experiment were received towards the 
end of my PhD study and therefore I was unable to perform further validation 
and follow up experiments. 
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Figure 4.15: Summary of proteins identified by mass spectrometry in VANGL1 
affinity purifications. (A) VANGL1 protein complexes were isolated from HEK293T cells 
expressing a flag-tagged VANGL1 construct alone or in combination with mFzd5, ROR2, a 
combination of mFzd5 and ROR2, activated R-RAS L87 (R-RasL) or the dominant negative 
analogue R-RAS N43 (R-RasN) as indicated in the illustration. (B) Cell lysates were 
harvested 48h after transfection and subjected to flag-sepharose purification. Purified 
proteins were precipitated and separated by SDS-PAGE, gel bands cut, trypsinised and 
analysed by tandem mass spectrometry. Proteins are ranked by percent coverage and are 
colored blue or coral if the interaction with VANGL1 was decreased or increased 
respectively, as judged by the number of peptides identified. 
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4.6 Discussion 
4.6.1 Identification and characterisation of VANGL1 interacting proteins  
Using TAP as an unbiased proteomic approach, multiple VANGL1 interacting 
proteins have been identified. Some of them such as DVL/Dsh, Scrib and Dlg1 
had been previously identified as interacting with the VANGL homologue in 
Drosophila, and confirm a role in cell polarity (Park and Moon 2002; Lee et al. 
2003; Bellaiche et al. 2004; Courbard et al. 2009). 
VANGL1 contains a PDZ domain binding motif at its C-terminus, allowing 
interaction with PDZ domain containing proteins. PDZ proteins are found from 
bacteria to vertebrates and are involved in various cellular functions including 
cell polarity (Ponting 1997; Subbaiah et al. 2011). Notably, a subset of PDZ 
containing VANGL1 interactors, such as SCRIB, DLG1 and CASK, which are 
involved in polarity and migration have been demonstrated to be strictly 
dependent on the VANGL1-PDZ binding motif for interaction. 
SCRIB, one of the identified VANGL1 interactors, has been reported in 
mammalian cells to associate with the PIX/GIT complex that regulates 
RAC/CDC42 and ARF GTPases (Audebert et al. 2004; Frank and Hansen 2008) 
and be involved in cell polarity during epithelial migration through regulation of 
RHO GTPase recruitment to the leading edge (Dow et al. 2007), and to mediate 
neural migration and CE (Qin et al. 2005a; Wada et al. 2005). SCRIB’s role in 
PCP is further strengthened by the observation that SCRIB mouse mutants have 
neural tube closure defects (Murdoch et al. 2003) and display hair cell polarity 
defects in the inner ear (Montcouquiol et al. 2003).  
SCRIB is a cytosolic protein but can localise to the plasma membrane, e.g. sites 
of cell-cell contact in epithelial cells and leading edge in migrating cells, 
nonetheless how SCRIB translocation to the membrane is regulated is not clear. 
A recent report has confirmed that SCRIB forms a complex with VANGL1 and 
further showed that VANGL1 co-localises with SCRIB at the leading edge in 
migrating cells (Anastas et al. 2011).  Therefore, SCRIB interaction with 
VANGL1, a membrane protein, may provide a mechanism to recruit SCRIB to the 
membrane. Based on our results, we propose that activation of R-RAS GTPases 
by extracellular signals would recruit the VANGL1-SCRIB complex to sites of 
activation at specialised membrane micro-domains and thus be a mechanism to 
spatially coordinate polarity with other signalling pathways regulated by R-RAS 
GTPases. 
182 
 
DLG1 has been shown to interact with VANGL1 in a PDZ binding motif dependent 
manner. Consistent with earlier findings in Drosohila, Dlg and Stbm form a 
complex which is important in plasma membrane formation (Lee et al. 2003). It 
has been suggested that this complex is required to recruit membrane-
associated proteins and lipids from internal membranes to sites of new plasma 
membrane formation (Lee et al. 2003). 
Notably, DLG1 null mice suffer from skeletal defects throughout the embryo and 
characteristic PCP defects such as open neural tube and misorientation of 
cochlear hair cell stereociliary bundles, consistent with the possibility that at 
least in mice, DLG1 functions with SCRIB in planar cell polarity (Rivera et al. 
2013). 
CASK, has been originally described to be localised at neuronal synapses (Zheng 
et al. 2011) and to act as a scaffold for proteins involved in synaptic junctions, 
vesicle exocytosis and ion channel trafficking (Butz et al. 1998; Setou et al. 
2000; Leonoudakis et al. 2004). In addition, CASK has been shown to interact 
with DLG1 (Sabio et al. 2005) and it remains to be determined if both bind 
independently to VANGL1 or as a complex with each other. 
Unlike other PDZ domain containing proteins like SCRIB, DLG1 and CASK, 
VANGL1 interaction with DVL2 is not exclusively mediated through the VANGL1 
PDZ-binding motif, which is in line with observations of the corresponding 
Drosophila homologue (Park and Moon 2002). Remarkably, R-RAS interaction is 
specific to VANGL1 and so is the DVL interaction. Furthermore, R-RAS and DVL3 
binding to VANGL1 is disrupted by the point mutant D259E, suggesting that both 
proteins could be competing for the same binding site. This is further confirmed 
by observations that active R-RAS modulates VANGL1-DVL binding, suggesting a 
common ‘axis’ of VANGL1 function.  
DVL proteins are major signalling hubs, which interact with a multitude of 
proteins, and mediate canonical and non-canonical WNT signalling (Boutros and 
Mlodzik 1999; Gao and Chen 2010; Wynshaw-Boris 2012) for example WNT5a 
induced migration through activation of RHOA or RAC in breast cancer cells (Zhu 
et al. 2012; Zhu et al. 2013). Therefore, VANGL1 interaction with all three DVL 
proteins highlights its potential role in downstream WNT signal mediation, which 
will be discussed later in this section. 
The observation that VANGL1 is able to bind to the intracellular domain of 
CELSR2 but not CELSR1, which was also the only CELSR isoform detected in 
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VANGL1-TAP experiments, indicates C-terminus mediated functional differences 
across CELSR proteins. Indeed, CELSR1 is a major player in PCP and is directly 
linked to cochlear stereocilia bundle misorientation and neural tube closure 
defects (Curtin et al. 2003; Devenport and Fuchs 2008; Robinson et al. 2011). 
CELSR2 and CELSR3 regulate less direct PCP processes such as ciliogenesis, 
maintenance of dendrites, neuronal migration and axon guidance (Shima et al. 
2002; Tissir et al. 2005; Wada et al. 2006; Shima et al. 2007; Tissir et al. 
2010), implicating that VANGL1 might not be directly involved in neurulation and 
related CE (Torban et al. 2008; Antic et al. 2010; Song et al. 2010), but rather 
in PCP directed processes associated with ciliogenesis and neuronal development 
and maintenance. 
Due to technical reasons, interaction studies were carried out with the 
intracellular C-terminus of CELSR1 and CELSR2, but it cannot be ruled out that 
the large ectodomain could be also involved in VANGL1 binding in order to 
establish PCP across a plane of cells. It has been reported for the Drosophila 
homologue of VANGL proteins, that stbm interacts with Frizzled proteins through 
their respective extracellular domains (Wu and Mlodzik 2008) and thus VANGL1-
CELSR protein interaction could also take place through extracellular domain 
association. 
The adhesion-GPCR Latrophilin 2 (LPHN2) was detected in the VANGL1-TAP co-
expressing activated R-RAS (Figure 4.1C). This is particular interesting since 
LPHN2 is structurally related to CELSR proteins and plays an essential role in the 
establishment of tissue polarity and thus could constitute a novel PCP pathway 
mediator (Langenhan et al. 2009). Unfortunately, several cloning attempts of the 
full length protein or truncation constructs led to very low or undetectable 
expression levels, rendering interaction approaches unfruitful. 
Multiple other novel VANGL1 - interacting proteins identified by TAP are involved 
in vesicle trafficking and imply additional roles for VANGL1 function. For example 
YIF1B interacts with the transport GTPases Ypt1p, Ypt31p and Sec4p, and loss of 
YIF1 function results in a block of ER-to-Golgi protein transport and vesicle 
accumulation, suggesting a vital role in vesicle docking and fusion (Matern et al. 
2000). YIF1B localisation to ER or Golgi membranes suggests that VANGL1 might 
interact with YIF1B on its way to the plasma membrane as shown for Sec24B 
and VANGL2 transport (Wendeler et al. 2007; Merte et al. 2011; Wansleeben et 
al. 2011). Another possibility is that VANGL1 could also localise to ER or Golgi 
membranes, consistent with what is observed for its subcellular localisation 
pattern (see section 5.4.  
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NDFIP1 is found associated with the exosome, Golgi or vesicles. It forms an 
adaptor for Nedd4 family proteins in order to bind respective target proteins for 
subsequent ubiquitination. Interestingly, NEDDL family proteins have been 
demonstrated to negatively regulate WNT signalling through DVL2 ubiquitination 
(Wei et al. 2012; Ding et al. 2013). Thus, it would be interesting to determine if 
VANGL1 could act as a modulator for DVL2 directed ubiquitination or might be a 
target of NEDD4 proteins itself.  
Endocytosis of WNT ligand-receptor complexes is required for WNT signalling 
regulation, which is achieved through clathrin or caveolin mediated endocytosis 
(Sorkin and von Zastrow 2009; Traub 2009; Lajoie and Nabi 2010). Clathrin 
mediated internalisation has been shown to regulate β-catenin dependent (Chen 
et al. 2001; Blitzer and Nusse 2006) and independent pathways (Sato et al. 
2010; Ohkawara et al. 2011; Sakane et al. 2012). SYNJ2BP a putative growth-
promoting factor implicated in breast tumourigenesis and tumour development 
(Li et al. 2009c), has been shown to be involved in clathrin-mediated 
endocytosis and recycling (Matsuzaki et al. 2002; Verstreken et al. 2003). 
VANGL1 interaction with SYNJ2BP, which takes place in a PDZ-dependent 
manner, suggests a regulatory function for VANGL1 in vesicle formation and 
trafficking.  
RAB proteins control intracellular trafficking (Chua et al. 2010; Mizuno-Yamasaki 
et al. 2012) and have been shown to regulate WNT signalling (Lee et al. 2007; 
Zhu et al. 2013). VANGL1 interacts specifically with the catalytic subunit of a 
RAB3GAP (RAB3GAP1), whereas DVL2 binds to the non-catalytic subunit 
(RAB3GAP2). Therefore it could be speculated that RAB3GAP2 could be 
associated with DVL2 and upon binding of VANGL1 to DVL2, the catalytic subunit 
is recruited to this complex and is now able to modulate RAB protein activity in 
vesicle trafficking processes.  
C17ORF62 still remains mostly uncharacterised besides the MS detected C-
terminal serine/tyrosine phosphorylation cluster (at position S159, S168, S170, 
S173, S175, S176, S178, S187 and Y124) (http://www.phosphosite.org). Initial 
co-localisation studies found C17ORF62 associated with the Golgi complex and it 
has been proposed that this protein could be involved in cell death induction 
(Deng et al. 2011). However, more studies will be required to shed light into 
C17ORF62 function and its relation to VANGL1.  
Sec24b has been recently demonstrated to be part of the endoplasmic reticulum 
to Golgi complex transport machinery, important for VANGL2 transport and thus 
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has not been the focus of our efforts (Merte et al. 2011; Wansleeben et al. 
2011).  
Although some of the proteins tested in this study bind to both VANGL1 and 
VANGL2 isoforms (SCRIB, DLG1, CASK, YIF1B, CELSR2-C2, RAP3GAP1, 
SYNTENIN-1), others show differential interaction affinities and suggest different 
functions for the two VANGL proteins (DVL proteins, SYNJ2BP).  
 
4.6.2 Frizzled expression leads to enhanced VANGL1-DVL2 interaction  
Immunoprecipitation experiments demonstrated that TC21 associates with ROR2 
in HEK293T cells co-expressing FZD2. Furthermore, employing HMEC and MDA-
MB-231 cells expressing stably mFzd5, endogenous TC21 but not R-RAS co-
immunoprecipitates with VANGL1. This is despite the fact that R-RAS protein 
levels could be readily detected in lysates of these cells. This suggests that 
depending on the receptor/co-receptor combination and cellular context different 
R-RAS GTPases might be differentially regulated.  
R-RAS and TC21 seem to be regulated by the same set of GEFs and GAPs, 
whereas M-RAS showed a regulation pattern more similar to classical RAS 
proteins (Ohba et al. 2000), suggesting that R-RAS and TC21  are likely to be 
co-activated by extracellular signals. On the other hand, TC21 has been shown 
to constitutively interact with the T-cell and B-cell antigen receptors (TCR and 
BCR, respectively) through a direct interaction with a signalling sequence known 
as the Immunoreceptor Tyrosine-based Activation Motif or ITAM, which is 
present in the CD3 signalling subunits of the TCR and the Igα and β subunits of 
the BCR (Alarcon and Martinez-Martin 2011). This fact highlights the possibility 
that there might be additional mechanisms to achieve differential regulation of 
R-RAS GTPases. It remains to be determined if in some contexts TC21 may 
interact directly with ROR2 by a mechanism similar to that shown for the ITAMs 
of the TCR and BCR. 
However, in section 6.2 I will provide evidence that R-RAS can also be activated 
by ROR2 expression or WNT5a stimulation, and thus both TC21 and R-RAS 
GTPases seem to play a role in non-canonical WNT signalling. 
DVL proteins interact with a multitude of proteins and serve as a key signalling 
components downstream of Frizzled receptors, regulating WNT/β-catenin and 
non-canonical WNT pathways (Wharton 2003; Wallingford and Habas 2005; 
Malbon and Wang 2006; Gao and Chen 2010). WNT-induced activation of DVL is 
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visible as a electrophoretic mobility shift of all three DVL isoforms (Gonzalez-
Sancho et al. 2004; Bryja et al. 2007a; Bryja et al. 2007b), and leads to 
activation of DVL downstream of WNT ligands (Peters et al. 1999; Sakanaka et 
al. 1999; Kishida et al. 2001; Cong et al. 2004a; Foldynova-Trantirkova et al. 
2010). 
VANGL1 interacts with all three DVL proteins. Deletion of the PDZ-binding motif 
in VANGL1 displays only a modest effect on interaction reduction, whereas the 
point mutation D259E, which is found in patients with NTDs, disrupts the 
interaction. This suggests that a membrane proximal region, which remains to 
be further mapped, interacts with a region of DVL other than the PDZ.  
Interestingly the interaction of VANGL1 with DVLs, but not with other proteins 
such as SCRIB, DLG1 and CASK (whose interactions are mediated via PDZ 
domains) is stimulated by a subset of FZD proteins as well as by ROR2. The 
underlying mechanism by which FZD and/or ROR2 achieve this stimulatory effect 
remains to be identified but may be related to DVL hyper-phosphorylation (see 
below). 
Based on the observation that the DVL bound to VANGL1 appears to migrate 
more slowly and that WNT stimulation of the DVL-VANGL1 interaction follows a 
delayed time course that correlates with DVL phosphorylation, it is tempting to 
speculate that the interaction of DVL with VANGL1 is stimulated by DVL 
phosphorylation. Therefore, DVL phosphorylation (by casein kinase or other 
kinases) may be at least part of the mechanism regulating this interaction. 
Future experiments should address this possibility. 
ROR2 contains WNT-binding domains in its extracellular region and could 
therefore bind WNTs directly (Green et al. 2008; Angers and Moon 2009). 
Further, ROR2 could also function as a co-receptor operating in combination with 
FZDs. It has been proposed that one mechanism by which WNTs can trigger 
canonical versus non-canonical signalling is through a differential use of co-
receptors in combination with FZD receptors (Sato et al. 2010; Niehrs 2012).  
Genetic interactions between ROR2 and WNT5a were suggested by observations 
that mice with inactivation of the gene encoding Ror2 showed striking similarities 
to Wnt5a−/− mice, including perinatal lethality, dwarfism, facial abnormalities, 
and limb shortening (Green et al. 2008). Of note, Ror2−/− embryos also exhibited 
defects in the orientation of the sensory hair cells in the inner ear, a hallmark of 
WNT planar polarity pathway aberrations observed in Wnt5a−/−, Fzd3−/−, and 
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Fzd6−/− mice (Wang et al. 2006; Qian et al. 2007; Yamamoto et al. 2008). In 
addition, ROR2 was shown to be involved in the effects of WNT5a in some 
cellular and developmental processes, such as polarised cell migration and 
convergent extension movements (He et al. 2008; Nomachi et al. 2008; 
Enomoto et al. 2009; Laird et al. 2011). 
FZDs recruit DVL to the plasma membrane by a still poorly understood 
mechanism. FZD proteins contain a C-terminal PDZ binding motif required for 
recruitment of PDZ proteins (Wawrzak et al. 2009), as well as an additional 
KTxxxW motif which is required for DVL translocation to the membrane and 
subsequent phosphorylation (Rothbacher et al. 2000; Umbhauer et al. 2000; 
Axelrod 2001; Cong et al. 2004b). Our studies demonstrated that deletion of the 
PDZ binding motif of mFzd5 has no effect on the stimulated VANGL1-DVL2 
binding, whereas a mutation in its KTxxxW motif (W530G) abolishes the 
enhanced interaction. Therefore, the ability of mFzd5 to stimulate the VANGL1-
DVL2 interaction correlates with its ability to translocate to the membrane and 
phosphorylate DVL2 and further suggests that DVL translocation and 
phosphorylation could be one mechanism of recruitment of VANGL1 (and its 
associated interactome) to sites of activation by WNT ligands. 
Of the tested panel of Frizzled receptors, FZD2, FZD4, mFzd5 and FZD7 
stimulate the VANGL1-DVL2 interaction, whereas FZD3 and FZD6 did not display 
a detectable interaction enhancement. Interestingly, FZD3 and FZD6 form a 
distinct phylogenetic branch of Frizzled proteins (Huang and Klein 2004), and 
have been demonstrated to be required with VANGL2, CELSR1 and PRICKLE2 for 
inner ear stereociliary bundle orientation (Montcouquiol et al. 2006; 
Montcouquiol et al. 2008).  
As mentioned earlier, DVL interacts preferentially with VANGL1 compared to 
VANGL2, and VANGL1 interacts with CELSR2 but not CELSR1. Taken together, 
these observations suggest the possibility that a subset of FZD receptors, 
possibly in combination with different CELSR co-receptors, may use different 
VANGL isoforms to regulate various aspects of non-canonical signalling. 
Notably, VANGL2 has been reported to form a WNT5a dependent complex with 
ROR2, which leads to VANGL2 phosphorylation and PCP induced limb elongation 
(Gao et al. 2011). It remains to be established if VANGL1 can also associate with 
ROR2, although in a preliminary experiment I was able to detect endogenous 
VANGL1 co-immunoprecipitating with ROR2 only in the presence of mFzd5 (data 
not shown).  
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Several observations strongly suggest that DVL phosphorylation correlates with 
the ability to interact with VANGL1. First, DVL2 that co-immunoprecipitates with 
VANGL1 appears to migrate more slowly on SDS-PAGE compared to lysates. 
Second, WNT stimulation of the DVL2-VANGL1 interaction follows a delayed time 
course that correlates with DVL phosphorylation. Third, co-expression of certain 
Frizzled receptors with ROR2 cooperates to enhance the VANGL1-DVL interaction 
and this correlates with enhanced DVL phosphorylation shift. Therefore, DVL 
phosphorylation may be at least part of the mechanism regulating the interaction 
with VANGL1. Future experiments should further address this possibility. 
DVL proteins display a variety of post translational modification sites (Wu et al. 
2012) and are phosphorylated by at least three kinases CK1 (Klimowski et al. 
2006; Bryja et al. 2007b; Corbit et al. 2008), CK2 (Wharton 2003) and PAR1 
(Sun et al. 2001; Elbert et al. 2006), whereas protein phosphatase 2A (PP2A) 
has been shown to negatively regulate DVL activity (Yokoyama and Malbon 
2007). 
CK1δ/ε have been identified as the relevant kinases hyper-phosphorylating DVL 
in response to WNT5a, whereas WNT3a stimulation leads to β-catenin 
stabilisation which was not reliant on hyper-phosphorylated DVL2 (Bryja et al. 
2007a; Bryja et al. 2007b). However, activation of DVL mediated β-catenin 
related downstream signalling appears in less than 10–15 min, whereas the 
earliest formation of hyper-phosphorylated DVL is detected after 30 min 
(Gonzalez-Sancho et al. 2004; Bryja et al. 2007b; Witte et al. 2010) and seems 
to be stable for at least 12 h (Bryja et al. 2007a). Additionaly, CK1 induced 
hyper-phosphorylation of DVL2 can result in the inactivation of β-catenin 
signalling (Bernatik et al. 2011). 
The role of DVL phosphorylation in WNT signalling remains obscure. Based on 
these and our observations, a model emerges where DVL phosphorylation may 
be a mechanism for the separate temporal control of β-catenin dependent and 
independent WNT signalling. According to this model, the phosphorylation of DVL 
that occurs at later time points of WNT stimulation and that correlates with 
increased interaction with VANGL1, may shift WNT signalling from the β-catenin 
pathway to the PCP pathway. 
Expression of active R-RAS leads to a modest decrease in the ability of VANGL1 
to interact with DVL2, CASK, DLG1, and SCRIB. This has been seen in co-
transfection-western blot experiments and was independently confirmed by mass 
spectrometry. The decreased binding of VANGL1 with DVL in the presence of R-
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RAS is consistent with the observation that mutation D259E in VANGL1 disrupts 
the interaction with both R-RAS and DVL3. This suggests that both R-RAS and 
DVL bind to the same region of VANGL1 and may therefore compete for its 
interaction. 
Furthermore, the proteomic study identified other proteins both negatively and 
positively modulated by R-RAS. While these additional results remain to be 
validated, our observations clearly suggest that R-RAS has the ability to regulate 
VANGL1 interaction with a subset of its partners.  
We propose a model where upon activation by extracellular signals, R-RAS 
GTPases will recruit VANGL1 (and its associated proteins) to sites of activation. 
This will not only lead to the localisation of VANGL1 complexes at spatially 
distinct micro-domains at the plasma membrane but also to a selective 
‘rearrangement’ of the interacting partners within the complex to give rise to 
VANGL1 complexes with specialised signalling properties. 
The observation that WNT stimulation can lead to both the activation of R-RAS 
GTPases and its association with VANGL1 on one hand and to the association of 
VANGL1 with DVL on the other hand, with both interactions potentially being 
mutually exclusive may seem counter-intuitive. However, the spatial-temporal 
dynamics have to be considered. R-RAS proteins are activated within minutes of 
WNT stimulation; whereas the WNT induced increase in the interaction of 
VANGL1 with DVL is first detected after 60 minutes and therefore clearly displays 
a delayed response that may correlate with DVL phosphorylation. This will be 
more clearly outlined and discussed in a subsequent chapter (see section 6.2) 
and the final discussion (see section 8.1). 
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Figure 4.16: Overview of VANGL1 binding partners and R-RAS dependent 
modulation of respective interactions. (A) VANGL1 interacts through its PDZ motif 
with polarity proteins like DLG, CASK, SCRIB or the WNT core proteins DVL or CELSR2. In 
addition, further interaction studies showed that VANGL1 binds to the Tetraspanin KAI1 or 
the Syndecan-binding protein SYNTENIN. (B) Other novel VANGL1 interactors are 
implicated in vesicle trafficking such as YIF1 (ER-GOLGI transport), RAB3GAP 
(intracellular trafficking), SYNJ2BP (clathrin-mediated endocytosis) or endosome 
associated (NDFIP1). (C) Overview of R-RAS modulating effect on identified VANGL1 
binding partners. (D) Biochemical studies presented that R-RAS subgroup members (at 
least TC21) are found associated with ROR2, suggesting that R-RAS GTPases act 
downstream of WNT inducing stimuli, leading to enhanced DVL-VANGL1 interaction and 
further to RHO GTPase modulation and PCP pathway activation. 
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CHAPTER 5 
 
R-RAS GTPases inhibit 
VANGL1 mediated 
PRICKLE degradation 
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5 R-RAS GTPases inhibit VANGL1 induced PRICKLE 
degradation  
 
5.1 VANGL1 interacts with PRICKLE1 and stimulates its 
destabilisation  
Strabismus and Prickle have been shown to form a functional complex in 
Drosophila that is proximal to the distally localised Frizzled-Dishevelled complex, 
and this asymmetric distribution is required for tissue polarity patterning 
(Bastock et al. 2003; Jenny et al. 2003; Rawls and Wolff 2003).  
Due to unavailability of commercial antibodies against human PRICKLE proteins 
at the time, human PRICKLE1 and PRICKLE2 were cloned by PCR. Vertebrate 
PRICKLE1 consists of an N-terminal Prickle, Espinas and Testin (PET) domain and 
three zinc binding LIN-11, Isl1 and MEC-3 (LIM) motifs. To test if these domains 
are required for VANGL1 binding and to map the interaction, two truncation 
constructs were further generated; PRICKLE1-N contains the PET and LIM 
domains, whereas the larger PRICKLE-C truncation construct contains the 
remaining part of the protein without any known domains (Figure 5.1A).  
Initial interaction studies in HEK293T cells using co-transfection showed that 
human VANGL1 binding maps to the C-terminal region of PRICKLE1 (Figure 
5.1B).  
Both VANGL1 and VANGL2 are able to interact with PRICKLE1 (Figure 5.1C). In 
the course of these studies it became apparent that co-expression of VANGL 
proteins leads to a strong reduction of transfected PRICKLE1 protein levels on 
lysates. This effect is more prominent with VANGL1 but differences in the levels 
of expression achieved between the two VANGL proteins have to be taken into 
consideration (Figure 5.1C). Under conditions were PRICKLE1 is destabilised by 
VANGL proteins, simultaneous binding experiments for VANGL1 interacting 
proteins such as the PCP core protein DVL1 displayed the expected binding, but 
did not exhibit any modulation effect on PRICKLE1 protein levels, indicating that 
the decreased PRICKLE1 protein level is specific for VANGL co-expression (Figure 
5.1C).  
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Figure 5.1: VANGL1 and VANGL2 interact with and destabilise PRICKLE1. (A) 
Diagram of PRICKLE1 structure and generated constructs. PRICKLE1 is an 831 amino acid 
(aa) protein, containing a N-terminal PET domain followed by three LIM zinc binding 
motives. FL-full length, PK-N or PK-C refer to respective N- or C-terminal truncations. (B) 
PRICKLE1 binds to VANGL1 through its C-terminus. GST-tagged VANGL1 or control 
expression plasmids (FLII) were co-transfected with flag-PRICKLE1 (PK1-FL), or 
respective N- (PK1-N) or C-terminal (PK1-C) truncations. GST-baits were purified with 
glutathione beads and flag-PRICKLE1 detected by western blotting using anti-flag 
antibodies. (C) PRICKLE1 binds to VANGL1 (V1) and VANGL2 (V2), independently of the 
PDZ-binding motif. Flag-PRICKLE1 levels (but not flag-DVL1) are reduced upon co-
expression of VANGL1/2. GST-VANGL2 or GST-VANGL1 full length proteins, VANGL1-PDZ 
binding motif truncation mutant (∆PDZ-BM), or R1A control protein were co-transfected 
with flag-PRICKLE1 into HEK293T cells. Proteins were purified and detected as described 
for B. (D) PRICKLE1 protein levels are negatively affected by VANGL1 in both soluble and 
insoluble lysate fractions. GST-tagged constructs as in C including GST-tagged DVL2 were 
co-transfected with flag-PRICKLE1 constructs in HEK293T cells and lysed two days later. 
Expression levels of flag-PRICKLE1 were assessed in the soluble fraction (lysate) and the 
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guanidinium chloride resolubilised pellet (pellet fraction). Total levels of ectopic PRICKLE1 
were detected with flag-antibodies. (E) Treatment with proteasome inhibitor MG132 does 
not counteract VANGL1-induced PRICKLE1 degradation. HEK293T cells were double 
transfected with GST-VANGL1 or control protein (R1A) and flag-PRICKLE1 as indicated. 
42h after transfection, cells were either treated with the proteasomal inhibitor MG132 or 
vehicle control (DMSO) at a concentration of 10 µM for 4.5 h. Cells were subsequently 
lysed and analysed by western blot, probing with either flag- or GST-antibodies. 
 
In order to confirm that PRICKLE1 protein levels are reduced and not associated 
with insoluble structures during the generation of lysates, insoluble lysate 
fractions were subjected to guanidinium chloride solubilisation and analysed by 
western blot for PRICKLE1 levels. Indeed, the pellet fraction showed the same 
relative reduced amounts of flag-PRICKLE1 in VANGL1 expressing cells, as 
observed for the soluble fractions (Figure 5.1D, compare lysates versus 
reconstituted lysates). 
These results suggest that VANGL proteins interact strongly with PRICKLE1, 
since even under conditions where expression levels were hardly detectable in 
whole cell lysates, PRICKLE1 could be readily detected in flag-VANGL co-
immunoprecipitates. Furthermore, these observations also imply that VANGL 
proteins may lead to the degradation of PRICKLE1 proteins. 
To test this possibility, similar experiments were performed in the presence of 
the proteasomal inhibitor MG132 which is known to interfere with the 26S 
proteasome function and consequently would allow stabilisation of proteins 
otherwise targeted for proteasomal degradation (Tawa et al. 1997). Treatment 
of cells with 10µM MG132 did not prevent reduced levels of PRICKLE1 induced 
upon VANGL1 expression (Figure 5.1E). Additional experiments employing higher 
concentrations of MG132 or longer treatment periods also failed to yield 
increased PRICKLE1 levels (data not shown).  This suggests that VANGL1 may 
decrease PRICKLE1 levels by a mechanism other than ubiquitin mediated 
proteasome degradation. 
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5.2 R-RAS GTPases inhibit VANGL1 induced PRICKLE1/2 
protein destabilisation  
I next addressed if R-RAS interaction with VANGL1 is able to regulate VANGL1 
binding to PRICKLE1 and/or regulate PRICKLE1 protein stability. Activated R-RAS 
L87 does not alter interaction between VANGL1 and PRICKLE1 taking VANGL1 
bait levels in consideration (Figure 5.2A), but significantly prevents the 
destabilisation effect of PRICKLE1 protein exerted by VANGL1 (Figure 5.2B).  
I also compared the effect of other R-RAS subgroup members on the 
degradation of both PRICKLE1 and PRICKLE2. Expression of all three R-RAS 
members can partially rescue the VANGL1 induced PRICKLE1/2 destabilisation in 
a manner dependent on an intact effector domain (Figure 5.2C). This effect is 
specific to R-RAS subgroup GTPases as the RAP2 member of the RAS family did 
not display a stabilisation effect. Surprisingly, the ability to prevent PRICKLE1/2 
destabilisation does not correlate with the binding affinity to VANGL1; TC21 and 
M-RAS do not show as strong an interaction with VANGL1 as observed for R-RAS 
(Figure 3.5) but can however prevent the VANGL1 induced PRICKLE1/2 
destabilisation more efficiently than R-RAS (Figure 5.2C). 
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Figure 5.2: R-RAS subgroup GTPases are able to rescue VANGL1 induced 
destabilisation of PRICKLE1 and PRICKLE2. (A) Activated R-RAS L87 does not 
modulate VANGL1 and PRICKLE1 interaction. HEK293T cells were triple transfected with 
GST-VANGL1 or control contstruct (R1A), GST-R-RAS active mutant L87 (R-RASL) or 
respective defective mutant L87 64A (R-RASLA) and flag-PRICKLE1, as indicated. 48h 
after transfection, cells were lysed and GST proteins precipitated using glutathione 
sepharose beads. Interactions were analysed by western blot, probing with flag- or GST-
antibodies. (B) R-RAS L87 partially rescues VANGL1-induced PRICKLE1 decay. HEK293T 
cells were triple transfected with GST-VANGL1 or control (R1A) contstructs, GST-R-RAS 
active mutant L87 (R-RASL) and flag-PRICKLE1, as outlined. 48h after transfection, cells 
were lysed and analysed by western blot, probing with flag- or GST-antibodies. (C) R-
RAS subgroup members TC21 and M-Ras (but not the closely related GTPase RAP2) 
rescue VANGL1-induced PRICKLE1/2 destabilisation more efficiently than R-RAS. 
HEK293T cells were triple transfected with GST-VANGL1 or R1A, flag-PRICKLE1 or flag-
PRICKLE2, and flag-RAP2 or flag-R-RAS subgroup GTPases using respective consitutive 
active (V or L), effector domain mutant (VA or LA) or empty vector (E). 48h post 
transfection, cells were subjected to lysis and analysed by western blot by probing with a 
flag antibody. Blotting of endogenous SCRIB protein served as loading control. Employed 
GTPase mutations are as followed: Rap2 V (V12), Rap2 VA (V12 A38), R-RAS L (L87), R-
RAS LA  (L87 A64), TC21 L (L71), TC21 LA  (L71 A48), M-Ras (L81), M-Ras LA  (L81 
A48). RFG – Ras Family GTPases.  
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5.3 VANGL1 localises to vesicle like structures upon 
autophagy induction 
Inhibition of proteasome-mediated degradation utilising the MG132 inhibitor 
could not prevent the decrease in PRICKLE1/2 levels, observed upon VANGL1 co-
expression, suggesting alternative mechanisms of degradation.  
Another mechanism for the degradation and recycling of cellular components is 
lysosome-mediated autophagy. Autophagy is a highly conserved self-digestion 
process to promote cell survival in response to nutrient starvation and other 
metabolic stresses (He and Klionsky 2009). During the autophagic process, 
portions of cytoplasm are first surrounded by a single-membrane structure and 
these autophagic vacuoles or autophagosomes then fuse with pre-existing 
lysosomes to form autolysosomes. Autophagic dysfunction is associated with 
cancer, neurodegeneration, microbial infection and ageing (Kundu and 
Thompson 2008).  
Consistent with a role of autophagy in the PCP pathway, DVL2 has been reported 
to be regulated through autophagy mediated degradation (Gao et al. 2010). 
Therefore, experiments were conducted in order to test if VANGL1 expression 
leads to PRICKLE1 protein destabilisation through the lysosome mediated 
pathway. 
Expression of YFP-VANGL1 or YFP-PRICKLE1 fusion proteins in HMEC cells allows 
monitoring their respective subcellular localisation in presence or absence of 
autophagy stimulants. In untreated cells, YFP-VANGL1 displays diverse 
localisation patterns with staining of various subcellular compartments including 
plasma membrane, vesicle-like structures and perinuclear rings (Figure 5.3A and 
B, Figure 5.4D).  
Notably, YFP-PRICKLE1 displays similar membrane (Figure 5.4A) and vesicle-like 
structures (Figure 5.3C and D, Figure 5.4A-C), suggesting that VANGL1 and 
PRICKLE1 localise to overlapping compartments such as vesicle-like structures, 
indicative of potential autophagosomes. 
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Figure 5.3: VANGL1 and PRICKLE1 localise to ring-like structures suggestive of 
autophagosomes. HMEC stably expressing YFP-VANGL1 (V1) or YFP-PRICKLE1 (PK1) 
constructs, were seeded in six well plates and used for live cell imaging purposes. Cells 
were maintained in full growth media and images represent a snap shot of an acquired 
video using a Zeiss CellObserver life cell imaging microscope at 40x magnification, scale 
bar represents 20 µm. Selected ring-like structures are indicated with arrows.   
 
Further studies of YFP-VANGL1 and YFP-PRICKLE1 cellular localisation at higher 
resolution confirmed life cell imaging results. Ectopic expression of YFP-VANGL1 
displayed dot-like structures and perinuclear-ring staining (Figure 5.4D, arrows). 
Similarly, YFP-PRICKLE1 expression exhibited membrane localisation (Figure 
5.4A) or vesicle/dot-like staining (Figure 5.4B and C), suggesting that a subset 
of YFP-PRICKLE1 expressing cells are able to form vesicle-like structures, 
whereas others display a more diffuse localisation pattern (Figure 5.4A-C). 
In order to assess if VANGL1 and/or PRICKLE proteins localise to 
autophagosomes, cells were treated with Chloroquine (CQ). CQ is a weak base 
that accumulates in acidic vesicles, leading to an increase pH and thus causes 
lysosomal dysfunction (Fedorko 1967). This in turn leads to a blockage of 
autophagosome fusion with lysosomes and therefore prevents cargo 
degradation, resulting in an accumulation of autophagosomes which appear as 
characteristic dot like structures (Figure 5.5).  
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Figure 5.4: YFP-PRICKLE1 and YFP-VANGL1 exhibit similar subcellular 
localisation. SaOS2 cells were stably transduced with YFP-PRICKLE1 (PK1) or YFP-
VANGL1 (V1) constructs, and seeded on coverslips and stained for F-actin (red) or the cell 
nucleus (blue). Images were aquired using a spinning disc confocal microscope and a 
cross section is displayed. YFP-PRICKLE1 displays membrane and vesicle-like structures 
similar to YFP-VANGL1 stainings. Bar represents 19 µm. 
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Figure 5.5: Treatment with Chloroquine (CQ) causes acumulation of VANGL1 and 
VANGL2 but not PRICKLE1 or DVL2 in autophagosome-like structures. HMEC cells 
stably expressing YFP-VANGL1 (V1), YFP-VANGL2 (V2), YFP-PRICKLE1 (PK1) or YFP-DVL2 
were treated with 25 µM CQ or DMSO vehicle control for 4h. Cells were fixed, 
counterstained with Hoechst to stain nuclei (blue) and imaged at 20x magnification. Bar 
represents 40 µm. YFP - Yellow fluorescent protein. 
 
DVL2 has been reported to be regulated both through proteasomal (Wei et al. 
2012) and autophagy processes (Gao et al. 2010), and therefore was included as 
a control (Figure 5.5 lowest panel). YFP-DVL2 resulted in a cytoplasmic or 
punctuate staining, which has been previously reported (Schwarz-Romond et al. 
2005), and this localisation pattern was not changed upon CQ treatment (Figure 
5.5). 
In contrast, CQ treatment resulted in a strong accumulation of both YFP-VANGL1 
and YFP-VANGL2 in dot-like structures that might represent autophagosomes. 
Surprisingly however, YFP-PRICKLE1 localisation did not change upon CQ 
treatment (Figure 5.5). 
In summary, YFP-VANGL1/2 but not PRICKLE1, DVL2 or SCRIB (data not shown) 
accumulate in endodome-like structures upon CQ treatment suggesting that 
VANGL proteins may be degraded through the lysosome-autophagy route.  
In order to test if this possibility, the autophagosome marker microtubule-
associated protein 1 light chain 3 (LC3) was chosen for detection of endogenous 
LC3B either for co-localisation studies with VANGL1/PRICKLE1 upon autophagy 
induction, or as read out to monitor autophagy-induced LC3B lipidation assessed 
by western blot, since the amount of phosphatidylethanolamine modified LC3 
correlates well with the number of formed autophagosomes and therefore serves 
as a good indicator of autophagosome formation (Kabeya et al. 2000). The latter 
approach was further combined with other autophagy inhibiting drugs such as 
Bafilomycin (Yamamoto et al. 1998; Sarkar et al. 2007) or 3-Methyladenine 
(Seglen and Gordon 1982; Wu et al. 2010).  
Because the PRICKLE1 degradation experiments were not entirely conclusive and 
critically were relying on exogenously expressed transfected protein, it was 
decided to put PRICKLE1 studies on hold, until we could detect the endogenous 
protein and validate the observed effects with the overexpressed tagged protein 
on endogenous PRICKLE1.  
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In order to generate an antibody against PRICKLE1, fragments of different 
lengths of PRICKLE1 N- and C-terminal regions were cloned into bacterial 
expression vectors. An N-terminal fragment, resulting in highest expression of 
recombinant protein, was purified and shipped to Thermo Scientific for rabbit 
immunisation. To our great disappointment, after arrival of the generated 
antibody and several company-caused delays, the provided anti-sera failed to 
recognise any specific protein bands on lysates and failed to immunoprecipitate 
exogenous flag-PRICKLE1 (data not shown). This setback, in combination with 
my focus on other areas of the project and time constrain issues meant that no 
further work was carried out in this area. Future studies should help elucidate 
the mechanism of VANGL-mediated degradation of PRICKLE1 as well as the 
potential role of VANGL proteins in autophagy. 
 
 
5.4 VANGL1 subcellular localisation studies 
R-RAS GTPases have been reported to be membrane associated and to localise 
to various subcellular localisations such as plasma membrane, Golgi, ER and 
endosomes (Ohba et al. 2000; Takaya et al. 2007). VANGL1, being a tetraspanin 
protein has been reported to be mostly plasma membrane associated (Kalabis et 
al. 2006; Gravel et al. 2010; Anastas et al. 2011; Iliescu et al. 2011).  
In order to study the intracellular localisation of VANGL1 and assess the 
possibility that its localisation might be regulated by interaction with R-RAS 
GTPases, ROR2 or WNT ligands, YFP fusion proteins of R-RAS GTPases and 
VANGL proteins were ectopically expressed in multiple cell types and its 
localisation studied in both live and fixed cells. 
During the course of localisation studies using stably expression of YFP-fusion 
proteins it became apparent that VANGL1 displays very diverse localisation in 
different cell types (Figure 5.4D, Figure 5.6A-D and Figure 5.6).  
In HMLE mammary epithelial cells, YFP-VANGL1 localises at the plasma 
membrane, at areas of cell-cell contact in some cells (Figure 5.6A), whereas in 
other cells it localised in vesicle/ring like structures as well as in an area 
surrounding the nucleus giving a  characteristic perinuclear staining (see arrows 
in Figure 5.6 B,C and Figure 5.7A, F).  
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Figure 5.6: VANGL1 localises to various subcellular compartments, whereas R-
RAS or TC21 are mostly found membrane associated. HMLE cells were stably 
transduced with lentivirus encoding YFP-VANGL1, YFP-VANGL2, YFP-R-RAS wt or YFP-
TC21 wt fusion proteins as indicated. YFP - yellow fluorescent protein, wt - wild type. 
Pictures were aquired with a Zeiss fluorescent micoscope at 20x magnification amd the 
scale bar represents 50 µm. 
 
VANGL1 observed subcellular localisations varied depending by cell type, cell 
density and also likely during phases of cell cycle as suggested by characteristic 
mitotic localisations observed in live cell imaging studies (data not shown). Even 
within a field of cells of the same cell type, different localisation patterns could 
often be detected. These observations strongly suggest that VANGL1 can localise 
to multiple membrane sub-compartments within the cell, and this localisation 
seems to be dynamically regulated.  
In contrast, expression of YFP-VANGL2 in various cell lines exhibited a staining 
pattern (Figure 5.6 and Figure 5.7), which is clearly different from VANGL1, 
highlighting potential functional differences.   
YFP-VANGL2 expression resulted in ER-type staining with little plasma 
membrane localisation in osteosarcoma (SaOS2) and thyroid-carcinoma cells 
(8505C) (Figure 5.7). Notably, breast cancer cells MDA-MB-231 displayed 
additionally vesicle-like structures, which seem to be similar for YFP-VANGL1 and 
YFP-VANGL2 expression (Figure 5.7H and I, respectively). 
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Figure 5.7: Localisation of YFP-VANGL1 and YFP-VANGL2 in different cell lines. 
Indicated cell lines stably transduced with either lentiviral or retroviral YFP-VANGL1 (V1) 
or YFP-VANGL2 (V2) constructs were seeded and fixed on coverslips for confocal image 
acquisition. Cells were counterstained for the cell nucleus (blue) and actin (red). Images 
were aquired using a spinning disc confocal microscope and a cross section displayed. 
YFP-VANGL1 displays various subcellular localisations such as membrane, vesicle-like 
structures or perinuclear staining. YFP-VANGL2 displays rather a Golgi/ER and vesicle 
staining pattern. Bar size in µm is indicated in individual images.  
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Initial localisation studies showed that YFP-R-RAS and TC21 are predominantly 
localised at the plasma membrane (Figure 5.6E-G). Therefore, CFP-R-RAS or 
CFP-TC21 constructs were generated in order to co-express them with YFP-
VANGL1-R-RAS for co-localisation studies. However, because of technical issues, 
I was not able to get these experiments to work.  
I also performed live cell imaging studies on YFP-VANGL1 cells to assess the 
dynamic localisation of the protein in different contexts (e.g. growing cells, cells 
stimulated with WNT ligands and cells induced to polarise in scratch/ wound 
closure assays). Mainly due to technical issues associated with lack of sensitivity 
I was unable to observe any changes on VANGL1 localisation in these studies.  In 
order to increase sensitivity, time course treatments of WNT5a stimulation were 
performed in YFP-VANGL1 cells and fixed cells analysed by confocal microscopy.  
However, no effects were observed in preliminary experiments and studies on 
the regulation of VANGL1 localisation were stopped. 
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5.5 Discussion:  
PRICKLE1 is involved in PCP signalling and has been demonstrated to be a key 
intermediate for gastrulation cell movements in Drosophila (Gubb et al. 1999) 
Xenopus (Takeuchi et al. 2003) and zebrafish (Carreira-Barbosa et al. 2003; 
Takeuchi et al. 2003; Veeman et al. 2003b). Furthermore, mouse knock out 
models of Prickle1 resulted in embryonic lethality (E5.5-6.5), whereas down 
regulation causes severe morphogenetic defects in CE. Prickle2 phenotypes 
appear less severe, while a combination of Prickle1 and Prickle2 loss 
demonstrates a synergetic effect on CE defects (Veeman et al. 2003b).  
In this chapter, I presented evidence that VANGL proteins strongly interact with 
PRICKLE1/2. Surprisingly, overexpression of VANGL1/2 leads to a strong 
reduction of PRICKLE1/2 protein levels, which can be partially rescued by active 
R-RAS subgroup GTPases without affecting VANGL1-PRICKLE1 interaction.  
It has been reported that that PRICKLE1 protein levels can be targeted for 
proteasomal degradation by SMURF1/2 ubiquitin ligases (Narimatsu et al. 2009). 
SMURF ubiquitin ligases regulate signalling, cell polarity and motility; and mice 
mutants for Smurf1 and Smurf2 display PCP defects in the cochlea and CE 
defects that include a failure to close the neural tube (Narimatsu et al. 2009). 
According to the proposed model, WNT5a stimulation leads to activation of DVL2 
by phosphorylation and subsequent recruitment of SMURF1/2, which then 
targets PRICKLE1 for ubiquitin-mediated degradation (Narimatsu et al. 2009). 
Besides proteasome mediated regulation of WNT signalling, autophagy regulation 
has been implicated to negatively impact WNT signalling through DVL2 
degradation (Gao et al. 2010). Another link between PCP and autophagy stems 
from the protein activating molecule Beclin-regulated autophagy (AMBRA), which 
upon functional inactivation, displays impaired autophagy (Fimia et al. 2007). In 
addition, homozygosity of Ambra1 mutation causes embryonic lethality and 
embryos exhibit PCP typical neural tube defects or spina bifida characteristics 
(Cecconi et al. 2007; Fimia et al. 2007).  
In endothelial cells, PCP signalling is required for cell growth, polarity, and 
migration (Masckauchan et al. 2006; Cheng et al. 2008). Silencing of either 
DVL2 or PRICKLE1 suppressed endothelial cell proliferation, highlighting the 
function of a DVL2-PRICKLE complex (Cirone et al. 2008). However, it also has 
been reported that PRICKLE1 acts as negative regulator of DVL/Dsh (Carreira-
Barbosa et al. 2003; Veeman et al. 2003b; Fujimura et al. 2009) and facilitates a 
208 
 
proteasome mediated degradation of DVL3 through its two destruction box 
motifs, essential for E3 ligase activity (Chan et al. 2006).  
Knockdown of PRICKLE1 causes reduced axonal and dendritic extension in 
hippocampal neurons, thus implicating a function for PRICKLE in axonal-dendritic 
development (Liu et al. 2013). Notably, studies in C.elegans, which contains only 
one Vangl isoform, demonstrated that Vangl co-operates with Prickle1 to 
negatively regulate neurite formation (Sanchez-Alvarez et al. 2011).  
Misshapen-like kinase (MINK1), a Ste20 group kinase, has been described to be 
important for clustering of VANGL1 within PRICKLE1 plasma membrane puncta. 
Further, MINK induced phosphorylation of PRICKLE1 at a conserved threonine 
residue (T370) regulates RAB5 mediated endosomal trafficking of PRICKLE1, 
which is important for localised plasma membrane accumulation and function 
(Daulat et al. 2012). Further, PRICKLE1 has been reported to be a farnesylation 
target, implying that this post translational modification can target cytoplasmic 
PRICKLE1 to (plasma) membrane subcellular localisations (Maurer-Stroh et al. 
2007). 
A role for VANGL in regulating PRICKLE levels is in agreement with localisation 
studies of VANGL/stbm and Prickle in Drosophila pupal wings, illustrating that in 
the absence of VANGL/stbm, Prickle protein levels were found to be increased 
within the cytosol and at the apicolateral cell cortex (Bastock et al. 2003; Jenny 
et al. 2003). 
PET/LIM domains have been reported to be important for PRICKLE function in 
zebrafish gastrulation (Takeuchi et al. 2003). Interestingly, VANGL1 binds to the 
C-terminal part of PRICKLE1, lacking both PET and LIM domains, but still harbour 
both destruction box motifs implicated in DVL degradation (Chan et al. 2006).  
Asymmetrical localisation of VANGL and PRICKLE1 is a hallmark of PCP in 
Drosophila and this interaction seems to be conserved from fly to humans (Jenny 
et al. 2003; Sanchez-Alvarez et al. 2011; Daulat et al. 2012). VANGL induced 
PRICKLE degradation could therefore be a mechanism to ensure the proteins are 
asymmetrically localised. Interestingly, PRICKLE1 has been reported to stimulate 
proteasomal degradation of DVL, another VANGL1 interacting protein (Chan et 
al. 2006). Therefore a complex regulatory interplay emerges between VANGL1, 
PRICKLE and DVL at the level of protein degradation where VANGL1, by 
regulating PRICKLE stability, may indirectly control DVL levels. Critically, R-RAS 
GTPases are able to modulate this regulatory interplay, potentially by recruiting 
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VANGL1 to specialised membrane domains and away from the pool of PRICKLE 
proteins. 
The mechanism of VANGL1/2 induced PRICKLE1/2 degradation remains to be 
determined as preliminary experiments suggested that this degradation is not 
proteasome mediated. Furthermore, localisation studies suggested a potential 
role for VANGL proteins in autophagy. Treatment with chloroquine resulted in a 
dramatic accumulation of YFP-VANGL1 and YFP-VANGL2 in autophagosome-like 
structures. However, due to technical and time constraining issues, I was not 
able expand on these studies. Future experiments need to be performed in order 
to elucidate the mechanism of VANGL-mediated degradation of PRICKLE1/2 as 
well as the potential role of VANGL proteins in autophagy. 
 
  
Figure 5.8: Chapter summary. VANGL1 interacts with PRICKLE1 and PRICKLE2 through 
its C-terminus. However, exogenous expression of VANGL1 results in PRICKLE protein 
destabilisation through a not fully understood mechanism, whereas other PCP core 
components such as DVL are not affected. Expression of activated R-RAS subgroup 
members like R-RAS, TC21 and M-RAS are able, at least partially, to rescue this effect. 
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6 Effect of WNT ligands and Frizzled receptors on R-
RAS and RHO activation 
Our working model aims to test if R-RAS GTPases act downstream of WNT 
ligands and Frizzled receptors, resulting in modulation of VANGL1 function. In 
order to assess R-RAS activity, RAS binding domain (RBD) assays were 
optimised and performed with the intention to assess R-RAS activity upon WNT 
stimulation. The receptor tyrosine kinase ROR2 was an attractive candidate to 
mediate R-RAS activation due to its WNT5a binding and signalling capabilities 
(Oishi et al. 2003; Mikels and Nusse 2006a; Nishita et al. 2010b), and the 
potential link through the common interactor filaminA (Nishita et al. 2006; 
Nomachi et al. 2008; Gawecka et al. 2010; Griffiths et al. 2011). Furthermore, 
VANGL2 has been demonstrated to be phosphorylated by ROR2 in a WNT5a 
dependent manner (Gao et al. 2011). And lastly, due to our observations, which 
detected the R-RAS member TC21 in ROR2 immunoprecipitations (Figure 4.11), 
indicating that ROR2, VANGL2 and R-RAS GTPase TC21 could form a complex. 
Therefore, WNT ligands will be tested in ROR2 contexts for R-RAS GTPase 
member activation. 
 
 
6.1 Establishment of RAS binding domain assays 
In order to monitor and assess R-RAS activation levels upon WNT stimulation in 
cell lysates, glutathione S-transferase (GST)-fused RAS binding domains (RBDs) 
from downstream effectors such as RAF1 and RALGDS were employed (Brtva et 
al. 1995; de Rooij and Bos 1997; Franke et al. 1997; Castro et al. 2005; 
Rodriguez-Viciana and McCormick 2006). These effector domains preferentially 
interact with GTP-bound RAS and act as activation specific probes, since affinity 
for GDP is three orders of magnitude lower (Herrmann et al. 1995). Thus, 
glutathione beads enable the selective purification from lysates and subsequent 
quantification of active RAS proteins by immunoblotting.  
Several reports suggest that R-RAS subgroup GTPases have considerably lower 
affinity in their ability to interact with RAF1 compared to classical RAS proteins, 
whereas they interact as strongly as classical RAS proteins with RALGEFs (Figure 
3.6) (Rodriguez-Viciana et al. 1994; Huff et al. 1997; Marte et al. 1997). 
However, these experiments assessed the interaction with the full length protein 
and it is known that the interaction with the isolated RBD may not accurately 
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reflect the affinity of the interaction with the full length protein (Rodriguez-
Viciana and McCormick 2006).  
In order to determine which RBD was more effective in capturing activated R-
RAS GTPases, GST fusion proteins immobilised on glutathione beads of either the 
RAF1 RBD (residues 2–140)  or RALGDS RBD (C-terminal 97 residues) were 
incubated with equal amounts of the same lysate of cells transfected with tagged 
GTPases. In order to evaluate the specificity of the interaction, activating and 
effector domain mutants were compared to the respective wild type protein 
(Figure 6.1A). After incubation, precipitated amounts of flag-tagged GTPases 
were detected by immunoblotting using flag antibodies.  
Both GST-RBD beads exhibited a strong increase in precipitated protein if the 
constitutive active mutant was expressed, compared to wild type protein. 
Moreover, GTPase effector domain mutants (A38 or equivalent) did not show any 
significant interaction, demonstrating that the interaction is specific and 
activation and effector domain dependent. Detection of lower levels of wild type 
RAS GTPases can be explained by the fact that under conditions of 
overexpression a significant amount of wild type protein may be GTP-bound 
(Figure 6.1A). 
Overall, both GST-RBDs performed similarly in their ability to selectively 
precipitate active tagged N-RAS, and the three R-RAS family members R-RAS, 
TC21 and M-RAS, although the RAF1 RBD beads displayed more sensitivity and 
were therefore used in all subsequent studies (Figure 6.1A). 
In order to measure the ability of our RAF1 beads to detect activation of 
endogenous GTPases, HEK293T cells were stimulated with EGF, a strong 
stimulator of classical RAS proteins and the MAPK pathway (Figure 6.1B) (Buday 
and Downward 1993; Zheng et al. 1994). 
Over a time course ranging from 0 to 20 min, samples were taken, incubated 
with GST-RAF1 RBD protein and precipitated using glutathione sepharose beads. 
Immunoblotting for H-RAS illustrated a characteristic activation pattern, which 
peaked around 2 min by over 20 fold compared to basal levels and started to 
decline within 5 min after stimulation and dropped to 8-fold over basal level 
within 20 min after stimulation (Figure 6.1B and C). This illustrates that 
detection of endogenous levels of RAS activation with our RBD beads is possible 
and specific.   
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Figure 6.1: RAF1 or RALGDS RAS binding domain (RBD) constructs are able to 
precipitate activated RAS and R-RAS. (A) HEK293T cells were transfected with 
indicated flag-tagged wild type (wt), activated mutant (V or L) or respective effector 
domain mutant (VA) GTPases constructs. 32h post transfection, cells were serum starved 
for 16h and then subjected to cell lysis and GST-RBD pull down. GTP loaded RAS Family 
GTPases (RFGs) were detected by western blotting using a flag antibody. (B) Activation 
of endogenous H-RAS by epidermal growth factor (EGF). HEK293T cells were grown to 
confluency and serum deprived for 16h prior stimulation with 100ng/mL EGF for 2, 5 or 
20 min as indicated. Cells lysates were incubated with GST-RBD beads and bound 
endogenous H-RAS detected with a the respective antibody. (C) Densitometry analysis of 
B. Western blot images of B were scanned and analysed using ImageJ software. The fold 
increase was normalised to basal activation levels of H-RAS in the untreated condition. 
Employed mutants: N-RAS V12 (A38), R-RAS V38 (A64), TC21 V13 (A48) and M-RAS L63 
(A48).   
 
Next, we tested if R-RAS or TC21 could be activated in this context using serum 
deprived HEK293T or HeLa cell lines stimulated with EGF. Immunoprobing of 
RAF1 RBD precipitates confirmed EGF dependent H-RAS activation (Figure 6.2A). 
However, under the same conditions, activation of R-RAS or TC21 activation 
could not be detected. Probing for phosphorylated ERK1/2 levels, the target of 
the MAPK signalling pathway downstream of RAS, served as EGF stimulation 
control (Minden et al. 1994; Yang et al. 2013).  
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Time course experiments performed in HEK293T (data not shown) or HeLa cells, 
confirmed the previous observation that EGF is a potent activator of H-RAS but 
fails to activate R-RAS or TC21 GTPases (Figure 6.2B). As shown earlier (Figure 
6.1C), EGF stimulation of H-RAS exhibits a short lived activation pattern, which 
starts to decline after 2-3 minutes, which was consistently observed (Figure 
6.2B). To exclude cell context dependent phenomena, this experiment was 
further carried out in U2OS and HMLE cells, with similar results (data not 
shown). 
 
 
 
Figure 6.2: EGF activates H-RAS not R-RAS or TC21 in HEK293T or HeLa cells. (A) 
HEK293T cells were grown to confluency and serum deprived for 16h, stimulated with 50 
ng/mL EGF for 5 min and subsequently lysed. Cleared cell lysates were incubated with 
GST-RAF1 RBD protein and precipitated using glutathione sepharose beads. Endogenous 
purified RAS GTPases were detected using respective antibodies. (B) Confluently grown 
HeLa cells were serum deprived for 14h prior EGF stimulation (50ng/mL) for 3 or 10 min 
or left untreated. Cells were subsequently lysed and purified as outlined in A. Endogenous 
RAS GTPases were detected using indicated antibodies. As control for sucessful EGF 
activation served ERK phosphorylation levels. 
 
RAS and R-RAS GTPases are activated by overlapping GEFs, but also exhibit 
different biological functions (see section 1.2.1 and Figure 1.5). In order to 
identify GEFs that selectively activate R-RAS proteins, and thus could serve as 
control in order to detect activation of wild type R-RAS GTPases in our RBD 
assay, as well as confirm previous studies of RASGEF specificity against R-RAS 
GTPases (Mitin et al. 2006), a panel of myristoylated RAS family GEFs was 
tested in co-transfection experiments. 
N-terminal N-myristoylation is a lipid anchor modification that targets proteins to 
membrane locations (Levental et al. 2010; Martin et al. 2011). The enzyme N-
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myristoyltransferase (NMT) recognises the sequence motif (MGSSKSKPK) of 
appropriate substrate proteins at the N terminus, and covalently attaches the 
myristoyl group to the α-amino group of an N-terminal amino acid of a nascent 
polypeptide (Martin et al. 2011). Thus, employed GEF constructs containing a 
myristoylation (myr) sequence are constitutively targeted to the cell membrane, 
even in the absence of an upstream activating signal, and therefore are able to 
constitutively activate their target RAS GTPases. 
Expressing myristoylated RASGEFs alongside flag-tagged wild type R-RAS in 
HEK293T cells resulted in a strong activation of R-RAS through RASGRF2, 
RASGRP1, RASGRP3 and RASGRP4. RASGRP2, despite having the highest levels 
of expression in lysates, showed a weaker activating ability. In contrast, mSOS 
and RAPGEF5, a RAP1 GEF that was used as a negative control, do not exhibit 
any effect on R-RAS activation compared to basal levels (empty vector) (Figure 
6.3). 
TC21 displays a similar GEF activation pattern as observed for R-RAS, but 
additionally demonstrates a mild activity increase over basal by mSOS (Figure 
6.3). 
M-RAS activation is stimulated by the same set of GEFs as observed for TC21 but 
mSOS can lead to a stronger activation, whereas RASGRP2 only marginally 
activates M-RAS (Figure 6.3).  
N-RAS, the representative classical RAS GTPase in the panel, is potently 
activated by mSOS and also by RASGRF2, RASGRP1, RASGRP3 and RASGRP4, 
but not by RASGRP2 or RAPGEF5. RASGRF1 does not display activity against any 
of the tested GTPases but the levels of expression achieved were relatively low 
so no conclusions can be drawn regarding its activity (Figure 6.3). 
In summary, mSOS preferentially activates N-RAS and more weakly M-RAS, but 
has little or no effect on TC21 and R-RAS, respectively. RASGRF2, RASGRP1, 
RASGRP3 and RASGRP4 work equally well on all the GTPases tested, whereas 
RASGRP2 has weaker activity that, however, appears to be specific for R-RAS 
and TC21 (Figure 6.3).   
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Figure 6.3: Characterisation of RAS family GEF activity towards RAS and R-RAS 
GTPases. (A) HEK293T cells were transfected with various myristoylated (myr) guanine 
exchange factors (GEF) or empty vector alongside with flag-tagged R-RAS, TC21, M-RAS 
or N-RAS. 32h post transfection, cells were serum deprived for 16 h and subsequently 
lysed. Cell lysates were incubated with GST-RAF1 RBD fusion proteins immobilised on 
glutathione beads and RAS family GTPases were detected by immunoblotting with a flag 
antibody. (B) Summary of myr-GEF stimulating activity towards individual GTPases. R - 
R-RAS, T – TC21, M – M-RAS, N – N-RAS. RasGRF - Ras-specific guanine nucleotide-
releasing factor, RasGRP - RAS guanyl nucleotide-releasing protein, mSOS – mouse Son 
of Sevenless. 
 
 
6.2 WNT ligands activate R-RAS  
In order to test if WNT ligands are able to stimulate R-RAS GTPase activity, 
various cell types were treated with recombinant WNT5a, and lysates subjected 
to the GST-RAF1 RBD pull down assay approach.   
There are 19 WNT genes in the human genome but my studies will focus on 
those that have been previously reported to activate the PCP pathway and/or 
affect cell motility, such as WNT5a and WNT7a, (Heisenberg et al. 2000; Veeman 
et al. 2003a; Ulrich et al. 2005; Kikuchi and Yamamoto 2008). 
WNT5a is known to activate PCP signalling through VANGL2 and to regulate cell 
migration processes (Qian et al. 2007; Gao et al. 2011). In addition, WNT5a is 
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up-regulated in many human tumours and stimulates cell motility and 
invasiveness of tumour cells (Iozzo et al. 1995; Lejeune et al. 1995; Weeraratna 
et al. 2002; Kurayoshi et al. 2006; Pukrop et al. 2006). Therefore, WNT5a 
provided an excellent candidate as potential R-RAS GTPase activator. 
However, WNT5a will initiate the PCP pathway by binding to specific FZD 
receptor and/or co-receptor combinations and these are likely differentially 
expressed in a cell type dependent manner. Similarly, R-RAS GEFs (or other 
factors) that could potentially mediate WNT5a activation of R-RAS GTPases may 
also be expressed in a cell type dependent manner. Because we could not 
control for these variables, R-RAS RBD assays were performed in different cell 
types and in different contexts in an attempt to find a suitable experimental 
system. 
Initial WNT5a stimulation experiments were carried out in stable HMLE mFzd5 
cells, which exhibit WNT5a ligand sensitivity upon mFzd5 expression (see 4.4.3). 
In order to determine the activation period of R-RAS downstream of WNT5a, 
time course experiments were carried out, covering the first 15 min after WNT5a 
treatment. This approach demonstrated WNT5a dependent R-RAS activation that 
peaks at around 3 minutes post treatment, and rapidly declines to basal levels 
within 6 min after stimulation (Figure 6.4).  
 
 
Figure 6.4: WNT5a stimulation leads to sharp and short lived R-RAS activation 
peak around 3 min after treatment. Stable HMLE mFzd5 cells were grown to 
confluency and further nutrient deprived for 14h by supplementing basal media with only 
5% of regular growth additives. HMLE cells were WNT5a stimulated at indictated times of 
a period from 0 to 15 min at a concentration of 150 ng/mL or with 10% FBS final 
concentration for 5min. Cells were immediately harvested and subjected to GST-RAF1-
RBD pull down assays. R-RAS ativity was detected by western blot for endogenous R-
RAS.  
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To test if the R-RAS signal could be increased, cell lines were stably transduced 
with retroviral flag-tagged R-RAS wild type constructs, selected and expanded 
for subsequent stimulation experiments. WNT5a addition again leads to a sharp 
and transient increase in R-RAS activity within three minutes, which returns to 
basal levels five minutes post stimulation (Figure 6.5).  Similar results have been 
observed with WNT5a time courses carried out in HCT116 cells (data not shown 
and Figure 6.7B). 
 
 
Figure 6.5: WNT5a stimulation leads to transient activation of flag-R-RAS in 
U2OS cells. U2OS cells stably expressing wild-type flag-R-RAS were serum deprived for 
period of 18h before recombinant WNT5a (100 ng/mL) stimulation for indicated time 
points between 0 and 90 min or treated with 10% FBS final concentration for 7 min. Cells 
were harvested and subjected to RAF1 RBD pull-down assays. Flag-R-RAS was detected 
using flag-tag specific antibody. 
 
 
ROR2 has been demonstrated to function as (co)-receptor for WNT5a (Oishi et 
al. 2003; Mikels and Nusse 2006a; Nishita et al. 2006), leading to the question if 
ROR2 expression is able to enhance WNT5a responsiveness. Therefore, time 
course experiments were set up covering the first 6 or 8 min after WNT5a 
stimulation in U2OS cells stably expressing ROR2 compared to parental control 
cells. Parental U2OS cells responded to recombinant WNT5a ligand as observed 
before, resulting in a fast and sharp peak at around three minutes post WNT5a 
ligand application, which rapidly declined to basal levels within six minutes after 
stimulation (Figure 6.6 A, left panel). However, stable introduction of ROR2 
exhibits accelerated response to WNT5a treatment which can now be detected 
after one minute, and in addition is sustained for longer time points (Figure 6.6, 
A, right panel).   
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Figure 6.6: ROR2 expression leads to sustained R-RAS activation in U2OS cells. 
U2OS cells stably expressing ROR2 were grown to confluency and starved for 16h. Cells 
were treated with recombinant WNT5a (150ng/mL) for either 1, 3, or 6 min or left 
untreated, and were subsequently lysed. Cleared cell lysates were subjected to GST-RAF1 
RBD pulldown assays and endogenous R-RAS detected by western blot using the 
respective antibody.  (B) Independent replicate of the experiment described in A. WNT5a 
ligand treatment times were performed for 4 or 8 min, and a control treatment using 10% 
fetal bovine serum (FBS) for 8 min was included. 
 
Repetitions of U2OS based experiments resulted in similar WNT5a induced R-
RAS activation pattern, demonstrating a short lived peak at around 4 minutes, 
which rapidly decreased to basal levels within the next 4 min (Figure 6.6B). 
Although, the effect of ROR2 expression in the time course used, in this 
independent experiment, was not as striking as observed previously, significant 
R-RAS activation is still detected 8 minutes after stimulation in U2O2- ROR2 
expressing cells compared to parental U2OS (Figure 6.6B)  No effect could be 
observed when activation of endogenous TC21 was measured (data not shown). 
As mentioned earlier, WNT5a and WNT7a have been implicated in PCP activation 
and thus I tested if WNT7a is able to stimulate R-RAS activity in a similar 
manner to WNT5a. Indeed, WNT7a is able to activate flag-tagged R-RAS to 
similar extents than WNT5a in HEK293T cells. Notably, stimulation with both 
WNT ligands results in phosphorylation of JNK, a downstream target of WNT5a 
induced PCP signalling although this effect in JNK phosphorylation was not 
consistently reproduced (Figure 6.7A). 
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Figure 6.7: WNT5a and WNT7a are able to activate R-RAS in different cellular 
contexts.  (A) HEK293T cells transiently expressing flag-R-RAS were grown to 
confluency, serum deprived for 16h and either stimulated for 3 min with WNT5a 
(120ng/mL), WNT7a (250 ng/mL)  or left untreated (-). Cells were subsequently 
harvested and subjected to GST-RAF1 RBD pulldown assays. Activity of flag-tagged R-
RAS or control GTPase N-RAS was detected by immunoblotting with a flag antibody, 
lysates we tested for c-Jun N-terminal kinase (pJNK) phosphorylation. (B) HCT116 cells 
stably expressing flag-R-RAS wild type were serum starved for 18h and recombinant 
WNT5a (150 ng/mL) stimulated  for 3 min or left untreated. RBD assay was performed 
and R-RAS activity determined as decribed in A. 
 
In summary, recombinant WNT5a and WNT7a ligands are able to induce a 
transient activation of R-RAS, which can be enhanced and prolonged when ROR2 
is overexpressed. 
 
 
6.3 R-RAS and TC21 is required for WNT5a dependent 
activation of RHOA and RHOB 
PCP signalling events lead to activation of RHO GTPases such as RHO or RAC, 
which are involved in cytoskeletal rearrangements and regulating cell 
morphology (Kikuchi et al. 2007; Schlessinger et al. 2009; Tada and Kai 2009), 
critical for vertebrate gastrulation movements (Keller 2002; Wallingford et al. 
2002; Veeman et al. 2003a).  
R-RAS can regulate RHO family GTPases in a cell type-dependent manner. In 
NIH3T3 fibroblasts and 32D myeloid cells, R-RAS stimulates RAC activity (Holly 
et al. 2005; Goldfinger et al. 2006), whereas in MCF10A and T47D epithelial cells 
R-RAS stimulates RHO but not RAC (Jeong et al. 2005; Wozniak et al. 2005). R-
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RAS stimulation of RAC may be mediated by PI3Ks, as R-RAS GTPases are 
strong activators of PI3K and several RACGEFs are activated in a PI3K-
dependent manner (Rodriguez-Viciana et al. 2004; Hawkins et al. 2006). On the 
other hand, how R-RAS activates RHO is not known.  
To assess RHO activation, pull-down assays using GST-fusion proteins using the 
RHO-binding domain of Rhotekin that specifically bind RHO family members were 
employed (Habas and He 2006; Mezzacappa et al. 2012). This activation-specific 
probe functions analogous to RAS RBD constructs and was used to test the 
possibility that R-RAS GTPases regulate the activation of RHO GTPases 
downstream of WNT ligand stimulation. GST-Rhotekin RBD functionality and 
specificity had already been tested in earlier experiments as part of the studies 
on ARHGEF17/p164RhoGEF (Figure 3.14).  
As mentioned above R-RAS has been reported to stimulate RHO in a cell type 
dependent manner. This could be due to the differential expression of different 
RHOGEFs in different cell types, only some of which may be regulated by R-RAS 
and/or the WNT/PCP pathway. Because the RHOGEFs used by R-RAS or the 
WNT/PCP pathway are not known, several cell types were screened for RHO 
activation in different contexts. 
Initially, I tested the panel of available Frizzled receptors in the absence or 
presence of ectopically expressed ROR2 for their ability to activate RHOA in co-
transfection experiments in HEK293T cells. ROR2 expression by itself in HEK293T 
is a strong RHO activator, achieving similar levels of active RHOA as FBS 
stimulation (for 15 min) which was used as a positive control (Figure 6.8).  
Overexpression of FZD2, FZD4, mFzd5 and FZD7 also stimulated RHOA 
activation compared to empty vector control with FZD4 exhibiting the largest 
effect. Interestingly, co-expression of ROR2 with FZD2 (but not other FZDs) 
leads to a synergistic activation of RHOA. Treatment of mFzd5/ROR2 expressing 
cells with recombinant WNT5a ligand only had a marginal effect compared to 
unstimulated mFzd5/ROR2 samples (Figure 6.8). 
In summary, ROR2 and Frizzled proteins can elevate RHOA activity to different 
degrees and in some cases can cooperate to stimulate RHO activity, highlighting 
a key role for ROR2 in the regulation of the RHO pathway. 
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Figure 6.8: ROR2 and Frizzled receptors stimulate RHOA activation. HEK293T cells 
were transiently transfected with FZD2, FZD4, mFzd5 or FZD7 in combination with empty 
vector (-) or ROR2. 36 hour later, cells were serum starved for 16h and harvested. Cell 
lysates were incubated with GST-Rhotekin RBD beads and associated GTP-loaded 
endogenous RHOA detected using a RHOA antibody. mFzd5 was transfected in duplicate 
(with or without ROR2), and one set was stimulated with 100 ng/mL recombinant WNT5a 
for 10 min prior to lysis, indicated with an asterisk (*). 
 
 
Next, employing the synergistic FZD2/ROR2 combination, I wanted to test 
whether WNT5a or WNT7a ligands could further enhance RHOA signalling in this 
context (Figure 6.9).  
As observed before (Figure 6.8) ROR2 expression by itself results in enhanced 
RHOA precipitation, which is not further enhanced by WNT5a or WNT7a 
stimulation. Expression of FZD2 also elevates RHOA activity, which is further 
increased when ROR2 is co-expressed. But WNT5a or WNT7a treatment was not 
able to further enhance RHOA activation in this experiment (Figure 6.9A). 
However, there appears to be some variability within experiments with regards 
to the effect of WNT addition, as in an independent experiment using the same 
cell line and conditions, both WNT5a and WNT7a were able increase activation of 
RHOA in ROR2 expressing cells (Figure 6.9B).  
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Figure 6.9: Expression of ROR2 in combination with FZD2 stimulates RHOA 
activity. (A) HEK293T cells were transiently transfected with empty vector or FZD2, in 
with the presence or absence of ROR2. 46h post transfection, cells were stimulated with 
recombinant WNT5a (125 ng/mL) or WNT7a (250 ng/mL) for 10 min or left untreated (-). 
Lysates were subjected to GST-Rhotekin RBD pull down assays and bound RHOA detected 
with the respective antibody. (B) Independent replicate of the same experiment as 
described in A. 
 
 
As demonstrated above, WNT5a can lead to the activation of both R-RAS and 
RHO GTPases. On the other hand, active R-RAS has been previously shown to 
lead to the activation of RHOA in MCF10A and T47D epithelial cells (Jeong et al. 
2005; Wozniak et al. 2005). 
In order to assess the possibility that R-RAS GTPases may mediate RHO 
activation by WNT ligands, the effect of inhibition of R-RAS GTPases by RNAi on 
the ability of WNT ligands to active RHO proteins was tested. In order to avoid 
the possibility of redundancy between R-RAS GTPases, both R-RAS and TC21 
were inhibited simultaneously by co-transfecting independent siRNA oligos in 
HMEC mFzd5 cells, which display responsiveness to WNT5a (Figure 4.9A). A time 
course of WNT5a stimulation was performed over 120 min and RHO RBD pull 
down assays performed. 
In contrast to previous results in HEK293T cells where RHOA but not RHOB was 
activated by WNT ligands and FZD receptors (Figure 6.9), in HMEC-mFzd5 cells, 
WNT5a led to a sharp and transient increase in RHOB activation that peaked at 5 
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min and returned to below basal levels 15 min after WNT5a addition (Figure 
6.10). It is noteworthy that this time course of RHOB activation is reminiscent of 
the early and transient activation of R-RAS (with a sharp peak at 3-4 min) 
observed before (Figure 6.4 to 6.7). 
Probing the same pull downs for RHOA, showed that RHOA activation followed a 
somewhat different time course, with a weaker activation detected by 5 min of 
WNT5a addition that was sustained over 30 min and returned to basal levels by 
60 min.  
Strikingly, depletion of both R-RAS and TC21 resulted in a strong inhibition of 
RHOA and RHOB activation by WNT5a. In contrast, RHO activation by FBS, which 
was used as a positive control, was not affected by R-RAS/TC21 depletion 
(Figure 6.10). Therefore R-RAS GTPases selectively function downstream of 
WNT5a to mediate the activation of RHO GTPases. 
 
 
Figure 6.10: R-RAS and TC21 depletion inhibits RHOA and RHOB activation by 
WNT5a but not FBS. HMEC mFZD5 cells were transfected with either control siRNA or a 
combination of R-RAS and TC21 siRNAs at a final concentration of 10nM. Cells were 
serum starved 62 h post transfection for 16h, and recombinant WNT5a (125ng/mL) added 
for the  indicated times. 10% FBS addition for 15 min served as a positive control of RHO 
activation. Lysates were subjected to GST-RBD pulldowns and endogenous RHOA and 
RHOB detected by immunoblotting using respective antibodies.  
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6.4 Discussion 
In this chapter I was able to show that WNT ligands alone or in combination with 
the receptor tyrosine kinase ROR2 are able to activate R-RAS in a specific and 
short lived manner. Furthermore, R-RAS and TC21 seem to be required in 
WNT5a mediated RHOA/RHOB activation. These findings demonstrate a novel 
link between R-RAS and WNT signalling networks. 
The PCP pathway has been demonstrated in Drosophila to genetically interact 
with the EGFR and Notch pathways (Brown and Freeman 2003; Gaengel and 
Mlodzik 2003; Strutt and Strutt 2003). Interestingly, to date, the only R-RAS 
activator described to stimulate R-RAS activity is the intracellular Notch fragment 
(Hodkinson et al. 2007). Whereas well established growth factors such as EGF, 
known to activate classical RAS proteins, fail to stimulate R-RAS activity.  
Other potential candidates thought to be able to activate R-RAS, which were not 
be tested in this thesis, are the migration regulators Trefoil Factors (TFFs) 
(Taupin and Podolsky 2003), which have been demonstrated to act upstream of 
VANGL1 (Kalabis et al. 2006). TFFs are known to synergise with the EGFR 
pathway (Taupin and Podolsky 2003) and it is likely that directed migration is 
regulated through cross-talk between multiple signalling pathways.  
One of the main types of membrane receptors that activate RAS GTPases are 
RTKs, which led to the appealing hypothesis that the tyrosine kinase ROR2 could 
be functioning as a potential R-RAS activator. Our findings support this 
possibility and suggest R-RAS interaction with VANGL1 could be modulated by 
WNT ligands downstream of ROR2.  
Studies showed that ROR2 can act as receptor for WNT5a through its 
extracellular cysteine-rich domain and WNT5a mediated activation resulted in 
ROR2 dependent phosphorylation of VANGL2 (Gao et al. 2011).  
WNT5a can lead to the activation of R-RAS in multiple cell lines with a 
characteristic activation pattern displaying a short lived burst of activation 3-4 
minutes after WNT5a treatment. Stable expression of ROR2 in U2OS cells 
exhibited an accelerated as well prolonged WNT5a mediated R-RAS stimulation, 
compared to parental cells. This is the first time that WNT ligands have been 
demonstrated to stimulate the activity of RAS family GTPases and confirm our 
model that R-RAS GTPases can function downstream of WNT ligands in the 
regulation of VANGL1 function.  
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I have been unable to detect activation of endogenous TC21 but this could be 
due to the lower sensitivity of the TC21 antibody, which may be below the 
threshold of detection achieved in our RBD assays.  Notably however, TC21 (but 
not R-RAS) can be detected in association with ROR2 in some contexts. 
How WNT signalling components are able to activate R-RAS GTPases remains to 
be determined. Regulation by GEFs or GAPs is a likely mechanism of R-RAS 
activation. Although GEF activation is the most direct and common mechanism 
for RAS protein activation (Quilliam et al. 2002), inhibition of GAPs by 
extracellular stimuli also occurs. For example, p120GAP inhibition after 
stimulation of T cells with phorbol ester or TCR engagement (Downward et al. 
1990), Ca2+ regulation of the RASGAP, CAPRI (Lockyer et al. 2001), PI3-
kinase/AKT mediated regulation of the RHEB GAP, TSC2 (Castro et al. 2003) or 
regulation of RAPGAP1 by G protein coupled receptors (Jordan et al. 1999). 
Another example is CK1ε, regulating gastrulation movements through induced 
phosphorylation of the RAPGAP SIPA1L1 (signal induced proliferation associated 
protein 1 like 1), which in turn leads to reduced protein stability and thus results 
in higher RAP1 activity (Tsai et al. 2007).  
Despite the fact that the mechanism by which WNT5a activates R-RAS remains 
to be determined, members of the RASGRP and RASGRF family of RAS family 
GEFs are likely candidates for R-RAS activation. RASGRPs possess a pair of 
atypical EF hands that may bind Ca2+ in vivo and contain a DAG-binding C1 
domain (Buday and Downward 2008; Stone 2011). A rise in the intracellular 
concentration of Ca2+ and DAG are therefore possible mechanisms that could 
lead to activation of R-RAS GTPases. Furthermore, accumulating evidence links 
Ca2+ signalling to WNT/PCP pathway, although the molecular links are not well 
understood  (refer to section 1.5.2 and 1.5.3)  (De 2011; Stone 2011; Niehrs 
2012). 
Interestingly, in prostate PC3 cells, WNT5a addition lead to a sharp and transient 
peak of Ca2+ release starting at around three min after stimulation, which 
subsided within six min after WNT5a treatment (Wang et al. 2010). This 
stimulation pattern is strikingly reminiscent of the time course of activation 
observed for R-RAS in our studies. Future experiments will aim to determine the 
link between Ca2+ signalling, R-RAS activation and the PCP pathway.  
There are multiple reports linking the WNT/PCP pathway to activation of RHO 
GTPases but the molecular mechanisms remains unclear. There are likely to be 
multiple mechanisms operating in a cell type and context dependent manner. For 
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example, our data shows that WNT5a can activate RHOA but not RHOB in some 
cells such as 293T whereas in others such as HMEC it activates RHOB more 
strongly that RHOA. Strikingly, in at least some context and cell types, R-RAS 
GTPases play a critical contribution to RHO activation downstream of WNT 
ligands as simultaneous knock-down of both R-RAS and TC21 in HMEC-mFZD5 
cells strongly inhibits RHOA and RHOB activation by WNT5a. Although the 
mechanism by which R-RAS/TC21 regulate RHO activity remains to be 
determined, based on our finding that ARHGEF17/p164RhoGEF functions as an 
effector of TC21 (see section 3.3), this RHOGEF is an excellent candidate to 
mediate this effect. Future studies should address this exciting possibility. 
 
  
Figure 6.11: Chapter summary. (A) It has been demostrated that WNT ligands are 
able to activate R-RAS, and the R-RAS subgroup member TC21 has been shown to be 
ROR2 associated. In addition, enhanced expression of a subset of FZD proteins lead to 
enhanced VANGL1-DVL2 interaction, sugesting that WNT signalling, R-RAS activation and 
VANGL1 recruitment are co-ordinated processes required for PCP pathway activation. (B) 
A potential mechanism of WNT signalling induced R-RAS GTPase activation could be 
mediated through WNT stimulated intracellular Ca2+ accumulation, which in turn binds to 
RASGRP family members, and thus leads to R-RAS activation and subsequent effector 
interaction. 
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7 Role of VANGL1 and R-RAS in polarised migration 
In both developmental models and in cultured mammalian cells, the PCP/WNT 
signalling pathway has been implicated in cell migration (Vladar et al. 2009; 
Endo et al. 2012b). VANGL1 has been demonstrated to affect cell migration and 
invasion in colorectal cancer cells (Lee et al. 2004; Lee et al. 2005), and VANGL2 
has been implicated in WNT5a mediated migration and invasion (Phillips et al. 
2005; Cantrell and Jessen 2010; Lindqvist et al. 2010; Kibar et al. 2011; Shafer 
et al. 2011; Williams et al. 2012a). Therefore, I aimed to establish biological 
assays in order to investigate if VANGL1 and R-RAS GTPases are involved WNT 
ligand mediated cellular migration processes. 
Cell migration is a complex process which is orchestrated through extensive 
transient signalling networks (Vicente-Manzanares et al. 2005; Ridley 2011). In 
general, cells start to polarise and protrude in the direction of migration before 
modulating adhesion, following translocation of the cell body by retraction of the 
rear (Ridley et al. 2003). In order to establish an experimental system to study 
VANGL1 and R-RAS function in this process in a mammalian context, two 
frequently used assays of directed or polarised migration were considered; the 
scratch/wound closure assay and the transwell migration assay.  
Wound scratch or wound healing assays have been widely employed to study 
migration as well as the establishment of cell polarity during directed locomotion 
(Nobes and Hall 1999; Etienne-Manneville and Hall 2001; Etienne-Manneville 
and Hall 2003). Wound induction within a compact monolayer provides a 
directional cue (or mechanotactic signal), which enables a cell to define a distinct 
front and rear (Valster et al. 2005; Etienne-Manneville 2006; Liang et al. 2007). 
This results in a strong actin polymerisation at the leading edge and creates 
protrusive structures such as filopodia or lamellipodia, while the nucleus is 
positioned in the centre of the cell and the centrosome reorients toward the 
direction of migration, serving as a microtubule-organizing centre and elongating 
microtubules to fill in protrusions (Ridley 2011). 
The Boyden chamber approach, also termed transwell assay, monitors cell 
migration towards a chemoattractant cue. This is achieved through two 
chambers separated by a microporous membrane, in which cells are seeded in 
the upper chamber and migrate towards chemotactic agents applied in the lower 
chamber (Chen 2005; Falasca et al. 2011). This method further allows 
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investigating signal pathway activation based on specific extracellular matrix 
components, which are coated onto the porous membrane. 
 
7.1 VANGL1 and R-RAS are required for migration  
Wound healing assays rely on a compact and dense monolayer of cells which is 
wounded with a pipette tip and repopulation and closure of the wound is 
monitored over time. No specific chemoattractants are required, since the wound 
scratch generates a strong directional migratory response, and cells migrate 
perpendicular into the generated wound space. Depending on the cell line used, 
cells can either break free and individually infiltrate the wound area, or remain 
intact as a cell sheet (Figure 7.1B to E). 
Initial experiments were carried out in order to establish suitable cell lines for 
wounding and closure analysis (Figure 7.1A). For read out purposes, we aimed 
to identify cell lines, which upon wound induction form a polarised leading edge, 
display protrusive features and preferentially migrate as sheet, rather than 
single cells. 
 
Figure 7.1: Establishment of wound scratch assays. Cells lines listed in A were 
seeded in 24 wells and upon reaching confluency, scratched and wound closure monitored 
over time. Created wound at t=0 is indicated as light grey area (B and C) or by a dotted 
line (D and E). The time point of wound closure assessment has been displayed as in 
hours post wounding. 
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The osteosarcoma U2OS cell line exhibited all the desired features (Figure 7.1A) 
and has been demonstrated to be a good system to study WNT5a mediated 
signalling processes (Liu et al. 2007; Liu et al. 2008b; Enomoto et al. 2009; 
Yamagata et al. 2012). Therefore, initial scratch wound experiments focused on 
investigating the effect of loss of VANGL proteins or R-RAS GTPases on migratory 
behaviour in U2OS cells. R-RAS GTPases or VANGL proteins were depleted using 
an RNAi approach. 72h post transfection, confluent monolayers were wounded 
with a tip, generating approximately 800µm wounds in width (Figure 7.2C and 
D). Within 24h, cells usually repopulated the wound, through sheet-like 
migration into the wound space (Figure 7.2C).  
Cell lysates were assessed for siRNA mediated knock down efficiency by 
immunoblotting. Overall, VANGL1, R-RAS and TC21 siRNA transfected samples 
exhibited significant reduction of respective protein levels (Figure 7.2A).  
Depletion of VANGL1, R-RAS or TC21 protein levels resulted in migration defects, 
exhibited as delayed wound closure (Figure 7.2 B and C). The strongest effect 
was observed in VANGL1 deficient conditions, that lead to a very strong block in 
migration, observable as early as 2h post wounding (Figure 7.2B, purple). Knock 
down of VANGL2 also inhibited migration, although not as strongly as VANGL1 
(Figure 7.3B) and double knock down of VANGL1 and VANGL2 did not display an 
additional effect (data not shown). 
R-RAS and TC21 knock down both resulted in slightly delayed wound closure 
compared to control cells (Figure 7.2B red, green, black). Notably, double knock 
down samples of R-RAS/TC21 displayed a slightly stronger inhibitory effect 
(Figure 7.2B, blue). However, this might be related to lower TC21 protein levels 
in R-RAS/TC21 double knock down samples (Figure 7.2A).  
Multiple siRNA oligomer sequences targeting the same gene were employed and 
tested for efficiency and required concentration (data not shown). Analysis of 
different VANGL1 RNAi oligomers confirmed the robust negative effect on 
migration, supported by the observation that VANGL1 protein expression 
correlates well with a less severe migration defect observed with a  second less 
efficient VANGL1  oligomer (oligo2), compared to oligo 1 (Figure 7.3B and C). 
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Figure 7.2: VANGL1 and  R-RAS/TC21 are required for wound closure. U2OS cells 
were transfected with siRNA oligomer targeting VANGL1 (V1), R-RAS or TC21 individually 
or in combination as indicated at final concentration of 10 nM each. 72h post transfection, 
cells were either harvested or scratched.  (A) In order to assess knock down levels, cells 
were lysed and targeted endogenous protein levels detected by immunoblotting, using 
indicated antibodies. Detection of SCRIB or DLG1 served as loading control. (B) 
Quantification of induced wound closure over a 24h period, assessed through wound 
repopulation in percent (wound density). Data were obtained using a IncuCyte imaging 
device (Essen Instruments) and plotted using Excel software (Microsoft) and represent 
the mean relative wound density ± S.D. of two independent experiments. (C) Confluent 
U2OS monolayers were wounded with a pipette tip and allowed to migrate for 24 h in the 
presence of 10% serum. Images were aquired periodically every 2h using a imaging 
IncuCyte (Essen Instruments) device. Dark grey areas represent the wound at the time 
point of wounding (t=0), whereas light grey regions display the wound area and highlight 
migrated cells after 14h. Yellow bar represents 200 µm. As control served a non-targeting 
Alexa-fluorophore labeled siRNA. 
 
Although R-RAS and TC21 knock down exhibited only mild effects on the rate of 
wound closure compared to VANGL1 knock down conditions, this effect was more 
apparent at earlier time points (Figure 7.2B) consistent with the possibility that 
R-RAS/TC21 may be preferentially involved in the initial polarisation associated 
with migration towards the wound. An enlarged phase contrast field of U2OS 
cells during wound closure 4 h post scratching, depicts cell migration and 
protrusion and further illustrates this point, as combinational knock down of R-
RAS and TC21 demonstrates a decreased amount of cell protrusion and  
migration into the wound (Figure 7.4A, right panel and arrow). 
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Figure 7.3: VANGL1 knock down leads to a more severe migration defect than 
VANGL2. Assessment of two individual VANGL1 siRNA oligomers (oligo 1 (1) and oligo 
(2)) and VANGL2 (pooled oligmers (p)) on wound closure (10 nM final concentration 
each). Confluent U2OS monolayers were wounded with a pipette tip and allowed to 
migrate for 24 h in the presence of 10% serum. (A) Immunoblotting of cell lysates to 
assess knock down efficency, as control served scramble (con1) or a non-targeting 
sequence Alexa-fluorophore (con2). (B) Quantification of induced wound closure over a 
24 h period, assessed through wound repopulation in percent (wound density). Data were 
obtained using a IncuCyte imaging device (Essen Instruments) and plotted using Excel 
software and represent the mean relative wound density ± S.D. of two independent 
experiments. (C) Representative images of the repopulated wound. Dark grey areas 
represent the wound at the time point of wounding (t=0), whereas light grey regions 
illustrate the wound area and highlight migrated cells after 14h.  
 
VANGL1 knock down cells fail to extend protrusions towards the wound (Figure 
7.4A middle panel), highlighting a key role for VANGL1 in this type of polarised 
migration. 
Immunostaining of the actin skeleton (red) and the Golgi marker protein 
(GM130, green) revealed that control U2OS cells displayed clear lamellipodial 
protrusions towards the wound, exhibiting an extensive and elongated actin 
polymerisation (Figure 7.4B, left image, red staining) as well as Golgi localisation 
(green) anterior of the nucleus towards the wound, which marks the first 
important step prior to actin polymerisation.  
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In comparison, lamellipodial protrusions are clearly shorter and compact in 
VANGL1 and R-RAS/TC21 knock down cells and lack the extensive actin 
polymerisation towards the wound detected in control cells (Figure 7.4B, middle 
and right panel). 
 
 
Figure 7.4: Loss of VANGL1 or R-RAS/TC21 inhibits membrane protrusion and 
migration in scratch/wound closure assays that is particularly apparent at early 
time points. U2OS cells were siRNA transfected and grown to confluency within 72h. 
Cells were wounded with a plastic pipette tip and either monitored for wound closure over 
time or immunostained for actin polymerisation and Golgi orientation. (A) siRNA 
mediated downregulation of VANGL1 or R-RAS and TC21 severely disrupts cell migration 
into the wound. The untouched cell monolayer at time of scratching is coloured in dark 
grey, whereas newly migrated cells are highlighted in light grey and the outmost cell 
border is emphasised with a white, dotted line for better visualisation. Control siRNA 
transfected U2OS cells displayed fan-like lamellipodia structures at the leading edge. 
Phase contrast images taken 4h after wound induction exhibit strong negative effect on 
wound closure in siRNA VANGL1 treated cells and a milder but clear effect in the siRNA R-
RAS and TC21 sample, compared to non-targeting scrambled siRNA control (siControl). 
Arrows depict lamellipodia protrusions into the wound. (B) Actin stainings of cells as in A  
shows inhibition of membrane protrusions and lamellipodial extension at the leading edge 
by VANGL1 or RRas/TC21 siRNAs. red - phalloidin, green-Golgi marker GM130, blue – 
nucleus stain by Hoechst. Arrows depict areas of actin polymerisation and the direction of 
wound triggered cell migration, which displays severely condensed and short lamellipodia 
formation (illustrated by arrow shapes) in VANGL1 or R-RAS/TC21 knock down cells. 
Yellow bar represents 60 µm.    
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Previous experiments were performed in the presence of 10% FBS. In order to 
study a selective role of R-RAS GTPases in the migratory response specifically 
stimulated by the WNT/PCP pathway, the ability of WNT ligands to stimulate 
migration in the scratch assay was initially tested in this assay.  
Unfortunately, using conditioned medium for an extensive panel of the WNT 
ligands generated (section 2.4.8.1) no additional effect over control conditioned 
medium was observed. Similarly, when purified WNT5a and WNT7a were used at 
different concentrations on serum starved cells, no stimulation on migration 
could be detected. These negative results precluded further studies using this 
experimental system. 
As an alternative assay to study polarised migration, the transwell assay was 
also employed. Small interfering RNA transfected U2OS cells were seeded in the 
upper chamber maintained in serum free media, while the lower chamber was 
filled with regular growth media containing 10% FBS, generating a serum 
gradient due to distinct pores within the membrane and thus providing a 
chemotactic migration cue. Assay quantification was performed based on percent 
of cell population travelled through the membrane towards the lower chamber, 
normalised by initial cell seeding density. 
Both knock down conditions, VANGL1 and R-RAS/TC21, displayed a lower 
number of membrane passed cells, compared to the control transfected sample 
(Figure 7.5). VANGL1 deficient cells showed a strong migratory reduction of 
about 5 fold, whereas the R-RAS/TC21 combination resulted in milder decrease 
of migrated cells. These results display a similar pattern as observed with wound 
scratch closure assays, where VANGL1 knock-down resulted in a much stronger 
inhibitory effect compared to R-RAS/TC21 depletion (Figure 7.2).  
In order to study a selective role of R-RAS GTPases in cellular migration 
specifically stimulated by the WNT/PCP pathway; experiments were set up using 
the transwell assay approach to test the ability of WNT ligands to stimulate 
migration.  
Unfortunately, addition of different WNT ligands at different concentrations in the 
absence of serum did not show a robust effect on migratory behaviour, in U2OS 
or other cell lines tested.  
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Figure 7.5: VANGL1 or R-RAS/TC21 are required for transwell migration. 
Migration of siRNA treated U2OS cells (either scramble (control), VANGL1 or combination 
of R-RAS and TC21), 72h post transfection, towards 10% FBS growth medium was 
assessed in a Boyden chamber assay using 24 well PET inserts of 8 µm pore size. (A) 
50000 cells were seeded in the top part of a 24 well transwell insert and after 
attachment, media was exchanged to serum free media. Left hand panel pictures were 
taken 30 min after cell seeding in order to correct for potential discrepencies in cell 
numbers. After 14h of incubation, the assay was terminated by removing non migrated 
cells on the top of the tranwell membrane, and subsequent staining of migrated cells on 
the membrane facing the lower chamber by crystal violet dye (right hand side panel). (B) 
Quantification of chemotactic migration was performed by counting representative fields 
of cells at 10x magnification, normalised by initial seeding densities and plotting the 
numbers of total migrated cells in percent for each condition. Data represent the mean ± 
standard error of the mean (SEM) from 3 independent experiments. (*p<0.001, 
**p<0.05). 
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7.2 VANGL1 and R-RAS are required for scratch induced 
polarisation  
In order to further explore the possibility that VANGL1 and R-RAS function in the 
context of the WNT/PCP pathway activation in order to control initial cell 
polarisation which take place at the onset of migration, Golgi and MTOC re-
orientation at a scratch-induced wound were analysed. 
U2OS cell based experiments were carried out in order to assess VANGL1 or R-
RAS/TC21 polarisation effects on Golgi orientation. Golgi structures within a cell 
can be detected by immunostaining for a Golgi marker such as the cis-Golgi 
protein GM130 (Nakamura et al. 1995).  
In order to analyse and quantify Golgi immunostained samples, set criteria for 
scoring parameters were determined, demanding that a cell is considered 
polarised if the entire Golgi staining localises within a 120° angle towards the 
wound edge (Figure 7.6A). A representative scored image is presented in Figure 
7.6B. A time course assessing Golgi re-orientation after wound scratch, 
comparing scramble control with VANGL1 knock down cells showed that VANGL1 
deficient cells exhibited delayed Golgi re-orientation. These differences in 
orientation were most apparent at 4h after wounding and thus this time point 
was used for subsequent experiments (Figure 7.6C).   
Knock-down of R-RAS, or TC21 had a similar inhibitory effect with 20-25% of 
cells showing an oriented Golgi compared to ~40% of cells in scramble controls. 
Simultaneous knock-down of R-RAS and TC21 had no further effect (Figure 
7.6D). Knock-down of VANGL1 caused the biggest disruption, with only ~15% 
cells showing wound oriented Golgi (Figure 7.6D). 
Another way of determining wound cell orientation is MTOC staining using γ-
tubulin detection (Stearns et al. 1991; Etienne-Manneville 2006). Due to the fact 
that the centrosome structure, which serves as MTOC towards the direction of 
migration, is a very distinct and confined structure, I applied more stringent 
scoring parameters. In order to be counted as correct polarised, MTOC staining 
has to be localised within a 90° angle towards the wound (Figure 7.7A), which is 
demonstrated on a representative image in Figure 7.7B.  
Time course experiments were performed to determine the most suitable point 
for cell fixation and MTOC assessment over the course of 7h post wounding. 
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Figure 7.6: VANGL1, SCRIB or R-RAS GTPases delay Golgi wound orientation. 
U2OS cells were transfected with indicated siRNAs and grown to confluency. 72h post 
transfection, cells were wounded and allowed to migrate for the indicated times. (A) 
Scoring schematic. Correctly oriented cells (+) were counted when GM130 Golgi staining 
(green) localised within the 120° wound oriented wedge. If GM130 Golgi staining localised 
partly or completely outside the 120° criteria, cells were quantified as non oriented (-). 
Cells were counted across multiple representative images per sample and more then 100 
cells per conditon were assessed for analysis. (B) Example of a representative scored 
GM130 image. Nuclei are stained with Hoechst dye (blue) and immunostained for the 
Golgi marker GM130 (green). (C) Time course experiment to determine the most 
appropriate time point for fixation of cells after wound scratch, comparing control 
transfected versus VANGL1 siRNA treated cells. Cells were scratched and fixed either 2, 4 
or 6 h after wounding and subsequently immunostained for visualisation of the nucleus 
(blue) and the Golgi (green). (D) Quantification of Golgi orientation towards the wound 4 
h post scratching were performed from immunostained samples using multiple images per 
condition, aquired with a Zeiss microscope and analysed applying criteria as described in 
A.  
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Figure 7.7: Loss of VANGL1 or R-RAS/TC21 disrupts MTOC polarisation towards a 
wound. U2OS cells were seeded on coverslips, transfected with siRNA targeting either 
SCRIB, VANGL1 or R-RAS and TC21 protein level expression at a final concentration of 10 
nM. Cells were grown to confluency and wounded 72h post transfection. (A) Scoring 
schematic. Correctly oriented cells (+) were counted when the distinctive γ-tubulin stain 
(MTOC, microtubule organisation centre) located within a 90° wound oriented wedge. If 
more than one MTOC stain was visible, the respective cell was not considered for analysis. 
Individual samples were imaged across multiple fields along scratch induced wound, and 
more then 100 cells per sample were analysed and counted for quantification.  (B) 
Example of a scored γ-tubulin image. Cells were nucleus counterstained with Hoechst 
(blue) dye and immunostained using the MTOC marker γ-tubulin (green). Note that the 
weak resiual staining of the cell body by γ-tubulin was utilised to assess the cell 
positioning towards the wound. (C) Time course experiment to determine the most 
suitable time point for fixation of cells after wound scratch induction. Cells were wound 
scratched and fixed either 1, 2, 3, 4, 6 or 7 h after wound scratch generation. Cells were 
immunostained for visualisation of the nucleus (Hoechst) and MTOC (γ-tubulin), and 
wound orientation quantified as described in B. (D) Quantification of wound scratch cell 
orientation using siRNA U2OS transfected samples, 90 min post wounding. Samples were 
immunostained for the nucleus and MTOC location and various images were recorded 
using a Zeiss fluorescent microscope. Wound cell orientation was quantified using criteria 
as described in A. Red line marks 25%, which indicates the expected percentage of a non 
polarised random cell population. 
 
240 
 
MTOC wound orientation appears to take place in a rapid fashion, showing the 
highest orientation within one hour post wounding, with a decline during the 
next hours (Figure 7.7C). Thus, experiments assessing MTOC orientation 
towards the wound were harvested between one and two hours post wounding. 
Analysis and quantification of MTOC orientation experiments confirmed Golgi 
orientation results (Figure 7.6), demonstrating that SCRIB, VANGL1 or R-
RAS/TC21 knock down negatively affects cellular polarisation. In addition, 
VANGL1 deficient cells demonstrated in both orientation assays the highest 
defects with only 29% correctly aligned cells, while SCRIB or R-RAS/TC21 siRNA 
treated cells displayed 35% or 41%, respectively (Figure 7.7D). These results 
indicate that VANGL1 and R-RAS/TC21 are required for initial migration 
processes such as correct polarisation towards as wound, consistent with our 
observation that a lack of VANGL1 or R-RAS/TC21 results in delayed wound 
closure.  
Interestingly, immunoblotting for endogenous VANGL1 protein in SCRIB deficient 
conditions revealed a gel-shift, compared to control transfected samples (Figure 
7.8). It is known that VANGL2 phosphorylation occurs at the N-terminus in a 
WNT5a mediated fashion through ROR2 (Gao et al. 2011). Since VANGL1 and 
VANGL2 share the same N-terminal serine/threonine cluster, and VANGL1 is 
reported to be N-terminal phosphorylated (Kalabis et al. 2006; Daub et al. 
2008), this gel-shift suggests potential protein phosphorylation if SCRIB is 
absent (Figure 7.8). SCRIB has been implicated in the regulation of directed cell 
movements and interacts with VANGL1 (Dow et al. 2007; Anastas et al. 2011), 
and thus this evidence implies a potential SCRIB dependent post-translational 
VANGL1 regulatory mechanism.  
 
Figure 7.8: Downregulation of SCRIB levels leads to VANGL1 gel migration shift. 
U2OS cells were siRNA transfected as indicated above and harvested 72h later. Cell 
lysates were immunoblotted for endogenous proteins with indiacted antibodies. Knock 
down of SCRIB induced a gel-shift of VANGL1 (V1) protein, which was absent in scramble 
or SHOC2 transfections, which interacts with SCRIB but not with VANGL1 and thus served 
as control protein. V2-VANGL2.  
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7.3 VANGL1 depletion leads to increased invadosome 
formation 
Recent studies have implicated VANGL2 in the regulation of endocytosis and cell-
surface availability of membane-type-1 matrix metalloprotease (MMP-14), and in 
formation or stability of invadopodia (Cantrell and Jessen 2010; Williams et al. 
2012a; Williams et al. 2012b).  
Regulation of MMPs and remodelling of ECM has been demonstrated to be 
required for non-canonical WNT signalling and vertebrate gastrulation 
movements (Coyle et al. 2008). This triggered the question if VANGL1 migratory 
and invasive properties are mediated through similar signalling events as 
reported for VANGL2. 
To test if a R-RAS and VANGL1 are required for invasiveness, the human 
osteosarcoma cell line SaOS2 was employed for invadopodium formation studies, 
since this cell line shows invasive properties in vitro and metastasis in mouse 
models (Dass et al. 2006; Guo et al. 2008).  
The invadopodium formation assay relies on a fluorophore labelled matrix and 
detection of potential extracellular matrix degradation through invadopodium 
formation (Figure 7.9A) (Artym et al. 2009). In order to assess if VANGL1 and R-
RAS/TC21 exhibit an effect on ECM degradation, siRNA transfected SaOS2 cells, 
which showed a significant down regulation of VANGL1, or R-RAS/TC21 (Figure 
7.9B), were seeded on Alexa568 fluorophore labelled gelatin coverslips. After 9h 
of incubation, coverslips were harvested and analysed for ECM degradation, 
apparent through loss of staining and thus resulting in black spots (Figure 7.9C).  
Quantification of ECM degradation ability was carried out by counting generated 
spots across fields of cells, resulting in a spots per field read out. Control SaOS2 
cells lead to an average of six generated spots per field, whereas down 
regulation of VANGL1 shows a significant reduction by more than 80% in 
generated spots. R-RAS/TC21 knock down samples also display a reduced spot 
number of almost 50% (Figure 7.9D). 
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Figure 7.9: VANGL1 or  R-RAS/TC21 knock down reduces invadosome formation.  
(A) Schematic of experimental setup and time line. SaOS2 cells were transfected with 
VANGL1, R-RAS and TC21 or scramble control siRNAs, and 72h later seeded at the same 
density on Alexa568-gelatin coated coverslips prepared as outlined in section 2.6.4. Cells 
were allowed to attach and to spread for 9h, during which time cells start to degrade the 
Alexa-gelatin layer through formed invadosomes, resulting in formation of dark spots 
within the red matrix layer. After the 9h incubation on Alexa coverslips, cells were fixed 
and subsequently prepared for immunofluorescence. (B) Western blot analysis for 
endogenous protein levels 81h post transfection using indicated antibodies. As loading 
control served tubulin. (C) Representative immunofluorecent image of scramble (control), 
R-RAS and TC21 or VANGL1 siRNA treated cell populations on coverslips and induced 
matrix degradation spots (black). Actin cytoskeleton was counterstained using Phalloidin 
(green) in order to assess if cell populations across conditions were comparable and 
equally disributed. Scale bar represents 45 µm. (D) Quantification was performed by 
counting yielded dark spots per field of cells (30 fields per condition) at a comparable 
density per condition. 
 
Due to reports that WNT5a/ROR2 signalling leads to MMP-13 (collagenase-3) 
expression (Yamagata et al. 2012), and further observations that MMP-13 has 
been implicated directly and indirectly to promote tumour angiogenesis (Kudo et 
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al. 2012), MMP-13 mRNA quantification experiments were carried out using the 
SaOS2 cell model. In this context, ROR2 knock down has been demonstrated to 
negatively affect MMP-13 levels (Enomoto et al. 2009) and thus was employed 
as positive control (Figure 7.10). 
Preliminary experiments showed consistently that loss of VANGL1 leads to 
decreased MMP-13 mRNA level (Figure 7.10), indicating that VANGL1 might be 
able to modulate migration and invasion properties through ECM remodelling. In 
contrast, R-RAS or TC21 by itself or in combination did not affect MMP-13 
expression levels (Figure 7.10A and B), suggesting MMP-13 expression is 
modulated through a VANGL1 dependent mechanism, which is independent of R-
RAS or TC21. 
 
 
Figure 7.10: MMP-13 expression is regulated through VANGL1 but not R-RAS or 
TC21. (A) SaOS2 cells were siRNA transfected using ROR2, either R-RAS and TC21 single 
or in combination (R+T) or VANGL1 (V1) and harvested 72h later for RNA extraction and 
were subjected to semi-quantitative RT-PCR. Amounts of yielded MMP-13 DNA was 
compared to 18S, serving as input control. (B) Independent replicate of experiment as 
described in A, examing a larger panel of siRNA conditions. As control served a non-
targeting scramble (scr) control. 
 
Taken together, VANGL1 and R-RAS/TC21 have been demonstrated to be 
required for cellular migration and are likely involved in initial polarisation 
processes through a yet undetermined mechanism. In addition, VANGL1 seems 
to be necessary for MMP-13 expression, required for remodelling of ECM and 
thus migration and invasion processes. 
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7.4 Discussion 
PCP signalling in vertebrates plays a vital role in convergent extension and 
gastrulation movements (Bisgrove and Yost 2006; Fliegauf et al. 2007; Zallen 
2007; Tada and Kai 2009) through activation of RHO GTPases and regulation of 
the formation and polarisation of actine rich membrane protrusions (Roszko et 
al. 2009).  
To study VANGL1 and R-RAS function in cell migration, wound closure and 
transwell (Boyden chamber) assays were chosen (Etienne-Manneville 2006; Dow 
et al. 2007) to assess migration and polarisation properties of VANGL1 or R-RAS 
GTPases deficient cell lines. Following wounding or migration stimulation by 
serum gradient, cells at the edge of the wound polarise the nucleus, actin 
cytoskeleton and microtubule organising centre/Golgi network in the axis of 
migration, a process known to involve RHO GTPases (Hall 2005; Ridley 2011). 
Inhibition of either VANGL1 or R-RAS/TC21 expression with two different siRNA 
oligos disrupted the scratch induced re-orientation of the Golgi and the 
centrosome towards the wound, membrane protrusion at the leading edge and 
inhibited directed migration when measured in transwell and scratch/wound 
closure assays. The wound closure delay upon VANGL1 and to a milder degree of 
R-RAS/TC21 was particularly apparent at early time points suggesting a possible 
role of VANGL1 and R-RAS/TC21 in the initial scratch-induced polarisation. Taken 
together these results strongly suggest that VANGL1 and R-RAS/TC21 play an 
important role in polarised migration. This is consistent with previous reported 
data using colorectal cancer cell lines, demonstrating that VANGL1 is critically 
required for migration and invasion (Lee et al. 2004; Kho et al. 2009; Lee et al. 
2009). 
As outlined earlier, VANGL1 interacts with SCRIB, a protein with a well-
established role in polarity and migration (Qin et al. 2005b; Osmani et al. 2006; 
Dow et al. 2007; Nola et al. 2008; Michaelis et al. 2013). Therefore, we 
hypothesised that R-RAS may be involved in recruiting the VANGL1-SCRIB 
complex to the membrane and thereby exert a role in polarised migration. In 
support of this idea, SCRIB is found associated at the leading edge with VANGL1 
(Anastas et al. 2011). In addition, it was noticed that knock down of R-
RAS/TC21 resulted in significantly shorter and compacter lamellipodial 
protrusions. Consistent with observations that R-RAS is found associated to sites 
of lamellipodia (Fernandez-Borja 2012). 
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In mammalian cells, SCRIB associates with the PIX/GIT complex that regulates 
RAC/CDC42 and ARF GTPases (Audebert et al. 2004; Frank and Hansen 2008), 
which has been implicated in the control of polarity associated with directed cell 
migration (Qin et al. 2005b; Osmani et al. 2006; Dow et al. 2007; Michaelis et 
al. 2013).  
Upon depletion of SCRIB, VANGL1 exhibits an altered, retarded gel migration 
shift. Since VANGL2 has been described to be phosphorylated (Gao et al. 2011) 
and both VANGL proteins share a N-terminal serine/threonine cluster, it is 
tempting to speculate that VANGL1 is phosphorylated by a kinase whose activity 
is normally inhibited by SCRIB. The identity of this kinase and the regulatory 
mechanisms involved remain to be determined. 
Notably, VANGL2 has been reported to affect cell adhesion and the cytoskeleton 
by recruiting RAC1 and targeting its activity in the cell to adherens junctions 
(Lindqvist et al. 2010). 
Using melanoma cell lines in a WNT5a/CXCL12-mediated cell migration model, it 
was observed that WNT5a promotes cell polarity in a manner that requires a 
chemokine CXCL12 gradient (Witze et al. 2008). CXCL12 signals through the 
CXCR4 receptor and has been shown to promote cell invasion (Murakami et al. 
2002; Bartolome et al. 2004). Based on experiments carried out by Witze and 
colleagues, in combination with our observation that initial polarisation seems to 
be strongly affected rather than migration, this suggests that the WNT/PCP 
pathway is regulating polarisation and not migration.  
Classical RAS proteins are activated in response to a wide variety of extracellular 
signals and function as master regulators of cell proliferation. We propose that 
R-RAS GTPases may function in a similar manner as master regulators of cell 
migration. 
VANGL2 has been implicated to modulate invasive properties through MMP 
regulation (Cantrell and Jessen 2010; Williams et al. 2012a). Utilising the 
invasive osteosarcoma cell line SaOS2, which has been established to show a 
ROR2 dependent MMP-13 expression (Enomoto et al. 2009; Yamagata et al. 
2012), it could be demonstrated that VANGL1 is required for ECM degradation 
and MMP-13 expression.  
MMP-13 facilitates local invasion (Milner and Cawston 2005) through its ability to 
degrade fibrillar collagen (Uitto et al. 1998) and a wide variety of ECM 
components (Ashworth et al. 1999; Tardif et al. 2004). MMP-13 has been 
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reported to be overexpressed in a variety of tumours (Freije et al. 1994; Pendas 
et al. 2000; Elnemr et al. 2003; Culhaci et al. 2004; Corte et al. 2005; Luukkaa 
et al. 2006) and has been correlated with tumour invasion, metastasis and poor 
prognosis in patients (Johansson et al. 1997; Pendas et al. 2000; Krecicki et al. 
2003; Roeb et al. 2004; Luukkaa et al. 2006). Expression studies in tumour cells 
showed that MMP-13 is predominantly found in the tumour invasive front and to 
a lower extent in stromal fibroblasts, surrounding tumour cells (Johansson et al. 
1997; Ashworth et al. 1999). 
WNT5a has been demonstrated to promote cell migration and invasion in 
osteosarcoma cells or prostate carcinoma cells (Enomoto et al. 2009; Yamamoto 
et al. 2010). In fact, constitutively active WNT5a/ROR2 is required for MMP-13 
expression and invasive properties of osteosarcoma SaOS2 cells. It has been 
established that for WNT5a/ROR2 dependent MMP-13 expression, SRC-family 
protein tyrosine kinases (SFKs), DVL and RAC are required, mediated through c-
JUN and ATF2 transcription factors, which are recruited to the AP-1 promotor site 
of MMP-13 (Enomoto et al. 2009; Yamagata et al. 2012). Notably, DVL2 and 
RAC1 but not DVL3 are required for MMP-13 expression in SaOS2. In contrast, 
studies carried out in U2OS cells reported that DVL3 and RAC1, but not DVL2 are 
required for MMP-13 expression (Yamagata et al. 2012), illustrating the presence 
of distinct signalling machineries in order to lead to MMP-13 expression in 
osteosarcoma cell lines. 
SiRNA mediated knock down of VANGL1 consistently showed a strong decrease 
of gelatin degraded areas (spots) indicating that VANGL1 is required for ECM 
degrading activities. This observation correlated well with a reduced level of 
MMP-13 expression in VANGL1 deficient cells.    
These findings are consistent with literature reports stating that ectopic VANGL1 
promoted cell adhesion to fibronectin, and invasion of ECM, while loss of VANGL1 
protein decreased adhesion and invasiveness (Lee et al. 2004). In addition, 
ectopically expressed VANGL1 increased tumour growth rates in mice and 
metastasis formation, whereas anti-sense VANGL1 mice exhibited a reduced 
tumour volume and no metastasis formation (Lee et al. 2004).  
MMP-13 was identified as a common up-regulated gene by cancer invasion-
related factors (Kudo et al. 2012). MMP-13 has been shown to mildly promoted 
tumour invasion, and to be involved in tumour angiogenesis. Furthermore, MMP-
13 promoted capillary tube formation was mediated by activation of FAK and 
247 
 
ERK. Based on findings by Kudo and colleagues it was suggest that MMP-13 may 
directly and indirectly promote tumour angiogenesis (Kudo et al. 2012). 
MMP-14 is required for cell polarity and CE and exhibits a genetic interaction with 
the WNT co-receptor GLYPICAN4 (Coyle et al. 2008). Studies investigating a 
potential connection between PCP mediated cell migration and MMP-dependent 
ECM remodelling, showed that VANGL2 regulates MMP-14 cell surface 
expression, MMP-2 activation and invasion through an ECM barrier (Cantrell and 
Jessen 2010). A subsequent study then revealed that VANGL2 directly regulates 
cell surface levels of MMP-14 by controlling its trafficking to and from the plasma 
membrane (Williams et al. 2012a). Moreover, VANGL2 dependent MMP-14 
endocytosis requires focal adhesion kinase phosphorylation at Y397 (Williams et 
al. 2012a). In summary, these findings suggest that VANGL2 mediated MMP-14 
trafficking might be coordinated with integrin function and the formation of cell 
matrix adhesions.  
Therefore, experiments are required in order to test if VANGL1 mediated MMP-13 
modulation might be regulated in a similar manner as discussed for VANGL2-
MMP-14. Due to time constraints, I was not able to investigate if VANGL1 is also 
able to modulate MMP-14 localisation as observed for VANGL2. 
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8 Final Discussion and Summary  
8.1 Conclusions and and proposed model  
To date, it is still poorly understood how signalling specificity is achieved among 
the closely related GTPases of the RAS subfamily. It has been suggested that 
individual GTPases have overlapping but specific blueprints of effector 
interactions, and that their signalling and biological properties should be 
considered in the context of the full spectrum of their many effector interactions 
(Rodriguez-Viciana et al. 2004). A further degree of complexity is illustrated by 
the observation that RAS family GTPases can cross-talk with each other and co-
operate in the activation of the same effector pathway (Rodriguez-Viciana et al. 
2006). 
Employing a proteomic approach in order to identify novel effectors of R-RAS 
and TC21 led to the discovery of VANGL1 and ARHGEF17/p164RhoGEF, 
respectively. Initial validation experiments demonstrated that 
ARHGEF17/p164RhoGEF binds to both TC21 activated mutants and R-RAS L87 in 
an activation and effector domain dependent manner. No interaction with M-
RAS, RAP1, RAP2 or N-RAS could be observed. Furthermore, I mapped the 
TC21-ARHGEF17/p164RhoGEF interaction region to the ARHGEF C-terminus 
downstream of the DH domain, and this interaction is direct as it can be 
observed in in vitro interaction assays with recombinant proteins. Employing 
RHO-RBD assays, I could confirm that ARHGEF17/p164RhoGEF acts as GEF for 
RHOA.   
Using activating or disrupting mutants of RAS family GTPases, I have shown that 
VANGL1 has all the hallmarks of a bona fide effector of R-RAS and TC21. The 
interaction is very specific for R-RAS subgroup members and VANGL1 does not 
exhibit binding to other closely related RAS proteins such as N-RAS or RAP2. 
VANGL1 binds preferentially to the activated mutants compared to the wild type 
protein and the interaction is disrupted by mutations in the effector domain. 
Furthermore, a GTP-dependent interaction can also be observed in vitro binding 
assays using purified proteins, suggesting that the interaction is direct. Taken 
together, these results indicate that VANGL1 is a direct and specific effector of R-
RAS and TC21. 
VANGL1 is a membrane protein with four transmembrane domains (Iliescu et al. 
2011). Interaction studies employing CAAX domain truncations showed that in 
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contrast to other effectors such as AF6 or BRAF, R-RAS need to be membrane 
associated in order to interact with VANGL1. 
Interaction studies analysing binding of VANGL1 point mutants identified in 
human NTDs, demonstrated a defective DVL interaction with VANGL1 D259E 
(Kibar et al. 2007). VANGL1 D259E also disrupts interaction with R-RAS. This 
suggests that R-RAS and DVL proteins bind to the same region in the VANGL1 C-
terminus and therefore may compete for interaction. Notably, even though the 
VANGL1 D259E mutation disrupted R-RAS and DVL3 binding, it did not affect the 
interaction with other proteins such as SCRIB, thus indicating that R-RAS and 
DVL bind to a different region than SCRIB and potentially linking R-RAS and DVL 
to the pathogenesis of NTDs.  
VANGL1 has no enzymatic domains or known function and it is likely to function 
as a scaffold-type protein by interaction with other proteins. In this model R-
RAS/TC21 could regulate VANGL1 function at least partly by regulating its 
localisation in some contexts: upon activation, RRAS/TC21 would recruit VANGL1 
to specialised signalling platforms at the membrane micro-domains where they 
reside. Furthermore, R-RAS/TC21 binding could also regulate the association of 
VANGL1 with its interacting partners and thereby modulate its signalling 
properties. 
In order to shed more light into VANGL1 function and interaction partners, we 
performed the tandem affinity method using VANGL1 as bait. This approach 
resulted in the identification of various VANGL1 binding partners, including 
several involved in polarity and vesicular trafficking. Although some of the 
proteins tested in this study bind to both VANGL1 and VANGL2 isoforms (SCRIB, 
DLG1, CASK, YIF1B, CELSR2-C2, RAP3GAP1, SYNTENIN-1), others show 
different interaction affinities and suggest different functions for the two VANGL 
proteins (e.g. DVL proteins and SYNJ2BP preferentially interact with VANGL1, as 
does R-RAS and TC21) (Figure 8.1).  
In order to test the hypothesis that R-RAS modulates VANGL1 interactor binding, 
pull down experiments in the presence of activated or effector domain R-RAS 
mutants were carried out. These studies revealed that indeed R-RAS is able to 
either inhibit the interaction of VANGL1 with polarity proteins such as DVL, 
SCRIB, DLG and CASK whereas it can stimulate VANGL1 interaction with the PCP 
member CELSR2 or membrane trafficking proteins such as YIF1B or SYNJ2BP.  
251 
 
Although R-RAS has no effect on the VANGL1-PRICKLE1 interaction, R-RAS 
GTPases partially inhibit the VANGL1 induced destabilisation of PRICKLE1/2 
protein levels, which occurs by a mechanism that remains to be determined. 
Taken together, these observations suggest that R-RAS regulates VANGL1 
function by direct recruitment and spatial localization and/or modulation of its 
interactome.  
We propose a model where upon activation by extracellular signals, R-RAS 
GTPases will recruit VANGL1 (and its associated proteins) to sites of activation. 
This will not only lead to the localisation of VANGL1 complexes at spatially 
distinct micro/nano-domains at the plasma membrane but also to a selective 
‘rearrangement’ of the interacting partners within the complex to give rise to 
VANGL1 complexes with specialised signalling properties. Furthermore, it will 
provide a mechanism to spatially coordinate VANGL1 function with other 
signalling pathways regulated by R-RAS GTPases that jointly contribute to 
regulate polarity. 
 
 
Figure 8.1: R-RAS-VANGL1 signalling model. See text for details.  
 
 
DVL proteins form major signalling hubs, which interact with a multitude of 
proteins, and mediate canonical and non-canonical WNT signalling (Boutros and 
Mlodzik 1999; Gao and Chen 2010; Wynshaw-Boris 2012). VANGL1 interaction 
with all three DVL proteins highlights its role downstream of WNT signalling. 
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Remarkably, R-RAS interaction is specific to VANGL1 and so is the DVL 
interaction. Furthermore, R-RAS and DVL3 binding to VANGL1 is disrupted by the 
point mutant D259E, suggesting that both proteins could be competing for the 
same binding site. This is further confirmed by observations that active R-RAS 
modulates VANGL1-DVL binding, suggesting a common ‘axis’ of VANGL1 
function. 
CELSR proteins are membrane adhesion proteins with key roles in PCP that 
remain to be fully understood. CELSR1 is directly linked to cochlear stereocilia 
bundle misorientation and neural tube closure defects (Curtin et al. 2003; 
Devenport and Fuchs 2008; Robinson et al. 2011). CELSR2 and CELSR3 regulate 
other PCP processes such as ciliogenesis, maintenance of dendrites, neuronal 
migration and axon guidance (Shima et al. 2002; Tissir et al. 2005; Wada et al. 
2006; Shima et al. 2007; Tissir et al. 2010). VANGL1 is able to bind to the 
intracellular domain of CELSR2 but not CELSR1, which was also the only CELSR 
isoform detected in VANGL1-TAP experiments. This finding is consistent with the 
possibility that VANGL1 might not be directly involved in neurolation and related 
CE (CELSR1 dependent functions) (Torban et al. 2008; Antic et al. 2010; Song et 
al. 2010), but rather in PCP directed processes associated with ciliogenesis and 
neuronal development and migration (CELSR2 dependent processes). 
Multiple other novel VANGL1 - interacting proteins identified by TAP (NDFIP1, 
SYNJ2BP, YIF1B, RAB3GAP) are involved in vesicle/membrane trafficking, and 
imply additional roles for VANGL1 function that remains to be further studied. 
VANGL1 might interact with these proteins as part of its regulated transport to 
the plasma membrane as shown for Sec24B and VANGL2 transport (Wendeler et 
al. 2007; Merte et al. 2011; Wansleeben et al. 2011). Another possibility is that 
VANGL1 could have specific functions within other endomembrane compartments 
such as ER, Golgi or endosomes where others and myself have shown that 
VANGL1 can also localise. Whether R-RAS can modulate VANGL1 function at 
these endomembrane compartments remains to be determined, but R-RAS as 
well as other RAS family proteins, in addition to residing primarily at the plasma 
membrane, have also been shown to localise at ER, Golgi and endosomes (Chiu 
et al. 2002; Bivona and Philips 2003) (Conklin et al. 2010; Sandri et al. 2012).   
In order to test the idea that WNT signalling modulates VANGL1 interaction with 
endogenous binding partners was assessed in the presence of a panel of FZD 
proteins and or ROR2. Interestingly stimulation of interaction of VANGL1 with 
DVLs, but not with other proteins such as SCRIB, DLG1 and CASK (whose 
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interactions are mediated via PDZ domains) is enhanced by a subset of FZD 
proteins as well as by ROR2. The underlying mechanism by which FZD and/or 
ROR2 achieve this stimulatory effect remains to be identified but may be related 
to DVL hyper-phosphorylation. 
FZDs recruit DVL to the plasma membrane by a still poorly understood 
mechanism. FZD proteins contain a C-terminal PDZ binding motif required for 
recruitment of PDZ proteins (Wawrzak et al. 2009), as well as an additional 
KTxxxW motif which is required for DVL translocation to the membrane and 
subsequent phosphorylation (Rothbacher et al. 2000; Umbhauer et al. 2000; 
Axelrod 2001; Cong et al. 2004b). The ability of mFzd5 to stimulate the 
VANGL1-DVL2 interaction is abrogated in the mFzd5 KTxxxW motif W530G 
mutant and thus correlates with the ability of mFZD5 to initiate DVL2 
translocation to the plasma membrane for subsequent phosphorylation events. 
This further suggests that DVL translocation and phosphorylation could be an 
additional mechanism of recruitment of VANGL1 to sites of activation by WNT 
ligands and of spatiotemporal control of VANGL1 function. 
The role of DVL phosphorylation in WNT signalling remains still incompletely 
understood, but a model has been proposed where DVL phosphorylation may be 
a mechanism for the separate temporal control of β-catenin dependent and 
independent WNT signalling. The interaction of DVL with VANGL1 correlates with 
the phosphorylation of DVL that occurs at later time points of WNT stimulation. 
The observation that WNT stimulation can lead to both the activation of R-RAS 
GTPases and its association with VANGL1 on one hand and to the association of 
VANGL1 with DVL on the other hand, with both interactions potentially being 
mutually exclusive may seem counter-intuitive. However, the spatial-temporal 
dynamics have to be considered. R-RAS proteins are activated within minutes of 
WNT treatment, whereas the WNT induced increase in the interaction of VANGL1 
with DVL is first detected after 60 minutes and therefore clearly displays a 
delayed response that may correlate with DVL phosphorylation. 
Of the tested panel of Frizzled receptors, FZD2, FZD4, mFzd5 and FZD7 
stimulate the VANGL1-DVL2 interaction, whereas FZD3 and FZD6 did not display 
a detectable interaction enhancement. Interestingly, FZD3 and FZD6 form a 
distinct phylogenetic branch of Frizzled proteins (Huang and Klein 2004), and 
have been demonstrated to be required with VANGL2, CELSR1 and PRICKLE2 for 
inner ear stereociliary bundle orientation (Montcouquiol et al. 2006; 
Montcouquiol et al. 2008).  
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As mentioned earlier, DVL interacts preferentially with VANGL1 compared to 
VANGL2, and VANGL1 interacts with CELSR2 but not CELSR1. Taken together, 
these observations suggest the possibility that a subset of FZD receptors, 
possibly in combination with different CELSR co-receptors, may use different 
VANGL isoforms to regulate various aspects of non-canonical signalling. 
In order to assess if WNT ligands or the tyrosine kinase ROR2 could be 
functioning as a potential R-RAS activators, RAS RBD assays were performed. 
Our findings demonstrated that WNT5a leads to the activation of R-RAS in 
multiple cell lines with a characteristic stimulation pattern displaying a short 
lived burst of activation 3-4 minutes after WNT5a treatment. Stable expression 
of ROR2 in U2OS cells exhibited an accelerated as well prolonged WNT5a 
mediated R-RAS stimulation, compared to parental cells. This is the first time 
that WNT ligands have been demonstrated to stimulate the activity of RAS family 
GTPases and confirm our model that R-RAS GTPases can function downstream of 
WNT ligands in the regulation of VANGL1 function.  
Despite the fact that the mechanism by which WNT5a activates R-RAS remains 
to be determined, Ca2+ dependent mechanisms provide a compelling possibility. 
RASGRPs are the only known GEFs for R-RAS regulated by Ca2+ in vivo. 
Furthermore, GAPs such as CAPRI and RASAL are also regulated by Ca2+. 
Therefore, a rise in the intracellular concentration of Ca2+, could account for the 
very transient activation of R-RAS observed by joint regulation of GEFs and 
GAPs. 
Multiple reports link Ca2+ signalling to WNT/PCP pathway, although the molecular 
links are still not well understood (De 2011; Stone 2011; Niehrs 2012). A 
compelling possibility is that Ca2+ dependent activation of R-RAS GTPases may 
be the missing link between Ca2+ signalling and the PCP pathway. Further 
experiments need to be performed to test this hypothesis. Additionally, how WNT 
ligands regulate Ca2+ signalling remains to be determined. 
There are multiple reports linking the WNT/PCP pathway to activation of RHO 
GPTases but the molecular mechanisms remains unclear. There are likely to be 
multiple mechanisms operating in a cell type and context dependent manner. 
Strikingly, R-RAS GTPases play a critical contribution to RHO activation 
downstream of WNT ligands as simultaneous knock-down of both R-RAS and 
TC21 in HMEC-mFZD5 cells strongly inhibits RHOA and RHOB activation by 
WNT5a. Although the mechanism by which R-RAS/TC21 regulate RHO activity 
remains to be determined, based on our finding that ARHGEF17/p164RhoGEF 
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functions as an effector of TC21, this RHOGEF is an excellent candidate to 
mediate this effect. Future studies should address this exciting possibility. 
Our results strongly suggest that VANGL1 and R-RAS/TC21 play an important 
role in polarised migration. This is consistent with previous reported data using 
colorectal cancers cell lines, demonstrating that VANGL1 is critically required for 
migration and invasion (Lee et al. 2004; Kho et al. 2009; Lee et al. 2009). 
As outlined earlier, VANGL1 interacts with SCRIB, a protein with a well-
established role in polarity and migration (Qin et al. 2005b; Osmani et al. 2006; 
Dow et al. 2007; Nola et al. 2008; Michaelis et al. 2013). SCRIB associates with 
the PIX/GIT complex that regulates RAC/CDC42 and ARF GTPases (Audebert et 
al. 2004; Frank and Hansen 2008). Therefore, we hypothesised that R-RAS may 
be involved in recruiting the VANGL1-SCRIB complex to the membrane and 
thereby help coordinate other members of the RAS superfamily of GTPases to 
help coordinate polarization associated with migration.  
In addition, VANGL1 seems to promote also R-RAS independent functions such 
as ECM degrading activities (Lee et al. 2004) and MMP-13 expression regulation.  
In conclusion, the discovery of WNT/ROR2 mediated activation of R-RAS GTPases 
in combination with the identification of VANGL1 and ARHGRF/p164RhoGEF as 
novel effectors of R-RAS GTPases provide an exciting new link between the R-
RAS subgroup and the WNT/PCP pathway. Perturbations in this pathway 
contribute to the pathogenesis of several diseases including NTDs and to the 
invasiveness of cancer cells. Identifying and characterising additional 
components in this pathway will hopefully lead to the identification of new genes 
involved in disease aetiology as well as reveal novel targets for drug discovery 
and therapeutic intervention. 
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